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CHAPTER I 
 
UMPOLUNG AMIDE SYNTHESIS 
 
1.1 Introduction and Background 
Amide bonds, which serve as the essential linkage between amino acids, are 
widely found in peptides and proteins as well as in pharmacologically active natural 
products and small molecule therapeutics (Figure 1). Of the top 200 drugs sold in 2007, 
10% were proteins and another 8% were peptides.
1
 Because of the important roles amide 
bonds play, their synthesis is an extremely important scientific tool. Nature constructs 
these essential bonds through the simple condensation of amines and carboxylic acids. 
Most synthetic methods in use today also utilize dehydrative approaches, with the help of 
coupling reagents. While this strategy works extremely well for most couplings, there are 
still areas of amide and peptide synthesis which can be improved. 
 
Figure 1. Examples of protein and peptide therapeutics. 
 
                                                          
1
 www.arizona.edu/njardarson/group/Top200PharmaceuticalProductsbyWorldwideSalesin2009.pdf 
2
 Jones, J. Amino Acid and Peptide Synthesis, Oxford Science Publications: Oxford, 1992. 
2 
 
1.1.1 Methods of Amide Coupling 
 Amide bond formation, which in its simplest form consists of the condensation of 
a carboxylic acid and an amine,
 2
 is one of the oldest known chemical transformations 
(Scheme 1). While this transformation occurs quite readily in nature with the help of 
enzymes, it does not occur quite so readily on the bench-top. The energy required to 
remove a single equivalent of water is surprisingly high, and it is for this reason that 
chemists have had to devise highly innovative synthetic methods for amide synthesis. 
One of the earliest advances,
3
 and arguably the most widely used, was the development 
of carbodiimide coupling reagents, such as dicyclohexyl carbodiimide (DCC, 1) (Figure 
2). Over the years, this reagent class has grown to include chloroformates, uronium salts 
(HATU, 2), phosphonium salts (PyBOP, 3) and acid halogenating reagents (TFFH, 4), 
among many others,
4
 all which have been developed to further increase the efficiency of 
amide coupling. 
 
Scheme 1. Condensation of a carboxylic acid and an amine. 
 
Figure 2. Common coupling reagents. 
 
                                                          
2
 Jones, J. Amino Acid and Peptide Synthesis, Oxford Science Publications: Oxford, 1992. 
3
 Sheehan, J. C. Hess, G. P. J. Am. Chem. Soc. 1955, 77, 1067. 
4
 For recent reviews, see: Han, S. Y.; Kim, Y. A. Tetrahedron 2004, 60, 2447. Montalbetti, C. A. G. N.; 
Falque, V. Tetrahedron 2005, 61, 10827. Valeur, E.; Bradley, M. Chem. Soc. Rev. 2009, 38, 606. 
3 
 
 While these coupling reagents work extremely well for most simple amide 
couplings, their strong foundation is oftentimes weakened upon moving to larger or more 
complex substrates. For example, the coupling of disubstituted amines or large peptides 
frequently results in low conversion. A second, and perhaps more daunting, challenge of 
peptide coupling is suppressing the racemization which can occur at the α-carbon of the 
activated carboxylic acid. This racemization, which occurs due to azlactone or ketene 
formation (Scheme 2),
5
 is especially prevalent when coupling peptidic carboxylic acid 
fragments, and even more so when coupling acidic amino acids such as aryl glycines. The 
addition of rate enhancers and/or racemization suppressants, such as 
dimethylaminopyridine (DMAP, 5) or hydroxybenzotriazole (HOBT, 6), can help to 
lessen the degree of racemization observed; however, they cannot completely eliminate 
this undesired process (Figure 3).
4 
 
Scheme 2. Racemization at the α-carbon of activated carboxylic acids. 
 
 
 
 
 
 
                                                          
5
 Benoiton, N. L. Chemistry of Peptide Synthesis; Taylor and Francis Group: Boca Raton, Florida, 2006. 
4 
 
 
 
Figure 3. Rate-enhancers and racemization suppressants. 
 
 Regardless of these difficulties, the use of peptide coupling reagents has prevailed 
over the years as the preferred method of amide synthesis. The application of these 
reagents to solid phase synthesis, in which reagent excess can be used to drive the 
condensation to completion, has made the synthesis and purification of peptides much 
faster.
6
 Recently, alternatives to conventional amide synthesis have emerged as chemists 
try to address these practical challenges.
7
 As seen in Scheme 3, these novel approaches 
include native chemical ligation,
8
 Staudinger ligation,
9
 hydrative amide synthesis through 
alkyne-azide coupling,
10
 oxidative amidation of alcohols,
11
 aldehydes,
12
 or alkynes,
13
 and 
ketoacid-hydroxylamine ligation,
14
 among others.
15
 
                                                          
6
 a) Atherton, E.; Sheppard, R. C. Solid phase peptide synthesis: a practical approach; IRL Press at Oxford 
University Press: Oxford, England; New York, 1989. b) Fields, G. B. Solid phase peptide synthesis; 
Academic Press: San Diego, 1997. c) Dorwald, F. Z. Organic synthesis on solid phase: supports, linkers, 
reactions; Wiley-VCH: Weinheim; Chichester, 2000. d) Sewald, N.; Jakubke, H. -D. Peptides: chemistry 
and biology; Wiley-VCH: Weinheim, 2002. 
7
 Bode, J. W. Curr. Opin. Drug Discover Dev. 2006, 9, 765. 
8
 Dawson, P. E.; Muir, T. W.; Clarklewis, I.; Kent, S. B. H. Science 1994, 266, 776. 
9
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Scheme 3. Recent novel approaches to amide synthesis 
 
 
1.1.2 Enduring Obstacles in Peptide Synthesis 
 Though these advances in the area of amide coupling have made the synthesis of 
complex peptides and other amide-containing natural products possible, there is still 
room in this field for improvement. The most common peptide coupling reagents in use 
today, in addition to being expensive, and in some cases toxic or shock-sensitive, have 
very high molecular weights and are usually used in superstoichiometric amounts, 
especially in solid phase synthesis. This, coupled with the fact that one also may need to 
use an additional racemization-suppressant additive, means that a significant amount of 
chemical waste is produced, all to simply remove one equivalent of water. In 2005, the 
ACS Green Chemistry Initiative Pharmaceutical Roundtable voted “amide coupling 
avoiding poor atom economy reagents” the number one key green chemistry research 
6 
 
area which needed improvement.
16
 Some of the recently developed methods look to solve 
this problem by taking steps to make amide coupling a greener reaction.
11a,14
 However, 
while these advances have been promising, the use of metal catalysts, or the complicated 
synthesis of specialized starting materials make these reactions not as green as they first 
appear.  
 Additionally, most, if not all, methods of amide coupling proceed through some 
sort of activated ester intermediate, in which the carbon destined to become the carbonyl 
carbon of the amide bond is electrophilic. This means that in all of these cases, 
racemization at the α-stereocenter of this coupling partner is still an obstacle, especially 
in more demanding coupling reactions, because azlactone and ketene formation are still 
possible.  
 
1.2 Umpolung Amide Synthesis 
Previously in our lab, a novel amide coupling reaction was discovered in which an 
α-bromo nitroalkane (7) could be coupled to an amine in the presence of an electrophilic 
halonium source to form the amide (Scheme 4).
17
  
 
Scheme 4. Halonium promoted coupling of α-bromo nitroalkanes and amines. 
 
                                                          
16
 Constable, D. J. C.; Dunn, P. J.; Hayler, J. D.; Humphrey, G. R.; Leazer, J. L.; Linderman, R. J.; Lorenz, 
K.; Manley, J.; Pearlman, B. A.; Wells, A.; Zaks, A.; Zang, T. Y. Green Chemistry 2007, 9, 411. 
17
 Shen, B.; Makley, D. M.; Johnston, J. N. Nature 2010, 465, 1027. 
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1.2.1 Reaction Discovery and Development 
Studies of this carbon-nitrogen bond forming reaction began with the hypothesis 
that an α-bromo nitroalkane (8), in the presence of an amine, might provide the proper 
oxidation state for conversion to the amide in much the same way nitroalkanes (9) are 
converted to aldehydes via the Nef reaction (Scheme 5).
18
 
 
Scheme 5. Nef reaction and proposed aza-Nef reaction. 
 
 The Nef reaction involves a two-step sequence which begins with nitronate (10) 
formation under basic conditions (KOH), followed by acid hydrolysis (aq. HCl). In order 
to adapt this reaction to amide formation - an ‘aza-Nef’ - two things must be done. First, 
instead of hydrolyzing the nitronic acid intermediate (11), an amine could trap this 
intermediate, forming a tetrahedral intermediate (12) which would normally lead to imine 
formation. If, however, an α-bromo nitroalkane was used in place of a nitroalkane, the 
oxidation state of the putative tetrahedral intermediate (13) would allow for production of 
                                                          
18
 Nef, J. U. Liebigs Ann. Chem. 1984, 280, 263. For recent reviews on the Nef reaction, see: a) Ballini, R; 
Petrini, M. Tetrahedron 2004, 60, 1017. b) Pinnick, H. W. Org. React. 1990, 38, 655. 
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the amide bond. In order to test this, α-bromo nitroalkane 8 was stirred with two 
equivalents of amine 14. After 10 days at room temperature, a trace amount of the amide 
product 15 could be detected (Scheme 6, eq 1). 
 
Scheme 6. Preliminary investigations. 
 
However, alongside this small amount of product, the debrominated nitroalkane 9 
could be seen. This led to the hypothesis that an N-haloamine (16) might be forming, 
through bromonium transfer from 8 to 14. The remaining α-bromo nitroalkane, once 
deprotonated to the nitronate (17), could then conceivably undergo electrophilic 
amination, forming a tetrahedral intermediate (18) which would lead to the desired amide 
(Scheme 6). Because of the perceived need to form the N-haloamine in this proposed 
reaction pathway, a stoichiometric amount of an external halogenating reagent, N-iodo 
succinimide (NIS, 19), was added. Gratifyingly, the yield of the desired amide product 
increased to 61% (Scheme 7, eq 2). The addition of an external base, K2CO3, allowed the 
amount of amine to be reduced to 1.2 equivalents (Scheme 7, eq 3). 
 
9 
 
Scheme 7. Optimization of the amide coupling of α-bromo nitroalkanes and amines. 
 
 
When a large excess of water (Scheme 7, eq 2 and 3) is used in these reactions, a 
significant amount of the dinitroalkane 20 is observed. This side product most likely is 
produced due to a competing ter Meer reaction
19,20
 (Scheme 7, eq 4) of the α-bromo 
nitroalkane 8 and nitrite, presumably produced as a byproduct in the amide coupling 
reaction. While the exact mechanism of this transformation has not been extensively 
studied,
21
 it is known that basic aqueous conditions are needed to deprotonate the α-halo 
nitroalkane and solvate the nitrite. By limiting the amount of added water (Scheme 7, eq 
                                                          
19
 E. ter Meer, Justus Liebigs Ann. Chem. 1876, 181, 1. 
20
 For applications in the synthesis of dinitroalkanes, see: a) Feuer, H.; Colwell, C. E.; Leston, G.; Nielson, 
A. T. J. Org. Chem. 1962, 27, 3598. b) Hamel, E. E.; Dehn, J. S.; Love, J. A.; Scigliano, J. J.; Swift, A. H. 
Ind. Eng. Chem. Prod. Res. Dev. 1962, 1, 108. 
21
 For a summary, see: Todres, Z.V. Ion-Radical Organic Chemistry: Principles and Applications, CRC 
Press Taylor & Francis Group: Boca Raton, Florida, 2008, 243. 
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5), and therefore the amount of solvated nitrite, the yield of the coupling can be increased 
to 75%, and production of the dinitro side product (20) can be minimized. 
The need for an added halogenating reagent, NIS, in this reaction strongly 
suggested it was proceeding through the proposed N-haloamine-nitronate coupling 
(Scheme 6). The mechanism of this amide coupling is fundamentally novel, in that the 
polarities of the reactants in the key C-N bond forming step are reversed (umpolung)
22
 
from those normally seen in amide coupling reactions. Instead of an electrophilic 
activated acid (21), or similar substrates, which will be attacked by a nucleophilic amine 
(22), this mechanism utilizes a nucleophilic carboxylic acid surrogate (23) which attacks 
an electrophilically activated N-haloamine (24) (Scheme 8). This umpolung mechanism 
offers certain advantages over conventional amide coupling; specifically, racemization at 
the α-carbon of the carboxylic acid is mechanistically prohibited due to the now 
nucleophilic character of the acyl donor carbon. 
 
Scheme 8. Reversed reactant polarities in umpolung amide coupling. 
 
 
These umpolung amide coupling conditions were then applied to other amines 
and α-bromo nitroalkane substrates, including sterically demanding and peptidic ones, 
with a promising level of generality (isolated yields of 48-81%). The only limitation at 
                                                          
22
 a) Seebach, D.; Corey, E. J. J. Org. Chem. 1975, 40, 231. b) Grobel, B. T.; Seebach, D. Synthesis 1977, 
357. c) Seebach, D. Angew. Chem. Int. Ed. 1979, 18, 239. 
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this time seems to be the use of aromatic amines, as aniline did not produce any of the 
desired amide product.17
 
 
1.2.2. Mechanistic Studies 
 In the proposed mechanistic pathway of this coupling (Scheme 9), it was assumed 
that the addition of water to tetrahedral intermediate 26, and subsequent loss of HNO2 
and HBr, resulted in the amide. If this were the case, the use of 
18
O
 
labeled water should 
result in 
18
O incorporation into the carbonyl of the amide bond. However, when this 
reaction was performed, less than 1% 
18
O incorporation was observed (eq 6).
23
 This 
suggested that the oxygen of the amide was coming from some other source. 
 
Scheme 9. Original mechanistic hypothesis and 
18
O labeling study. 
 
 
                                                          
23
 Shen, B.; Johnston, J. N. Ph.D. Dissertation 2010, Department of Chemistry, Vanderbilt University. 
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 Another possible source of oxygen in this reaction system is the nitro group. The 
rearrangement of bromonitromalonate 28 to the corresponding nitrite 29, followed by 
elimination of nitrosyl bromide to afford ketone 30 was reported in 1904 (Scheme 10, eq 
7).
24
 Years later, a similar rearrangement was reported by Schollkopf and co-workers.
25
 
They observed that, under thermal conditions, substituted nitroacetate 31 partially 
rearranged to the corresponding nitrite (33). Additionally, the recovered unreacted 
starting material had partially racemized (eq 8). Based on this, the authors proposed that 
the nitro-nitrite rearrangement occurred via a radical pair intermediate (32), formed from 
homolytic cleavage of the C-N bond. Recombination of this radical pair could then either 
form the new C-O bond of the nitrite, or could reform the C-N bond of the starting 
material, due to the ambident character of the nitro radical. This would then explain the 
observed racemization of the starting nitroacetate. 
 
Scheme 10. Examples of the nitro-nitrite rearrangement. 
 
 These two examples, as well as others which involve the conversion of gem-halo 
nitro functionalities into carbonyl groups,
26
 bear commonality in that a tertiary gem-halo 
                                                          
24
 Willstatter, R.; Hottenroth, V. Chem. Ber. 1904, 37, 1775. 
25
 Hochstein, W.; Schollkopf, U. Justus Liebigs Ann. Chem. 1978, 1823. 
26
 Selected examples: a) Nguyen, N. V.; Baum, K. Tetrahedron Lett. 1992, 33, 2949. b) Ketari, R.; 
Foucanud, A. J. Org. Chem. 1981, 46, 4498. c) Hartshorn, M. P.; Ing, H. T.; Richards, K. E.; Thompson, R. 
S.; Vaughan, J. Aust. J. Chem. 1982, 35, 221. d) Hartshorn, M. P. Ing, H. T.; Richards, K. E.; Sutton, K. H.; 
Vaughan, J. Aust. J. Chem. 1982, 35, 1635. e) Chanbers, M. V.; Harshorn, M. P.; Robinson, W. R.; 
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nitro is needed for the transformation to occur. Additionally, at least one of the 
substituents on the tertiary carbon must be a radical stabilizing group, such as an ester or 
alkoxy group (Scheme 11). These observations are consistent with the radical pair 
intermediate proposed by Schollkopf. 
 
Scheme 11. Summary of nitro-nitrite rearrangement of gem-halo nitro compounds. 
 
 
 In order to test whether or not a similar nitro-nitrite rearrangement was occurring 
to give the amide from the gem-bromo nitro tetrahedral intermediate, 
18O labeled α-
bromo nitroalkane was prepared (82% 
18
O) and coupled to amine 14 (Scheme 12, eq 9). 
A small amount of 
18
O label (17%) was observed in the amide, suggesting that the nitro-
nitrite rearrangement was occurring, but was not the only pathway in operation. The only 
other possible sources of oxygen in the reaction, carbonate and molecular oxygen, were 
identified and removed from the reaction conditions. When carbonate was replaced by 
excess amine, the amount of 
18
O label incorporated into the amide increased to 49% 
(Scheme 12, eq 10), and when the reaction was degassed and done under argon, it 
increased to 66% (Scheme 12, eq 11).
27
 
 
 
 
                                                                                                                                                                             
Vaughan, J. Aust. J. Chem. 1985, 38, 133. f) Hartshorn, M. P.; Robinson, W. T.; Wright, G. J.; Cheng, L. 
Y. Aust. J. Chem. 1989, 42, 1569. g) Baum, K.; Archibald, T. G.; Tzeng, D.; Gilardi, R.; Flippen-Anderson, 
J. L.; George, C. J. Org. Chem. 1991, 56, 537. 
27
 Shackleford, J. P.; Shen, B.; Johnston, J. N. Proc. Natl. Acad. Sci. 2012, 0, 0. 
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Scheme 12. Additional 
18
O labeling experiments. 
 
 
This suggested that the possibility of two different reaction pathways leading 
from the tetrahedral intermediate (18) to the amide product (15): one anaerobic and one 
aerobic (Scheme 13). The aerobic pathway would still proceed through homolytic 
cleavage to a radical pair intermediate. However, instead of recombining with the nitro 
radical, the tertiary carbon radical (35) reacts with molecular oxygen to form oxygen 
radical 37; it is this intermediate which leads to amide formation. This hypothesis was 
confirmed when the coupling was done under an atmosphere of 
18
O2, and 81% 
18
O label 
was incorporated into the product (Scheme 13, eq 12). This high level of 
18
O, in addition 
to validating this reaction pathway, suggested that the aerobic pathway is much faster 
than the anaerobic one, a fact that can also be seen experimentally. When performed 
under argon, the reaction takes two days to reach full conversion; under an oxygen 
atmosphere it is done within two hours.
27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
Scheme 13. Proposed anaerobic and aerobic reaction pathways. 
 
 
 It was also apparent that under aerobic conditions there was the opportunity for 
regeneration of an equivalent of halonium, in the transformation from radical 37 to amide 
15. The nitro radical would likely combine with radical 37, forming intermediate 38 
Homolytic cleavage of both the Br-C bond, as well as the O-O bond would result in 
amide 15, while releasing Br and NO3
. A redox reaction between these two radicals 
should then give Br
+
 and NO3
-
 (Scheme 14). This hypothesis was confirmed when, under 
16 
 
an atmosphere of O2, only 0.05 equivalents of NIS resulted in full conversion and high 
yield of 15 (Scheme 14, eq 13).
28
 
 
Scheme 14. Regeneration of halonium catalyst. 
 
 
1.2.3 Investigation of Halonium Reagent Effects 
 While the mechanism of amide formation from the tetrahedral intermediate was 
being studied, we also wished to investigate the electrophilic amination of the α-bromo 
nitroalkane which would lead to this intermediate. As discussed previously, it is proposed 
that this amination occurs via the N-haloamine, an intermediate that, though uncommon, 
is known to electrophilically aminate carbon nucleophiles. 
 
Electrophilic Amination with N-Haloamines 
Though N-haloamines
29
 have been extensively utilized in the Hoffman-Loffler-
Freytag reaction,
30
 their use as electrophilic amination reagents is relatively limited.
31
 
                                                          
28
 Shen, B.; Johnston, J. N. unpublished results. 
29
 For a review, see: Kovacic, P.; Lowery, M. K.; Field, K. W. Chem. Rev. 1970, 70, 639. 
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Coleman and co-workers reported that monochloroammonia and monobromoammonia 
reacted with Grignard reagents to give monosubstituted amines (39) in moderate to good 
yield (57-85% yield for NH2Cl and 29-63% yield for NH2Br, Scheme 15, eq 14).
32
 This 
reaction occurs in an SN2 fashion, with Cl
-
 or Br
-
 acting as the leaving group. However, 
because of the electronegativity of the nitrogen atom, N-haloamines can act as ambident 
electrophiles. Because of this, a competing side reaction can occur in which an SN2 
substitution occurs at the halogen, with NH2
-
 acting as the leaving group, producing the 
alkyl halide (40) and ammonia (eq 15). 
The Coleman group later used N-chloro alkyl amines in the amination of Grignard 
reagents. However, the isolated yields of the disubstituted amines (41) were low, 
apparently due to this ambident reactivity; the major products isolated were the de-
halogenated primary amines (42) (Scheme 15, eq 16).
33
 Recently, N-chloro alkyl amines 
were used, with aryl Grignard reagents, to prepare tertiary anilines (43) in moderate to 
good yields (33-73%) (Scheme 15, eq 17).
34
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 For reviews, see: a) Wolff, M. E.; Chem. Rev. 1963, 63, 55. b) Neale, R. S. Synthesis 1971, 1. c) 
Majetich, G.; Wheless, K. Tetrahedron 1995, 51, 7095. 
31
 For reviews on electrophilic amination, see: a) Erdik, E.; Ay, M. Chem. Rev. 1989, 89, 1947. b) 
Dembech, P.; Seconi, G.; Ricci, A. Chem. Eur. J. 2000, 6, 1281. c) Watson, I. D. G.; Yudin, A. K. Curr. 
Opin. Drug Discovery Dev. 2002, 5, 906. d) Erdik, E. Tetrahedron 2004, 60, 8747. 
32
 a) Coleman, G. H.; Hauser, C. R. J. Am. Chem. Soc. 1928, 50, 1193. b) Coleman, G. H.; Yager, C. B. J. 
Am. Chem. Soc. 1929, 51, 567. 
33
 Coleman, G. H. J. Am. Chem. Soc. 1933, 55, 3001.  
34
 Sinha, P.; Knochel, P. Synlett 2006, 3304. 
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Scheme 15. Examples of N-haloamines in the electrophilic amination of Grignard reagents. 
 
 
 Organoboranes, generated from the hydroboration of alkenes, are also reported to 
react with monochloroammonia to give monosubstituted amines (44) in moderate yields 
(Scheme 16, eq 18).
35
 Organolithium
36,37
 and organozinc
36
 reagents have also been 
reported to undergo electrophilic amination in the presence of N-haloamines, but with 
less success than Grignard reagents.
31
 The lone exception to this is a recent report of a 
Ni(0) catalyzed electrophilic amination of diarylzinc reagents with N,N-dialkyl-N-
chloroamines, which gave trisubstituted anilines (45) in high yields (Scheme 16, eq 19).
38
 
Several reports of the electrophilic amination of enolates, utilizing N-haloamines, have 
                                                          
35
 Brown, H. C.; Heydkamp, W. R.; Breuer, E.; Murphy, W. S. J. Am. Chem. Soc. 1964, 86, 3565. 
36
 Coleman, G. H.; Hermanson, J. L.; Johnson, H. L. J. Am. Chem. Soc. 1937, 59, 1868. 
37
 Wolf, V.; Kowitz, F. Justus Liebigs Ann. Chem. 1960, 683, 33. 
38
 Barker, T. J.; Jarvo, E. R. J. Am. Chem. Soc. 2009, 131, 15598. 
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been made,
39
 several of which have focused on an intramolecular amination to afford 
nitrogen-containing heterocycles (Scheme 16, eq 20).
40
 
 
Scheme 16. Other examples of electrophilic amination using N-haloamines. 
 
 
N-Haloamines in Umpolung Amide Synthesis 
 Although it was known that the use of NIS as a halonium source afforded the 
amide product 15 in good yields, it is one of the most expensive halogenating reagents 
with a price of $879 per mole of I
+
. Therefore, the efficacy of other halonium ions (Br
+
 
and Cl
+
) and halogenating reagents in this umpolung amide coupling was explored; not 
only to understand more about this interesting mechanism, but also with the hope of 
finding a cheaper halonium source. 
 To start, the reactivities of N-bromosuccinimide (NBS) and N-chlorosuccinimide 
(NCS) were compared to that of NIS. As seen in Table 1, both NBS (entry 2) and NCS 
                                                          
39
 a) Yamada, S. I.; Shioiri, T.; Oguri, T. J. Chem. Soc., Chem. Comm. 1972, 623. b) Oguri, T.; Shioiri, T.; 
Yamada, S. Chem. Pharm. Bull. 1975, 23, 167. 
40
 a) Clemo, G. R.; Hoggarth, M. J. Chem. Soc. 1954, 95. b) Grieco, P. A.; Dai, Y. J. Am. Chem. Soc. 1998, 
120, 5128. c) Bew, S. P.; Hughes, D. L.; Palmer, N. J.; Savic, V.; Soapi, K. M.; Wilson, M. A. Chem. 
Commun. 2006, 4338. d) Makosza, M.; Bobryk, K.; Krajewski, D. Heterocycles 2008, 76, 1511. 
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(entry 3) gave much lower preliminary yields of the amide (25% and 21%, respectively) 
than NIS (entry 1). In the case of NBS, this appeared to be an issue of reactivity, as the 
reaction only went to 50% conversion. Additionally, a build-up of the dibromo 
nitroalkane (47b), produced from the halogenation of 7, was observed. This compound 
has been isolated and resubjected to reaction conditions, resulting in production of the 
amide product, though at a very slow rate, proving it is a competent intermediate in this 
reaction.
23
 
The reaction which utilized NCS did not have these same problems; conversion of 
the α-bromo nitroalkane 7 was high, and none of the dihalo nitroalkane was observed. 
However, the crude 
1
H NMR analysis showed a much messier reaction, with a significant 
amount of unreacted amine remaining. This suggests that decomposition of the α-bromo 
nitroalkane may be occurring when this reagent is used. 
 
Table 1. Comparison of NIS, NBS and NCS in umpolung amide coupling. 
 
 The fact that build-up of dibromo nitroalkane 47 readily occurs when a 
brominating reagent is used, but the α-chloro-α-bromo and α-iodo-α-bromo nitroalkanes 
(47a, 47c) are rarely seen, can be understood by looking at the electronegativities of each 
halogen (Scheme 17). The dihalo intermediates are produced when nitronate 17 is 
21 
 
halogenated before amine 14 (pathway b). If this happens, iodonium, the least 
electronegative halogen, will transfer fastest from 47a to 14; hence the α-iodo-α-bromo 
nitroalkane (47) is a transient intermediate only observed if the reaction is stopped at a 
very early stage. Bromonium and chloronium transfer would be much slower, which 
would explain why the dibromo nitroalkane is observed to such a great extent under these 
reaction conditions. The absence of a significant amount of the α-chloro-α-bromo 
nitroalkane in the reaction mixture could be due to the decomposition of this 
intermediate, which would explain the high conversion but low yield of amide product. 
Once the nitronate 17 and N-haloamine 16 have formed, electrophilic amination 
occurs. In this step, chlorine would be the most reactive of the halogens, as it would 
polarize the halogen-nitrogen bond to the greatest extent, making the nitrogen more 
electrophilic. This trend in electrophilic amination can be seen in the literature; N-
chloroamines, when reacted with Grignard reagents, exhibit the highest reactivity, while 
N-bromoamines are seen to be less reactive.
31
 Though N-iodoamines have rarely been 
used in electrophilic amination, their success in this reaction can be explained by the fact 
that iodonium, as the largest halogen, would be the best leaving group in the SN2-type 
amination (Scheme 17). 
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Scheme 17. Halogen reactivity. 
 
 Though NBS initially gave a low yield of the amide, the reaction seemed 
promising in that no decomposition was observed, only low conversion. Therefore, 
attempts were made to increase conversion to the amide, and push the equilibrium of the 
reaction past the dibromo resting state. This was initially done by increasing the amount 
of amine used. As seen in Table 2, increasing the equivalents of amine from 1.2 to 2 
increased the conversion to 78%, and the yield to 38% (entry 2). Additionally, less of the 
dibromo nitroalkane 47b was observed. By increasing the equivalents of amine to 5, and 
raising the reaction to room temperature, full conversion of both the starting α-bromo 
nitroalkane 7 and dibromo nitroalkane 47b was achieved, giving a 68% yield of the 
amide. 
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Table 2. Pushing the equilibrium past the dibromo nitroalkane intermediate. 
 
 It was hypothesized that a second possible way to achieve full conversion, 
without resorting to excess amine, would be to avoid production of the dihalo 
intermediate all together by pre-mixing the halogenating reagent and amine before adding 
the α-bromo nitroalkane or base. It was hoped that by doing this, the N-haloamine would 
have a chance to form before the α-bromo nitroalkane could become halogenated. This 
method of addition was utilized, with NIS, NBS and NCS, to assess how, if at all, it 
would affect their reactivity. For NIS and NCS, the yields remained unchanged from the 
standard order of addition (Table 3, entries 1 and 3) respectively. However, an increase in 
conversion and yield could be seen with NBS (Table 3, entry 2), and notably no dibromo 
nitroalkane was observed. 
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Table 3. Avoiding the dihalo nitroalkane by “preforming” the N-haloamine. 
 
 After having studied the basic differences in reactivity observed between Cl
+
, Br
+
 
and I
+
, a more extensive screen of halogenating reagents was performed, with a focus on 
the price per mole of halonium for each of the reagents. As seen in Table 4, the absence 
of a halonium source resulted in a 3% yield of amide 15, with some of the de-brominated 
starting material also observed (entry 1). At this time, it was found that by switching the 
solvent from THF to DME, chlorinating reagents gave cleaner reaction mixtures and 
higher yields (entries 2-5, 22-54%), with trichlorocyanuric acid (TCCA) giving the 
highest yield (entry 4, 55%). This reagent, which is commonly used to chlorinate 
swimming pools,
41
 is also the cheapest of the halogenating reagents screened. 
 While the new order of addition in which the amine and halogenating reagent are 
pre-mixed was used and the reactions allowed to stir for an extended period (4 d), 
conversions and yields of the brominating reagents were still relatively low (Table 4, 
entries 6-9, 28%-54%). However, N-bromophthalimide gave a promising yield of 54%, 
which could most likely be increased by using several equivalents of amine. Other 
iodonium sources were looked at, specifically I2 and ICl; gratifyingly, it was found that 
                                                          
41
 Barros, J. C. Synlett  2005, 2115. 
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I2, a readily available and less expensive source of iodonium, gave a yield comparable to 
that of NIS (Table 4, entry 10, 70%). 
 
Table 4. Full halogenating reagent screen. 
 
 
 Since it had been discovered that this reaction could be carried out with catalytic 
amounts of halonium,
28
 we decided to try to use sub-stoichiometric amounts of several 
chloronium sources which had previously given us low yields and messy reaction 
mixtures. It was thought that if undesirable side reactions or decomposition pathways 
were occurring when the concentration of chloronium was high, perhaps by keeping the 
chloronium concentration low, and relying on the inherent catalytic turnover seen with 
26 
 
this coupling, these could be avoided. Therefore, decreasing equivalents of Ca(OCl)2 
were used to couple 7 and 14 (Scheme 18, entries 1-4). It was found that by using only 
0.2 eq of Ca(OCl)2, the yield of this reaction could be increased to 58% (entry 4). It was 
also found that by using only half an equivalent of NCS in this reaction, the yield could 
be increased from 40% (Table 4, entry 3) to 52% (Scheme 18, eq 22). 
 
Scheme 18. Coupling under catalytic conditions with Cl
+
: improved yields. 
 
 In conclusion, a better understanding of the reactivities of the N-iodoamine, N-
bromoamine and N-chloroamine was gained by examining the effectiveness of NIS, 
NBS, and NCS in the umpolung amide coupling of 7 and 14. Additionally, several less 
expensive halogenating reagents were identified which could be used in place of NIS, 
including TCCA, NBP and I2, though only I2 gave yields comparable to NIS. Ca(OCl)2 
can also be used, under catalytic conditions, to give moderate yields of the amide. 
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CHAPTER II 
 
APPLICATIONS IN ENANTIOSELECTIVE PEPTIDE SYNTHESIS 
 
2.1 Introduction and Background 
Arylglycines are an important class of non proteinogenic amino acids, as they are 
found in many complex, naturally occurring peptide antibiotics. Somewhat difficult to 
synthesize and couple due to the ease with which they racemize, these amino acids have 
received significant attention since the discovery of vancomycin (51),
42
 a potent 
glycopeptide antibiotic used as a last defense against resistant strains of bacteria. The 
discovery of the umpolung amide coupling of α-bromo nitroalkanes and activated amines 
presents a unique opportunity for the synthesis of arylglycine-containing compounds 
(50). Aryl α-bromo nitroalkanes (49), arylglycine precursors, can be enantioselectively 
synthesized via the aza-Henry addition of bromonitromethane to aryl imines (48, Scheme 
19), in the presence of a chiral proton catalyst.
28
 These enantioenriched α-bromo 
nitroalkanes can then be coupled using umpolung amide synthesis with no detectable 
racemization at the acidic α-carbon of the aryl glycine. 
 
 
 
 
 
 
 
 
 
                                                          
42
 McCormick, M.H.; Stark, W.M.; Pittenger, G.E.; Pittenger, R.C.; McGuire, G.M. Antibiot. Annu. 1955, 
606. 
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Scheme 19. Arylglycine synthesis via an enantioselective aza-Henry and umpolung amide synthesis. 
 
 
2.1.1 Methods of Enantioselective Arylglycine Synthesis 
The asymmetric synthesis of arylglycines has historically been a very daunting 
task for synthetic chemists.
43
 Due to the electron withdrawing nature of the aryl ring, the 
acidity of the α-proton is quite high. Therefore, racemization at this stereocenter can 
readily occur, especially under basic conditions. In the past 10 to 15 years, however, there 
have been a number of highly innovative approaches to the asymmetric synthesis of these 
compounds. Many of these methods came about in the midst of intense synthetic focus on 
vancomycin (51), a heptapeptide containing three arylglycine residues, and its family 
members. 
 
 
 
 
                                                          
43
 Williams, R.M.; Hendrix, J.A. Chem. Rev. 1992, 92, 889. 
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Figure 4. Aryl glycine containing natural products: vancomycin family of antibiotics. 
 
 
Towards the Synthesis of Vancomycin 
The Vancomycin class of glycopeptide antibiotics, seen in Figure 4, includes 
vancomycin, isolated in 1956 from Streptomyces orientalis, eremomycin (52), orienticin 
C (53), teicoplanin (54) and ristocetin A (55). These compounds are known to inhibit 
bacterial cell wall biosynthesis,
44
 and are therefore potent antibiotics. Vancomycin is 
clinically used to treat severe staphylococcal and pseudomembranous colitis infections.
45
 
In addition to these important biological activities, the interesting structure of 
vancomycin
46
 has made it a synthetically desirable target. The western portions of all five 
structures are very similar, being composed of three cross-linked arylglycine residues. 
Teicoplanin
47
 and ristocetin’s48 structures incorporate two additional cross-linked 
                                                          
44
 (a) Nieto, M.; Perkins, H. R. Biochem. J. 1971, 123, 789. (b) Nieto, M. ; Perkins, H. R. Biochem. J. 1971, 
124, 845.  
45
 (a) Williams, D. H.; Rajananda, D.; Williamson, M. P.; Bojeson, G. Top. Antibiot. Chem. 1980, 5, 119. 
46
 (a) Williamson, M. P.; Williams, D. H. J. Am. Chem. Soc. 1981, 103, 6580. (b) Harris, C. M.; Kopecka, 
H.; Harris, T. M. J. Am. Chem. Soc. 1983, 105, 6915.  
47
 Cavelleri, B.; Ferrari, P.; Malabarba, A.; Magni, A.; Pallanza, R.; Gallo, G. G. J. Antibiot. 1987, 40, 49. 
48
 Harris, C. M.; Fesik, S. W.; Thomas, A. M.; Kannan, R.; Harris, T. M. J. Org. Chem. 1986, 51, 1509. 
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arylglycines in their eastern sections. The total synthesis of these compounds is 
challenging for several reasons, one being the issue of atropisomerism associated with the 
fused aryl rings, the other being the ease with which the arylglycine residues can 
epimerize. 
In 1998, Evans
49
 and Nicolaou
50
 simultaneously reported independent syntheses 
of the aglycon of vancomycin, in back to back articles in the same journal. Prior to that, 
however, Evans reported the synthesis of orienticin C (bis-deschlorovancomycin).
51
 The 
arylglycine residues required for his synthesis of both orienticin C and vancomycin were 
constructed using a chiral auxillary directed asymmetric enolate azidation reaction, which 
had been previously developed in his lab.
52
 Enolate formation occurs upon treatment of 
56 with KHMDS. Azidation, directed by the chiral auxillary, occurs on the least hindered 
face, giving 57 in moderate dr. In most cases, however, the diastereomers are separable, 
giving aryl glycine 58, after hydrogenation and saponification, in high enantiomeric 
excess (ee). Evans used this methodology to synthesize arylglycines 5 (59) and 7 (60) in 
98% and 96% ee, respectively, while arylglycine 4 was derived from commercially 
available D-4-hydroxyphenylglycine (Figure 2). Derivatives of these three arylglycine 
residues were then used to complete the syntheses of 51 and 53. 
                                                          
49
 (a) Evans, D. A.; Wood, M. R.; Trotter, B. W.; Richardson, T. I.; Barrow, J. C.; Katz, J. L. Angew. Chem. 
Int. Ed. 1998, 37, 2700.(b) Evans, D. A.; Dinsmore, C. J.; Watson, P. S.; Wood, M. R.; Richardson, T. I.; 
Trotter, B. W.; Katz, J. L. Angew. Chem. Int. Ed. 1998, 37, 2704. 
50
 (a) Nicolaou, K. C.; Natarajan, S.; Li, H.; Jain, N. F.; Hughes, R.; Solomon, M. E.; Ramanjulu, J. M.; 
Boddy, C. N. C.; Takayanagi, M. Angew. Chem. Int. Ed. 1998, 37, 2708.(b) Nicolaou, K. C.; Jain, N. F.; 
Natarajan, S.; Hughes, R. ; Solomon, M. E.; Li, H.; Ramanjulu, J. M.; Takayanagi, M.; Koumbis, A. E.; 
Bando, T. Angew. Chem. Int. Ed. 1998, 37, 2714.(c) Nicolaou, K. C.; Takayanagi, M.; Jain, N. F.; 
Natarajan, S.; Koumbis, A. E.; Bando, T.; Ramanjulu, J. M. Angew. Chem. Int. Ed. 1998, 37, 2717. 
51
 (a) Evans, D. A.; Watson, P. S. Tet. Lett. 1996, 37, 3251. (b) Evans, D. A.; Barrow, J. C.; Watson, P. S.; 
Ratz, A. M.; Dinsmore, C. J.; Evrard, D. A.; DeVries, K. M.; Ellman, J. A.; Rychnovsky, S. D.; Lacour, J. 
J. Am. Chem. Soc. 1997, 119, 3419. 
52
 (a) Evans, D. A.; Evrard, D. A.; Rychnovsky, S. D.; Fruh, T.; Wittingham, W. G.; DeVries, K. M. Tet. 
Lett. 1992, 33, 1189.(b) Evans, D. A.; Britton, T. C.; Ellman, J. A.; Dorow, R. L. J. Am. Chem. Soc. 1990, 
112, 4011.(c) Evans, D. A.; Weber, A. E. J. Am. Chem. Soc. 1987, 109, 7151.  
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Scheme 20. Evans’ chiral auxillary directed synthesis of aryl glycines. 
 
 
Nicolaou, on the other hand, synthesized the required arylglycine residues via a 
Sharpless asymmetric dihydroxylation
53
 of the appropriate styrene derivative. The 
dihydroxylation of 61 and 64 gave diols 62 and 65, respectively, both in high ee and 
yield. Diol 62 was then transformed, in 6 steps that included a Mitsunobu azide 
substitution
54
 and subsequent Staudinger reduction,
55
 to arylglycine 63 in 49% yield. Diol 
64 required less synthetic transformations before being incorporated into the natural 
product, as Nicolaou brought this piece (66) in via a Suzuki coupling with aryl iodide 67 
(synthesized in 4 steps from D-4-hydroxyphenylglycine). A subsequent Mitsunobu 
reaction gave the azide, which was reduced to the amine only just before coupling with 
amino acid fragment 67 (Scheme 21). 
 
 
 
                                                          
53
 Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2484. 
54
 Lal, B.; Pramanik, B.; Manha, M. S.; Bose, A. K. Tet. Lett. 1977, 1977. 
55
 Staudinger, H.; Meyer, J. Hel. Chem. Acta. 1919, 2, 635. 
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Scheme 21. Nicolaou’s use of Sharpless asymmetric dihydroxylation in the synthesis of Vancomycin. 
 
 
The same year Evans’ and Nicolaou’s syntheses of vancomycin were published, 
Sharpless reported the asymmetric aminohydroxylation of styrenes,
56
 giving the N-
carbamate protected arylglycinols (A), one oxidation step away from arylglycines, in 
high ee. The regioselectivity of this reaction proved troubling, with some of the undesired 
regioisomer (B) always observed (Scheme 22). Regardless of this minor drawback, 
Sharpless asymmetric aminohydroxylation became the method of choice for the 
asymmetric construction of arylglycine residues in subsequent syntheses of peptide 
antibiotics.
57
 
 
 
 
 
                                                          
56
 Reddy, K. L.; Sharpless, K. B. J. Am. Chem. Soc. 1998, 120, 1207. 
57
 Vancomycin: (a) Crowley, B. M.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 2885. Teicoplanin: (b) 
Evans, D. A.; Katz, J. L.; Peterson, G. S. J. Am. Chem. Soc. 2001, 123, 12411. Ristocetin: (c) Crowley, B. 
M.; Mori, Y.; McComas, C. C.; Tang, D.; Boger, D. L. J. Am. Chem. Soc. 2004, 126, 4310.(d) McComas, 
C. C.; Crowley, B. M.; Hwang, I.; Boger, D. L. Bioorg. Med. Chem. Lett. 2003, 13, 2933. Chloropeptin/ 
Complestatin: (e) Elder, A. M.; Rich, D. H. Org. Lett. 1999, 1, 1443. Feglymycin: (f) Dettner, F.; Hanchen, 
A.; Schols, D.; Toti, L.; Nuber, A.; Sussmuth, R. D. Angew. Chem. Int. Ed. 2009, 48, 1856. 
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Scheme 22. Sharpless asymmetric aminohydroxylation. 
 
 
For example, in Boger’s synthesis of vancomycin,58 a Sharpless asymmetric 
aminohydroxylation protocol is utilized in the construction of arylglycines 4 (67) and 7 
(68), in excellent enantioselectivity and good overall yields. Boger used this same 
procedure to make arylglycines 3 (69) and 1 (70), required in the synthesis of 
teicoplanin
59
 (Scheme 23). While the enantioselective step of these syntheses is slightly 
lower yielding, the advantage in this method is that fewer synthetic steps are then 
required to obtain the desired arylglycine derivative. 
 
                                                          
58
 Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Castle, S. L.; Loiseleur, O.; Jin, Q. J. Am. Chem. Soc. 
1999, 121, 10004. 
59
 (a) Boger, D. L.; Kim, S. H.; Miyazaki, S.; Strittmatter, H.; Weng, J. H.; Mori, Y.; Rogel, O.; Castle, S. 
L.; McAtee, J. J. J. Am. Chem. Soc. 2000, 122, 7416.(b) Boger, D. L.; Kim, S. H.; Mori, Y.; Weng, J. H.; 
Rogel, O.; Castle, S. L.; McAtee, J. J. J. Am. Chem. Soc. 2001, 123, 1862.(c) Boger, D. L.; Weng, J. H.; 
Miyazaki, S.; McAtee, J. J.; Castle, S. L.; Kim, S. H.; Mori, Y.; Rogel, O.; Strittmatter, H.; Jin, Q. J. Am. 
Chem. Soc. 2000, 122, 10047.(d) Boger, D. L. Med. Res. Rev. 2001, 21, 356.  
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Scheme 23. Boger’s application of Sharpless asymmetric aminohydroxylation. 
 
Recent Approaches 
Although asymmetric aminohydroxylation is still primarily used
60
 in the total 
syntheses of aryl glycine containing natural products, there have been a number of new 
methodologies reported in this area in recent years. In addition to chiral auxillary directed 
enolate azidations and aminations,
61
 aminohydroxylations,
62
 and asymmetric versions of 
                                                          
60
 With the exception of Pearson, who uses Evans’ chiral auxillary directed enolate azidation in his efforts 
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the Strecker reaction,
63
 a classic method of amino acid synthesis which involves the 
addition of cyanide to an imine, arylglycines can now be assembled through a variety of 
novel asymmetric methodologies.
64
 In 2004, Pagenkopf reported the asymmetric 
hydrogenation of aryl enamides (71), in the presence of a chiral rhodium catalyst, giving 
the corresponding arylglycinols (72) in excellent yield and ee (Scheme 24, eq 23).
65
 
Several years later, Zhang reported the asymmetric hydrogenation of imino esters (73), 
utilizing a similar rhodium catalyst, which led directly to arylglycines (74) in excellent 
conversion and good to excellent ee
66
 (eq 24). 
 
Scheme 24. Asymmetric hydrogenation of enamides and imino esters. 
 
 
Asymmetric imine additions can also be used to construct arylglycines. In 2006, 
Ellman reported
67
 the rhodium catalyzed addition of arylboronic acids (75) to chiral, non-
racemic sulfinyl imino esters (76), giving the N-sulfinyl arylglycines (77) in good yield 
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 (a) Strecker, A. Annalen der Chemie und Pharmazie 1850, 75, 27.(b) Banphavichit, V.; Mansawat, W.; 
Bhanthumnavin, W.; Vilaivan, T. Tetrahedron 2009, 65, 5849, and references therein. 
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and excellent d.r. (Scheme 25). An organocatalytic version of this reaction was reported 
several years later.
68
 
 
Scheme 25. Asymmetric addition of arylboronic acids to imino esters. 
 
One of the more recent developments in this field is the asymmetric N-H insertion 
reaction between α-diazo esters and carbamates.69 Reported by Fu in 2007, the 
enantioselective insertion of diazo 79 into the N-H bond of Boc carbamate (78), catalyzed 
by a chiral copper/bipyridine catalyst, gives direct acess to N-Boc protected arylglycines 
(80) in good yield and relatively high ee (Scheme 26). 
 
Scheme 26. Asymmetric N-H insertion reactions. 
 
 
Although these methods are highly innovative and offer advantages over 
traditional methods of arylglycine synthesis, namely in that they allow access to 
arylglycines in fewer steps and greater overall yield, they have largely not been applied in 
the total synthesis of arylglycine containing natural products. This may be due, in part, to 
the fact that access to enantioenriched arylglycines is only one of the challenges 
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 Dai, H.; Yang, M.; Lu, X. Adv. Synth. Catal. 2008, 350, 249 
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 Lee, E. C.; Fu, G. C. J. Am. Chem. Soc. 2007, 129, 12067. 
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associated with the synthesis of these peptides, the other being the coupling of these 
sensitive amino acids while avoiding epimerization. 
 
2.2 Enantioselective Synthesis of Arylglycine-Containing Peptides 
 
2.1.2 Enantioselective Synthesis of Chiral α-Bromo Nitroalkanes 
 In recent years the development of asymmetric Henry reactions,
70
 aza-Henry 
reactions
71
 and Michael additions to nitroalkenes
72
 has occurred at a very rapid pace, 
resulting in a diverse population of chiral, enantioenriched nitroalkanes.
73
 In the Johnston 
lab, much work has been done on the development of the enantioselective addition of 
nitroalkanes to aryl imines (Scheme 81), using chiral bis-amidine (BAM) proton catalysts 
(82).
74
 
 
Scheme 27. Chiral proton catalyzed aza-Henry addition of nitroalkanes to imines. 
 
 It order to use this chemistry to produce compounds which could then be coupled 
using umpolung amide synthesis, bromonitromethane could conceivably be added to N-
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 For recent reviews, see: a) Palomo, C.; Oiarbide, M.; Mielgo, A. Angew. Chem. Int. Ed. 2004, 43, 5442. 
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Boc-imines (83) to give the N-Boc α-bromo nitroalkanes (84). Therefore, we first tested 
the asymmetric addition of bromonitromethane to N-Boc aryl imine 83, using various 
chiral proton catalysts.
75
 While H,Quin-BAMHOTf (85HOTf) provided the adduct 84 
in only 83% ee (Table 5, entry 1), H,Quin(
6
(
9
Anth)
2
Pyr)-BAMHOTf (86HOTf, entry 2), 
as well as PBAMHOTf (87HOTf, entry 3) and the free base PBAM (87, entry 4), all 
gratifyingly afforded the adduct in high yield (87-98%) and excellent ee (94-99%), with 
PBAM giving the best results (94% yield, 99% ee). The isolated product from these 
reactions was a 1:1 mixture of diastereomers, all with conserved stereochemistry at the 
benzylic carbon. The lack of defined stereochemistry at the α-bromo nitro carbon is 
insignificant, as any stereochemistry at that carbon will be lost in the subsequent 
umpolung amide coupling step. 
 
Table 5. Catalyst screen for the addition of bromonitromethane to N-Boc imines. 
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 With Bo Shen. 
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 Following the success of adding bromonitromethane to the 
p
Cl-N-Boc imine, we 
next turned to applying these conditions to a variety of imine substrates. For this substrate 
screen, PBAMHOTf (87HOTf) and the free base PBAM (87), the two catalysts which 
had given us the best results previously, were used. In most cases the free base of PBAM 
gave slightly better yields and higher ee’s than its protonated form, though in some cases 
PBAMHOTf gave better results. As seen in Scheme 28, the results of this screen were 
very encouraging. Electron neutral (96), electron withdrawing (84, 90, 91, 92, and 93) 
and electron donating (94 and 95) imines all gave high yields (81-100%) and ee’s (81-
99%) of their corresponding α-bromo nitroalkane adducts. 
 
Scheme 28. Scope of bromonitromethane addition to N-Boc imines. 
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2.2.1 Coupling of Aryl α-Bromo Nitroalkanes 
 After synthesizing the α-bromo nitroalkanes (84, 90-96), the next step was to 
couple them, using our umpolung amide coupling conditions, to give aryl glycine-
containing peptides. It had previously been shown that 84 could be coupled to methyl 
benzylamine, in the presence of NIS, giving amide 98 in 76% yield and as a single 
diastereomer.17 This was encouraging in that, as hypothesized, no epimerization was 
observed at the α-carbon of the phenylglycine residue (Scheme 29). 
 
Scheme 29. Coupling of α-bromo nitroalkane 84 to α-methyl benzylamine. 
 
Therefore, we next wished to couple α-bromo nitroalkanes to more complicated 
amine substrates- specifically peptidic ones such as the AlaPheOMe dipeptide. As seen 
in Scheme 30, α-bromo nitroalkanes 84 and 90-96 were all coupled successfully, in 
moderate to good yields, to the AlaPheOMe dipeptide. Gratifyingly, epimerization was 
not observed in any of these cases. 
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Scheme 30. Coupling of α-bromo nitroalkanes to Ala-Phe dipeptide. 
 
 Having established that epimerization was not occurring when these aryl glycine 
surrogates were coupled, and that the umpolung amide coupling conditions were 
compatible with the AlaPheOMe dipeptide, we next wanted to ascertain whether or not 
the various functionalities of all 20 canonical amino acids were compatible with these 
reaction conditions. Therefore, α-bromo nitroalkane 84 was coupled to these amino acids. 
We were very excited to see that, with all 20 amino acids, moderate to good yields (41-
81%) of the desired dipeptides (108a-t) (Table 6, entries 1-20) were observed, all as 
single diastereomers. 
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Table 6. Coupling of α-bromo nitroalkane 84 to the 20 canonical amino acids. 
 
 Notably, serine (Table 6, entry 6) and threonine (Table 6, entry 7) were able to be 
successfully coupled without the need of an alcohol protecting group. However, tyrosine 
(Table 6, entry 9) did require protection of the free phenol; when unprotected, aryl 
iodination occurred to give the diiodotyrosine. Asparagine (Table 6, entry 11) and 
glutamine (Table 6, entry 13) also did not require protection. We were especially pleased 
to see that proline, the only disubstituted amino acid, was able to be coupled in 67% 
yield, and that the more complex amino acids, such as arginine (Table 6, entry 18), 
histidine (Table 6, entry 19) and tryptophan (Table 6, entry 20), produced amide product, 
though in slightly lower yields (41-44%). While these couplings have not been optimized, 
the preliminary results indicate that umpolung amide synthesis is compatible with the 20 
canonical amino acids. This is quite promising as this indicates the reaction could have 
broad applicability in peptide synthesis. 
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Scheme 31. Enantioselective peptide synthesis: Iterative α-bromo nitroalkane coupling. 
 
 
 With the success we had incorporating single phenylglycine residues into 
dipeptides or tripeptides, the next logical step was to attempt to couple the α-bromo 
nitroalkanes in an iterative fashion. To this end, the coupling of α-bromo nitroalkane 90 
to methyl amine hydrochloride, in the presence of NIS, and subsequent Boc-deprotection, 
afforded the N-methyl-
p
Br-phenylglycine 109 in 45% yield (two steps). This compound 
was then coupled to α-bromo nitroalkane 84, and the resulting dipeptide was Boc-
deprotected, to give 110 in 43% yield (two steps). A third iterative coupling was then 
done, giving the tripeptide 111 in 73% yield (Scheme 31). Notably, this compound was 
isolated as a single diastereomer, and at no point during these iterative couplings was any 
epimerization detected. Also exciting was the fact that this sequence of reactions 
44 
 
represents a completely enantioselective peptide synthesis, as only achiral starting 
materials (N-Boc imines and bromonitromethane) were utilized. 
 In conclusion, it was demonstrated that by using a tandem enantioselective aza-
Henry reaction/umpolung amide coupling, arylglycine containing peptides can be 
synthesized very easily and efficiently from inexpensive achiral starting materials. In 
addition, the umpolung amide coupling conditions have been proved to be mild enough to 
tolerate all functionalities found in the 20 canonical amino acids. Lastly, a completely 
enantioselective peptide synthesis of a tripeptide composed of three arylglycine residues 
was achieved through the iterative umpolung amide coupling of α-bromo nitroalkanes. 
  
45 
 
CHAPTER III 
 
ENANTIOSELECTIVE AZA-HENRY ADDITION TO SILYL IMINES: ACCESS TO 
MULTIPLE PROTECTING GROUPS 
 
3.1 Introduction and Background 
 While the tandem reaction sequence discussed in the previous chapter was able to 
provide us arylglycine containing peptides in two short steps from the Boc imine, the fact 
that only Boc-protected aryl glycine residues could be produced using this method was 
seen as a limitation. While the Boc-protecting group is used in peptide synthesis, it is not 
the most widely used and requires harshly acidic deprotection conditions.5 Therefore, we 
decided to pursue methods of incorporating other protecting groups into this chemistry. 
Through these efforts, a novel methodology has been developed which allows access to 
the most commonly used protecting groups in peptide synthesis. 
 
Figure 5. Concept behind aza-Henry additions to silyl imines. 
 
The concept behind the development of this reaction, seen in Figure 5, was to add 
bromonitromethane to an imine protected by a labile protecting group (112), which could 
then be replaced, in situ after aza-Henry addition, by a more stable protecting group. The 
main advantage in this would be that, because the enantioselective addition would always 
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occur to the same 
L
Pg-imine (112), the resulting ee of the variously protected α-bromo 
nitroalkanes (113) should be the same regardless of the protecting group introduced. 
 
Scheme 32: Enantioselective aza-Henry addition to silyl imines: Access to multiple protecting groups. 
 
 
This concept was realized by the addition of bromonitromethane to TMS-imines 
(114). The resulting TMS-amine (115), which was stable enough to not undergo retro 
aza-Henry in solution but not stable enough to be isolated, can then be acylated by a 
variety of acid chlorides or chloroformates, giving the enantioenriched α-bromo 
nitroalkanes (116). Using this method we are able to access the acetate (Ac), 
phenylacetate (PhAc), azidoacetate (N3Ac), benzoyl (Bz), pivaloyl (Piv), methoxy 
carbonyl (Moc), carbobenzyloxy (Cbz), fluorenylmethyloxy carbonyl (Fmoc), 
trichloroethyloxy carbonyl (Troc) and allyloxy carbonyl (Alloc) protected arylglycine 
amino acids surrogates (Scheme 32). 
 
3.1.1 The Enantioselective aza-Henry Reaction 
 The aza-Henry reaction, also known as the nitro-Mannich, involves the 
nucleophilic addition of nitroalkenes to imines.
76
 This addition usually requires the 
presence of an acid or a base, to either activate the amine or generate the nitronate. The 
nitroamine (117) generated in this reaction is useful in that it can be transformed into a 
                                                          
76
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variety of synthetically useful compounds such as vicinal diamines (120), α-amino 
carbonyl compounds (119) or protected secondary amines (118) (Scheme 33). 
 
Scheme 33. The aza-Henry reaction. 
 
 
 The first aza-Henry reaction was reported in 1950, by Hurd and Strong.
77
 They 
reported the condensation of nitromethane with N-benzylidene aniline, in refluxing 
ethanol, to afford N-(2-nitro-1-phenylethyl)aniline (121) in 65% yield (Scheme 34, eq 
25). Utility for the aza-Henry reaction was found in 1998 when Anderson and coworkers 
used this reaction in the synthesis of vicinal diamines (123).
78
 By reacting deprotonated 
nitroalkanes with PMB imines, they were able to produce β-nitro amines (122) in high 
yields and up to 10:1 dr. (Scheme 34, eq 26). 
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Scheme 34. Early examples of the aza-Henry reaction. 
 
 
The following year, the same group reported that this reaction could be catalyzed 
by Sc(OTf)3 with improved yields and diastereoselectivity.
79
 Soon after, Qian discovered 
Yb(O
i
Pr)3 could also catalyze the aza-Henry addition of nitromethane with 
sulfonylimines, giving the desired β-nitroamines in 81-100% yield.80 Since then, there 
has been much work done on the development of an enantioselective version of the aza-
Henry reaction. 
Metal Catalyzed Enantioselective aza-Henry Reactions 
 The first report of a catalytic enantioselective aza-Henry reaction was by 
Shibasaki in 1999.
81
 He used a heterobimetallic complex (124), formed by mixing Yb, K, 
and BINOL in a 1:1:3 ratio, to catalyze the addition of nitromethane to N-
phosphinoylimines. The resulting aza-Henry adducts (125) were obtained in up to 91% ee 
(Scheme 35, eq 27). By moving to an AlLi[(R)-binaphthoxide]2 catalyst (126), they were 
then able to extend the scope of this reaction to include substituted nitroalkanes, which 
                                                          
79
 Anderson, J. C.; Peace, S.; Pih, S. Synlett 2000, 42, 4673. 
80
 Qian, C. T.; Gao, F. F.; Chen, R. F. Tetrahedron Lett. 2001, 42, 4637. 
81
 Yamada, K; Harwood, S. J.; Groger, H.; Shibasaki, M. ANgew. Chem. Int. Ed. 1999, 38, 3504. 
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gave good diastereoselectivity (3:1 to 7:1, favoring the anti diastereomer 127) but slightly 
lower enantioselectivity (60-83% ee) (Scheme 35, eq 28).
82
 
 
Scheme 35. Shibasaki’s work on the first catalytic enantioselective aza-Henry reaction. 
 
 Shortly thereafter, Jørgensen reported the catalytic asymmetric aza-Henry 
addition of silyl nitronates to α-imino esters, in the presence of chiral copper(II)-
bisoxazoline complex 128, giving 129 in excellent enantio- and diastereoselectivity 
(Scheme 36, eq 29).
83
 Shortly after, the same group reported the direct aza-Henry 
addition of nitroalkanes, in which an external base was added, generating the nitronate in 
situ, and allowing them to obtain equally good results (Scheme 36, eq 30).
84
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
82
 a) Yamada, K.; Moll, G.; Shibasaki, M. Synlett 2001, 980. b) Shibasaki, M.; Kanai, M. Chem. Pharm. 
Bull. 2001, 49, 511. 
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Scheme 36. Jørgensen’s enantioselective aza-Henry addition of silyl nitronates and nitroalkanes to imines. 
 
 Since Shibasaki’s and Jørgensen’s pioneering work in this area, several other 
metal catalysts have been developed for the asymmetric aza-Henry reaction. Seen in 
Figure 6, these include the 
t
Bu-BOX-Cu(OTf)2 complex (131),
85
 an (-)-N-
methylephedrine-Zn(OTf)2 combination (132),
86
 a dinuclear zinc catalyst (133),
87
 and an 
N,N’-dioxide-Cu(OTf) complex (134).88 
 
Figure 6. Metal catalysts for the enantioselective aza-Henry reaction. 
 
Organocatalytic Enantioselective aza-Henry Reactions 
 Recently, much progress has also been made in the area of organocatalytic aza-
Henry additions. These reactions offer an advantage over metal catalyzed reactions in 
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Lupton, D. W. Org. Lett. 2007, 9, 2023. 
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that they are environmentally friendly; only a proton is needed to catalyze the reaction, 
and in most cases the catalysts can be recovered and recycled. In 2004, Takemoto 
demonstrated that, in the presence of their chiral thiourea catalyst (135), the addition of 
nitromethane to phosphinoylimines (136) gives the β-nitroamines (137) in up to 76% ee 
and 91% yield (Scheme 37).
89
 They proposed that the thiourea catalyst was acting in a 
bifunctional manner by first deprotonating the nitroalkane and subsequently activating 
the imine through hydrogen bonding. By using N-Boc aryl imines, Takemoto later 
extended this reaction to include a broader scope of imines and nitroalkanes with high 
enantio- and diastereoselectivity.
90
 
 
Scheme 37. Takemoto’s enantioselective, thiourea-catalyzed aza-Henry reaction. 
 
 Since then, various other chiral urea and thiourea catalysts have been reported to 
catalyze the enantio- and diastereoselective aza-Henry reaction, including those 
developed by Jacobsen (138),
91
 Schaus (139a),
92
 Ricci (139b),
93
 Ellman (140),
94
 Chang 
(141),
95
 Zhou (142),
96
 Chen (143),
97
 Wang (144),
98
 and Wulff (145)
99
 (Figure 7). 
 
                                                          
89
 Okino, T.; Nakamura, S.; Furukawa, T.; Takemoto, Y. Org. Lett. 2004, 6, 625. 
90
 Xu, X.; Furukawa, T.; Okino, T.; Miyabe, H.; Takemoto, Y. Chem. Eur. J. 2006, 12, 466. 
91
 Yoon, T. P.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2005, 12, 466. 
92
 Bode, C. M.; Ting, A,; Schaus, S. E. Tetrahedron 2006, 62, 11499. 
93
 Bernardi, L.; Fini, F.; Herrera, R. P.; Ricci, A.; Sgarzani, V. Tetrahedron 2006, 62, 375. 
94
 Robak, M. T.; Trincado, M.; Ellman, J. A. J. Am. Chem. Soc. 2007, 129, 15110. 
95
 Chang, Y. W.; Wang, J. J.; Dang, J. N.; Xue, Y. X. Synlett 2007, 2283. 
96
 Wang, C.; Zhou, Z.; Tang, C. Org. Lett. 2008, 10, 1707. 
97
 Han, B.; Liu, Q. –P.; Li, R.; Tian, X.; Xiong, X. –F.; Deng, J. –G.; Chen, Y. –C. Chem. Eur. J. 2008, 14, 
8094. 
98
 Wang, C. J.; Dong, X. Q.; Zhang, Z. H.; Xue, Z. Y.; Teng, H. L. J. Am. Chem. Soc. 2008, 130, 8606. 
99
 Rampalakos, C.; Wulff, W. D. Adv. Synth. Catal. 2008, 350, 1785. 
52 
 
Figure 7. Chiral urea and thiourea catalysts used in the enantioselective aza-Henry reaction. 
 
 Other developments in this area include the chiral phosphoric acid 146 catalyzed 
asymmetric addition of nitroalkanes to α-iminoesters to provide β-nitro-α-amino esters 
(147) (Scheme 38, eq 31),
100
 as well as the use of the more stable α-amido sulfones (149), 
which can eliminate to the imine in situ (Scheme 38, eq 32).
101
 
 
Scheme 38. Recent developments in the enantioselective aza-Henry reaction. 
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 In 2004, simultaneous with Takemoto’s report of the thiourea-catalyzed 
aza-Henry reaction, the Johnston group reported the development of a novel “chiral 
proton” catalyst. A protonated chiral bisamidine (H,Quin-BAMHOTf 85), it catalyzed 
the addition of nitroalkanes to N-Boc imines, giving the aza-Henry adducts (150) in high 
enantiomeric excess and d.r. (Scheme 39, eq 33).
74a
 It was found that the chiral proton 
was important in catalyzing this reaction, as the unprotonated catalyst resulted in a very 
slow addition rate. Further work in this area has extended the chiral proton catalyzed aza-
Henry addition to nitroacetic acid additions, using the unsymmetrical catalyst 86 (Scheme 
39, eq 34, 35).
74d,e
 These adducts (151) are useful in that they can further be transformed, 
through reduction or denitration, to give α,β-diamino acids (153) or β-amino acids (152), 
respectively. The addition of α-nitrophosphonate (154) to N-Boc imines, in high ee and 
d.r., could be affected by 85 (Scheme 39, eq 36);
74b
 however, the more reactive methoxy-
substituted unsymmetrical BAM catalyst 156 was needed for the addition of α-
nitroacetate, to generate the quaternary center of the resulting adduct (155) in excellent ee 
and dr.
74c
 In general, it has been found that increasing the Brønsted basicity of these 
BAM catalysts, through quinoline substitution, increases their reactivity in an orthogonal 
manner; this can be seen in the enhanced reactivity of 
4
Pyrrolidine-Quin-BAMHOTf 
(PBAM, 87).
74e 
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Scheme 39. Johnston’s chiral proton catalyzed aza-Henry reaction. 
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3.1.2 Reactivity of N-Silyl Imines 
 
Figure 8. N-Silyl imines as stabilized ammonia imine surrogates. 
 
 Easily prepared from amines and aldehydes or ketones, imines are a highly useful 
synthetic tool which have been widely used to introduce amines into compounds, often 
with concomitant carbon-carbon bond formation.
102
 With many imines, the N-substituent 
is simply acting as a protecting group, stabilizing the imine and activating it towards 
nucleophilic addition. This group is then removed to reveal the unprotected amine. N-
silyl imines (157) have been used to circumvent this additional deprotection step; during 
work-up, the N-silyl bond is easily hydrolyzed.
103
 Therefore, these imines can essentially 
be thought of as stabilized, protected ammonia imine surrogates (Figure 8). They are 
unique in that the nitrogen of the imine is fairly nucleophilic.
104
 Therefore, N-silyl amines 
can react as an electrophile or a nucleophile, and occasionally as both (Figure 7). 
 
Figure 9. Nucleophilic and electrophilic character of silyl imines. 
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 N-Silyl amines can be synthesized in a variety of ways. The most common 
method is through the reaction of metal silazanes and aldehydes (158). Silyl transfer, 
from the silazane to the resulting alkoxide, results in loss of the silanolate and imine 
formation (Scheme 40, eq 38). A similar alkoxide intermediate (159) can be reached via 
nucleophilic addition to N,N-disilyl formamides (160) (Scheme 40, eq 39). Other 
methods include oxidation of N-silyl protected amines (162) to afford the N-haloamine 
(163), which is subsequently eliminated in the presence of DBU (Scheme 40, eq 40). 
Lastly, reduction of nitriles (164) with an aluminum hydride source results in the N-
metalloimine (165). Transmetalation of this compound then gives the desired N-silyl 
imine (Scheme 40, eq 41).
103
 
 
Scheme 40. Synthesis of N-silyl imines. 
 
 Selected examples of the nucleophilic reactivity of N-silyl amines can be seen in 
Scheme 41. N-silyl imines readily react with acid and sulfonyl chlorides; therefore, they 
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are often used as precursors to N-acyl (165)
105
 or N-sulfonyl imines (166) (Scheme 41, eq 
42,43).
106
 Acylation of N-silyl imines with enolizable acid chlorides and subsequent 
treatment with base has been used in the synthesis of azadienes (167), which are used in 
the synthesis of nitrogen-containing heterocycles such as (168) (Scheme 41, eq 44).
107,108
 
A second method of synthesizing azadienes from N-silyl imines is to react them with 
isocyanates. In addition to [4+2] cyclizations,
109
 these dienes can undergo [2+2] 
cycloadditions
110
 to give the β-lactam (169) (Scheme 41, eq 45). There have also been 
several examples of N-silyl imines used as dieneophiles in Diels-Alder cycloadditions.
111
 
 
Scheme 41. Silyl imines as nucleophiles. 
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 A second method of β-lactam synthesis using N-silyl imines involves the 
nucleophilic addition of an ester enolate (170) to the electrophilic imine carbon. 
Subsequent acyl substitution gives the desired β-lactam (171) (Scheme 42, eq 46).112 In 
many instances the diastereoselectivity, or in some cases the enantioselectivity, of this 
condensative cyclization can be controlled to a high degree.
113
 Amines (172)
114
 and 
aminols (173)
115
 can also be synthesized from N-silyl imines through the nucleophilic 
addition of aryl and alkyl lithium or Grignard reagents, in varying degrees of enantio- or 
diastereoselectivity (Scheme 42, eq 47,48). Diamine (174) synthesis, through the 
dimerization of N-silyl imines in the presence of NbCl4(THF)2, can also be achieved 
(Scheme 42, eq 49).
116
 
 
Scheme 42. Silyl imines as electrophiles. 
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 The enantioselective allylboration of N-silyl imines was reported by Itsuno, in 
1997 to give homoallylamines (175) in good enantioselectivity (Scheme 43, eq 50).
117
 
However, several years later Brown, trying to repeat Itsuno’s work, discovered that the 
allylation actually occurred during reaction work-up.
118
 He later proved that upon 
hydrolysis or methanolysis, the N-silyl imine was deprotected to give the N-unsubstituted 
organoborane adduct (176).
119
 It was through this intermediate, which could be isolated 
and was stable at room temperature, that the allylation occurred. 
 
Scheme 43. Enantioselective allylboration using silyl imines. 
 
 Recent uses of N-silyl amines include their palladium coupling to aryl bromides to 
afford the N-aryl imines (177) (Scheme 44, eq 51).
120
 They have also been used in the 
multicomponent synthesis of propargyl amides (178) (Scheme 44, eq 52).
121
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Scheme 44. Recent applications of silyl imines. 
 
 
3.2 Enantioselective aza-Henry Addition to N-Silyl Imines 
 As mentioned previously, work in this area began with the hope of incorporating 
an N-protecting group into the enantioselective aza-Henry reaction which was more 
widely used in peptide synthesis. Therefore, our initial aims were to simply make the N-
fluorenylmethyloxy carbonyl (Fmoc) protected imine, and optimize the asymmetric 
addition of bromonitromethane to this compound. It was anticipated that incorporating 
different protecting groups into this chemistry would be a formidable challenge as the N-
substituent plays a significant role in the reactivity and enantioselectivity seen in the aza-
Henry reaction. 
 
3.2.1 Reaction Discovery and Development 
Importance of the Imine Protecting Group 
 There are several requirements a substituent must fulfill in order to be a 
successful N-protecting group in the asymmetric aza-Henry reaction. It must be able to 
activate the imine towards nucleophilic addition as well as stabilize the resulting adduct. 
It is for this reason that electron withdrawing functionalities, such as the Boc group, work 
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so well in this reaction. It has been seen that Boc imines react much faster than alkyl 
imines and due to the resonance stability they offer to the resulting adduct, the retro aza-
Henry is rarely seen. The N-protecting group will also affect how the imine sits in the 
chiral pocket of the catalyst (Figure 10).
122
 Therefore, the enantioselective addition of 
bromonitromethane would have to be optimized for each different protecting group used. 
 
Figure 10. Importance of N-protecting group in the aza-Henry reaction. 
 
 It is for these reasons that use of a silyl N-protecting group was not initially 
considered; it was assumed that they would offer little by means of activation or 
stabilization as the N-Si bond is rather weak and not highly polarized.
123
 Therefore, 
attention was instead turned to N-Fmoc-protected imines. This protecting group would 
offer the same advantages of a Boc protecting group, but is widely used in peptide 
synthesis.  
Synthesis and Coupling of N-Fmoc-α-Bromo Nitroalkane 
 In order to incorporate the Fmoc-protecting group into the aza-Henry reaction the 
N-Fmoc-imine must first be synthesized, a task that proved to be more difficult than 
expected. Attempts were made to synthesize the Fmoc-protected sulfone (178), as 
                                                          
122
 Yoder, R. A.; Nugent, B. M.; Singh, A.; Smith, T. A.; Johnston, J. N. unpublished results. 
123
 Jensen, J. H.; Carroll, M. T.; Gordon, M. S. Organometallics 1991, 10, 2657. 
62 
 
subsequent treatment of this compound with base would result in elimination to the 
Fmoc-imine (179) (Scheme 45). While this transformation occurs quite readily when the 
Boc protecting group is employed, the Fmoc-sulfone was never able to be synthesized as 
the reaction returned only starting materials. 
 
Scheme 45. Attempts to synthesize the Fmoc-protected sulfone. 
 
 After trying a variety of conditions to synthesize the Fmoc-sulfone with no 
success, we turned to a procedure reported by Vidal and Collet
124
 in which they acylate 
the TMS-imine with FmocCl, forming the Fmoc-imine in high yield (Scheme 46). 
Therefore, TMS-imine 181 was synthesized in good yield from the corresponding 
aldehyde, and treated it with FmocCl. Though our substrate (181) was very similar to the 
one reported in the literature, in our hands this reaction did not go cleanly to Fmoc-imine 
(180) under a variety of conditions. It seemed as though the TMS-imine was 
decomposing as a 1:1 mixture of product to unreacted FmocCl was always seen, 
accompanied by other unidentifiable side products (Scheme 46). 
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Scheme 46. Synthesis of the Fmoc-imine from the TMS-imine. 
 
 Unfortunately, the Fmoc-imine (180) which had formed was not able to be 
purified, as it was extremely moisture sensitive. Therefore, this imine was taken on as a 
crude mixture and subjected it to asymmetric aza-Henry reaction conditions (Scheme 47, 
eq 53). Gratifyingly, we were able to obtain the Fmoc-α-bromo nitroalkane adduct (182), 
though in low yield (28%), as a mixture of diastereomers each with high ee (84, 83%). 
This adduct was then coupled with methyl benzyl amine under umpolung amide synthesis 
(UmAS) conditions (Scheme 47, eq 54). There was some concern about the compatibility 
of the Fmoc protecting group with the slightly basic UmAS conditions, as this protecting 
group is deprotected under basic conditions. However, these were soon laid to rest- the 
dipeptide 183 was obtained in 66% yield, with no detectable deprotection. 
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Scheme 47. Synthesis and coupling of N-Fmoc-α-Bromo Nitroalkane 182. 
 
 A second concern was that the Fmoc-adduct could possibly be deprotected by the 
basic chiral proton catalyst (PBAM, 87, Scheme 47) used to affect the transformation. 
However, stirring both 182 and 183b with a full equivalent of catalyst 87 at room 
temperature resulted in no detectable deprotection over the time period of the aza-Henry 
reaction (1 day). 
Discovery and Optimization of aza-Henry Addition to N-TMS Imines 
 While it was exciting that the Fmoc-α-bromo nitroalkane adduct (182) could be 
synthesized in good enantiomeric excess and successfully coupled under UmAS 
conditions, other routes to the Fmoc-imine (180) were explored in the hopes of increasing 
the overall yield of the Fmoc-adduct. Since TMS-imine (181) was on hand, a 
transamination between this compound and Fmoc-NH2 was attempted. Unfortunately, 
only starting materials were observed in this reaction, even after stirring at room 
temperature for several days (Scheme 48). 
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Scheme 48. Attempt at trans-imination. 
 
 
 It was thought the Fmoc-imine could possibly be forming in this reaction, but 
only in trace amounts. The transimination reaction would be a reversible one and if the 
equilibrium were to lie on the side of the TMS-imine, Fmoc-imine production might not 
be detectable. To see if this was the case, PBAM (87) and bromonitromethane were 
added to this reaction. The hypothesis was that while bromonitromethane could add to 
either imine (181 or 180), it would be more likely to add to the Fmoc-imine (180). 
Additionally, while addition to the Fmoc-imine would be reversible, it was hypothesized 
that equilibrium would lie towards the addition product. In the addition to the TMS-imine 
(181), however, it was unclear whether the reaction equilibrium would favor the reactants 
or the product. Therefore, if any of 180 was being formed, the equilibrium should be 
driven by the addition to this compound, giving the Fmoc-adduct (182) (Scheme 48). 
 What was observed in this reaction was unexpected. The TMS-imine (181) was 
completely consumed, however none of the Fmoc-adduct (182) was observed. Instead, it 
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appeared that the bromonitromethane had added to the TMS-imine, giving the TMS-
adduct 184 (Scheme 49, eq 56). This was confirmed when the product was treated with 
FmocCl and production of the Fmoc-α-bromo nitroalkane adduct (182) was seen 
(Scheme 49, eq 57). Surprisingly, the enantiomeric excess of this adduct was found to be 
11% for each diastereomer. While low, this indicated that the aza-Henry addition to the 
TMS-imine had the potential to be an asymmetric one. 
 
Scheme 49. Attempts to trap Fmoc-imine: First observation of aza-Henry addition to TMS-imine. 
 
 
 The utility of this transformation, if it was able to be optimized, was immediately 
clear. Any number of different acylating reagents could be used to trap the resulting 
TMS-amine adduct, allowing us access to a multitude of protected α-bromo nitroalkane 
donors. It was for this reason optimization of the aza-Henry addition of 
bromonitromethane to TMS-imines was pursued. 
 It was immediately apparent that the TMS-amine adduct could not be isolated. 
While it can be observed by 
1
H and 
13
C NMR and seems to be stable when dilute, 
concentration of this intermediate leads to rapid formation of imine 186. It is thought that 
this occurs when some of the adduct 184 undergoes a retro aza-Henry reaction, to give 
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back either the TMS-imine or the unprotected imine (185). A transimination between 181 
or 185 and remaining TMS-adduct 184 then results in the production of 186 (Scheme 50). 
 
Scheme 50. Undesired transimination. 
 
 It was therefore realized the TMS-amine adduct (184) needed to be trapped by 
FmocCl in situ, before solvent removal. A one pot reaction in which the TMS-imine 
(181), PBAM catalyst (87, Scheme 47) and bromonitromethane were stirred at -78 °C in 
toluene for 24 hrs before addition of FmocCl was attempted (Scheme 51, eq. 58). It was 
exciting to see that this resulted in an increased yield (60%) and enantiomeric excess (76, 
77% for each diastereomer) of the Fmoc-α-bromo nitroalkane adduct (182).  
However, it was found that the FmocCl was not reactive towards the TMS-amine 
at low temperatures; the reaction had to be warmed to room temperature for acylation to 
occur. If the aza-Henry addition to the TMS-imine was not complete before warming the 
reaction, a portion of the addition could be occurring at a higher temperature which 
would result in lower enantioselectivity. Therefore, an acylating reagent was required 
which would be reactive enough to acylate the TMS-amine adduct at -78 °C. It was found 
that acetyl bromide could be used for this purpose. By keeping the reaction at -78 °C and 
quenching with water before warming to room temperature, an accurate picture of the 
reactivity and enantioselectivity of this reaction could be obtained. It was found that the 
addition to imine 181 was complete in 20 hours, as the Ac-α-bromo nitroalkane adduct 
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(187) was isolated in 58% yield and 74, 76% enantiomeric excess, which was comparable 
to that of the Fmoc-α-bromo nitroalkane adduct (182) (Scheme 51, eq 59). 
 
Scheme 51. Initial optimization. 
 
 A comprehensive catalyst screen was then undertaken in order to ascertain 
whether another catalyst might give the desired adduct in higher enantiomeric excess. 
Initially, the triflic acid salts of PBAM (87) were examined. While in other aza-Henry 
reactions to Boc-imines it had been observed that the protonated catalysts were more 
active and gave higher enantioselection than the unprotonated catalysts, the opposite was 
true in this chemistry. The 1:1 PBAMHOTf salt (87HOTf) gave significantly lower 
conversion and enantiomeric excess (Table 7, entry 2) than the free base (87, Table 7, 
entry 1). Interestingly, the 2:3 salt (872(HOTf)3), Table 7, entry 3) performed even worse, 
giving results very similar to those of the unactivated H, Quin-BAM (85, Table 7, entry 
4). This suggested that the increased Brønsted basicity of PBAM was vital to this 
reaction. Therefore, other PBAM derivatives (188-191, 193-198, Table 7, entries 5-8, 11-
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16) were utilized,
125
 though none gave higher enantioselection than PBAM. Several 
thiourea catalysts (135,192)
89,126
 were also used, with poor results (Table 7, entries 9-10). 
 
Table 7. Catalyst screen. 
 
 With no catalyst able to out-perform PBAM, we next turned to a solvent screen 
(Table 8). A number of solvents were tested, and while no solvent performed better than 
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toluene, Et2O and methyl 
t
butylether (MTBE) (entries 3 and 4, respectively) gave 
comparable levels of enantioselection (Table 8, entry 1), but low isolated yields, of the 
adduct 187. It should be noted that at this time a small jump in enantiomeric excess was 
observed under standard reaction conditions (from 74, 76% to 84, 82%). This is attributed 
to the handling of the TMS-imine. While silyl imines are stable at low temperatures, they 
are very moisture and temperature sensitive. By taking the imine into the glovebox (an 
inert Ar atmosphere), it could be stored and measured out under cool, anhydrous 
conditions which resulted in less decomposition and/or hydrolysis. Fortunately, this 
increase in purity of the imine seems to translate into increased enantioselectivity (Table 
8, entry 1).  
 
Table 8. Solvent screen. 
 
 
 Since no catalysts or solvents surveyed resulted in an increase in 
enantioselectivity, we next decided to look at the effect catalyst loading (of PBAM, 87) 
had on the enantioselectivity of the addition. It was realized that due to their increased 
basicity (relative to Boc-amines and imines), the TMS-amine (184) or imine (181) could 
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be competing with PBAM to catalyze the aza-Henry reaction. Therefore, by increasing 
the catalyst loading, PBAM should become a more effective catalyst. As seen in Table 9, 
this was proved to be the case. By increasing the loading of PBAM to 20 mol% (entry 4), 
the ee of the desired adduct rose to 87, 88% (for both diastereomers). Additionally, it was 
seen that when no catalyst was used (Table 9, entry 1), some product was observed, 
though in very low amounts. This suggests that even at very low temperatures, there is a 
small background reaction in which PBAM is not necessary. 
 
Table 9. Catalyst loading. 
 
 Knowing that the TMS-amine (184) could be competitively catalyzing this 
reaction, we wished to determine if the enantioselectivity of this addition was greater 
towards the beginning of the reaction when the concentration of TMS-amine would be 
lowest. Therefore, 0.3 equivalents of bromonitromethane were added to imine 181 
(Scheme 52, eq 60). After several hours, the bromonitromethane was consumed, with 
30% conversion of 181. The enantiomeric excess of this reaction was determined to be 
89, 88% (for each diastereomer). Initially, this result suggested that our hypothesis was 
correct. However, when an excess of bromonitromethane was used (Scheme 52, eq 61) 
the result was a dramatic decrease in enantiomeric excess. Interestingly, these results 
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seemed to mirror the results obtained with the protonated PBAM catalysts (Table 7, 
entries 2 and 3). It was thought that perhaps the excess bromonitromethane was acting as 
an acid, protonating PBAM and decreasing its reactivity. To test this, a reaction was done 
in which bromonitromethane was kept at low concentration by adding it in aliquots over 
8 hours. Gratifyingly, this slow addition resulted in increased enantioselection (93, 91%, 
both diastereomers) of the adduct 187 (Scheme 52, eq 62). 
 
Scheme 52. Examining bromonitromethane concentration. 
 
 Satisfied with the enantioselectivity of this reaction, we next looked into 
optimizing the conditions of the acylation step. Up to this point, acetyl bromide had been 
used to acylate the TMS-amine at -78 °C. However, it was known that most acid 
chlorides or chloroformates would not react at such low temperatures. Therefore the 
acylation of TMS-amine 184 with acetyl chloride was tested at incremental temperatures. 
It was found that by raising the temperature of the acylation step to 0 °C, an optimal yield 
of 83% could be achieved (Table 10, entry 4). 
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Table 10. Optimization of acylation conditions. 
 
 
3.2.2 Reaction Scope 
With the optimal conditions of both the asymmetric aza-Henry addition and 
subsequent acylation in place, the next step was to extend the scope of this reaction in 
regard to both the acylating reagents and TMS-imines used. 
Protecting Group Scope 
 As seen in Table 11, a variety of different acid chlorides (entries 1-6) and 
chloroformates (entries 7-11) were used to trap the TMS-amine (184) in good yields (67-
85%) and high to excellent ee (90-97%). Excitingly, using this procedure gives access to 
the acetate (Ac, 197), phenylacetate (PhAc, 199a), azidoacetate (N3Ac, 199b), benzoyl 
(Bz, 199c), pivaloyl (Piv, 199d), methoxy carbonyl (Moc, 199e), carbobenzyloxy (Cbz, 
199f), fluorenylmethyloxy carbonyl (Fmoc, 182), trichloroethyloxy carbonyl (Troc, 
199g) and allyloxy carbonyl (Alloc, 199h) protecting groups. The use of benzyl 
isocyanate (Table 11, entry 12) and Boc anhydride (Table 11, entry 13) as trapping 
reagents gave the urea and Boc-protected adducts (199i,j), respectively, in good 
enantiomeric excess but poor yields. It seems that these substrates do not trap the TMS-
amine substrate fast enough, as large amounts of the transimination side product 186, 
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which results from the TMS-deprotection and retro aza-Henry reaction of 184, were 
observed. 
 
Table 11. Protecting group scope. 
 
 Particularly exciting was the fact that the N-N3Ac-α-bromo nitroalkane (199a) 
was able to be synthesized in good yield (82%) and high enantiomeric excess (91,91%, 
each diastereomer) (Table 11, entry 2), as this compound could have applications in click 
chemistry,
127
 or Staudinger ligation.
9
  
                                                          
127
 Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2001, 40, 2004. 
75 
 
Imine Scope 
 The scope of the reaction as a function of the imine was next investigated. Initial 
results were very promising, as a variety of electron poor aryl imines worked well in this 
chemistry (Table 12, entries 1-7), giving the corresponding Fmoc-adducts (182, 201a-1) 
in good yields (64-83%) and high enantiomeric excess (76-91%). Also notable was the 
fact that meta- and ortho-substituted aromatic imines were well tolerated, with no loss in 
enantioselectivity (Table 12, entries 2-3) 
 
Table 12. Imine scope. 
 
However, when electronically neutral and electron rich imines were examined, a 
drop in enantioselection was observed. The electronically neutral phenyl imine (200g) 
and the electron rich 4-methoxy aryl imine (200j) gave the lowest levels of 
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enantioselection (65, 66% and 62, 62%, Table 12, entries 8 and 11). Curiously, the 
enantioselection seemed to increase with bulkier electron neutral and electron rich 
imines, allowing for the synthesis of the 2-naphthalene (201i) and 3,5-dibenzyloxy (201l) 
α-bromo nitroalkanes in enantiomeric excesses comparable to those seen with electron 
poor substrates (83, 84% and 79, 82%, Table 12, entries 10 and 13). However, we were 
pleased to see the use of (S,S)-PBAM allowed us access to the S-enantiomer of the α-
bromo nitroalkanes (Table 12, entry 12), and that this chemistry was amenable to scale-
up (Table 12, entry 13). 
 
Electron Rich Imines: Mechanistic Studies 
 In order to understand why lower levels of enantioselection were observed with 
electron rich substrates, we investigated these reactions further. It was hypothesized that 
the aza-Henry addition to electron neutral and electron poor imines might be slower, 
since the imines should be less reactive electrophiles. If this were the case, the reactions 
would not have reached full conversion before warming to room temperature. Therefore, 
the acetyl protected products of the 
p
MeO and 
p
BnO aryl aldimines (202j, k) were 
synthesized by quenching the reactions at -78 °C (Table 13, entries 1 and 2). While 
neither reaction had reached 100% completion, the conversions were higher than 
expected (93 and 80%, respectively). Disappointingly, the enantioselection observed in 
these reactions was only slightly higher in the case of the 
p
MeO substrate (202j, 70, 
69%), and lower in the case of the 
p
BnO substrate (202k, 61, 67%). 
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Table 13. Imine scope: electron rich imines quenched at -78 °C. 
 
 While it appeared that the lower enantioselection was not a result of warming the 
reaction too soon, it was clear that these reactions were slightly slower. This is especially 
true in the case of the 
p
BnO imine (200k)- after 10 h, the timeframe over which 
bromonitromethane is added, the addition to this imine had only reached 66% conversion 
(Scheme 53, eq 63). It was therefore thought that perhaps the aliquot addition of 
bromonitromethane was being done over too short of a time period. If the added 0.2 
equivalents of this reagent was not given sufficient time to react before the next addition, 
the concentration of bromonitromethane would gradually build, leading to decreased 
enantioselectivity. Therefore, a reaction was done in which bromonitromethane was 
added in aliquots over 32 hours to imine 200k (Scheme 53, eq 65). While the yield of 
adduct 202k was slightly improved, the enantiomeric excess remained relatively 
unchanged from the 8 hour addition reaction (Scheme 53, eq 64). 
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Scheme 53. Further work with 
p
BnO-imine. 
 
 It was therefore clear that something other than the low reactivity of these 
substrates was contributing to the decrease in enantioselection. At this point, it was 
realized that the rate of the uncatalyzed background reaction in the addition to electron 
rich imines had not yet been examined. It was known that the addition of 
bromonitromethane to both electron rich and electron poor TMS-imines occurs quite 
readily at room temperature, without the need for an added base. However, with electron 
poor imines this background reaction was almost negligible at -78 °C (Table 9, entry 1). 
Because electron rich imines seemed to be less reactive, it was assumed that the 
background reaction would be comparable to, if not slower than, what was seen in 
electron deficient imines. However, a surprising result was observed in the reaction of 
p
MeO TMS-imine 200j with bromonitromethane at -78 °C, in the absence of PBAM. A 
significant amount of the 
p
MeO Ac-adduct 202j was seen (23% conversion at 20 hours, 
Scheme 54, eq 66). 
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Scheme 54. Measurement of the non-catalyzed reaction rate by conversion using an electron rich imine. 
 
 
 The aza-Henry reaction involves the addition of nitronate to an activated imine 
203. In order to form these two reactive intermediates, PBAM deprotonates 
bromonitromethane at a rate assigned here as k1 (Figure 11). This complex can activate 
the imine through hydrogen bonding (Lewis acid- Lewis base complexation). The three 
dimensional nature of this catalyst-substrate complex is the source of stereocontrol in the 
addition step. In the case of Boc-imines (205), this addition is presumably fast. However, 
the silyl imines (203) are more basic at the nitrogen of the imine, and the addition product 
204 is more basic as well. These two (203, 204) may be able to compete with PBAM in 
the deprotonation of bromonitromethane, at a rate assigned as k2. This competing 
deprotonation reaction, the rate of which would be higher in electron rich imines (207), 
would result in activation of the imine by either bromonitromethane or the protonated 
amine intermediate (204H+), leading to nonselective addition. 
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Figure 11. Mechanistic hypothesis of observed reactivity and enantioselection. 
 
In order to determine if the protonated product (204H+) was catalyzing the 
addition reaction, a competition reaction was performed between the 
p
Cl and 
p
MeO aryl 
imines. By adding a single equivalent of bromonitromethane to 1 equivalent of the 
p
Cl 
imine 181 and 1 equivalent of the 
p
MeO imine 200j, we sought several relative rates. By 
observing the relative amounts of the products formed (187, 202j), it would be possible to 
directly compare the differences in reactivity between the two imines. Additionally, by 
observing the enantiomeric excess of each product, insight could be gained into the 
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mechanism leading to low levels of enantioselection with electron rich imines. If the 
product of the aza-Henry addition with these imines (204H+, or 202j in this example) 
was indeed catalyzing the reaction, a similar decrease in the enantiomeric excess of the 
p
Cl addition product (187) should be observed.  
 
Scheme 55. Competition reaction between 
p
Cl imine 181 and 
p
MeO imine 200j. 
 
 
After subjecting 181 and 200j to standard addition conditions for 3 hours, they 
were quenched with acetyl bromide.
1
H NMR analysis of the crude reaction mixture 
indicated that the addition had gone to 50% completion, with a 1.3:1 ratio of the products 
187 and 202j. This indicated that the reactivities of these two imines were very similar, 
with the 
p
Cl imine reacting slightly faster. When these products were isolated, and the 
enantiomeric excess determined for each compound, it was surprising to see that the 
levels of enantioselection observed were essentially the same as what we had seen in 
previous reactions. The two diastereomers of the 
pCl α-bromo nitroalkane 187 were 
formed in 92 and 94% ee, respectively, and the two diastereomers of the 
pOMe α-bromo 
nitroalkane 202j were formed in 67 and 72% ee, respectively (Scheme 55). Therefore, the 
product 202j is not catalyzing non-selective aza-Henry addition. It is also not the case 
that the low levels of enantioselectivity observed with electron rich imines are due to a 
large difference in reactivity. Instead, it seems that it is the increased basicity of the imine 
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nitrogen that is problematic. Based on these results, we hypothesize that the competing 
pathway in which bromonitromethane is deprotonated by the imine, activating it towards 
non-selective addition, is leading to lower levels of enantioselectivity.  
This reaction mechanism is also able to explain some of the trends seen with 
addition to TMS-imines. PBAM, the most Brønsted basic of the BAM catalysts, was the 
only catalyst which was able to give high levels of enantioselectivity, most likely because 
it was able to deprotonate bromonitromethane at a much faster rate (increased k1). 
Protonation of this catalyst resulted in low levels of enantioselection, as it decreased the 
basicity of the catalyst (decreased k1). High concentrations of bromonitromethane also 
resulted in decreased enantioselectivity. This could be due to the fact that when the 
concentration of this substrate was higher than that of PBAM, more was deprotonated 
through the undesired pathway (k2), as catalyst turnover (k3, nitronate addition and 
regeneration of the PBAM free base) would likely be slow. 
 In order to overcome this background reaction, several options were considered. 
The first was to decrease the temperature of the reaction, thereby increasing the rate 
difference between k1 and k2, in favor of the enantioselective k1 pathway. However, this 
reaction was already done at -78 °C, and performing a reaction at even lower 
temperatures over the timespan needed for addition was unpractical. The second option 
was to try to eliminate k1 and k2 altogether. We wished to do this by using the silyl-
nitronate 208 in place of bromonitromethane (Scheme 56). Eliminating k1 and k2 would 
hopefully give us a true picture of the addition step (k3) for electron rich TMS-imines. 
With this reaction setup, the protonated catalyst PBAMHOTf would have to be used to 
activate the imine, hopefully in an exclusive manner. 
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Scheme 56. Using silyl nitronates to eliminate k1 and k2. 
 
 
 In order to do this, nitronate 208 must first be synthesized. Our first attempt 
involved treating bromonitromethane first with TMSCl and then triethylamine, in 
benzene. After concentrating the crude reaction mixture, 
1
H NMR analysis showed only 
starting material (Scheme 57, eq 67). It was thought that perhaps the product was 
forming, but was reverting to starting material upon concentration. Therefore, the same 
reaction was performed in which an aliquot was taken from the reaction and observed by 
1
H NMR prior to concentration. We were pleased to see that the desired product 208 was 
present and that the reaction had reached 78% conversion after 5 minutes. Unfortunately, 
after letting the reaction stir for an additional 40 minutes, we observed a slight decrease 
in conversion (Scheme 57, eq 68). 
 
Scheme 57. Attempts to make silyl nitronate 208. 
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Several other reaction conditions were tried, none of which resulted in full 
conversion. Since concentration and purification of 208 was not possible, we attempted to 
synthesize a more stable silyl nitronate. After treating bromonitromethane with 
TBDMSCl and then triethylamine, nitronate 209 was observed as the major product, even 
after concentration (Scheme 58). Also present, however, was the TBDMS-protected 
nitroalkane 210, as well as remaining starting material. Since this nitronate appeared to 
be more stable, an attempt was made to purify it by distillation. Unfortunately, the 
desired product distilled concomitantly with bromonitromethane, as well as TBDMSCl. 
 
Scheme 58. Attempts to make silyl nitronate 209. 
 
Because nitronates 208 and 209 were not able to be synthesized in pure form, we 
weren’t able to use them in the subsequent aza-Henry addition. In both cases, the main 
contaminant was bromonitromethane, which would react with imine and not allow 
accurate results to be obtained for the addition of the nitronate. Therefore, we next turned 
to other methods to attempt to slow the background reaction. The first was to use 
nitromethane in place of bromonitromethane. Because nitromethane is less acidic than 
bromonitromethane, it was thought that perhaps the nitrogen of the imine would not be 
sufficiently basic to deprotonate this reagent, thus eliminating the background reaction. 
Imine 200j was treated with nitromethane under standard reaction conditions at -78 °C, 
but no conversion was observed after 16 hours (Table 14, entry 1). Therefore, the 
reaction was run at warmer temperatures. At -20 °C, only trace amounts of product were 
observed (Table 14, entry 2). At 0 °C and room temperature, the desired product 211 
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could be isolated, but in low yield (16% and 20%, respectively) as well as low 
enantiomeric excess (20% and 19%, respectively).  
 
Table 14. Addition of nitromethane to 
p
MeO imine 200j. 
 
Though the addition of nitromethane was slow at -20 °C, we wished to determine 
the enantioselection at that temperature. Therefore, a reaction was run in which the 
reactants were stirred at -20 °C for 5 days. Curiously, the results were very similar to 
those at higher temperatures, with a 22% yield and 19% enantiomeric excess (Scheme 59, 
eq 69).  
 
Scheme 59. Addition of nitromethane to 
p
MeO imine 200j. 
 
 The final attempt to overcome the background reaction was to try and add 
bromonitromethane to the reaction in even smaller aliquots. Because it seemed that the 
background reaction occurred to a greater extent when the concentration of 
bromonitromethane was higher, it was thought that if the concentration of this reagent 
was kept even lower in these reactions it may result in an increase in enantioselectivity. 
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 When we added 0.1 equivalents of bromonitromethane every hour, as opposed to 
0.2 equivalents, we saw a decrease in yield and no change in enantiomeric excess (Table 
15, entry 2). Adding bromonitromethane in even smaller portions, 0.05 equivalents every 
30 minutes, raised the enantiomeric excess of the product by only 1% (Table 15, entry 3). 
It was therefore clear that the limiting the concentration of bromonitromethane past a 
certain extent was not beneficial. 
 
Table 15. Addition of bromonitromethane in smaller aliquots. 
 
 Despite a background reaction seen with electron rich imines, it is worth noting 
that the present reaction conditions give levels of enantioselection that are synthetically 
useful. Using the case of poorest selectivity (
p
OMe, 62, 62% ee, Table 12, entry 11), a 4:1 
mixture of diastereomers would be anticipated after amide coupling. Additionally, we 
have found that many of the Fmoc-protected α-bromo nitroalkane adducts are able to be 
fractionally recrystallized to give the product as a single enantiomer (Scheme 60). 
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Scheme 60. Fractional recrystallization of Fmoc-protected α-bromo nitroalkane adducts. 
 
 In this way, α-bromo nitroalkanes 201k and 201l were able to be obtained in very 
high levels of enantiopurity. These compounds were of special interest to us, as 
hydroxyphenylglycine and dihydroxyphenylglycine amino acids are found in a number of 
biologically active natural product peptides, such as the potent antibacterial compound 
vancomycin.
128
 
 
3.2.3 UmAS Coupling of Protected α-Bromo Nitroalkane Donors 
After synthesizing the protected α-bromo nitroalkanes, the next step was to 
submit them to umpolung amide synthesis (UmAS) coupling conditions in order to access 
the corresponding protected amino amides. It was exciting that the first adduct coupled, 
N-Fmoc-protected 182, resulted in a good yield (66%) of the desired amide 212 (Scheme 
61). There was some concern that the Fmoc protecting group would not survive the 
slightly basic conditions of this coupling, as it is typically deprotected with base (e.g. 
piperidine, morpholine, etc.); however, Fmoc cleavage was not detected in this case. It 
was also exciting to see that the dipeptide was isolated as a single diastereomer, again 
indicating that no epimerization occured at the otherwise acid aryl glycine residue. 
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Scheme 61. Umpolung amide coupling of N-Fmoc-protected α-bromo nitroalkane 182. 
 
While no signs of Fmoc-deprotection were seen in the coupling of 182, several 
NMR studies were done to determine the stability of product 212 to both aza-Henry 
reaction conditions and UmAS reactions conditions. To do this, 212 was first stirred with 
a full equivalent of PBAM in CDCl3 at rt. After one day, no Fmoc protection was 
observable (Table 16, entry 1). However, after 3 days approximately 7% and 13% 
deprotection were measured at 3 and 5 days, respectively (Table 16, entries 2 and 3). 
While this shows that the catalyst PBAM is sufficiently basic to deprotect an Fmoc 
group, it does so slowly. Therefore, under the standard aza-Henry reaction conditions and 
times (10 mol% PBAM, 0 °C, 24 h) it is most likely that little to no Fmoc-deprotection 
occurs. 
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Table 16. Determining Fmoc-deprotection by PBAM. 
 
entry time (d) deprotection (%)a 
1 1 0 
2 3 7 
3 5 13 
a Based on 1H NMR analysis of crude reaction 
mixture, measuring relative amount of fulvene 
214 to remaining amide 212. 
 
The standard UmAS reaction conditions were tested in the same way. Amide 212 
was stirred at room temperature in CDCl3 with the amine, K2CO3 and water. After 
stirring for a day under these conditions, a small amount of Fmoc-deprotection was 
observed (5%, Table 17, entry 1). After 3 and 5 days, 8% and 11% Fmoc-deprotection 
was observed, respectively (Table 17, entries 1 and 2). These results show that the Fmoc-
protected dipeptide is somewhat susceptible to deprotection under our reaction 
conditions. However, this should only be a significant problem when longer reaction 
times are used. 
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Table 17. Determining Fmoc-deprotection by UmAS reaction conditions. 
 
entry time (d) deprotection (%)a 
1 1 5 
2 3 8 
3 5 11 
a Based on 1H NMR analysis of crude reaction 
mixture, measuring relative amount of fulvene 
214 to remaining amide 212. 
 
It was also exciting that α-bromo nitroalkane 199a was able to be coupled to the 
methyl ester of alanine to give dipeptide 215 in 50% yield (Scheme 62). As mentioned 
previously, this azido acetate protecting group is very synthetically useful. It could be 
reduced to give a glycine residue or used in click chemistry
127
 or a Staudinger ligation.
9
 
 
Scheme 62. Catalytic umpolung amide coupling of N-azidoacetate-protected α-bromo nitroalkane 199a. 
 
After successfully coupling α-bromo nitroalkanes 182 to a simple amine and 199a 
to the methyl ester of alanine, attention was next turned to coupling several adducts 
bearing protecting groups commonly found in peptide synthesis. Specifically, we wished 
to couple the N-Fmoc, Bz, Cbz and Alloc (182, 199c,f-g) protected adducts to an amino 
acid, thus incorporating these protected residues into a dipeptide fragment. However, 
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when these compounds were submitted to UmAS conditions, the yields of the desired 
dipeptides (216-219) were lower than expected (Table 18, entries 1-4). Only the N-Bz 
adduct 199c gave the corresponding dipeptide 217 in an acceptable yield (65%, Table 18, 
entry 2). The other protected adducts gave slightly lower yields (52-57%, Table 18, 
entries 1,3,4), prompting optimization of these coupling conditions. 
 
Table 18. UmAS coupling of differentially protected α-bromo nitroalkanes with alanine methyl ester. 
 
entry product  yield (%)a 
1 
 
216 52 
2 
 
217 65 
3 
 
218 53 
4 
 
219 57 
a All reactions run with 2 eq of amine at 0 °C for 2 d. 
 
In order to optimize the UmAS coupling conditions for these substrates, the N-
Fmoc adduct 182 was coupled under a variety of conditions. It was found that removing 
the oxygen atmosphere was detrimental to the reaction, resulting in a 43% yield of 
dipeptide 216 (Table 19, entry 2). In order to make sure the low yield was not due to the 
amino acid coupling partner, 182 was also coupled to alanine and valine residues. These 
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couplings resulted in no improvement, with similar yields (46 and 44%, respectively, 
Table 19, entries 3 and 4) of the corresponding dipeptides 220 and 221. 
 
Table 19. Optimization of UmAS coupling of 182 with amino acids. 
 
entry amino acid time (d)a product yield (%) 
1a HClH2NLeuOMe 2 216 52 
2 HClH2NLeuOMe 2 216 43 
3 HClH2NAlaOMe 2 220 46 
4 HClH2NValOMe 2 221 44 
5 HClH2NLeuOMe 4 216 37 
a Reaction performed under an atmosphere of O2. 
 
Because the 
1
H NMR resonances of the starting materials are very broad, it can be 
very hard to determine the conversion of these reactions. Therefore, a reaction was 
performed in which the coupling was allowed to run for 4 days, as opposed to 2 days 
(Table 19, entry 5). The results of this reaction were surprising. Instead of staying the 
same or increasing, the yield of dipeptide 216 actually decreased. This indicated that the 
product was decomposing in some way under the coupling conditions. As mentioned 
previously, Fmoc-deprotection might be possible. However, it had been shown that under 
these reaction conditions Fmoc-deprotection occurred very slowly. Additionally, no signs 
of Fmoc-deprotection (e.g. fulvene) were seen in the crude reaction mixtures for any of 
the couplings. A second decomposition pathway was therefore considered. Hydrolysis of 
the methyl ester could theoretically occur under the reaction conditions, which include 
K2CO3 and water. If this were to happen, the resulting acid would most likely be lost to 
the aqueous layer during workup and would not be observed in the crude reaction 
mixture. 
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In order to test this possibility, an amino acid residue was needed that was less 
susceptible to hydrolysis. Therefore, the tert-butyl ester of leucine was synthesized.
129
 
Because the 
t
Bu ester 222 was volatile as the free amine, the HCl salt of this compound 
was formed. In order to do this without deprotecting the newly-formed tert-butyl group, a 
work-up was devised in which the free amine was extracted into ether and then treated 
with 4M HCl in dioxane. It was found that in any other solvent, tert-butyl deprotection 
occurred upon concentration to return starting material. In this way, the tert-butyl ester of 
leucine (222) was synthesized in 45% yield (Scheme 63). 
 
Scheme 63. Synthesis of the tert-butyl ester of leucine. 
 
 Following preparation of the required tert-butyl amino acid, several reactions 
were planned to compare the stability of the tert-butyl ester dipeptide 223 to that of the 
methyl ester dipeptide 216. Coupling 182 to the tert-butyl ester of leucine afforded 
dipeptide 223 in 62% after 2 days, 10% higher than the yield of 216 produced from the 
coupling of the methyl ester (Table 20, entries 1 and 2). When these reactions were run 
for a longer time, 4 days, a remarkable difference in yield was seen. While the coupling 
with the tert-butyl ester yielded 223 in 65% yield, a 2% increase from the 2 day reaction, 
the coupling with the methyl ester yielded 216 in 37% yield, a 15% decrease from the 2 
day reaction (Table 20, entries 3 and 4). 
 
 
 
                                                          
129
Chen, H.; Feng, Y.; Xu, Z.; Ye, T. Tetrahedron 2005, 61, 11132. 
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Table 20. Comparison of the tert-butyl and methyl esters of leucine in UmAS coupling of 182. 
 
entry amino acid time (d)a product yield (%) 
1 HClH2NLeuOMe 2 216 52 
2 HClH2NLeuO
tBu 2 223 62 
3 HClH2NLeuOMe 4 216 37 
4 HClH2NLeuO
tBu 4 223 65 
a Reactions run with 2 eq of amine at 0 °C. 
 
These results suggested that hydrolysis of the methyl ester was responsible, in 
part, for the low yield of the dipeptides after UmAS coupling, and that the corresponding 
tert-butyl esters were much more resistant to hydrolysis. Therefore, the protected adducts 
182, 199f and 199g were all coupled to the tert-butyl ester of leucine, resulting in good 
yields (62-68%) of the dipeptides 223, 224 and 225, respectively (Table 21, entries 1-3). 
 
Table 21. UmAS coupling of differentially protected α-bromo nitroalkanes with the tert-butyl ester of 
alanine. 
 
entry product  yield (%)a 
1 
 
223 62 
2 
 
224 63 
3 
 
225 68 
a All reactions run with 2 eq of amine at 0 °C for 2 d. 
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It was pleasing to see that these protecting groups commonly used in peptide 
synthesis were compatible with the UmAS coupling conditions. This, combined with the 
fact that no epimerization was observed during any of these couplings, makes the aza-
Henry addition to TMS-imines a powerful methodology to introduce variously protected 
aryl glycine residues into peptides. In three steps from inexpensive aldehydes, amino acid 
residues can be synthesized and incorporated into peptides in a highly stereocontrolled 
manner. Additionally, due to the novel use of N-TMS imines, this is the first example of 
an enantioselective amino acid synthesis in which the protecting group is not determined 
by the method used. This methodology allows for the incorporation of a number of 
protecting groups, including the widely used Fmoc group which is not readily accessible 
by most methods of enantioselective amino acid synthesis. 
 
3.2.4 Heteroaromatic and Aliphatic N-TMS Imines 
 While work thus far had focused on the synthesis and incorporation of aryl 
glycine residues, extending this methodology to include other non-natural amino acids 
was a logical next step. The number of readily available aldehydes is vast, allowing for 
the synthesis of a wide variety of amino acid side chains. We therefore wished to extend 
this chemistry to include both heteroaromatic and aliphatic substrates in order to broaden 
the utility of this methodology.  
 Attention was first turned to heteroaromatic aldehydes, as it was thought they 
should behave most similarly to aromatic substrates. Several examples of heteroaromatic 
N-TMS imines could be found in the literature,
130,131,132
 and it is known that these 
                                                          
130
 Betschart, C.; Schmidt, B.; Seebach, D. Helevetica Chimica Acta 1998, 71, 1999. 
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compounds are relatively stable. The first substrates subjected to enantioselective aza-
Henry conditions were the known furanyl
130
 and thiophenyl
131
 N-TMS imines (226 and 
228). Upon slow addition of bromonitromethane, followed by acetyl bromide quench, the 
desired α-bromo nitroalkanes (227 and 229) were isolated. However, the reactions were 
low yielding, and the observed enantioselection was moderate (48, 36% ee for 227, eq 70, 
and 39, 37% ee for 228, eq 71, Scheme 64). While unfortunate, based on the reactivity of 
electron rich aryl imines, these results were not surprising.  
 
Scheme 64. Preliminary aza-Henry addition to heteroaromatic N-TMS imines 226 and 228. 
 
Additionally, it was observed that these adducts slowly racemized upon standing 
and were not stable for extended periods of time. Therefore, these compounds were 
immediately subjected to umpolung amide synthesis (UmAS) conditions, in the hope that 
the resulting amides would be more stable. Unfortunately, when the furanyl derivative 
227 was stirred with α-methyl benzylamine, in the presence of base and NIS, none of the 
desired product 230 was observed (eq 72, Scheme 65). At the same time, a coupling was 
                                                                                                                                                                             
131
 Ramanchandran, P.; Burghardt, T. Chem. Eur. J. 2005, 11, 4387. 
132
 Hart, D.; Kanai, K.; Thomas, D.; Yang, T. J. Org. Chem. 1983, 48, 289. 
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attempted in which the crude aza-Henry reaction mixture was subjected to the UmAS 
conditions. It was hoped that the α-bromo nitroalkane 227 would react before it had a 
chance to racemize. This coupling also resulted in none of the desired amide 230 (eq 73, 
Scheme 65). 
 
Scheme 65. Attempted UmAS coupling of 227. 
 
 
 The same couplings were attempted with the thiophene derivative 229. In both 
attempted UmAS couplings, with the pure α-bromo nitroalkane 229 (eq 74, Scheme 66) 
as well as the crude (eq 75, Scheme 66), trace amounts of the desired amide 231 were 
detected by 
1
H NMR analysis. Aromatic thiophene resonances were observed at 7.91, 
6.56 and 6.45 ppm, as well as a broad doublet at 5.83 and a broad multiplet at 5.12 ppm 
which could correspond to the methynes adjacent to the amide nitrogens. However, after 
purification by column chromatography the amide was not isolated, presumably due to 
decomposition. 
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Scheme 66. Attempted UmAS coupling of 229. 
 
 
 While we were able to achieve moderate levels of enantioselection with the 
furanyl and thiophenyl N-TMS imines (226 and 228), the fact that the resulting adducts 
(227 and 229) were unstable and not able to be coupled under UmAS conditions 
prompted us to move to a less electron-rich imine. Therefore, the known
132
 pyridyl N-
TMS imine 233 was synthesized. All previous N-TMS imines were successfully 
synthesized using the protocol by Vidal and Collet,
124
 in which the aldehyde and LHMDS 
are stirred at ambient temperature in THF before being diluted with hexanes and filtered 
under an inert atmosphere. However, when we used these conditions with pyridine 
carboxaldehyde 232, none of the desired imine 233 was seen after filtration (Table 22, 
entry 1). Several known procedures for the synthesis of this imine called for reaction 
temperatures as low as -78 °C. Therefore, the reaction temperature was lowered to -78 
°C, and the same filtering procedure used. Again, no product was observed (Table 22, 
entry 2). A third attempt, in which the reaction was kept at low temperatures during 
filtration step as well, finally yielded some of the desired imine 233 (Table 22, entry 3). 
However, the crude reaction mixture was messy and, due to its instability, the imine was 
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unable to be purified via distillation. Therefore, the filtration step was eliminated, and the 
imine 233 isolated as a crude mixture with LiCl (Table 22, entry 4). 
 
Table 22. Synthesis of pyridine N-TMS imine 233. 
 
entry conditions resulta 
1 
rt, diluted with hexanes 
and filtered 
no product 
2 -78 °C, diluted with 
hexanes and filtered 
no product 
3 -78 °C, diluted with cold 
hexanes and filtered 
messy, product 
present 
4 -78 °C, did not filter product present 
(crude with LiCl) 
 
 With the crude pyridyl imine 233 in hand, we next subjected it to standard aza-
Henry conditions. Initially, we chose to quench the addition with acetyl bromide in the 
hopes that we would be able to judge the conversion of the reaction after 16 hours. 
However, the desired amide could not be identified in the NMR of the crude reaction 
mixture. While some remaining aldehyde could be seen, indicating that the reaction had 
not reached complete conversion, the 
1
H NMR resonances of the other products of this 
reaction were very broad and could not be readily identified. The crude reaction mixture 
was subjected to column chromatography, and a polar fraction was collected which 
contained a product with a mass that matched that of the desired product 234, as indicated 
by LCMS. However, this product co-eluted with the pyridine carboxaldehyde and the 
PBAM catalyst. After subjecting this mixture to column chromatography a second time, 
none of the desired product could be isolated, indicating that it is unstable under these 
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purification conditions (eq 76, Scheme 67). An attempt was made to couple the crude α-
bromo nitroalkane 234, since purification of this compound proved challenging. 
However, upon treatment of the crude aza-Henry reaction mixture with standard UmAS 
coupling conditions, none of the desired amine 235 was observed (eq 77, Scheme 67). 
 
Scheme 67. Aza-Henry addition to N-TMS imine 233: AcBr protection. 
 
While it is unclear whether or not the desired product was formed, it is possible 
that, due to the high reactivity of the acetyl bromide, the pyridyl nitrogen was acylating 
before the N-TMS protected amine, to give the pyridyl salt 236 which has the same mass 
as the desired product 234. This would explain the observed polarity, as well as the 
instability, of the observed product. It would also explain why the amide 235 was not 
observed in the crude reaction mixture for the coupling. 
 Because the acylation with acetyl bromide seemed to be causing problems, 
attention was next turned to quenching the addition reaction with FmocCl. It was hoped 
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that due to the bulkiness of this reagent, the pyridyl nitrogen would not react, and only 
the TMS-amine would be protected. Additionally, the Fmoc protecting group should 
make the product less polar and easier to isolate. When this reaction was carried out, the 
desired product could be seen by both crude NMR as well as LCMS (eq 78, Scheme 68). 
Upon column chromatography, some of the product could be isolated, but as a mixture 
with the FmocOH 238. The presence of this side product, which would result from 
hydrolysis of the corresponding fulvene, indicates Fmoc-deprotection. It was therefore 
not surprising that repurification failed to return the desired product. We hypothesized 
that the α-bromo nitroalkane 237 was deprotecting on the column, resulting in 
decomposition.  
 
Scheme 68. Aza-Henry addition to N-TMS imine 233: FmocCl protection. 
 
In order to prevent this from occurring, several different column conditions were 
used, including using DCM/MeOH as the eluent and running the column with neutral 
alumina, neither of which were successful. Because it is likely that the basic pyridyl 
nitrogen is responsible for the Fmoc-deprotection, a column was also run in which AcOH 
was added as an additive to the EtOAc/hex eluent. This was done to try and form the 
102 
 
acetic acid salt of the product, thereby masking the basicity of the pyridyl nitrogen. 
Unfortunately, these conditions were equally unsuccessful. 
 Since the α-bromo nitroalkane 237 proved to be unstable under purification 
conditions, we decided to take it directly on to the amide 239. Therefore, the crude aza-
Henry reaction mixture was submitted to UmAS coupling conditions. We were pleased to 
see that the mass of the desired amide 239 could be seen by LCMS (eq 79, Scheme 68); 
however, upon attempted purification of this product, the same problems were 
encountered. The product could be isolated after column chromatography as a mixture 
with the FmocOH 238, but upon repurification could not be isolated. As before, several 
different column conditions were examined, but none resulted in isolation of amide 239. 
 It was clear at this point that the Fmoc protecting group also would not work with 
this substrate. Therefore, we next turned to Cbz-protection. By quenching the aza-Henry 
addition reaction with CbzCl, we were excited to see that the desired Cbz-protected 
pyridyl α-bromo nitroalkane 240 could be isolated in 23% yield. Unfortunately the 
enantioselection observed in this reaction was quite low (9, 12% ee, eq 80, Scheme 69). 
This was surprising, as the pyridyl imine should be less electron rich, and thus have less 
of a background reaction, than the furanyl and thiophenyl derivatives that gave higher 
levels of enantioselection (48, 36% ee and 37, 36% ee, respectively, Scheme 64). We 
hypothesize that this low enantioselectivity most likely is a result of the basic pyridyl 
nitrogen, which could compete with PBAM to catalyze a non-selective addition pathway.  
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Scheme 69. Aza-Henry addition to N-TMS imine 233: CbzCl protection. 
 
 Additionally, it was observed that upon standing in solution, the adduct 240 
readily racemized (eq 80, Scheme 69). Thus, after a slow addition reaction with this 
substrate, the product was quickly purified and subjected to HPLC analysis. The ee of 
adduct 240, isolated in 17% yield, was only slightly higher (15, 15% ee, eq 81, Scheme 
69). An attempt was also made to quickly couple the α-bromo nitroalkane 240, in order to 
prevent racemization of this intermediate. Therefore, the crude aza-Henry reaction 
mixture was subjected to UmAS coupling conditions. Unfortunately, the desired product 
241 was not observed in the crude reaction mixture. Instead, a product was isolated that 
contained pyridyl and α-methyl benzylamine peaks by 1H NMR, but no amide or Cbz 
peaks. The mass of this isolated product corresponded to the imine 242, which most 
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likely resulted from a retro-aza-Henry addition of 240 and subsequent transimination 
with the α-methyl benzylamine.  
Due to our evolving hypothesis that the basic nitrogen of the pyridine was 
responsible for low enantioselection and a difficult isolation, attempts were made to 
synthesize a pyridyl N-TMS imine (244) in which the pyridyl nitrogen was protected as 
the methyl salt. Therefore, the methyl salt of the pyridine carboxaldehyde (243) was 
stirred with LHMDS in THF at ambient temperature. After the reaction was complete, it 
was quenched with TMSCl, diluted with hexanes and filtered under an inert atmosphere 
(Table 23, entry 1). Usually, the filtration step removes only the LiCl produced as a 
byproduct of the reaction. However, in this case a large amount of red solid was filtered 
off, and the filtrate contained none of the desired imine. It is thought that the imine was 
not soluble in hexanes, and was simply filtered off. Therefore, a second attempt was 
made in which the filtration step was removed. This resulted in a crude reaction mixture 
that was completely insoluble in CDCl3. By dissolving this mixture in d6-DMSO a crude 
1
H NMR could be obtained which indicated that there was still a significant amount of 
the starting aldehyde 243 present. However, a second compound could be observed 
which appeared to be the desired imine 244 (Table 23, entry 2). 
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Table 23. Synthesis of the Me-protected pyridyl N-TMS imine 244. 
 
entry conditions resulta 
1 
diluted with hexanes and 
filtered 
no product 
2 concentrated, with no 
filtration 
1H NMR in DMSO-aldehyde 
still present, some imine 
 
 Since it appeared some imine had been produced, a portion of the crude reaction 
mixture containing 244 was stirred with excess bromonitromethane in toluene at room 
temperature to see if any aza-Henry addition would occur (Scheme 70). The crude 
material was completely insoluble in toluene, but seemed to be slightly soluble in 
bromonitromethane. After stirring for several hours, the reaction was quenched with 
CbzCl and allowed to stir overnight. After concentrating the reaction mixture, 
1
H NMR 
analysis in CDCl3 revealed only remaining bromonitromethane and CbzCl. Analysis by 
1
H NMR in d6-DMSO, allowed us to determine that no aldehyde or imine remained. 
However, while there were pyridine-containing products, none of the resonances 
exhibited the appearance typical of a mixture of diastereomers, as the desired product 245 
would. Furthermore, the mass of the desired product 245 could not be seen when the 
crude reaction material was analyzed by LCMS. 
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Scheme 70. Attempted aza-Henry addition to Me-protected pyridyl N-TMS imine 244. 
 
 Due to the lack of success with pyridyl N-TMS imines provided, we returned to 
inherently electron rich aryl aldimines in the form of a protected indole N-TMS imine. 
Initially, synthesis of the acetyl-protected indole N-TMS imine 247 was attempted. 
Unfortunately, upon addition of LHMDS to the aldehyde 246, an insoluble substance 
precipitated from the reaction mixture, and none of the desired imine could be recovered 
(eq 83, Scheme 71). It is thought that the LHMDS either deprotected the acetyl group, or 
deprotonated at the methyl position, leading to an undesired reaction pathway such as 
polymerization of the substrate. Therefore, attention was next turned to the synthesis of 
the tosyl-protected indole N-TMS imine 249. The synthesis of this imine was performed 
on small scale (>250 mg of aldehyde 248), and while it appeared some of the desired 
imine 249 was present, the crude reaction mixture was complex, and there was at least 
one other major product (eq 84, Scheme 71). Instead of attempting to synthesize this 
imine on larger scale, we instead decided to move to a nosyl-protected indole N-TMS 
imine (251). It was hypothesized that the electron-withdrawing nature of this protecting 
group should help with the reactivity of this substrate in the subsequent aza-Henry 
addition step. We were pleased to see that after reacting aldehyde 250 with LHMDS, and 
subsequently quenching with TMSCl, the desired imine 251 could be isolated as a crude 
mixture with LiCl (eq 85, Scheme 71). 
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Scheme 71. Synthesis of a protected indole N-TMS imine. 
 
 When unpurified imine 251 was subjected to standard aza-Henry reaction 
conditions, we were pleased to see that the desired α-bromo nitroalkane 252 could be 
isolated in 25% yield. However, the isolated product was nearly racemic (3, 3% ee, eq 86, 
Scheme 72). Upon slow addition of bromonitromethane, the enantioselection was 
increased slightly, to give the product 252 in 15% yield and 8, 8% ee (eq 87, Scheme 72). 
These results made little sense to us, as this imine, like the pyridyl derivative, should be 
less electron rich than the furanyl and thiophenyl N-TMS imines. If only the electronics 
of the imine are considered, the Ns-protected indole N-TMS imine 251 should have given 
higher levels of enantioselectivity than observed. Therefore, it is hypothesized that 
perhaps the nitro-group of the Ns-protecting group is interfering in the enantioselective 
step in some way, perhaps through a hydrogen bonding mechanism.  
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Scheme 72. Aza-Henry addition to N-TMS imine 251. 
 
 Because the Ns-protected indole N-TMS imine 251 gave surprising results, we 
decided to return to the Ts-protected indole carboxaldehyde 248 with the hope that the 
synthesis of the corresponding N-TMS imine 249 would be more facile on a larger scale. 
When this was attempted, the desired N-TMS imine 249 was again present in addition to 
a second major compound. It was determined that this product was dimer 253, formed by 
nucleophilic addition of the N-TMS imine nitrogen to a second equivalent of imine. By 
1
H NMR analysis, it was determined that these two products were present in a 2:1 
(249:253) ratio (Scheme 73). 
 
Scheme 73. Returning to the Ts-protected indole N-TMS imine 249. 
 
 This mixture was subsequently subjected to aza-Henry reaction conditions. While 
the conversion was low (44%), it was possible to see the desired product 254 by 
1
H NMR 
analysis of the crude reaction mixture. However, a second major product was also 
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observed, the transimination product 255. This product had been observed previously in 
our work with aryl imines- it usually occurs when the reaction has not gone to complete 
conversion. By NMR analysis it was determined that these two products were present in a 
1.8:1 ratio (254:255). Upon column chromatography, only the transimination product 255 
was initially isolated, in 24% yield. It was exciting to see that this side product had a 
fairly high level of enantiopurity, with an ee of 74, 63% (eq 88, Scheme 74). While this 
was not the desired acylated product 254, the two should theoretically have very similar 
levels of enantioselectivity. Because of these promising results, a second reaction was 
done in which bromonitromethane was added to the crude mixture of imine 249 and 
dimer 253 over 48 h. This extended reaction time was used in order to try to increase the 
conversion of the reaction and prevent the formation of transimination product 255. This 
did seem to help somewhat, as the reaction proceeded to 70% conversion, and the ratio of 
254:255 was determined to be 4:1. The desired α-bromo nitroalkane 254 was isolated in 
29% yield and 55, 56% ee (eq 89, Scheme 74), which are the best results obtained so far 
for a heteroaromatic N-TMS imine substrate.  
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Scheme 74. Aza-Henry addition to the Ts-protected indole N-TMS imine 249. 
 
 While these results were promising, the yield of 254 was still lower than what 
would be synthetically useful, mostly due to the low conversion of the reaction as well as 
the formation of the undesired transimination product 255. While a longer reaction time 
helped somewhat, we thought that perhaps the presence of the imine dimer 253 was 
contributing to these problems. It is possible that bromonitromethane addition to 256, 
followed by elimination of TMSNH2, could form the transimination product 257 (Scheme 
75). Even if this were not the case, and the dimer 256 was simply unreactive, this would 
then contribute to the low conversion of the reaction. 
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Scheme 75. Attempted optimization of synthesis and aza-Henry addition to N-TMS imine 249. 
 
 Therefore, indole N-TMS imine 249 was synthesized a second time. By reducing 
the reaction temperature to -78 °C, the ratio of desired product 249 to imine dimer 253 
could be increased to 8:1 (eq 90, Scheme 75). A slow addition of bromonitromethane to 
this mixture was carried out over 10 hours. Acetyl bromide was then added to quench the 
reaction. The results obtained from this reaction were unfortunately not what was 
expected. The conversion was only 50%, and the ratio of the desired product 259 to 
transimination product 255 was 1.4:1 The α-bromo nitroalkane 254 could be isolated in 
21% yield and 56, 58% ee, and the transimination product 255 was isolated in 31% yield, 
as a mixture with the starting aldehyde 248, and 64, 64% ee (eq 91, Scheme 75). 
112 
 
 Since so much of the transimination product 255 was forming in these reactions, it 
was decided to attempt to convert this product into the acylated product 254. It was 
hypothesized that this could be done by treating 255 with acetic anhydride and a catalytic 
amount of water. Nucleophilic addition of acetic acid to the imine and subsequent acyl 
transfer and collapse of the tetrahedral intermediate could give the desired product 254 
(eq 92, Scheme 76).  
 
Scheme 76. Conversion of transimination product 255 to acetylated product 254. 
 
 In order to test this, a small amount of the transimination product 255 was 
dissolved in CDCl3. One equivalent of Ac2O and a catalytic amount of water were added, 
and the mixture was monitored by 
1
H NMR. A trace amount of the desired product 254 
could be seen after 2 days, along with some of the aldehyde 248, and after 10 days, the 
conversion to 254 was determined to be 80%. While this transformation was slow, we 
were excited to be able to convert the undesired product 255 to the desired α-bromo 
nitroalkane 254, thereby increasing the overall yield of the aza-Henry addition. 
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Therefore, the transimination product produced from the aza-Henry addition in Scheme 
75 (eq 91) was subjected to these conditions. After 10 days, the acylated product 254 was 
isolated in 29% yield and 59, 59% ee, increasing the total yield of the aza-Henry addition 
to 25%. 
 While the results obtained with the tosyl-protected indole imine (249) were the 
best to date for a heteroaromatic substrate, it was clear that these substrates were too 
electron rich to be used successfully in our chemistry at this time. We therefore decided 
to turn our attention to aliphatic N-TMS imines, with the hope that these would be more 
successful. However, it was known that aliphatic N-TMS imines are less stable than their 
aromatic counterparts. Specifically, they are volatile and not stable at high temperatures, 
and are therefore often difficult to isolate. In fact, most aliphatic N-TMS imines are 
prepared and reacted in situ in order to avoid isolation.
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 With this in mind, we attempted to synthesize the aliphatic α-bromo nitroalkane 
257 directly from butyraldehyde. Known butyl N-TMS imine 256
104
 was first prepared by 
adding LHMDS to the aldehyde in toluene. After stirring for 30 minutes at room 
temperature, complete conversion to the N-TMS imine (256) could be observed by 
1
H 
NMR. The reaction mixture was cooled to -78 °C and bromonitromethane was added 
along with the chiral PBAM catalyst. After stirring overnight at -78 °C, the reaction was 
quenched with benzoyl chloride and concentrated. Analysis of the crude reaction mixture 
by 
1
H NMR revealed full conversion of imine 256; however, the major product of this 
reaction was not the desired α-bromo nitroalkane (257). It appeared that addition to the 
imine had occurred but that the benzoyl protecting group had not been incorporated into 
the major product of this reaction. While we were able to isolate this product after 
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column chromatography, it was unfortunately not sufficiently stable for full 
characterization and structure elucidation. However, it was clear that this one-pot reaction 
sequence was not following the desired reaction pathway to produce α-bromo nitroalkane 
257 (Scheme 77). 
 
Scheme 77. Synthesis of aliphatic N-TMS imine 256 and in situ aza-Henry addition. 
 
 At this point we decided to reevaluate the synthesis of N-TMS imines in situ with 
this methodology. While we were unable to synthesize aliphatic α-bromo nitroalkane 
257, it was unclear if this was due to the reactivity of aliphatic N-TMS imines or the fact 
that the imine had been synthesized in situ. Therefore, a test reaction was carried out in 
which 
p
Cl-benzaldehyde was treated with LHMDS in toluene at room temperature. After 
stirring for 30 minutes, TMSCl was added and the reaction was stirred for an additional 
30 minutes before it was cooled to -78 °C. This reaction mixture was then subjected to 
our standard aza-Henry conditions for N-TMS imines. The results of this reaction were 
surprising. While the α-bromo nitroalkane (182) was isolated, the yield of the reaction 
was low and the enantioselection significantly decreased (36% yield, 8, 12% ee, Scheme 
78). When compared to the results acquired when a two-step reaction sequence was 
carried out (76% yield, 91, 91% ee), it was clear that forming the imine in situ is 
detrimental to the subsequent addition reaction. Because the conditions for imine 
synthesis are quite basic, it is hypothesized that trace amounts of these reagents remained 
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unquenched in the reaction mixture and interfered in the subsequent base-catalyzed aza-
Henry addition step. 
 
Scheme 78. Making the N-TMS imine in situ: A test reaction. 
 
 Based on this result, we surmised that for the aza-Henry addition to N-TMS 
imines to be successful, one must be able to concentrate the desired N-TMS imine after 
its synthesis to remove the volatile reagents and sideproducts. Therefore, alkyl N-TMS 
imine synthesis was next attempted with an aldehyde that was less volatile than 
butyraldehyde, with the hope that the corresponding imine could be isolated by filtering 
and concentrating the crude reaction mixture. Towards this end, hydrocinnamaldehyde 
was treated with LHMDS in THF. The reaction was quenched with TMSCl, filtered 
under argon and concentrated to give a crude reaction mixture in which N-TMS imine 
258 was determined to be present by 
1
H NMR analysis. Unfortunately, imine 258 did not 
appear to be the major product, as it was accompanied by several other unidentified 
products (eq 95, Scheme 79). Regardless, this crude material was submitted to standard 
aza-Henry reaction conditions and subsequently quenched with acetyl bromide. When the 
resulting crude reaction was analyzed by 
1
H NMR, a complex mixture was observed 
which did not appear to contain desired α-bromo nitroalkane 259 (eq 95, Scheme 79). 
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Scheme 79. Synthesis of hydrocinnamyl N-TMS imine 258 and attempted aza-Henry addition. 
 
 It is known that aliphatic N-TMS imines are susceptible to enamine formation, 
perhaps due to the basic conditions used for their synthesis and the similar bond 
dissociation energies of alkene and imine π-bonds.104 In the case of N-TMS imine 258, it 
is possible that enamine formation occured, so non-enolizable aliphatic aldehydes were 
prepared for evaluation in this chemistry. 
 The simplest non-enolizable aldehyde, tert-butyraldehyde, was used to synthesize 
known 
t
Bu N-TMS imine 260.
114
 This imine could be purified by distillation, allowing 
use of pure 260 in the aza-Henry reaction. In order to synthesize racemic α-bromo 
nitroalkane 261, imine 261 was treated with bromonitromethane in toluene at room 
temperature and then quenched with acetyl bromide. From this reaction, we were excited 
to isolate desired product 261 in 11% yield (eq 97, Scheme 80). However, when the 
reaction temperature was lowered, and the PBAM catalyst added, none of α-bromo 
nitroalkane 261 could be isolated. The major product of this reaction was determined to 
be hemiaminal 262, a product type which has been observed in other work by our group 
in aza-Henry additions to imines.
133
 It is thought that the formation of this product over 
desired product 261 can be attributed to the steric bulk of imine 260, which may make it 
difficult for bromonitromethane to add. 
                                                          
133
 Wilt, J. C.; Johnston, J. N. unpublished results. 
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Scheme 80. Aza-Henry addition to 
t
Bu N-TMS imine 260. 
 
 The next imine attempted to be synthesized was the adamantyl N-TMS imine 263. 
While the adamanyl group is quite bulky, it was hoped that the cage-like structure of this 
substituent would decrease the steric hindrance around the electrophilic imine carbon by 
constraining the neighboring methylene carbons. Unfortunately, upon treatment of 
adamantyl aldehyde with LHMDS, no evidence of desired imine 263 could be observed 
by 
1
H NMR analysis. Clean conversion of the aldehyde was observed, however it was 
difficult to determine what product was produced in this reaction as no resonances 
downfield of 2.5 ppm were present (Scheme 81). 
 
Scheme 81. Attempted synthesis of adamantyl N-TMS imine 263. 
 
 It was thought that perhaps an α-halogen substituted aliphatic N-TMS imine might 
be less sterically hindered than the fully-carbon substituted derivatives just tried. 
Therefore, α,α-dichloro hydrocinnamaldehyde 264 was synthesized by treating 
hydrocinnamaldehyde with 
t
BuNH2 and NCS. Aldehyde 264 was then treated with 
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LHMDS in THF. We were excited to find that desired N-TMS imine 265 was sufficiently 
stable to isolate via distillation (Scheme 82). 
 
Scheme 82. Synthesis of α,α-dichloro hydrocinnamyl N-TMS imine 265. 
 
 We first attempted the synthesis of racemic α-bromo nitroalkane 266 by treating 
aldehyde 265 with bromonitromethane at -78 °C in the presence of a catalytic amount of 
DMAP. After stirring overnight and quenching with FmocCl, 
1
H NMR analysis of this 
reaction showed that the imine had fully reacted, and that an addition product had formed 
as evidenced by the presence of a broad doublet around 6 ppm. This resonance could 
correspond to the methine alpha to the amine. However, this addition product did not 
appear to be the desired α-bromo nitroalkane 266, as the resonance at 6 ppm appeared to 
be split only by the N-H of the amine, and no peak could be seen which would 
correspond to the methine at the α-bromo nitro center. Additionally, an unassigned 
resonance at 8.1 ppm was observed. This product was not isolated following purification 
attempts by column chromatography (eq 99, Scheme 83).  
 
Scheme 83. Racemic aza-Henry addition to α,α-dichloro hydrocinnamyl N-TMS imine 265. 
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 We next attempted to synthesize racemic α-bromo nitroalkane 266 at room 
temperature in the absence of any catalyst. After quenching with FmocCl, a major 
product was seen by crude 
1
H NMR analysis that was determined to be different from 
both the observed product in eq 99, as well as desired 266. Upon purification and 
characterization, this compound was assigned to be aminal 267 (eq 100, Scheme 83). 
 While it was unclear how the aminal side product 267 formed, we decided to 
attempt to synthesize α-bromo nitroalkane 266 by enantioselective methods since we had 
not observed 267 in the reaction at low temperature (eq 99). Therefore, imine 265 was 
subjected to our standard aza-Henry conditions at -78 °C. Analysis of the resulting crude 
reaction mixture showed that the same unknown product in eq 99 had formed (eq 101, 
Scheme 84). Again, attempts to purify this product were unsuccessful.  
 
Scheme 84. Attempted aza-Henry addition to α,α-dichloro hydrocinnamyl N-TMS imine 265. 
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A second attempt to synthesize 266 was carried out, in which N-TMS imine 265 
was reacted with FmocCl before the addition of bromonitromethane with the hope that 
the N-Fmoc imine would form in solution, and that this would give results different from 
the N-TMS imine. It was seen that this was not the case, as the crude reaction mixture 
appeared much the same by 
1
H NMR analysis - again, the unknown addition product 
could be seen. However, before this mixture could be purified it sat open to the 
atmosphere for several hours. After this time period, analysis by TLC showed the 
presence of aminal 267, which was not present earlier in the crude reaction mixture. 
Subsequent 
1
H NMR analysis confirmed the presence of 267 and the absence of the 
unassigned addition product (eq 102, Scheme 84). In addition to this, it could be seen that 
the mixture now contained more of aldehyde 264 and less unreacted FmocCl. Therefore, 
it was hypothesized that the unassigned addition product observed in these reactions 
might be the Fmoc-protected imine dimer 268, which could convert to aminal 267 in the 
presence of atmospheric water and unreacted FmocCl (eq 103, Scheme 84). In order to 
confirm this, a third aza-Henry reaction was performed with imine 265. After the reaction 
was complete, the crude material was kept dry and subjected to LCMS analysis. Indeed, 
the mass of dimer 265 could be observed as a major component of the crude reaction 
mixture (eq 104, Scheme 84). 
It is thought that this undesired imine dimerization is once again a result of the 
steric bulk of the imine. It was clear that imine addition was occurring at a faster rate than 
the desired addition of bromonitromethane. Addition to the imine can occur, but perhaps 
bromonitromethane is sterically too large. Therefore, attempts were made to synthesize 
fluoronitromethane (269), which should be less sterically bulky. In order to do this, 
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nitromethane was treated with KOH in water. After stirring for 1 hour, Selectfluor® was 
added. The presence of fluoronitromethane (269) was supported by 
1
H NMR analysis; 
however, the reaction had proceeded to only 53% conversion (eq 105, Scheme 85). From 
our previous studies of this reaction, we knew that nitromethane would not add to N-TMS 
imines at -78 °C. Therefore, fluoronitromethane (269) was added to N-TMS imine 265 as 
a mixture with nitromethane. Unfortunately, 
1
H NMR analysis showed that while none of 
imine dimer 268 was present, only starting material could be observed and α-fluoro 
nitroalkane 270 had not formed (eq 106, Scheme 85).  
 
Scheme 85. Synthesis of flouronitromethane and addition to N-TMS imine 265. 
 
 Since fluoronitromethane seemed to be unreactive toward imine 265, a different 
approach was attempted to reduce the unfavorable steric interactions in this reaction. The 
synthesis of α,α-difluoro hydrocinnamaldehyde 271 was attempted. By replacing the 
chlorine substitutents with fluorines, it was hoped that the resulting N-TMS imine would 
be less hindered, and therefore more reactive toward bromonitromethane addition. 
Unfortunately, the synthesis of aldehyde 271 proved challenging. By simply treating 
cinnamaldehyde with 
t
BuNH2 and Selectfluor®, we were unable to see any of the doubly-
fluorinated product 271, as only single fluorination was observed (eq 107, Scheme 86). 
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We next turned to a known procedure for the synthesis of aldehyde 271.
134
 In this 
procedure, the authors did not isolate the aldehyde directly, but instead used it in crude 
form in a reductive amination. This may be due in part to the instability of the product, as 
in our hands aldehyde 271 could not be isolated (eq 108, Scheme 86). 
 
Scheme 86. Attempts to synthesize α,α-difluoro hydrocinnamaldehyde 271. 
 
 Thus far, we had seen that unsubstituted aliphatic imines were unstable and prone 
to enamine formation, giving complex reaction mixtures after aza-Henry addition, and 
that fully substituted aliphatic imines were too sterically hindered for bromonitromethane 
addition. Therefore, we decided to turn to unsaturated aliphatic imine derivatives. These 
imines should be stable, as enamine formation is prevented, and significantly less 
hindered than the saturated aliphatic imines. We first synthesized alkynyl imine 273 by 
treating TMS-alkynyl aldehyde 272 with LHMDS in THF. The desired imine (273) could 
be isolated by distillation, however, the isolated yield was quite low (13%, eq 109, 
Scheme 87). Regardless, a sufficient amount of pure imine 273 was obtained to submit 
this compound to our standard aza-Henry conditions. After quenching with FmocCl, we 
were disappointed to see no sign of desired α-bromo nitroalkane 274 by 1H NMR 
analysis of the crude reaction mixture. While imine 273 had been completely consumed, 
large amounts of remaining bromonitromethane and FmocCl were observed, suggesting 
                                                          
134
 Fadeyi, O.; Lindsley, C. W. Org. Lett. 2009, 11, 943. 
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that aza-Henry addition had not occurred. A number of unidentified TMS resonances 
were also observed around 1-2 ppm, but no other clues as to the fate of alkynyl imine 273 
could be detected (eq 110, Scheme 87). It was noted at this point that the pure sample of 
alkynyl N-TMS imine 273 had turned from a light yellow oil to a viscous dark brown oil. 
Subsequent 
1
H NMR analysis of this material showed that imine 273 had completely 
decomposed to give a similar composition as was seen after the aza-Henry reaction- only 
TMS resonances between 1 and 2 ppm were observed. This led us to conclude that 
alkynyl N-TMS imine 273 quickly decomposed under the aza-Henry reaction conditions 
before addition could occur. 
 
Scheme 87. Synthesis of alkynyl N-TMS imine 273 and attempted aza-Henry addition. 
 
 Attention was therefore next turned to the synthesis of known cinnamyl N-TMS 
imine 275.
114
 After treating cinnamaldehyde with LHMDS in THF and filtering under an 
inert atmosphere, desired imine 275 was isolated in 62% yield after distillation (eq 111, 
Scheme 88). When imine 275 was submitted to our standard aza-Henry reaction 
conditions and quenched with FmocCl, we were pleased that the desired α-bromo 
nitroalkane 276 could be isolated in 45% yield. Additionally, the two diastereomers 
produced in this reaction were determined to be 67 and 66% ee (eq 112, Scheme 88). 
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While this level of enantioselection is moderate, it is comparable to the results obtained 
with the simple phenyl aryl N-TMS imine 200g (Table 12, entry 8, 63% yield, 65, 66% ee 
for 201g). It is also the highest level of enantioselection observed to date for a non-aryl 
imine substrate. 
 
Scheme 88. Synthesis of cinnamyl N-TMS imine 275 and aza-Henry addition. 
 
 A brief catalyst screen was performed with the catalysts that had provided the 
highest levels of enantioselection with 
p
Cl aryl N-TMS imine 181, as an increase in ee 
was sought. Unfortunately this was not the case, as both 
6,7
MeO-PBAM (188) and Stilb-
PBAM (191) catalysts gave α-bromo nitroalkane 276 in lower yields and enantioselection 
(Table 24, entry 2 and entry 3, respectively). 
 
Table 24. Catalyst screen for aza-Henry addition to cinnamyl N-TMS imine 275. 
 
entry catalystb yield (%)a ee (%)c 
1 PBAM (87) 45 67,66 
2 6,7MeO-PBAM (188) 19 9,10 
3 Stilb-PBAM (191) 34 13,12 
a An aliquot addition (0.2 eq/2 h) of bromonitromethane over 
10 h was used in all cases.b Catalyst structures are shown in 
Table 7.c Enantiomeric excess reported for each diastereomer. 
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 Since these initial results suggested that PBAM was once again the ideal catalyst 
for this system, we delayed a more complete catalyst screen. Instead, fractional 
recrystallization of α-bromo nitroalkane 276 was attempted in order to obtain highly 
enantioenriched material to use in the subsequent UmAS reaction. It was pleasing to see 
that after a single fractional recrystallization in DCM and hexanes, α-bromo nitroalkane 
276 could be recovered in 20% overall yield and 92, 94% ee (Scheme 89). 
 
Scheme 89. Recrystallization of cinnamyl α-bromo nitroalkane 276. 
 
 With this high ee material in hand, an UmAS coupling was attempted between α-
bromo nitroalkane 276 and α-methyl benzylamine. After stirring for 2 days in the 
presence of NIS, K2CO3 and H2O, desired amide 277 could be isolated as a single 
diastereomer in 30% yield (eq 113, Scheme 90). While it was exciting that 277 was 
obtained, and that no epimerization was observed, the yield of this reaction (30%) was 
lower than desired. Therefore, a second coupling in which 2 equivalents of α-methyl 
benzylamine were used was performed. Unfortunately, this only resulted in a 4% increase 
in yield (to 34%, eq 114, Scheme 90).  
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Scheme 90. Initial UmAS coupling of cinnamyl α-bromo nitroalkane 276. 
 
 In order to increase the yield further, a solvent screen for the UmAS step 
performed. It was found that THF gave a slight improvement in yield for 277 (33%, 
Table 25, entry 2) over DME (27% yield, Table 23, entry 1), after stirring for 1 day under 
the reaction conditions. 2-Me-THF gave an unusually low yield (15%, Table 25, entry 3), 
and TBME resulted in no reaction, as the starting α-bromo nitroalkane 276 was not 
soluble in this solvent (Table 25, entry 4). 
 
Table 25. Investigation of solvent effects in the UmAS coupling of cinnamyl α-bromo nitroalkane 276. 
 
entry solvent yield (%) 
1 DME 27 
2 THF 33 
3 2-Me-THF 15 
4 TBME --a 
a 276 was not soluble in TBME, no 
reaction occurred. 
 
 Since THF provided the best results, a series of reactions to explore the optimal 
reaction time for the UmAS coupling in this solvent were performed. After only 3 hours, 
amide 277 was isolated in 33% yield (Table 26, entry 1). However, the starting α-bromo 
nitroalkane (276) was also isolated, indicating that the reaction had not yet reached full 
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conversion. After 6 hours, amide 277 was isolated in 45% yield (Table 26, entry 2). In 
this case, no starting material was isolated, indicating a complete reaction. Extended 
reaction times (24 and 72 hours) led to an unexpected drop in yield (Table 24, 33% yield 
after 24 hours, entry 3, and 27% yield after 72 hours, entry 4). This was troubling, as a 
decrease in yield over a longer reaction time usually indicates that the product is 
decomposing in some way. 
 
Table 26. Time study of the UmAS coupling of cinnamyl α-bromo nitroalkane 276. 
 
entry time (h) yield (%) 
1 3 33(41% brsm) 
2 6 45 
3 24 33 
4 72 27 
 
 The most obvious pathway for decomposition of amide 277 is Fmoc-deprotection. 
As discussed in Section 3.2.3, the basic conditions of the UmAS coupling can result 
Fmoc-deprotection. However, our previous studies (Table 17) had shown that Fmoc-
deprotection happens slowly, so that over the standard reaction time (2 days) only trace 
amounts of deprotection occur. We wondered if amide 277 was more prone to Fmoc-
deprotection than other Fmoc-protected peptides previously evaluated. Therefore, pure 
amide 277 was resubjected to the UmAS reaction conditions. After 1 day, a small amount 
of Fmoc-deprotection could be seen (7%, Table 27, entry 1). After 3 days, the amount of 
Fmoc-deprotection could not be determined, as the 
1
H NMR resonances were too broad 
for accurate integrations (Table 27, entry 2). However, it was clear that a large fulvene 
(214) peak was present at this time. After 5 days, it was confirmed that a significant 
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amount of Fmoc-deprotection had occurred (65% deprotection, Table 27, entry 3). This 
confirmed our fears that amide 277 had limited stability under the alkaline coupling 
conditions. 
 
Table 27. Resubmitting Fmoc-protected amide 277 to reaction conditions. 
 
entry time (d) deprotection (%)a 
1 1 7 
2 3 --b 
3 5 65 
a Based on 1H NMR analysis of crude reaction 
mixture, measuring relative amount of fulvene 
214 to remaining amide 277.b1H NMR too 
broad to accurately integrate peaks. 
 
 It was hypothesized that the Fmoc-deprotection was occurring as a result of the 
K2CO3 and H2O present in the reaction mixture. Therefore, two reactions were performed 
in which these reagents were eliminated and the equivalents of amine, which can also act 
as a base to deprotonate α-bromo nitroalkane 276, were increased. One reaction was done 
under an atmosphere of O2, and one under an atmosphere of Ar, as we know that under 
these conditions the UmAS coupling can proceed through two distinct mechanisms.
27
 
Unfortunately, in both of these reactions, no product was observed in the crude reaction 
mixture. By 
1
H NMR analysis, a large fulvene resonance was observed at 6.1 ppm, 
indicating Fmoc-deprotection (eq 115 and 116, Scheme 91). These results seem to 
support the conclusion that the basic amine is primarily responsible for Fmoc-
deprotection in these coupling reactions. 
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Scheme 91. UmAS coupling of α-bromo nitroalkane 276 without K2CO3 and H2O. 
 
 In order to avert Fmoc-deprotection by the basic α-methyl benzylamine, a 
coupling was attempted between α-bromo nitroalkane 276 and the HCl salt of leucine. It 
was hoped that using the protonated salt form of this amino acid would attenuate the 
basicity of the amine and lower the amount of Fmoc-deprotection observed. This proved 
to not be the case, however, as amide 279 could not be isolated from this reaction 
(Scheme 92). What was isolated from this reaction was a large amount of FmocOH, 
indicating Fmoc-deprotection had occurred under these conditions as well.  
 
Scheme 92. Attempted UmAS coupling of α-bromo nitroalkane 276 with HClH2NLeuO
t
Bu. 
 
 At this point, it was clear that the Fmoc-protecting group was hindering our 
attempts to successfully couple 276 using UmAS conditions. Therefore, it was decided to 
investigate a different protecting group that might be more stable under our coupling 
conditions. By quenching the aza-Henry addition to cinnamyl N-TMS imine 275 with 
CbzCl, Cbz-protected α-bromo nitroalkane 280 could be isolated in 55% yield and 
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69/70% ee (Scheme 93). It was pleasing to see that the enantiopurity of this product could 
be enriched through fractional recrystallization in toluene and hexanes, to give Cbz-
protected α-bromo nitroalkane 280 in 32% overall yield and 93, 93% ee (Scheme 94). 
 
Scheme 93. Synthesis and recrystallization of cinnamyl α-bromo nitroalkane 280. 
 
 Although the ee of α-bromo nitroalkane 280 could be enriched through 
recrystallization, several reactions were performed with the hope of optimizing the 
enantioselectivity of the aza-Henry addition of bromonitromethane to imine 275. In order 
to determine the effect a slow addition of bromonitromethane had on the enantioselection 
of the reaction, a reaction was performed in which bromonitromethane was added as a 
single portion at the beginning of the reaction. The ee of the α-bromo nitroalkane product 
(280) was only 30, 31%, indicating that the enantioselectivity of the addition to N-TMS 
imine 275 is highly dependent on the concentration of bromonitromethane (eq 117, 
Scheme 94). This outcome is similar to what was observed with aryl N-TMS imines. 
Based on these results, a second reaction was attempted in which the bromonitromethane 
was added slowly over 10 h, and the catalyst loading was increased to 20 mol% (from 10 
mol%, Scheme 94). It was hypothesized that by increasing the catalyst loading, the 
relative ratio of bromonitromethane to catalyst would be lowered, increasing the 
enantioselection of the addition. This was not the case, however, as a lower yield and ee 
was observed in this reaction (48% yield, 59, 59% ee, eq 118, Scheme 94). While it is 
131 
 
unclear why a higher catalyst loading is detrimental in this case, it is clear that the 
optimal catalyst loading for this reaction is 10 mol%. 
 
Scheme 94. Attempted optimization of the aza-Henry addition to cinnamyl N-TMS imine 275. 
 
 Attention was next turned to the UmAS coupling of α-bromo nitroalkane 280. 
When this compound was subjected to standard coupling conditions, in the presence of 2 
equivalents of α-methyl benzylamine, a single major product was observed by 1H NMR 
analysis of the crude reaction mixture. Upon isolation we were surprised to see this 
compound was not the desired amide 281, but was instead the epoxy amide 282, isolated 
as a single diastereomer in 17% yield (eq 119, Scheme 95).
135
 
 Since the results of this reaction were surprising, a second coupling was 
performed using leucine 
t
butyl ester as the amine component. While the aminal side 
product was not observed in this reaction, the main product was again not the desired 
amide 283, but the epoxy amide 284 (34% yield, eq 120, Scheme 95). This suggests that 
this unusual epoxide formation is common to α-bromo nitroalkane 280, regardless of the 
amine coupling partner.  
 
                                                          
135
 The relative stereochemistry of the epoxide has not yet been determined. Attempts obtain a crystal 
structure are underway. Based on our mechanistic hypothesis, the epoxide has been temporarily assigned as 
syn to the amine. 
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Scheme 95. UmAS coupling of cinnamyl α-bromo nitroalkane 280. 
 
 While it was surprising that epoxidation of the double bond was occurring under 
these reaction conditions, a mechanism for this transformation can be drawn which would 
account for the high degree of observed diastereoselection. In the presence of an 
electrophilic source of iodine, the double bond could be activated towards nucleophilic 
addition through the formation of a cyclic iodonium species. This intermediate could then 
react with water, to form the iodo alcohol first and then the epoxide. However, because 
this epoxidation occurs with a high level of stereocontrol, it is possible that the carbamate 
functionality of the Cbz-protecting group assists with the hydrolysis. This could happen 
through the formation of a cyclic oxazine intermediate 285, which would form the iodo 
alcohol after hydrolysis. A subsequent SN2 would result in the observed epoxide 282 
(Scheme 96). 
 
Scheme 96. Proposed mechanism for formation of epoxy amide 282. 
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 While epoxy amide 282 was not the expected product of the UmAS coupling of 
α-bromo nitroalkane 280, this unexpected transformation could be a useful way to affect 
amide coupling and double bond functionalization in a single synthetic step. Therefore, 
we decided to optimize the UmAS reaction while increasing the yield of this product. 
After stirring for one day in THF, epoxy amide 282 was isolated in 17% yield (Table 28, 
entry 1). By increasing the reaction time to 2 d, the yield of 282 was increased to 36% 
(Table 28, entry 2). Performing this reaction in DME did not significantly increase the 
yield of epoxy amide 282 (30% yield, Table 28, entry 3), and longer reaction times in this 
solvent unfortunately proved unhelpful (24% yield of 282, Table 28, entry 4), as did 
using an excess of α-methyl benzylamine (Table 28, entry 5). Based on this observation, 
a reaction was run with only a slight excess of α-methyl benzyl amine (1.2 equiv) instead 
of the 2 equiv used previously. However, this also resulted in a lower yield of epoxy 
amide 282 (30%, Table 28, entry 6). A slight improvement was seen when 2-Me-THF 
was used as the solvent, which gave a less complex crude reaction mixture and increased 
yield of epoxy amide 282 (40%, Table 28, entry 7). In order to try and promote the 
epoxidation, a reaction was run with an excess of NIS and H2O. Unfortunately, this 
resulted in only trace amounts of epoxy amide 282. By 
1
H NMR analysis, it was revealed 
that the major component of the crude reaction mixture was the α-iodinated α-bromo 
nitroalkane 287 (Table 28, entry 8). 
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Table 28. Optimization studies of the UmAS coupling of cinnamyl α-bromo nitroalkane 280. 
 
entry solvent time (d) 282 yield (%) 
1 THF 1 17 
2 THF 2 36 
3 DME 1 30 
4 DME 2 24 
5b DME 2 tracea 
6c THF 2 30 
7 2-Me-THF 2 40 
8d THF 2 tracea 
a Based on 1H NMR analysis of crude reaction mixture. b Excess 
of amine (5 eq) used as base in this reaction in place of K2CO3. 
c 
1.2 eq amine, 1.5 eq of K2CO3 used in reaction. 
d 1.2 eq amine, 
1.5 eq K2CO3, 3 eq NIS, 15 eq H2O used in reaction. 
e  In all 
cases, amide 281 was not isolated. 
 
 At this point, it was still unclear whether the epoxidation of the double bond was 
occurring before or after amide coupling. Therefore, a test reaction was performed in 
which α-bromo nitroalkane 280 was stirred with NIS and H2O in THF. 
1
H NMR analysis 
of the crude reaction mixture revealed clean formation of α-iodo α-bromo nitroalkane 
287, and none of the epoxy α-bromo nitroalkane 286 was observed (Scheme 97). This 
suggests that epoxide formation occurs after amide formation, or even perhaps at some 
point during amide formation. 
 
Scheme 97. Attempted formation of 286. 
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 While the epoxy amide (282) formed under these conditions is an interesting and 
potentially useful non-natural amino acid residue in its own right, it was subjected to 
hydrogenolysis conditions to form the 4-phenyl threonine derivative 288. After 
subjecting 282 to H2 and 10% Pd/C, β-hydroxyl-α-amino amide 288 was isolated in 
quantitative yield (Scheme 98). 
 
Scheme 98. Hydrogenation of product 282. 
 
 While unexpected, this unusual epoxidation allows us to use this methodology to 
access non-natural functionalized aliphatic amino acid residues. Further work will be 
done to determine whether this transformation occurs exclusively with cinnamyl 
substrates, or if other alkene side chains undergo a similar epoxidation under the UmAS 
reaction conditions. 
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CHAPTER IV 
 
PROGRESS TOWARDS THE TOTAL SYNTHESIS OF FEGLYMYCIN 
 
4.1 Introduction and Background 
 When used in conjunction with Umpolung Amide Synthesis (UmAS), the 
enantioselective aza-Henry addition of bromonitromethane to N-TMS imines provides a 
powerful new pathway for the synthesis of aryl glycine containing peptides. In three steps 
from the aldehyde, aryl glycine residues can be synthesized and incorporated into 
peptides with a very high degree of stereocontrol. Additionally, multiple protecting 
groups can now be accessed through this methodology, allowing for its use in orthogonal 
peptide synthesis. 
 In order to demonstrate the utility of this methodology, we decided to apply it to 
the synthesis of an aryl glycine-containing natural product. There are several notable aryl 
glycine-containing natural products, seen in Figure 12, most of which possess potent 
antibacterial activity. As discussed in Section 2.1.1, the most prominent of these is 
perhaps vancomycin (51),
46
 which generated much synthetic interest following its 
discovery.
49,50
 This interest was driven by the fact that, due to its potent antibacterial 
activity, vancomycin is used as a “line of last defense” against bacteria that have become 
resistant to other antibiotics.
45
 The vancomycin-related ristocetin A (55)
136
 and the more 
recently discovered cyclic peptide ramoplanin A1 (288)
137
 are also clinically used to fight 
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certain resistant strains of bacteria. Additionally, some commonly used antibiotics, such 
as cefadroxil (289) and amoxicillin (290), also contain aryl glycine residues. 
 While our methodology would be useful in the synthesis of any of these 
medicinally important compounds, we decided to first pursue the total synthesis of the 
newly discovered straight-chain peptide natural product feglymycin (291, Figure 12).
138
 
Like other aryl glycine containing peptides, this compound exhibits interesting biological 
activity, including antibacterial activity. This, along with the high proportion of aryl 
glycines present in the molecule made it an attractive target for our chemistry. 
 
Figure 12. Aryl glycine-containing natural products: potent antibiotics. 
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4.1.1 Feglymycin 
Isolation and Structure Determination 
 Feglymycin (291) was isolated in 1999 from a fermentation culture of 
Streptomyces sp. DSM 11171.
138
 It was isolated by using solid phase extraction, size 
exclusion chromatography and reverse-phase chromatography. Upon its isolation, it was 
determined by mass spectroscopy that the molecular weight of the compound was 
1900.90 g/mol and that the molecular formula was C95H97N13O30. 
1
H and 
13
C NMR 
analysis revealed that feglymycin contained 13 amino acid residues, four of which are 4-
hydroxy phenylglycine (Hpg) residues and five of which are 3,5-dihydroxy 
phenylglycine (Dpg) residues. The other four amino acid residues were identified as ʟ-
valine (2), ʟ-phenylalanine and ʟ-aspartic acid after peptide hydrolysis in aqueous HCl. 
The linear arrangement of these residues was determined by 2D NMR analysis (HSQC, 
HMBC, COSY, TOCSY and NOESY) and confirmed by MS-MS analysis.
138
 The 
relative stereochemistry of each amino acid residue was assigned in 2005, when the 
crystal structure of feglymycin was obtained.
139
 The absolute stereochemistry of the 
phenylglycine residues were then able to be assigned by correlation to the known 
stereocenters of the ʟ-valine, ʟ-phenylalanine and ʟ-aspartic acid residues (Figure 13). 
 
Figure 13. Structure of feglymycin (291). 
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 Through the crystal structure of feglymycin (291), several interesting aspects of 
its structure were brought to light. The first is that the absolute stereochemistry of the 
phenylglycine residues is not conserved throughout the molecule. Three of the 4-hydroxy 
phenylglycine residues were assigned as ʟ-Hpg, while the terminal 4-hydroxy 
phenylglycine residue had the opposite configuration (ᴅ-Hpg). All of the 3,5-dihydroxy 
phenylglycine residues were assigned as ᴅ-Dpg (Figure 13).139 
 
Figure 14. Double-helical dimer of feglymycin (291).
140
 
 
 As observed with other alternating ᴅ,ʟ-peptides,141 the crystal structure of 
feglymycin showed that it had formed a double-helical dimer upon crystallization (Figure 
14). When lined up end to end, the feglymycin dimers form an infinite helical structure 
which can be described as a right-handed, wide, antiparallel, double-stranded β-helix.139  
 
Biological Activity 
 At the time of its isolation, feglymycin (291) was reported to have weak 
antibacterial activity against Gram positive bacteria (IC50 of 32-64 µg/mL against several 
strains of Staphylococcus aureus). However, later biological studies performed by 
Süssmuth and coworkers revealed that this peptide was active against methicillin-
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resistant Staphylococcus aureus (MRSA) with an IC80 value of 2 µg/mL.
142
 This finding 
prompted further studies into the mechanism of action of feglymycin (291). Based on the 
structure and molecular weight of feglymycin, it was thought that it might have a similar 
mechanism of action to other aryl glycine containing peptides, such as vancomycin (51) 
or ramoplanin (55). These compounds interfere in cell wall biosynthesis by inhibiting the 
late stages of peptidoglycan production, as do most clinically important antibiotics. 
However, initial studies by Süssmuth and coworkers indicated feglymycin had no effect 
on the last two stages of peptidoglycan biosynthesis, but instead was inhibiting earlier 
biosynthetic steps. Based on this observation, the authors examined feglymycin’s effect 
on enzymes Mur Α-F, which catalyze the first six steps of peptidoglycan synthesis. They 
found that feglymycin noncompetitively inhibited the enzymes Mur A (IC50 of 3 µM) and 
Mur C (IC50 of 1 µM), making it the first known natural inhibitor of these enzymes. This 
unique mechanism of action could make feglymycin a useful antibiotic against resistant 
bacterial strains.
142
 
 In addition to possessing antibacterial activity, feglymycin was also reported to 
strongly inhibit the formation of HIV syncytia in vitro (IC50 of ~5 µM).
138 
Syncytia are 
multinucleate cells which are formed by the joining of two or more single nucleate 
cells.
143
 A hallmark of HIV infection, syncytia formed through the joining of multiple 
CD
4+ 
T-cells can often be seen in the patient’s blood stream. The mechanism of syncytia 
formation in HIV infected cells involves the viral membrane fusion protein gp41. This 
glycoprotein, which is a subunit of the envelope protein complex of the HIV retrovirus, is 
responsible for the second step by which HIV infects white blood cells. After the virus is 
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bound by the CD
4+
 T-cell, gp41 acts to fuse the HIV to the cell membrane of the T-cell, 
allowing it to enter into the cell.
144
 
After HIV invades a healthy CD
4+
 T-cell, it induces the cell to produce viral 
proteins, including the membrane fusion protein gp41, which are then displayed on the 
cell membrane. These proteins then allow the infected cell to fuse to other nearby CD
4+
 
helper T-cells, through the same mechanism with which HIV enters a cell. Once fused, 
the cell membrane of these cells will join, forming a large, non-functional syncytium.
145
 
In this way, a single HIV virion can infect and kill many CD
4+
 T-cells. Syncytia 
formation is often monitored as a way to assay a compound’s efficacy at inhibiting the 
binding of the viral membrane fusion protein gp41 to a cell membrane. Because this 
protein plays a vital role in both HIV infection and syncytia formation, a compound that 
successfully inhibits syncytia formation will likely also inhibit HIV infection. 
Though the molecular mechanism of the antiviral activity of feglymycin has not 
yet been investigated, its structure offers clues as to how this peptide might function. 
While similar helical peptides
141
 have been shown to function as membrane transport 
proteins, it is unlikely that feglymycin performs a similar function. The feglymycin helix 
is not long enough to span a cell membrane, and its channel is blocked by the 
phenylalanine side chains. Vértesy and co-workers suggest that perhaps feglymycin could 
act as an ion carrier instead, providing a mechanism for membrane penetration which 
may disrupt the binding of the fusion protein gp41.
139
 
 
                                                          
144
 Kim P. S.; Malashkevich V. N.; Chan D. C.; Chutkowski C. T. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 
9134. 
145
 Huerta, L.; López-Balderas, N.; Rivera-Toledo, E.; Sandoval, G.; Gȑmez-Icazbalceta, G.; Villarreal, C.; 
Lamoyi, E.; Larralde, C. The Scientific World Journal 2009, 9, 746. 
142 
 
4.1.2 Previous Synthesis of Feglymycin 
 The total synthesis of feglymycin has been achieved only once, by Süssmuth and 
co-workers in 2009.
146
 They utilize a highly convergent approach in which di- and 
tripeptide fragments are synthesized and then condensed to give the 13 amino acid 
residue peptide. The retrosynthetic approach used by the authors can be seen in Scheme 
99. They envisioned that a disconnection could be made between Hpg residue 7 and Dpg 
residue 8, breaking feglymycin (291) into two smaller peptide fragments (292 and 293) 
which would subsequently come from six di- and tripeptide fragments (294-298). These 
fragments could then be synthesized from the commercially available amino acids valine, 
phenylalanine, aspartic acid, ᴅ-Hpg 299 ($1/g from Sigma Aldrich) and ʟ-Hpg 300 
($10/g from Sigma Aldrich). The only residue which is not commercially available, ᴅ-
Dpg 301, could come from the Sharpless asymmetric aminohydroxylation (SAA) of 
styrene 302. 
As mentioned previously, phenylglycine residues readily epimerize under 
standard peptide coupling conditions. This holds especially true for the highly 
racemization prone amino acid 3,5-dihydroxy phenylglycine (Dpg). With this in mind, 
the authors specifically designed this approach to avoid activation of Dpg when 
condensing the di- and tripeptide fragments, as they knew it would be more difficult to 
separate diastereomers at later stages of the synthesis (Scheme 99).
146
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Scheme 99. Sussmuth’s retrosynthetic approach to feglymycin (291). 
 
 The authors began with the synthesis of protected ᴅ-Dpg 301. Starting from 3,5-
dibenzyloxy benzaldehyde 303, a Wittig reaction provided styrene 302 in 91% yield. A 
subsequent Sharpless asymmetric aminohydroxylation (SAA) gave the amino alcohol 
304 in 52% yield and 98% ee. A two-step oxidation provided the desired carboxylic acid 
301 in 97% yield, with no loss in enantiopurity (Scheme 100).
146
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Scheme 100. Süssmuth’s synthesis of (R)-Dpg 301. 
 
 With 301 successfully synthesized, the di- and tripeptide fragments were 
synthesized through condensative amide coupling. The authors found that the coupling 
reagent 3-(diethyloxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT, 305, $10/g 
from Sigma Aldrich) was the only reagent able to successfully couple Dpg 301 without 
significantly epimerizing the α-stereocenter. All other coupling reagents resulted in lower 
conversion and substantial epimerization of the hydroxyphenyl glycine amino acids.
146
 
Using 2 equiv DEPBT, Dpg 301 was coupled to valine benzyl ester to give the dipeptide 
306 in 98% yield, after Boc-deprotection. A second DEPBT coupling and protecting 
group manipulation gave the tripeptide fragment 307 in 69% yield (Scheme 101).
146
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Scheme 101. Süssmuth’s synthesis of the tripeptide fragment 308. 
 
 The synthesis of the dipeptide fragments proceeded in similar fashion. Using 2 
equiv DEPBT, Dpg 301 was coupled to the Hpg methyl ester (308) in 78% yield, giving 
the free amine dipeptide 309 after hydrogenolysis and Boc-deprotection (eq 121, Scheme 
102). Dpg 301 was also successfully coupled to the benzyl ester of valine and the benzyl 
ester of Hpg (310), giving the free acid dipeptides 297 and 295, respectively, after 
hydrogenolysis (eq 122 and eq 123, Scheme 102). The authors found it necessary to fully 
deprotect the Dpg residues at the dipeptide stage, as condensation of the protected 
dipeptides resulted in peptide fragments with very low solubility in both aqueous and 
organic solvents.
146
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Scheme 102. Süssmuth’s synthesis of the dipeptide fragments of feglymycin 291. 
 
 With the di- and tripeptide fragments synthesized, the authors proceeded to 
assemble the two larger peptide fragments 292 and 293. DEPBT coupling of 295 with the 
dipeptide 298, synthesized from the EDT coupling of phenylalanine and the benzyl ester 
of aspartic acid, gave the tetramer 311, after Boc-deprotection. 311 was then coupled to 
297 to give the peptide fragment 293 which constitutes the eastern portion of feglymycin 
291, in good yield (Scheme 103).
146
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Scheme 103. Condensation of the dipeptide fragments to form the peptide 293. 
 
 The western portion of feglymycin 291 was synthesized in a similar fashion. 
Dipeptides 295 and 309 were coupled to give the tetramer 312 in 54% yield after Boc-
deprotection. This was then coupled to the tripeptide fragment 294, providing the free 
acid 292 after saponification with trimethyltin hydroxide (Scheme 104).
146 
 
Scheme 104. Condensation of the di- and tripeptide fragments to form peptide 292. 
 
 The peptide fragments 292 and 293 were then condensed, through another 
DEPBT coupling, to provide feglymycin 291 in 37% yield after global deprotection by 
148 
 
hydrogenolysis (Scheme 105). Thus, the authors were able to complete the synthesis of 
feglymycin 291 in 34 steps (14 steps in the longest linear sequence) and 4% overall yield. 
By using the specialized coupling reagent DEPBT, they were able to minimize the 
epimerization of the sensitive Hpg and Dpg amino acid residues and synthesize 
feglymycin as a single diastereomer.
146
 
 
Scheme 105. Süssmuth’s completion of feglymycin 291. 
 
 
4.2 Proposed Retrosynthesis of Feglymycin 
 Because Umpolung Amide Synthesis (UmAS) is by its nature an iterative method 
of amino acid homologation, it is most useful when used in a complementary manner 
with standard peptide coupling methods. The synthesis of feglymycin 291 provides an 
excellent opportunity for us to demonstrate this concept, as this peptide contains multiple 
sensitive arylglycine residues as well as several canonical amino acid residues. In order to 
make the synthesis of this compound a convergent one, we envisioned the amide bonds 
between Val residue 3 and Dpg residue 4, and Val residue 9 and Dpg residue 10 could be 
formed through conventional amide coupling methods. These key disconnections would 
lead to three smaller peptides, assigned as fragment A (313), fragment B (314) and 
fragment C (315), which could be synthesized using iterative UmAS chemistry (Scheme 
106). 
 
149 
 
Scheme 106. First generation retrosynthesis of feglymycin 291. 
 
 An orthogonal protecting group strategy was devised for the synthesis of 
feglymycin (291) in which the internal aryl glycine residues of the three peptides will be 
protected with an Fmoc group, allowing the N-terminal amine to be deprotected while 
leaving the benzyl-protected phenols and C-terminal esters untouched. We wish to 
protect the terminal aryl glycine residues with a Cbz group, allowing for concomitant 
deprotection of the benzyl-protected phenols and N-terminal amine after synthesis of the 
peptide fragments is complete. The N-terminal free amine of fragment A (313) will then 
150 
 
be reprotected with a Boc group before coupling to fragment B (314). Subsequent 
saponification of the methyl ester of the resulting peptide will give the C-terminal 
carboxylic acid, allowing for this to be coupled to the N-terminal free amine of fragment 
C (315). Acid-mediated deprotection of the N-terminal Boc group and the C-terminal 
tert-butyl esters will then give the natural product (Scheme 106). 
 The three peptides could therefore be synthesized from the protected canonical 
amino acids ʟ-Val, ʟ-Phe and ʟ-Asp, as well as the α-bromo nitroalkane precursors to the 
Hpg and Dpg amino acid residues. This would include the Fmoc-protected 4-benzyloxy 
aryl α-bromo nitroalkane 201k and 3,5-dibenzyloxy aryl α-bromo nitroalkane 201l 
synthesized in Section 3.2.2 (Table 12, entries 12 and 13). The two additional α-bromo 
nitroalkanes needed for the synthesis of feglymycin would be the Cbz-protected 4-
benzyloxy aryl and 3,5-dibenzyloxy aryl derivatives 316 and 317, which could be easily 
obtained through a CbzCl quench of the aza-Henry addition reaction to the appropriate N-
TMS aryl imine (Scheme 106). 
 
4.3 Total Synthesis of Feglymycin 
 
4.3.1 Synthesis of the α-Bromo Nitroalkane Donors 
 As mentioned previously, Fmoc-protected 4-benzyloxy aryl α-bromo nitroalkane 
201k had been previously synthesized, through the aza-Henry addition of 
bromonitromethane to N-TMS imine 200k, in the presence of (S,S)-PBAM, and 
subsequent quench with FmocCl. This procedure provided 201k in 74% yield and 76, 
74% ee. While this enantioselection was relatively good for an electron rich substrate, in 
order to use this material in the synthesis of feglymycin, a higher level of enantiopurity 
was needed. Therefore, a fractional recrystallization of 201k was performed in 
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dichloromethane and hexanes, providing the α-bromo nitroalkane in 97/97% ee (eq 124, 
Scheme 107). A similar procedure was used to synthesize Cbz-protected 4-benzyloxy 
aryl α-bromo nitroalkane 316. By treating imine 200k with bromonitromethane in the 
presence of (R,R)-PBAM, and quenching with CbzCl, 316 could be obtained in 56% 
yield and 67/67% ee. While the enantioselection was slightly lower than what was 
observed with Fmoc-protected derivative 201k, the ee of Cbz-protected derivative 316 
was also able to be enriched through fractional recrystallization in dichloromethane and 
hexanes to 97/96% ee (eq 125, Scheme 107). We were pleased with these results, as a 
97/96% ee would correspond to a 49:1 ratio of diastereomers after UmAS coupling of the 
α-bromo nitroalkanes. 
 
Scheme 107. Synthesis and recrystallization of Hpg α-bromo nitroalkanes 201k and 316. 
 
 Fmoc-protected 3,5-dibenzyloxy aryl α-bromo nitroalkane 201l, synthesized 
previously in 61% yield and 79, 82% ee, was also subjected to fractional recrystallization. 
In doing so, this product was enriched to 97, 97% ee (eq 126, Scheme 108). A CbzCl 
quench of the aza-Henry addition to N-TMS imine 200l provided the Cbz-protected 3,5-
dibenzyloxy α-bromo nitroalkane 317 in 53% yield and 71, 71% ee. The enantiopurity of 
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317 was similarly enriched through fractional recrystallization to 97, 97% ee (eq 127, 
Scheme 108). 
 
Scheme 108. Synthesis and recrystallization of Dpg α-bromo nitroalkanes 201l and 317. 
 
4.3.2 Synthesis of Fragment A 
 With the required α-bromo nitroalkanes in hand, we first turned to the synthesis of 
fragment A (313). In order to install the first Dpg residue in fragment A, Fmoc-protected 
3,5-dibenzyloxy aryl α-bromo nitroalkane 201l was coupled to the TFA salt of valine 
benzyl ester 318. Under standard UmAS conditions, the dipeptide 319 was isolated in 
47% yield (Table 29, entry 1).  
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Table 29. UmAS coupling of 201l with the TFA salt of valine benzyl ester 318. 
 
     
entry 
eq of α-bromo 
nitroalkane (201l) 
                                 
eq of amine (318) 
                         
yield of 319 (%) 
1 1 1.2 47 
2 1 2 52 
3 2 1 27 
4a 1 1.2 37 
5b 1 1.2 23 
6c 1 1.2 35 
a Reaction performed at room temperature. b Reaction not run under an 
atmosphere of O2. 
c O2 balloon refreshed every 2 hours for first 8 
hours. 
 
The moderate yield of this reaction prompted optimization of this initial coupling. 
By increasing the amount of valine benzyl ester 318 to 2 eq, the yield of 319 could be 
increased slightly, to 52% (Table 29, entry 2). Increasing the equivalents of the α-bromo 
nitroalkane resulted in a lower yield of 319 (27%, Table 29, entry 3), as did performing 
the reaction at ambient temperature and removing O2 from the reaction conditions (37% 
and 23% yield, respectively, Table 29, entries 4 and 5). The low yield of 319 obtained 
when the reaction was run without O2 prompted us to perform a reaction in which the O2 
balloon was refreshed periodically throughout the time period of the reaction. However, 
this unfortunately also resulted in a lower yield of dipeptide 319 (35% yield, Table 29, 
entry 6).  
 Although we previously had success coupling the TFA salts of amines, it was 
thought that perhaps it was this reagent that was causing the low yield of 319. The TFA 
salt of valine benzyl ester 318 had been prepared via a TFA deprotection of the N-Boc 
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protected amino acid, and it was possible that not all of the excess TFA had been 
removed from the amino acid salt upon concentration of the crude reaction mixture. This 
excess TFA would have a detrimental effect on the UmAS coupling reaction, as alkaline 
conditions are needed to deprotonate the α-bromo nitroalkane. Therefore, the HCl salt of 
valine benzyl ester 320 was prepared, via an HCl/dioxane deprotection of the N-Boc 
amino acid. In this case, the resulting amino acid salt was precipitated from ether and 
isolated via filtration in order to make sure no excess HCl remained. 
 It was pleasing to see that when this amino acid was subsequently coupled to α-
bromo nitroalkane 201l, a substantial increase in the yield of the UmAS reaction was 
observed. The dipeptide 319 was able to be isolated as a single diastereomer in 63% yield 
(Scheme 109).  
 
Scheme 109. UmAS coupling of 201l with the HCl salt of valine benzyl ester 320. 
 
 While we were able to optimize the yield of 319 on small scale (50 mg of the 
starting α-bromo nitroalkane 201l), several problems were encountered upon scale-up of 
this coupling reaction. When 250 mg of the starting α-bromo nitroalkane 201l was used, 
it was observed that on this scale the starting materials weren’t completely soluble at a 
concentration of 0.2 M in DME. Additionally, this reaction stopped stirring after several 
hours due to its heterogeneous nature (Table 30, entry 2). In order to solubilize the 
starting materials, the reaction was diluted to 0.05 M in DME. This did improve the 
stirring of the reaction, and the dipeptide 319 was able to be isolated. However, the yield 
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after stirring for 2 days under these conditions was only 52% (Table 30, entry 3). It was 
hypothesized that the dilute conditions caused the coupling to proceed at a slower rate. 
This was confirmed when the yield of dipeptide 319 was increased back to 63% after 
allowing the reaction to stir for 4 days (Table 30, entry 4). 
 While these conditions worked well on this scale, increasing the amount of 
starting material further, to 0.5 g of α-bromo nitroalkane 201l, again resulted in a 
decrease in yield (38%, Table 30, entry 5). It was hypothesized that this was again due to 
poor stirring in the reaction. By switching from using a magnetic stir bar to a mechanical 
stirrer, the scale of the reaction could be increased to 1 g while still maintaining an 
acceptable yield of dipeptide 319 (59%, Table 30, entry 6). Moreover, it was found that 
on this scale, a majority of the dipeptide 319 could be isolated through an EtOAc/hexanes 
recrystallization of the crude reaction mixture, eliminating the need for column 
chromatography in this step. 
 
Table 30. Scale up of the UmAS coupling of 201l with the HCl salt of valine benzyl ester 320. 
 
     
entry 
scale of reaction 
(g of 201l) 
concentration 
(M) 
time          
(d) 
yield           
(%) 
1 0.05 0.2 2 63 
2 0.25 0.2 2   --a 
3 0.25 0.05 2 52 
4 0.25 0.05 4 63 
5 0.50 0.05 4 38 
6b 1.0 0.1 2 59 
a Reaction stopped stirring after several hours. Due to low conversion, 
the yield of this reaction was not determined. b Reaction run with 
mechanical stirring. Product isolated via EtOAc/Hex recrystallization 
directly from crude reaction mixture. 
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 With the first UmAS coupling towards fragment A (313) optimized, we next 
turned to the Fmoc-deprotection of the dipeptide 319. The most common method of 
Fmoc-deprotection, treatment with piperidine in DMF,
147
 was first attempted. 
Unfortunately, these conditions resulted in a complex crude reaction in which only trace 
amounts of the free amine 321 could be observed (Table 31, entry 1). Deprotection with 
morpholine in DCM gave better results, with the major product of this reaction 
determined to be the desired amine 321 by 
1
H NMR analysis. However, several other 
baseline products could also be observed (Table 31, entry 2). Treatment of DIEA in DCM 
resulted in no deprotection, even after stirring for 24 hours (Table 31, entry 3). 
 
Table 31. Screen of conditions for the Fmoc-deprotection of 319. 
 
entry conditions resulta yield (%) 
1 20% piperidine/DMF messy, trace product -- 
2 50% morpholine/DCM 
full conversion, other products 
observed 
-- 
3 50% DIEA/DCM no conversion -- 
4b TBAF, iPrOH/THF clean conversion to 321 87 
a As determined by 1H NMR analysis of the crude reaction mixture. b Reaction run with 
8 eq TBAF, 10 eq iPrOH. Product isolated as the free amine by column 
chromatography, using 10% acetone/hexanes as the eluent. 
 
 Upon examining literature concerning the synthesis of Hpg and Dpg containing 
peptides, it was found that the Fmoc-deprotection of peptides containing these sensitive 
amino acid residues is most often carried out through treatment with TBAF and 
i
PrOH.
148
 
                                                          
147
 Albericio, F.; Kneib-Cordonier, N.; Biancalana, S.; Gera, L.; Masada, R. I.; Hudson, D.; Barany, G. J. 
Org. Chem. 1990, 55, 3730. 
148
 Rew, Y.; Shin, D.; Hwang, I.; Boger, D. L. J. Am. Chem. Soc. 2004, 126, 1041. 
157 
 
These mildly basic conditions worked well for us, cleanly deprotecting dipeptide 319 to 
provide the free amine 321 in 87% yield after purification (Table 31, entry 4).  
 
Scheme 110. UmAS coupling of 316 with dipeptide 321. 
 
 The free amine 321 was then coupled to the Cbz-protected 4-benzyloxy aryl α-
bromo nitroalkane 316, under standard UmAS conditions. We were pleased to see that 
the protected-fragment A (322) could be isolated in 64% yield (Scheme 110). In order to 
complete the synthesis of fragment A (313), global deprotection and subsequent 
reprotection of the resulting free amine with a Boc group was necessary. Therefore, a 
hydrogenolysis of 322 was attempted, using 10% Pd/C and cyclohexene as a source of 
H2. After stirring for several days at elevated temperature, the crude reaction mixture was 
treated with Boc2O. Unfortunately, based on 
1
H NMR analysis of the crude reaction 
mixture, the desired Boc-protected fragment A (313) was not present. Instead, a large 
amount of starting tripeptide 322 was observed, indicating that deprotection had not 
occurred (Scheme 111). 
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Scheme 111. Attempted hydrogenolysis of 322, with concomitant Boc protection. 
 
 Since it appeared that deprotection of the Cbz and Bn protecting groups in 322 
would be more challenging than originally thought, optimization of the deprotection 
conditions before reprotecting the free amine with a Boc-protecting group was pursued. 
A second hydrogenolysis, this time using a H2 balloon, was attempted. After several 
hours at room temperature, analysis by TLC indicated full conversion of the starting 
tripeptide 322. Upon analysis by 
1
H NMR, however, it was clear that the major product 
of this reaction still contained at least one benzyl group, suggesting incomplete 
deprotection. Isolation and full characterization of this product proved difficult, however, 
upon analysis by LCMS it was determined that it had a MW of 579.3. This mass is 
consistent with the methyl ester 324, in which the phenols have been deprotected, but the 
N-terminal amine has not. While conversion from the benzyl ester to the methyl ester is 
curious, this may be an artifact of the conditions used for LCMS analysis (Scheme 112). 
 
Scheme 112. Attempted hydrogenolysis of 322. 
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 Since deprotection of the Cbz-protecting group was problematic with this 
substrate, alternative N-terminal protecting groups were considered. Boc-protected α-
bromo nitroalkane 325 was targeted, as an N-terminal Boc-protecting group was 
ultimately desired. This would eliminate the need for a deprotection/reprotection 
sequence, simplifying the synthesis of feglymycin 291 (Scheme 113). 
 
Scheme 113. Second generation retrosynthesis of feglymycin 291. 
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We anticipated that synthesis of this α-bromo nitroalkane would be challenging. It 
was previously found that quenching the aza-Henry addition of bromonitromethane to N-
TMS imines with Boc2O resulted in a very low yield of desired Boc-protected α-bromo 
nitroalkane 84 (36%, Section 3.2.2, Table 11, entry 13). Use of acid chlorides and 
chloroformates worked best in this chemistry, perhaps due to the ability of the chloride 
(Cl
-
) produced as a byproduct of the acylation step to subsequently deprotect the TMS 
group. We therefore wished to synthesize BocCl, and use that reagent to quench the aza-
Henry addition. 
 
Table 32. Attempted in situ preparation of BocCl. 
 
entry conditions resultsa 
1 
reagents combined at -78 °C, stirred 
for 4 h, added to reaction messy, trace product 
2 
reagents combined at -78 °C, warmed 
to rt, stirred for 1 h, added to reaction 2:3 ratio of 84:186
 
3 same as entry 2, 3 eq of reagents used mostly 186 
4b same as entry 2, pyridine added  186 cleanly formed 
a As determined by 1H NMR analysis of the crude reaction mixture.  
 
 While BocCl is a known compound, 149 it is not an easy reagent to work with. It is 
a highly volatile compound, with a boiling point of 3 °C at 2 mmHg. It can only be 
purified using low temperature distillation, as it is unstable at temperatures above 10 °C. 
It must therefore be stored at low temperatures, as a solution, and lasts no longer than a 
few days.
149
 It is for these reasons we decided it would be best to make BocCl in situ, and 
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immediately add the crude solution containing this product to the aza-Henry reaction in 
order to quench the N-TMS amine. 
This was first attempted by combining the NaO
t
Bu and phosgene at -78 °C. The 
solution was stirred for 4 hours, and then directly cannulated into the aza-Henry reaction 
of bromonitromethane and 
p
Cl aryl N-TMS imine 181 that had been stirring overnight. 
Unfortunately, only a trace amount of desired Boc-protected α-bromo nitroalkane 84 was 
observed by 
1
H NMR analysis of the crude reaction mixture (Table 32, entry 1). The 
major product produced in this reaction was the transimination product 186, which had 
been observed previously in this chemistry. The formation of this byproduct seems to 
occur when the acylation of the N-TMS amine has not gone to completion. Therefore, we 
hypothesized that the BocCl may not have formed at such low reaction temperatures (-78 
°C), resulting in little acylation of the N-TMS amine. In order to test this, a second 
reaction was done in which the solution of NaO
t
Bu and phosgene was warmed to room 
temperature for an hour before recooling to -78 °C and cannulating into the aza-Henry 
reaction. This did improve the outcome of the reaction, as the product 84 was present in a 
2:3 ratio with transimination product 186 (Table 32, entry 2). In order to improve this 
ratio further, an excess of NaO
t
Bu and phosgene was used. Unfortunately, this resulted 
mostly in formation of transimination product 186 (Table 32, entry 3). Finally, in an 
attempt to promote the formation of BocCl, pyridine was added to the reaction mixture. 
This also resulted in clean formation of 186 (Table 32, entry 4). 
 
 
 
 
 
162 
 
Scheme 114. Attempted stepwise synthesis of 199j. 
 
 Due to the minimal success when preforming BocCl, an attempt was made to 
introduce the Boc protecting group in a stepwise fashion. After the aza-Henry addition to 
181 was complete, phosgene was added to the crude reaction mixture of N-TMS amine 
184, and the reaction was stirred for an additional 1 hour at -78 °C. It was hoped that 
intermediate 326 would form, which would then be reactive towards NaO
t
Bu. However, 
after addition of this reagent, desired Boc-protected α-bromo nitroalkane 84 was not 
observed in the complex crude reaction mixture (Scheme 114).  
 
Scheme 115. Previous efforts towards the synthesis of 4-benzyloxy aryl sulfone 328. 
 
While we had hoped to be able to optimize the aza-Henry addition to N-TMS 
imines to include the introduction of Boc-protecting groups, this was proving to be 
problematic. Therefore, we decided to approach the synthesis of the Boc-protected 4-
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benzyloxy aryl α-bromo nitroalkane 325 in a different way. From previous work, we 
knew that the enantioselective aza-Henry addition of bromonitromethane to the N-Boc 
imine would be a reliable way to access the Boc-protected α-bromo nitroalkane 325. 
However, past attempts to synthesize the sulfone precursor (328) to the N-Boc imine had 
not been successful. The 4-benzyloxy benzaldehyde 327 was not soluble under the 
standard reaction conditions for sulfone synthesis (eq 128, Scheme 115). Increasing the 
amount of MeOH used and decreasing the concentration of the reaction helped to 
solubilize aldehyde 327, however sulfone 328 still could not be synthesized under these 
conditions, even after stirring for several days at elevated temperatures (eq 129, Scheme 
115). Preforming the sulfinic acid and switching to a toluene solvent system resulted in 
the production of 328, however only trace amounts of this product were observed by 
1
H 
NMR analysis, even after several days (eq 130, Scheme 115).
150
 
 
Table 33. Synthesis of 4-benzyloxy aryl sulfone 328. 
 
entry solvent result 
1 
1:2 MeOH:H2O, DCM to 
dissolve aldehyde 
16% conversiona, 327 and 
328 fully soluble in DCM 
2 
ether, H2O to dissolve 
sulfinic acid 
0% conversiona 
3 
toluene, H2O to dissolve 
sulfinic acid 
30% yield, 327 insoluble in 
tol, 328 soluble 
a As determined by 1H NMR analysis of the crude reaction mixture.  
 
 Based on this final result, we decided to return to re-examine the synthesis of 
sulfone 328. Several different solvent systems were examined, and a focus was placed on 
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solubilizing all of the starting materials of this reaction. Under standard reaction 
conditions (1:2 MeOH:H2O solvent system), we knew that benzaldehyde 327 was not 
soluble. Therefore, a small amount of DCM was added to the reaction in order to dissolve 
this compound. We were pleased to see that this resulted in 16% conversion to sulfone 
328 (Table 33, entry 1). However, both sulfone 328 and aldehyde 327 were soluble in 
dichloromethane, which made the isolation of 328 challenging. The ideal solvent system 
for this reaction would solubilize the starting materials of this reaction, but allow the 
sulfone product to precipitate out so that it could be isolated via filtration. We therefore 
chose to use ether as the organic phase in this reaction, as we hypothesized the sulfone 
328 would be insoluble in this solvent. Unfortunately, though we were able to solubilize 
the starting materials through the addition of H2O, these conditions resulted in no 
conversion to sulfone 328 (Table 33, entry 2). The final solvent to be screened was 
toluene, with some added H2O to solubilize the sulfinic acid. We were excited to see that 
after stirring for 4 days, a white precipitate had formed. After filtration, this precipitate 
was confirmed to be sulfone 328, isolated in 30% yield (Table 33, entry 3). 
 
Scheme 116. Optimized synthesis of Boc-protected α-bromo nitroalkane 325. 
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 By stirring this reaction for a longer period of time, the yield of sulfone 328 was 
increased to 52% (Scheme 116). Treatment of 328 with K2CO3 and Na2SO4 resulted in 
clean conversion to desired N-Boc imine 329. This imine was then subjected to the 
standard conditions for aza-Henry addition of bromonitromethane to N-Boc imines, and 
we were excited to see that the Boc-protected 4-benzyloxy aryl α-bromo nitroalkane 325 
could be synthesized in 90% yield and 92, 92% ee (Scheme 116). 
 With the Boc-protected α-bromo nitroalkane 325 in hand, the next step was to 
couple this compound to dipeptide 321, in order to install the final Hpg residue of 
fragment A (313). Under standard UmAS conditions, the Boc-protected tripeptide 330 
was isolated, though in low yield (23%, eq 131, Scheme 117).  
 
Scheme 117. Completion of fragment A (313). 
 
The protected tripeptide 330 was then subjected to hydrogenolysis conditions. We 
were pleased to see that after stirring at room temperature for 10 minutes, quantitative 
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conversion to 313 could be seen by 
1
H NMR analysis (eq 132, Scheme 117).
151
 Future 
work in this area will include the optimization and scale up of the final UmAS coupling 
in this sequence. 
 
4.3.3 Synthesis of Fragment C 
In order to make fragment C (315), we first needed to synthesize terminal 
PheAsp di-tbutyl ester 334. We began by following a known procedure152 for the 
synthesis of 
t
butyl esters, in which the free acid is treated with perchloric acid and 
t
butyl 
acetate before work up with aqueous base. However, it was found that the resulting free 
amine aspartic acid di-
t
butyl ester (331) was volatile, leading to a very low isolated yield 
(7% yield, eq 133, Scheme 118). Therefore, upon repeating this reaction we attempted to 
form the ammonium salt 332 by treating the organic phase with HCl in dioxane. 
Unsurprisingly, it was found that the formation of 332 was very sensitive. When 
dichloromethane was used as the organic phase, only deprotected aspartic acid could be 
isolated. However, by extracting the free amine into diethyl ether before the addition of 
HCl in dioxane, 332 could be isolated, though in moderate yield (34% yield, eq 134, 
Scheme 118). 
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 Chen, H.; Feng, Y.; Xu, Z.; Te, Y. Tetrahedron 2005, 61, 11132. 
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Scheme 118. Synthesis of aspartic acid di-
t
butyl ester 332. 
 
 The free amine aspartic acid di-
t
butyl ester 331 was first coupled to N-Boc 
protected phenyl alanine, as it was readily available. After EDC coupling and subsequent 
selective deprotection of the N-Boc protecting group, the dipeptide ammonium salt 333 
was isolated in 45% yield (eq 135, Scheme 119). Upon scale up, the yield of this 
dipeptide was increased by coupling ammonium salt 332 to N-Fmoc protected phenyl 
alanine. This gave free amine dipeptide 334 in 82% yield after coupling and Fmoc-
deprotection (eq 136, Scheme 119). 
 
Scheme 119. Synthesis of free amine dipeptide 334. 
 
 With the dipeptide 334 in hand, we next attempted the UmAS coupling of this 
substrate with α-bromo nitroalkane 201k. Pleasingly, we were able to isolate the desired 
tripeptide 335 in 85% yield, as a single diastereomer (Scheme 120). 
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Scheme 120. Synthesis of tripeptide 335. 
 
 Similarly, Fmoc-deprotection of 335 and subsequent UmAS coupling with α-
bromo nitroalkane 317 gave the protected-fragment C (336) in 54% overall yield 
(Scheme 121). Future work will include the scale up of these UmAS coupling reactions, 
as well as the investigation of deprotection conditions to give fragment C (315). 
 
Scheme 121. Synthesis of protected fragment C (336). 
 
 
 
4.3.4 Progress Towards the Synthesis of Fragment B 
 To synthesize fragment B (314), we first started with the UmAS coupling of α-
bromo nitroalkane 201k with the methyl ester of valine. While dipeptide 337 was 
successfully synthesized, the yield was only moderate (49%, eq 137, Scheme 122). 
Additionally, the yield of the subsequent Fmoc-deprotection to give free amine 338 was 
also low (22%, eq 138, Scheme 122). While attempts were made to increase the yield of 
these reactions, none were successful. We thought that the low yields we were obtaining 
might be a result of the fact that the C-terminal carboxylic acid of 337 is protected as a 
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methyl ester, which can be easily saponified. We had previously observed that 
t
butyl ester 
amino acids gave higher yields in UmAS couplings than did their corresponding methyl 
ester derivatives (Section 3.2.3, Table 20). It is therefore likely that under the UmAS 
reaction conditions, which include water and K2CO3, the methyl ester of 337 is 
competitively partially saponified. While the free acid product was never observed, this 
would be lost to the aqueous layer during the work up of the reaction. The low yield of 
the subsequent deprotection of 337 could likewise be a result of transesterification, as iso-
propoxide would form under the reaction conditions. 
 
Scheme 122. Synthesis and deprotection of dipeptide 337. 
 
 Though the coupling of α-bromo nitroalkane 201l to the methyl ester of valine 
was problematic, we knew that this compound could be successfully coupled to the 
benzyl ester of valine (63% yield, Scheme 109). Therefore, we reexamined our 
retrosynthetic approach to feglymycin (291) to see if it would be possible to start the 
synthesis of fragment B (314) with dipeptide 319, the same dipeptide successfully used to 
synthesize fragment A (313). It was decided that this would be possible if we switched 
the order of fragment ligation in the end stages of the synthesis. By protecting the N-
terminal amine of fragment B with an Fmoc group (339), as opposed to a Cbz group, the 
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benzyl ethers and benzyl ester could be selectively deprotected while leaving the N-
terminal amine protected. Fragment B (339) could then be coupled to fragment C (315). 
Following Fmoc-deprotection, this peptide could then be ligated to fragment A (313), 
which would then give feglymycin (291), after global deprotection (Scheme 123). 
 
Scheme 123. Third generation retrosynthesis of feglymycin 291. 
 
 In order to proceed with this new synthetic plan, free amine 321 was coupled to α-
bromo nitroalkane 201k. We were happy to see tripeptide 340 was isolated, in good yield 
(59%, Scheme 124). 
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Scheme 124. Synthesis of tripeptide 340. 
 
 Current attempts involve deprotection and homologation of tripeptide 340. Future 
work to complete the synthesis of fragment B (339) from the tripeptide 340 will include 
three iterative aryl glycine homologations, using UmAS coupling conditions, and 
subsequent deprotection by hydrogenolysis (Scheme 125). 
 
Scheme 125. Future elaboration of 340 to fragment B (314). 
 
 
4.3.5 Future Work 
 In order to complete the synthesis of feglymycin, the deprotection of fragment C 
(315) will be carried out, as well as the completion of fragment B (339). Once complete, 
these fragments will be ligated, using traditional amide coupling reagents. Because we 
will be activating the carboxylic acid of hexapeptide 339 as an the active ester, we 
anticipate the need to screen several carbodiimide coupling reagents in order to find one 
that enables us to couple these two fragments with no epimerization at valine residue 9. 
Once this coupling has been optimized, Fmoc deprotection will give the free amine 
172 
 
dipeptide which can then be ligated to fragment A (314), hopefully avoiding 
epimerization of valine residue 3. A global deprotection of the N-terminal Boc protecting 
group and C-terminal 
t
butyl esters will then give feglymycin (291), as a single 
diastereomer (Scheme 126). 
 
Scheme 126. Future work: completion of feglymycin (291). 
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CHAPTER V 
EXPERIMENTAL 
 
Glassware was oven-dried overnight at 120 °C for all non-aqueous reactions. All 
reagents and solvents were commercial grade and purified prior to use when necessary. 
Tetrahydrofuran (THF) was dried by passage through a column of activated alumina as 
described by Grubbs.
153
 This was done to accurately quantitate the amount of water in 
each reaction. NIS was recrystallized from dioxane/CCl4. 
Thin layer chromatography (TLC) was performed using glass-backed silica gel 
(250 µm) plates, and flash chromatography utilized 230-400 mesh silica gel from 
Scientific Adsorbents. Products were visualized by UV light, iodine, and/or the use of 
ninhydrin, potassium permanganate, p-anisaldehyde, ceric ammonium molybdate, and 
potassium iodoplatinate solutions. 
Melting points were measured on a Meltemp melting point apparatus and were 
not corrected. IR spectra were recorded on a Nicolet Avatar 360 spectrophotometer and 
are reported in wavenumbers (cm
-1
). Liquids and oils were analyzed as neat films on a 
NaCl plate (transmission), whereas solids were applied to a diamond plate (ATR). 
Nuclear magnetic resonance spectra (NMR) were acquired on a Bruker DRX-400 (400 
MHz) or a Bruker AVIII-600 (600 MHz) spectrometer. Chemical shifts are measured 
relative to residual solvent peaks as an internal standard set to 7.26 and 77.1 for CDCl3. 
Mass spectra were recorded on a Thermo Electron Corporation MAT 95XP-Trap mass 
spectrometer by use of chemical ionization (CI), electron impact ionization (EI) or 
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electrospray ionization (ESI) by the Indiana University Mass Spectrometry Facility. A 
post-acquisition gain correction was applied using sodium formate or sodium iodide as 
the lock mass. Optical rotations were measured on a Perkin Elmer-341 polarimeter. 
 
Chapter II: Applications in Enantioselective Arylglycine Synthesis 
General Procedure A: Sulfone Synthesis 
tert-Butyl carbamate (1 equiv) and benzene sulfinic acid (2 equiv) were dissolved in a 1:2 
mixture of methanol and water (0.3 M). The aldehyde (1.2 equiv) and formic acid (2 
equiv) were added and the reaction was then allowed to stir for a period of 11 to 15 days 
at rt. The mixture was filtered, and the resulting solid washed several times with ether to 
remove remaining aldehyde. The solid was then dried under vacuum at 60 C to give the 
pure sulfone. 
General Procedure B: Synthesis of N-Boc-Protected Imines 
To a round bottom flask, potassium carbamate (6 equiv) and sodium sulfate (7 equiv) 
were added. The flask was then flame dried and the contents placed under argon. The 
sulfone (1 equiv) was then added to the flask, and dissolved in THF (0.1 M). The reaction 
mixture was then allowed to reflux for 4-5 hours. The solid salts were then filtered off, 
and the resulting mixture was concentrated in vacuo to give the pure imine. 
General Procedure C: Bromonitromethane Addition to N-Boc-Protected Imines 
A solution of the imine (1 equiv) and PBAM or PBAMTfOH (0.01 or 0.05 equiv) in 
toluene (0.3 M) was cooled to -20 C and treated with bromonitromethane (1.2 equiv). 
The reaction was stirred at -20 C for 24 hours. The solvent was removed in vacuo, and 
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the crude reaction mixture purified by column chromatography to give the -bromonitro 
adduct as a mixture of inseparable diastereomers. 
General Procedure D: Amide Synthesis Using an Amine (Free Base) 
The amine (1.2 equiv) was added drop wise to a solution of α-bromo nitroalkane (1.0 
equiv, 0.2 M) and NIS (1.0 equiv) in THF and H2O (5.0 equiv) at 0 °C, or rt, followed by 
K2CO3 (2.0 equiv). The reaction mixture was stirred at 0 °C, or rt, for 2 d. The resulting 
mixture was diluted with dichloromethane, dried with MgSO4 and then filtered through 
Celite. The filtrate was concentrated and subjected to purification by flash column 
chromatography on silica gel.  
General Procedure E: Amide Synthesis Using an Ammonium Salt 
K2CO3 (3.2 equiv) was added to the suspension of the ammonium salt (1.2 equiv) and the 
α-bromo nitroalkane (1.0 equiv, 0.2 M) in THF and H2O (5.0 equiv) at 0 °C, or rt, 
followed by NIS (1.0 equiv). The reaction mixture was stirred at 0 °C, or rt, for 2 d. The 
resulting mixture was diluted with dichloromethane, dried with MgSO4 and then filtered 
through Celite. The filtrate was concentrated and subjected to purification by flash 
column chromatography on silica gel.  
 
tert-Butyl (1R)-2-bromo-1-(4-bromophenyl)-2-nitroethylcarbamate (90). Following 
General Procedure C, the N-Boc-imine (200 mg, 704 μmol) and bromonitromethane 
(65.0 μl, 845 μmol) provided the α-bromo nitroalkane (1:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 100% ethyl acetate), as a white solid (280 mg, 
94%). The enantiomeric excess of each diastereomer was determined to be 95% ee by 
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chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1 mL/min, tr(major) = 20.5, 
27.2 min, tr(minor) = 16.0, 17.5 min). Rf = 0.42 (20% EtOAc/hexanes); mp = 184-185 C 
(decomposition); IR (film) 3355, 2979, 1686, 1567, 1523, 1350, 1159 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3, 1:1 mixture of diastereomers)  7.53 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 
8.6 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.31 (br s, 1H), 6.29 (br s, 
1H), 5.71 (d, J = 8.8 Hz, 1H), 5.61 (br s, 1H), 5.43 (br s, 1H), 5.41 (d, J = 9.0 Hz, 1H), 
1.45 (s, 9H), 1.44 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 154.6, 154.3, 134.3, 133.7, 
132.3, 132.2, 128.6, 128.4, 123.5, 123.3, 84.6, 81.4, 81.3, 81.1, 57.5 (2C), 28.2, 28.1; 
HRMS (ESI): Exact mass calcd for C13H16Br2N2NaO4
 
[M+Na]
+
 444.9369, found 
444.9377. 
 
Tert-butyl (4-iodophenyl)(phenylsulfonyl)methylcarbamate (S-1). Following the 
General Procedure A, p-iodobenzaldehyde (1.30 g, 5.60 mmol) gave the sulfone (280 mg, 
11%), as a white powder. Rf = 0.57 (30% EtOAc/hexanes); mp = 175-176 C; IR (film) 
3184, 3066, 1702, 1584, 1444, 1222, 1175 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.93 (d, J 
= 7.7 Hz, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.68 (dd, J = 7.2, 7.2 Hz, 1H), 7.58 (dd, J = 7.6, 
7.6 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 5.89 (d, J = 10.8 Hz, 1H), 5.72 (d, J = 10.3 Hz, 
1H), 1.26 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 153.3, 137.9 (2C), 136.5, 134.1, 
130.5, 129.4, 129.1, 96.3, 81.5, 73.3, 28.0; HRMS (ESI): Exact mass calcd for 
C18H20INNaO4S [M+Na]
+
 496.0050, found 496.0038. 
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(E)-tert-Butyl-4-iodobenzylidenecarbamate (S-2). Following General Procedure B, the 
sulfone (250 mg, 530 μmol) provided the imine (170 mg, 98%) as a white paste. Rf = 0.40 
(30% EtOAc/hexanes); IR (film) 2977, 1716, 1626, 1585, 1255, 1153 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3)  8.81 (s, 1H), 7.85 (d, J = 12.6 Hz, 2H), 7.64 (d, J = 12.6 Hz, 2H), 
1.60 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 168.6, 162.3, 138.2, 133.4, 131.3, 101.2, 
82.5, 27.9; HRMS (ESI): Exact mass calcd for C7H7IN [M-C5H7O2]
+
 231.9618, found 
231.9591.
154
 
 
tert-Butyl (1R)-2-bromo-1-(4-iodophenyl)-2-nitroethylcarbamate (91). Following 
General Procedure C, the N-Boc-imine (80.0 mg, 242 μmol) and bromonitromethane 
(22.0 µL, 280 µmol) provided the α-bromo nitroalkane (2.6:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 100% ethyl acetate), as a white solid (101 mg, 
90%). The enantiomeric excess of the major and minor diastereomers was determined to 
be 93 and 85% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1 mL/min, tr(major) = 22.0, 31.9 min, tr(minor) = 18.6, 20.3 min). Rf = 
0.57 (30% EtOAc/hexanes); mp = 180-181 C (decomposition); IR (film) 3373, 1684, 
1560, 1524, 1167 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 2.6:1 mixture of diastereomers)  
7.73 (d, J = 8.5 Hz, 2 H), 7.72 (d, J = 9.7 Hz, 2H), 7.08 (d, J = 8.3 Hz, 2H), 7.04 (d, J = 
8.3 Hz, 2H), 6.30 (br s, 1H), 6.27 (br s, 1H), 5.67 (br s, 1H), 5.59 (br s, 1H), 5.40 (br s, 
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1H), 5.35 (br s, 1H), 1.45 (s, 9H), 1.44 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 154.3 
(2C), 138.3, 138.2, 135.0 (2C), 128.8, 128.6, 95.3, 95.0, 84.7, 81.1, 79.9 (2C), 57.7 (2C), 
28.2, 28.2; HRMS (ESI): Exact mass calcd for C13H16BrIN2NaO4 [M+Na]
+
 492.9230, 
found 492.9225. 
 
tert-Butyl (1R)-2-bromo-2-nitro-1-(4-nitrophenyl)ethylcarbamate (92). Following 
General Procedure C, the N-Boc-imine (200 mg, 800 μmol) and bromonitromethane 
(75.0 µL, 960 µmol) provided the α-bromo nitroalkane (1.5:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 20% ethyl acetate in hexanes), as a white solid 
(159 mg, 51%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 93% ee by chiral HPLC analysis (Chiralcel IA, 10% 
i
PrOH/hexanes, 1.0 
mL/min, tr(major) = 25.7, 33.6 min, tr(minor) = 15.7, 18.6 min). Rf = 0.33 (20% 
EtOAc/hexanes); mp = 144-148 C (decomposition); IR (film) 3351, 2999, 1681, 1562, 
1518, 1352, 1155 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.5:1 mixture of diastereomers)  
8.27 (d, J = 8.8 Hz, 2H), 8.26 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 
8.6 Hz, 2H), 6.39 (br s, 1H), 6.35 (br s, 1H), 5.78 (d, J = 8.6 Hz, 2H), 5.57 (br s, 1H), 
5.49 (d, J = 8.9 Hz, 1H), 1.46 (s, 9H), 1.44 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 
154.7 (2C), 148.3, 148.2, 142.3, 141.6, 128.2, 127.9, 124.3, 124.2, 84.1, 81.7 (2C), 80.5, 
57.5 (2C), 28.1 (2C); HRMS (CI): Exact mass calcd for C13H17BrN3O6 [M+H]
+
 
390.0295, found 390.0273. 
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tert-Butyl (1R)-2-bromo-1-(4-(trifluoromethyl)phenyl)-2-nitroethylcarbamate (93). 
Following General Procedure C, the N-Boc-imine (200 mg, 730 μmol) and 
bromonitromethane (70.0 µL, 880 µmol) provided the α-bromo nitroalkane (1.8:1 
mixture of diastereomers), after flash column chromatography (SiO2, 100% ethyl 
acetate), as a white solid (277 mg, 92%). The enantiomeric excess of the major and minor 
diastereomers was determined to be 93 and 82% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1 mL/min, tr(major) = 15.3, 19.8 min, 
tr(minor) = 10.5, 11.9 min). Rf = 0.57 (30% EtOAc/hexanes); mp = 175-176 C 
(decomposition); IR (film) 3373, 1686, 1561, 1525, 1330, 1167, 1127 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3, 1.8:1 mixture of diastereomers)  7.67 (d, J = 8.3 Hz, 2H), 7.66 (d, J 
= 10.1 Hz, 2 H), 7.48 (d, J = 8.2 Hz, 2 H), 7.44 (d, J = 8.2 Hz, 2 H), 6.36 (br s, 1 H), 6.32 
(br s, 1 H), 5.74 (br s, 2 H), 5.53 (br s, 1 H), 5.43 (br s, 1 H), 1.46 (s, 9 H), 1.44 (s, 9 H); 
13
C NMR (150 MHz, CDCl3) ppm 154.6, 154.3, 139.2, 138.6, 131.3 (q, 
2
JCF = 32.8 Hz, 
2C), 127.5, 127.3, 126.1 (m, 2C), 125.4 (q, 
1
JCF = 272.4 Hz, 2C), 84.6, 81.6, 81.4, 80.9, 
57.6 (2C), 28.2, 28.1; HRMS (ESI): Exact mass calcd for C14H16BrF3N2NaO4 [M+Na]
+
 
435.0138, found 435.0126. 
 
tert-Butyl (1R)-2-bromo-1-(4-methoxyphenyl)-2-nitroethylcarbamate (94). Following 
General Procedure C, the N-Boc-imine (200 mg, 850 μmol) and bromonitromethane 
(80.0 µL, 1.02 mmol) provided the α-bromo nitroalkane (1:1 mixture of diastereomers), 
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after flash column chromatography (SiO2, 100% ethyl acetate), as a white solid (301 mg, 
95%). The enantiomeric excess of each diastereomer was determined to be 90 and 91% 
ee by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 0.7 mL/min, tr(major) 
= 13.6, 22.3 min, tr(minor) = 16.3, 18.1 min). Rf = 0.33 (20% EtOAc/hexanes); mp = 161-
162 C (decomposition); IR (film) 3367, 2977, 1681, 1561, 1251, 1169, 1027 cm-1; 1H 
NMR (600 MHz, CDCl3, 1:1 mixture of diastereomers)  7.24 (d, J = 8.7 Hz, 2H), 7.21 
(d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.31 (br s, 1H), 
6.27 (br s, 1H), 5.63 (br s, 1H), 5.57 (d, J = 4.2 Hz, 1H), 5.41 (br s, 1H), 5.30 (d, J = 9.0 
Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 1.45 (s, 9H), 1.44 (s, 9H); 
13
C NMR (100 MHz, 
CDCl3) ppm 160.1, 160.0, 154.5 (2C), 128.2, 128.1, 126.5 (2C), 114.4 (2C), 85.1, 82.0, 
81.1, 80.9, 57.7 (2C), 55.2 (2C), 28.2, 28.1; HRMS (ESI): Exact mass calcd for 
C14H19BrN2NaO5 [M+Na]
+
 397.0370, found 397.0362. 
 
4-((1R)-2-Bromo-1-(tert-butoxycarbonylamino)-2-nitroethyl)phenyl acetate (95). 
Following General Procedure C, the N-Boc-imine (200 mg, 760 μmol) and 
bromonitromethane (71.0 µL, 910 µmol) provided the α-bromo nitroalkane (1:1 mixture 
of diastereomers), after flash column chromatography (SiO2, 100% ethyl acetate), as a 
white solid (287 mg, 94%). The enantiomeric excess of each diastereomer was 
determined to be 85% ee by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 
0.7 mL/min, tr(major) = 13.2, 28.2 min, tr(minor) = 14.9, 16.2 min). Rf = 0.33 (30% 
EtOAc/hexanes); mp = 162 C (decomposition); IR (film) 3372, 3010, 1754, 1682, 1563, 
1372, 1223, 1170 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1:1 mixture of diastereomers)  7.35 
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(d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 
2H), 6.32 (br s, 2H), 5.82 (br s, 1H), 5.66 (br s, 1H), 5.53 (br s, 1H), 5.49 (br s, 1H), 2.30 
(s, 3H), 2.29 (s, 3H), 1.45 (s, 9H), 1.44 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 169.2, 
169.1, 154.6, 154.4, 151.1, 151.0, 132.8, 132.3, 128.3, 128.1, 122.2 (2C), 84.8, 81.2, 81.0 
(2C), 57.6, 57.4, 28.2 (2C), 21.1 (2C); HRMS (ESI): Exact mass calcd for 
C15H19BrN2NaO6 [M+Na]
+
 425.0319, found 425.0318. 
 
tert-Butyl (1R)-2-bromo-1-(naphthalen-2-yl)-2-nitroethylcarbamate (96). Following 
General Procedure C, the N-Boc-imine (200 mg, 780 μmol) and bromonitromethane 
(70.0 µL, 940 µmol) provided the α-bromo nitroalkane (1:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 100% ethyl acetate), as a white solid (282 mg, 
92%). The enantiomeric excess of each diastereomer was determined to be 94 and 92% 
ee as determined by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 0.7 
mL/min, tr(major) = 14.8, 30.7 min, tr(minor) = 18.7, 20.8 min). Rf = 0.5 (30% 
EtOAc/hexanes); mp = 168-169 C (decomposition); IR (film) 3373, 2979, 1688, 1562, 
1516, 1165 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1:1 mixture of diastereomers)  7.88 (m, 
6H), 7.82 (s, 1H), 7.80 (s, 1H), 7.55 (m, 4H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 7.39 (dd, J = 
8.5, 1.7 Hz, 1H), 6.44 (br s, 2H), 5.87 (br s, 2H), 5.67 (br s, 1H), 5.54 (d, J = 9.2 Hz, 1H), 
1.48 (s, 9H), 1.47 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 154.8, 154.5, 133.4, 133.3, 
133.1, 133.0, 132.5, 132.0, 129.2, 129.1, 128.1 (2C), 127.7 (2C), 126.9 (2C), 126.8 (2C), 
126.7, 126.4, 123.8, 123.7, 85.2, 81.4, 81.1 (2C), 58.2 (2C), 28.2 (2C); HRMS (ESI): 
Exact mass calcd for C17H19BrN2NaO4 [M+Na]
+
 417.0420, found 417.0416. 
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N-Boc-4-Br-Phenylglycine-Ala-Phe-OMe (101). Following General Procedure E, the 
-bromo nitroalkane (20.0 mg, 50.0 μmol) and ammonium salt of the Ala-Phe dipeptide 
(16.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after flash column 
chromatography (SiO2, 30% ethyl acetate in hexanes), as a white solid (23.0 mg, 87% 
yield). [α]  -32.0 (c 1.0, CHCl3); Rf = 0.10 (30% EtOAc/hexanes); mp = 195-197 C; IR 
(film) 3373, 1686, 1561, 1523, 1329, 1167, 1127 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.49 (d, J = 7.9 Hz, 2 H), 7.27 (m, 5 H), 7.10 (d, J = 6.6 Hz, 2 H), 6.49 (br s, 2 H), 5.80 
(br s, 1 H), 5.11 (br s, 1 H), 4.82 (ddd, J = 6.1, 6.1, 6.1 Hz, 1 H), 4.44 (dq, J = 6.8, 6.8 
Hz, 1 H), 3.74 (s, 3 H), 3.15 (dd, J = 13.7, 5.3 Hz, 1 H), 3.07 (dd, J = 13.7, 6.2 Hz, 1 H), 
1.43 (s, 9 H), 1.23 (d, J = 6.8 Hz, 3 H); 
13
C NMR (150 MHz, CDCl3) ppm 171.6, 171.2, 
169.3, 154.9, 137.2, 135.5, 132.1, 129.2, 128.9, 128.6, 127.2, 122.5, 80.4, 58.0, 53.3, 
52.5, 48.9, 37.7, 28.3, 18.0; HRMS (ESI): Exact mass calcd for C26H33BrN3O6 [M+H]
+
 
562.1547, found 562.1556. 
 
N-Boc-4-I-Phenylglycine-Ala-Phe-OMe (102). Following General Procedure E, the -
bromo nitroalkane (20.0 mg, 40.0 μmol) and the ammonium salt of the Ala-Phe dipeptide 
(15.0 mg, 50.0 μmol) provided the tripeptide (single diastereomer), after flash column 
chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (14.7 mg, 58% 
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yield). [α]  -32.6 (c 2.5, CHCl3); Rf = 0.10 (30% EtOAc/hexanes); mp = 169-171 C; IR 
(film) 3279, 2932, 1645, 1538, 1367, 1167 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.69 (d, J 
= 8.3 Hz, 2H), 7.28 (m, 3H), 7.11 (d, J = 4.4 Hz, 2H), 7.10 (d, J = 2.9 Hz, 2H), 6.46 (br s, 
1H), 6.42 (br s, 1H), 5.75 (br s, 1H), 5.07 (br s, 1H), 4.82 (ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 
4.43 (dq, J = 7.1, 7.1 Hz, 1H), 3.74 (s, 3H), 3.15 (dd, J = 14.0, 5.7 Hz, 1H), 3.07 (dd, J = 
14.0, 6.5 Hz, 1H), 1.43 (s, 9H), 1.24 (d, J = 6.7 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) 
ppm 171.6, 171.2, 169.3, 154.9, 137.2, 135.5, 132.1, 129.2, 128.9, 128.6, 127.2, 122.5, 
80.4, 58.0, 53.3, 52.5, 48.9, 37.7, 28.3, 18.0; HRMS (ESI): Exact mass calcd for 
C26H33IN3O6 [M+H]
+
 610.1409, found 610.1423. 
 
N-Boc-4-NO2-Phenylglycine-Ala-Phe-OMe (103). Following General Procedure E, the 
-bromo nitroalkane (20.0 mg, 50.0 μmol) and ammonium salt of the Ala-Phe dipeptide 
(18.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after flash column 
chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (12.6 mg, 47% 
yield). [α]  -23.6 (c 2.5, CHCl3); Rf = 0.13 (40% EtOAc/hexanes); mp = 79-80 C; IR 
(film) 3341, 2927, 1745, 1686, 1640, 1524, 1350, 1171 cm
-1
; 
1
H NMR (600 MHz, 
CDCl3)  8.23 (d, J = 8.7 Hz, 2H), 7.57 (d, J = 8.6 Hz, 2H), 7.30 (m, 3H), 7.11 (d, J = 6.9 
Hz, 2H), 6.58 (br s, 1H), 6.33 (d, J = 5.1 Hz, 1H), 5.89 (br s, 1H), 5.35 (br s, 1H), 4.85 
(ddd, J = 6.1, 6.1, 6.1 Hz, 1H), 4.41 (dq, J = 7.1, 7.1 Hz, 1H), 3.76 (s, 3H), 3.18 (dd, J = 
14.0, 5.6 Hz, 1H), 3.10 (dd, J = 14.0, 6.4 Hz, 1H), 1.44 (s, 9H), 1.25 (d, J = 7.0 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 171.5, 171.0, 168.3, 154.8, 147.8, 145.3, 135.4, 129.2, 
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128.7, 128.1, 127.3, 124.2, 80.7, 58.0, 53.3, 52.5, 49.0, 37.7, 28.2, 18.1; HRMS (ESI): 
Exact mass calcd for C26H33N4O8 [M+H]
+
 529.2293, found 529.2294. 
 
N-Boc-4-CF3-Phenylglycine-Ala-Phe-OMe (104). Following General Procedure E, the 
-bromo nitroalkane (20.0 mg, 50.0 μmol) and ammonium salt of the Ala-Phe dipeptide 
(17.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after flash column 
chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (15.8 mg, 60% 
yield). [α]  -20.6 (c 1.6, CHCl3); Rf = 0.23 (40% EtOAc/hexanes); mp = 175-176 C; IR 
(film) 3283, 3260, 1645, 1532, 1326, 1166, 1125 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  
7.64 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.31 (m, 3H), 7.12 (d, J = 8.0 Hz, 2H), 
6.40 (d, J = 6.8 Hz, 1H), 6.34 (br s, 1H), 5.78 (br s, 1H), 5.19 (br s, 1H), 4.85 (ddd, J = 
6.1, 6.1, 6.1 Hz, 1H), 4.42 (dq, J = 7.2, 7.2 Hz, 1H), 3.75 (s, 3H), 3.18 (dd, J = 14.0, 4.0 
Hz, 1H), 3.10 (dd, J = 13.6, 6.4 Hz, 1H), 1.44 (s, 9H), 1.25 (d, J = 6.8 Hz, 3H); 
13
C NMR 
(150 MHz, CDCl3) ppm 171.5, 171.2, 168.9, 154.9, 135.5, 130.6 (q, 
2
JCF = 32.3 Hz), 
129.2, 128.6, 128.0, 127.5, 127.2, 126.0 (q, 
3
JCF = 3.5 Hz), 123.8 (q, 
1
JCF = 272.1 Hz), 
80.5, 58.2, 53.3, 52.4, 49.0, 37.7, 28.2, 15.2; HRMS (ESI): Exact mass calcd for 
C27H33F3N3O6 [M+H]
+
 552.2316, found 552.2322. 
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N-Boc-4-OMe-Phenylglycine-Ala-Phe-OMe (105). Following General Procedure E, the 
-bromo nitroalkane (20.0 mg, 50.0 μmol) and the ammonium salt of the Ala-Phe 
dipeptide (18.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after flash 
column chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (19.7 mg, 
72% yield). [α]  -38.1 (c 2.2, CHCl3); Rf = 0.17 (40% EtOAc/hexanes); mp =179-180 
C; IR (film) 3282, 2927, 1651, 1512, 1247, 1169 cm-1; 1H NMR (600 MHz, CDCl3)  
7.25 (m, 5H), 7.09 (d, J = 6.6 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 6.60 (br s, 1H), 6.36 (d, J 
= 7.8 Hz, 1H), 5.66 (br s, 1H), 5.06 (br s, 1H), 4.80 (ddd, J = 6.6, 6.6, 6.6 Hz, 1H), 4.45 
(dq, J = 6.6, 6.6 Hz, 1H), 3.78 (s, 3H), 3.70 (s, 3H), 3.12 (dd, J = 13.8, 6.0 Hz, 1H), 3.03 
(dd, J = 13.8, 6.6 Hz, 1H), 1.42 (s, 9H), 1.22 (d, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, 
CDCl3) ppm 171.6, 171.4, 170.2, 159.6, 155.1, 135.7, 130.0, 129.2, 128.6, 128.5, 127.2, 
114.4, 80.1, 58.2, 55.3, 53.3, 52.3, 48.8, 37.7, 28.3, 17.9; HRMS (ESI): Exact mass calcd 
for C27H36N3O7 [M+H]
+
 514.2548, found 514.2552. 
 
N-Boc-4-OAc-Phenylglycine-Ala-Phe-OMe (106). Following General Procedure E, the 
-bromo nitroalkane (20.0 mg, 50.0 μmol) and ammonium salt of the Ala-Phe dipeptide 
(17.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after column 
chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (13.2 mg, 49% 
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yield). [α]  -34.3 (c 1.8, CHCl3); Rf = 0.23 (40% EtOAc/hexanes); mp = 178-179 C; IR 
(film) 3284, 2924, 1651, 1505, 1367, 1205, 1166 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.37 (d, J = 8.4 Hz, 2H), 7.29 (m, 3H), 7.10 (m, 4H), 6.57 (br s, 1H), 6.39 (d, J = 7.4 Hz, 
1H), 5.68 (br s, 1H), 5.12 (br s, 1H), 4.84 (ddd, J = 12.5, 6.3, 6.3 Hz, 1H), 4.44 (dq, J = 
7.1, 7.1 Hz, 1H), 3.73 (s, 3H), 3.16 (dd, J = 13.9, 5.7 Hz, 1H), 3.09 (dd, J = 13.9, 6.5 Hz, 
1H), 2.30 (s, 3H), 1.44 (s, 9H), 1.24 (d, J = 7.0 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) 
ppm 171.5, 171.2, 169.6, 169.2, 154.9, 150.6, 135.6, 129.2 (2C), 128.6, 128.4, 127.2, 
122.1, 80.3, 58.0, 53.3, 52.4, 48.9, 37.7, 28.2, 21.1, 17.8; HRMS (ESI): Exact mass calcd 
for C28H36N3O8 [M+H]
+
 542.2497, found 542.2507. 
 
N-Boc-2-Naphylglycine-Ala-Phe-OMe (107). Following General Procedure E, the -
bromo nitroalkane (20.0 mg, 50.0 μmol) and ammonium salt of the Ala-Phe dipeptide 
(17.0 mg, 60.0 μmol) provided the tripeptide (single diastereomer), after flash column 
chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (15.5 mg, 57% 
yield). [α]  -49.7 (c 1.9, CHCl3); Rf = 0.20 (40% EtOAc/hexanes); mp = 183-185 C; IR 
(film) 3286, 2977, 1749, 1645, 1531, 1166 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.85 (d, J 
= 8.3 Hz, 4H), 7.51 (d, J = 3.8 Hz, 2H), 7.43 (d, J = 8.0 Hz, 1H), 7.29 (m, 3H), 7.36 (d, J 
= 6.4 Hz, 2H), 6.48 (br s, 1H), 6.31 (d, J = 7.0 Hz, 1H), 5.85 (br s, 1H), 5.27 (br s, 1H), 
4.83 (ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 4.46 (dq, J = 7.0, 7.0 Hz, 1H), 3.73 (s, 3H), 3.16 (dd, 
J = 13.6, 5.0 Hz, 1H), 3.08 (dd, J = 13.8, 6.4 Hz, 1H), 1.44 (s, 9H), 1.20 (d, J = 6.8 Hz, 
3H); 
13
C NMR (150 MHz, CDCl3) ppm 171.5, 171.3, 171.2, 155.0, 135.6, 133.3, 133.1, 
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129.2, 129.1, 128.6, 128.1, 127.7, 127.2, 127.2, 126.8, 126.5, 126.4, 124.3, 80.2, 58.9, 
53.4, 52.4, 48.9, 37.7, 28.3, 17.8; HRMS (ESI): Exact mass calcd for C30H35N3NaO6 
[M+Na]
+
 556.2418, found 556.2445. 
 
N-Boc-4-Cl-Phenylglycine-Gly-OMe (108a). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of glycine (8.00 mg, 63.6 
μmol) provided the dipeptide after flash column chromatography (30% ethyl acetate in 
hexanes) as a white solid (14.9 mg, 79%). [α]  -72.8 (c 0.13, CHCl3); Rf = 0.08 (20% 
EtOAc/hexanes); mp 89-91 °C; IR (film) 3315, 2927, 1750, 1714, 1699, 1520, 1493, 
1666 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.35 (s, 4H), 6.39 (br s, 1H), 5.77 (br s, 1H), 
5.21 (br s, 1H), 4.08 (dd, J = 18.5, 5.5 Hz, 1H), 3.99 (dd, J = 18.2, 4.6 Hz, 1H), 3.75 (s, 
3H), 1.42 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 169.9, 169.8, 155.0, 136.5, 134.4, 
129.2, 128.7, 80.4, 57.8, 52.4, 41.3, 28.2; HRMS (ESI): Exact mass calcd for 
C16H21ClN2NaO5 [M+Na]
+
 379.1031, found 379.1032. 
 
N-Boc-4-Cl-Phenylglycine-Ala-OMe (108b). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-alanine (9.00 mg, 63.6 
μmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(20% ethyl acetate in hexanes) as a white solid (12.3 mg, 63%). [α]  -57.7 (c 0.18, 
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CHCl3); Rf = 0.22 (30% EtOAc/hexanes); mp 122-125 °C; IR (film) 3314, 1745, 1716, 
1662, 1492, 1366, 1163 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.33 (d, J = 6.0 Hz, 2H), 
7.32 (d, J = 4.8 Hz, 2H), 6.34 (d, J = 7.2 Hz, 1H), 5.72 (s, 1H), 5.14 (s, 1H), 4.56 (dq, J = 
7.2, 7.2 Hz, 1H), 3.75 (s, 3H), 1.41 (s, 9H), 1.31 (d, J = 7.2 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) ppm 173.0, 169.1, 154.9, 136.7, 134.3, 129.2, 128.6, 80.3, 57.9, 52.6, 48.3, 
28.2, 18.0; HRMS (ESI): Exact mass calcd for C17H23ClN2NaO5 [M+Na]
+
 393.1188, 
found 393.1211. 
 
N-Boc-4-Cl-Phenylglycine-Val-OMe (108c). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-valine (11.0 mg, 63.6 
μmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(20% ethyl acetate in hexanes) as a white solid (14.7 mg, 70%). [α]  -54.4 (c 0.13, 
CHCl3); Rf = 0.32 (30% EtOAc/hexanes); mp 105-108 °C; IR (film) 3318, 2967, 1742, 
1716, 1661, 1524, 1492, 1168 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.33 (s, 4H), 6.28 (d, 
J = 6.6 Hz, 1H), 5.74 (br s, 1H), 5.15 (br s, 1H), 4.53 (dd, J = 8.9, 4.9 Hz, 1H), 3.74 (s, 
3H), 2.08 (qqd, J = 6.8, 6.8, 5.0 Hz, 1H), 1.41 (s, 9H), 0.76 (d, J = 6.6 Hz, 3H), 0.71 (d, J 
= 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 172.0, 169.4, 154.9, 137.0, 134.3, 
129.2, 128.6, 80.3, 58.2, 57.0, 52.3, 31.3, 28.2, 18.7, 17.3; HRMS (ESI): Exact mass 
calcd for C19H28ClN2O5 [M+H]
+
 399.1681, found 399.1703. 
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N-Boc-4-Cl-Phenylglycine-Leu-OMe (108d). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-leucine (12.0 mg, 63.6 
μmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(20% ethyl acetate in hexanes) as a white solid (17.8 mg, 81%). [α]  -58.1 (c 0.20, 
CHCl3); Rf = 0.10 (10% EtOAc/hexanes); mp 79-81 °C; IR (film) 3313, 2958, 1747, 
1716, 1661, 1539, 1493, 1167 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.32 (s, 4H), 6.24 (d, 
J = 8.2 Hz, 1H), 5.74 (br s, 1H), 5.15 (br s, 1H), 4.59 (ddd, J = 8.9, 8.9, 5.1 Hz, 1H), 3.73 
(s, 3H), 1.58 (ddd, J = 13.8, 8.5, 5.2 Hz, 1H), 1.44 (ddd, J = 14.8, 9.2, 5.8 Hz, 1H), 1.40 
(s, 9H), 1.35 (m, 1H), 0.81 (d, J = 4.2 Hz, 3H), 0.80 (d, J = 4.1 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) ppm 173.1, 169.4, 154.9, 136.9, 134.3, 129.1, 128.6, 80.3, 58.0, 52.4, 50.9, 
41.2, 28.2, 24.7, 22.7, 21.7; HRMS (ESI): Exact mass calcd for C20H29ClN2NaO5 
[M+Na]
+
 435.1657, found 435.1673. 
 
N-Boc-4-Cl-Phenylglycine-Ile-OMe (108e). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-isoleucine (12.0 mg, 
63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (20% ethyl acetate in hexanes) as a white solid (14.4 mg, 66%). [α]  -
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25.6 (c 0.32, CHCl3); Rf = 0.32 (30% EtOAc/hexanes); mp 120-122 °C; IR (film) 3318, 
1967, 1742, 1716, 1660, 1525, 1492, 1366, 1168 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.34 (d, J = 3.0 Hz, 2H), 7.33 (d, J = 3.0 Hz, 2H), 6.27 (d, J = 6.0 Hz, 1H), 5.72 (br s, 
1H), 5.14 (br s, 1H), 4.57 (dd, J = 8.8, 4.9 Hz, 1H), 3.74 (s, 3H), 1.81 (m, 1H), 1.41 (s, 
9H), 0.96 (m, 1H), 0.88 (m, 1H), 0.82 (t, J = 7.4 Hz, 3H), 0.73 (d, J = 6.9 Hz, 3H); 
13
C 
NMR (150 MHz, CDCl3) ppm 172.0, 169.3, 154.9, 136.9, 134.3, 129.2, 128.6, 80.3, 58.2, 
56.4, 52.2, 37.8, 28.2, 24.8, 15.2, 11.3; HRMS (ESI): Exact mass calcd for 
C20H29ClN2NaO5 [M+Na]
+
 435.1657, found 435.1670. 
 
N-Boc-4-Cl-Phenylglycine-Ser-OMe (108f). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-serine (10.0 mg, 63.6 
μmol), after stirring at rt for 5 h, provided the dipeptide (single diastereomer) after flash 
column chromatography (50% ethyl acetate in hexanes) as a white solid (13.0 mg, 64%). 
[α]  -38.2 (c 0.46, CHCl3); Rf = 0.10 (40% EtOAc/hexanes); mp 122-125 °C; IR (film) 
3322, 2926, 1667, 1493, 1367, 1166 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.35 (d, J = 9.6 
Hz, 2H), 7.33 (d, J = 9.0 Hz, 2H), 6.95 (br s, 1H), 5.61 (br s, 1H), 5.16 (br s, 1H), 4.62 
(ddd, J = 6.6, 3.0, 3.0 Hz, 1H), 3.92 (br s, 2H), 3.79 (s, 3H), 2.52 (br s, 1H), 1.42, (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 170.6, 169.9, 155.4, 135.9, 134.6, 129.3, 128.7, 80.9, 
62.5, 58.7, 54.8, 52.9, 28.2; HRMS (ESI): Exact mass calcd for C17H23ClN2NaO6 
[M+Na]
+
 409.1137, found 409.1133. 
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N-Boc-4-Cl-Phenylglycine-Thr-OMe (108g). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-threonine (11.0 mg, 
63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (40% ethyl acetate in hexanes) as a white solid (9.5 mg, 45%). [α]  -
48.1 (c 0.14, CHCl3); Rf = 0.11 (40% EtOAc/hexanes); mp 130-133 °C; IR (film) 3332, 
2926, 1715, 1665, 1516, 1492, 1367, 1166 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.39 (d, J 
= 8.4 Hz, 2H), 7.35 (d, J = 9.0 Hz, 2H), 6.70 (br s, 1H), 5.73 (d, J = 5.4 Hz, 1H), 5.22 (br 
s, 1H), 4.58 (dd, J = 9.5, 2.2 Hz, 1H), 4.34 (qd, J = 6.6, 2.4 Hz, 1H), 3.79 (s, 3H), 2.04 
(br s, 1H), 1.43 (s, 9H), 1.02 (d, J = 6.0 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
171.1, 70.1, 154.9, 136.6, 134.4, 129.2, 128.7, 80.5, 67.9, 58.3, 57.1, 52.7, 28.2, 19.7; 
HRMS (ESI): Exact mass calcd for C18H25ClN2NaO6 [M+Na]
+
 423.1293, found 
423.1311. 
 
N-Boc-4-Cl-Phenylglycine-Phe-OMe (108h). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-phenylalanine (14.0 
mg, 63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (20% ethyl acetate in hexanes) as a white solid (15.2 mg, 64%). [α]  -
16.4 (c 0.1, CHCl3); Rf = 0.13 (20% EtOAc/hexanes); mp 113-116 °C; IR (film) 3318, 
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2926, 1742 (br), 1661, 1492, 1367, 1168 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.31 (d, J = 
8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.17 (t, J = 7.4 Hz, 1 H), 7.10 (t, J = 7.4 Hz, 2H), 
6.67 (d, J = 5.1 Hz, 2H), 6.04 (br s, 1H), 5.82 (br s, 1H), 5.08 (br s, 1H), 4.87 (ddd, J = 
7.8, 6.0, 6.0, Hz, 1H), 3.73 (s, 3H), 2.98 (m, 2H), 1.40 (s, 9H); 
13
C NMR (150 MHz, 
CDCl3) ppm 171.3, 168.9, 154.8, 137.0, 134.9, 134.3, 129.2, 128.9, 128.5 (2C), 127.1, 
80.2, 57.9, 53.0, 52.5, 37.5, 28.2; HRMS (ESI): Exact mass calcd for C23H27ClN2NaO5 
[M+Na]
+
 469.1501, found 469.1513.  
 
N-Boc-4-Cl-Phenylglycine-Tyr(O
t
Bu)-OMe (108i). Following General Procedure E, 
the α-bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of tert-butyl protected 
ʟ-tyrosine (18.0 mg, 63.6 μmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (20% ethyl acetate in hexanes) as a viscous oil (17.6 mg, 64%). 
[α]  16.9 (c 0.17, CHCl3); Rf = 0.22 (30% EtOAc/hexanes); IR (film) 3319, 2978, 1743, 
1663, 1506, 1492, 1366, 1163 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.35 (d, J = 8.3 Hz, 
2H), 7.26 (d, J = 8.3 Hz, 2H), 6.71 (d, J = 8.4 Hz, 2H), 6.53 (d, J = 5.4 Hz, 2H), 6.07 (br 
s, 1H), 5.85 (br s, 1H), 5.08 (br s, 1H), 4.84 (ddd, J = 10.9, 5.4, 5.4 Hz, 1H), 3.71 (s, 3H), 
2.95 (dd, J = 14.1, 5.6 Hz, 1H), 2.90 (dd, J = 13.7, 4.5 Hz, 1H), 1.39 (br s, 9H), 1.31 (s, 
9H); 
13
C NMR (150 MHz, CDCl3) ppm 171.3, 168.8, 154.8, 154.5, 137.1, 134.3, 129.6, 
129.4, 129.3, 128.6, 124.0, 80.2, 78.4, 57.9, 53.1, 52.4, 36.9, 36.4, 28.8, 28.2; HRMS 
(ESI): Exact mass calcd for C27H35ClN2NaO6 [M+Na]
+
 541.2076, found 541.2078. 
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N-Boc-4-Cl-Phenylglycine-Asp(OMe)-OMe (108j). Following General Procedure E, 
the α-bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-aspartic acid 
(13.0 mg, 63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (30% ethyl acetate in hexanes) as a white solid (14.6 mg, 64%). [α]  -
32.0 (c 0.05, CHCl3); Rf = 0.14 (30% ethyl EtOAc/hexanes); mp 110-113 °C; IR (film) 
3320, 2928, 1734, 1718, 1684, 1670, 1507, 1490, 1368, 1219, 1168 cm
-1
; 
1
H NMR (600 
MHz, CDCl3)  7.34 (d, J = 2.4 Hz, 2H), 7.33 (d, J = 3.6 Hz, 2H), 6.87 (br s, 1H), 5.67 
(br s, 1H), 5.17 (br s, 1H), 4.83 (ddd, J = 8.5, 4.4, 4.4 Hz, 1H), 3.78 (s, 3H), 3.57 (s, 3H), 
2.97 (dd, J = 17.2, 4.3 Hz, 1H), 2.74 (dd, J = 16.8, 3.2 Hz, 1H), 1.42 (s, 9H); 
13
C NMR 
(150 MHz, CDCl3) ppm 171.1, 170.6, 169.4, 154.9, 136.6, 134.3, 129.2, 128.6, 80.4, 
58.1, 53.0, 52.0, 48.7, 35.5, 28.2; HRMS (ESI): Exact mass calcd for C19H25ClN2NaO7 
[M+Na]
+
 451.1242, found 451.1258. 
 
N-Boc-4-Cl-Phenylglycine-Asn-O
t
Bu (108k). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-asparagine (14.0 mg, 
63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (60% ethyl acetate in hexanes) as a white solid (12.5 mg, 52%). [α]  -
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32.6 (c 0.33, CHCl3); Rf = 0.03 (40% EtOAc/hexanes); mp 124-126 °C; IR (film) 3298, 
2928, 1732, 1685, 1666, 1521, 1493, 1368, 1167 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.37 (br s, 1H), 7.36 (d, J = 9.6 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 5.76 (br s, 1H), 5.62 
(br s, 1H), 5.56 (br s, 1H), 5.21 (br s, 1H), 4.66 (ddd, J = 8.3, 4.3, 4.3 Hz, 1H), 2.86 (dd, J 
= 16.2, 4.2 Hz, 1H), 2.63 (dd, J = 16.2, 4.2 Hz, 1H), 1.46 (s, 9H), 1.42 (br s, 9H); 
13
C 
NMR (150 MHz, CDCl3) ppm 172.0, 169.7, 169.3, 155.0, 136.5, 134.2, 129.0, 128.6, 
82.7, 80.3, 58.1, 49.6, 36.7, 28.2, 27.8; HRMS (ESI): Exact mass calcd for 
C21H30ClN3NaO6 [M+Na]
+
 478.1715, found 478.1727. 
 
N-Boc-4-Cl-Phenylglycine-Glu(OEt)-OEt (108l). Following General Procedure E, the 
α-bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-glutamic acid (15.0 
mg, 63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (20% ethyl acetate in hexanes) as a viscous oil (14.1 mg, 57%). [α]  -
53.3 (c 0.24, CHCl3); Rf = 0.22 (30% EtOAc/hexanes); IR (film) 3327, 2980, 1736, 1665, 
1510, 1492, 1386, 1247, 1168 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.34 (s, 4H), 6.64, (d, 
J = 7.2 Hz, 1H), 5.75 (br s, 1H), 5.16 (br s, 1H), 4.56 (ddd, 7.9, 7.9, 4.6 Hz, 1H), 4.22 
(dq, J = 10.7, 7.6 Hz, 1H), 4.21 (dq, J = 10.8, 7.5 Hz, 1H), 4.10 (dq, J = 10.9, 7.1 Hz, 
1H), 4.07 (dq, J = 10.9, 7.9 Hz, 1H), 2.22 (m, 1H), 2.15 (m, 2H), 1.93 (m, 1H), 1.42 (s, 
9H), 1.29 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
172.7, 171.3, 169.6, 154.9, 136.8, 134.3, 129.2, 128.6, 80.3, 61.8, 60.8, 58.0, 51.9, 29.8, 
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28.2, 26.8, 14.1 (2C); HRMS (ESI): Exact mass calcd for C22H32ClN2O7 [M+H]
+
 
471.1893, found 471.1889. 
 
N-Boc-4-Cl-Phenylglycine-Gln-O
t
Bu (108m). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of ʟ-glutamine (15.0 mg, 
63.6 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (70% ethyl acetate in hexanes) as a viscous oil (14.7 mg, 59%). [α]  -
54.7 (c 0.08, CHCl3); Rf = 0.17 (70% EtOAc/hexanes); IR (film) 3322, 2930, 1732, 1652, 
1522, 1492, 1368, 1161 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.34 (s, 4H), 6.90 (d, J = 7.8 
Hz, 1H), 5.79 (br s, 1H), 5.66 (br s, 1H), 5.40 (br s, 1H), 5.13 (br s, 1H), 4.42 (br s, 1H), 
2.14 (m, 1H), 2.08 (m, 1H), 1.86 (m, 2H), 1.46 (s, 9H), 1.42 (s, 9H); 
13
C NMR (150 
MHz, CDCl3) ppm 174.3, 170.6, 169.9, 155.0, 136.5, 134.4, 129.2, 128.6, 82.8, 80.5, 
58.2, 52.4, 31.3, 29.7, 28.2, 27.9; HRMS (ESI): Exact mass calcd for C22H32ClN3NaO6 
[M+Na]
+
 492.1872, found 492.1896.  
 
N-Boc-4-Cl-Phenylglycine-Lys(Cbz)-OMe (108n) . Following General Procedure E, 
the α-bromo nitroalkane (20.0 mg, 52.7 μmol) and ammonium salt of carboxybenzyl 
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protected ʟ-lysine (22.0 mg, 63.6 μmol) provided the dipeptide (single diastereomer) after 
flash column chromatography (30% ethyl acetate in hexanes) as an off-white solid (16.0 
mg, 55%). [α]  -54.5 (c 0.20, CHCl3); Rf = 0.11 (30% EtOAc/hexanes); mp 93-95 °C; 
IR (film) 3318, 2925, 1702 (br), 1671, 1522, 1492, 1455, 1367, 1248, 1167 cm
-1
; 
1
H 
NMR (600 MHz, CDCl3)  7.36 (d, J = 4.2 Hz, 4H), 7.31 (s, 5H), 6.39 (br s, 1H), 5.70 
(br s, 1H), 5.14 (br s, 1H), 5.10 (s, 2H), 4.80 (br s, 1H), 4.56 (ddd, J = 7.5, 7.5, 7.5 Hz, 
1H), 3.74 (s, 3H), 3.08 (dddd, J = 12.8, 12.8, 6.4, 6.4 Hz, 2H), 1.80 (m, 2H), 1.61 (m, 
2H), 1.40 (s, 9H), 1.14 (m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 172.3 (2C), 169.4, 
156.5, 136.5, 134.3, 129.2, 128.6, 128.5 (2C), 128.1 (2C), 80.4, 66.6, 58.1, 52.5, 51.9, 
40.4, 31.5, 29.7, 29.1, 28.2, 22.6, 21.8; HRMS (ESI): Exact mass calcd for 
C28H36ClN3NaO7 [M+Na]
+
 584.2134, found 584.2150. 
 
N-Boc-4-Cl-Phenylglycine-Pro-OMe (108o). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of ʟ-proline (11.0 mg, 63.6 
µmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(15-20% ethyl acetate in hexanes) as a viscous yellow oil (a mixture of two rotamers in 
approximately 5:1 ratio, 14.0 mg, 67%). []  -152 (c 1.24, CHCl3); Rf = 0.28 (20% 
EtOAc/hexanes); IR (neat) 3416, 3320, 2977, 1747, 1710, 1650, 1490, 1434, 1169 cm
-1
; 
1
H NMR (400 MHz, CDCl3) major rotamer:  7.35-7.28 (m, 4H), 6.10 (br d, J = 7.0 Hz, 
1H), 5.37 (br d, J = 7.0 Hz, 1H), 4.42 (dd, J = 8.2, 3.4 Hz, 1H), 3.76 (s, 3H), 3.74-3.69 
(m, 1H), 3.10 (td, J = 9.5, 7.4 Hz, 1H), 2.09-1.94 (m, 3H), 1.84-1.79 (m, 1H), 1.39 (s, 
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9H); 
13
C NMR (100 MHz, CDCl3) major rotamer: ppm 172.3, 168.5, 154.8, 136.3, 134.3, 
129.5, 129.2, 79.9, 59.4, 56.1, 52.5, 46.8, 29.0, 28.4, 24.6; HRMS (ESI): Exact mass 
calcd for C19H25ClN2NaO5 [M+Na]
+
 419.1350, found 419.1356. 
 
N-Boc-4-Cl-Phenylglycine-Cys(Bn)-OMe (108p). Following General Procedure E, the 
α-bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of benzyl protected ʟ-
cysteine (8.00 mg, 63.6 µmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (30% ethyl acetate in hexanes) as a viscous oil (13.5 mg, 52%). 
[]  -59.2 (c 0.13, CHCl3); Rf = 0.11 (20% EtOAc/hexanes); IR (film) 3318, 2925, 
1748, 1668, 1559, 1540, 1507, 1367, 1219, 1167 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.34 (m, 7H), 7.18 (d, J = 7.8 Hz, 2H), 6.59 (br s, 1H), 5.73 (br s, 1H), 5.21 (br s, 1H), 
4.77 (ddd, J = 5.4, 5.4, 5.4 Hz, 1H), 3.76 (s, 3H), 3.53 (d, J = 13.3 Hz, 1H), 3.48 (d, J = 
13.3 Hz, 1H), 2.83 (dd, J = 14.0, 4.9 Hz, 1H), 2.78 (dd, J = 14.0, 5.8 Hz, 1H), 1.43 (s, 
9H); 
13
C NMR (150 MHz, CDCl3) ppm 170.8, 169.5, 154.9, 137.2, 136.5, 134.4, 129.2, 
128.8, 128.7, 128.5, 127.3, 80.4, 58.0, 52.8, 51.8, 36.4, 33.1, 28.2; HRMS (ESI): Exact 
mass calcd for C24H29ClN2NaO5S [M+Na]
+
 515.1378, found 515.1386. 
 
N-Boc-4-Cl-Phenylglycine-Met-OMe (108q). Following General Procedure E, the α-
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bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of ʟ-methionine (13.0 mg, 
63.6 µmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (20% ethyl acetate in hexanes) as a viscous oil (9.9 mg, 43%). []  -
32.8 (c 0.20, CHCl3); Rf = 0.24 (30% EtOAc/hexanes); IR (film) 3319, 2923, 1742, 1714, 
1673, 1492, 1367, 1166 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.36 (s, 2H), 7.35 (s, 2H), 
6.51 (d, J = 6.0 Hz, 1H), 5.74 (br s, 1H), 5.16 (br s, 1H), 4.72 (ddd, J = 7.4, 7.4, 4,9 Hz, 
1H), 3.78 (s, 3H), 2.28 (m, 2H), 2.11 (m, 1H), 1.97 (s, 3H), 1.92 (m, 1H), 1.42 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 171.9, 169.4, 154.8, 134.4, 130.9, 129.2, 128.6, 80.4, 
58.2, 52.7, 51.6, 31.0, 29.6, 28.2, 15.3; HRMS (ESI): Exact mass calcd for 
C19H27ClN2NaO5S [M+Na]
+
 453.1221, found 453.1231. 
 
N-Boc-4-Cl-Phenylglycine-Arg(NO2)-OMe (108r). Following General Procedure E, the 
α-bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of nitro-protected ʟ-
arginine (17.0 mg, 63.6 µmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (80% ethyl acetate in hexanes) as a viscous oil (11.7 mg, 44%). 
[]  -37.3 (c 0.15, CHCl3); Rf = 0.10 (70% EtOAc/hexanes); IR (film) 3309, 2927, 
1667, 1629, 1560, 1492, 1367, 1268, 1163 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.34 (s, 
4H), 5.56 (br s, 1H), 5.26 (br s, 1H), 4.57 (br s, 1H), 3.78 (s, 3H), 3.41 (br s, 1H), 3.22 (br 
s, 1H), 1.93 (m, 1H), 1.66 (m, 1H), 1.60 (br s, 6H), 1.42 (s, 9H); 
13
C NMR (150 MHz, 
CDCl3) ppm 172.1, 170.9, 159.4, 155.2, 134.8, 130.9, 129.4, 128.5, 81.1, 58.6, 52.9, 
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47.9, 40.4, 29.7, 28.2, 24.3; HRMS (ESI): Exact mass calcd for C20H29ClN6NaO7 
[M+Na]
+
 523.1678, found 523.1691. 
 
N-Boc-4-Cl-Phenylglycine-His(Tr)-OMe (108s). Following General Procedure E, the α-
bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of trityl-protected ʟ-
histidine (28.0 mg, 63.6 µmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (70% ethyl acetate in hexanes) as a white solid (14.1 mg, 41%). 
[]  -18.1 (c 0.22, CHCl3); Rf = 0.03 (40% EtOAc/hexanes); mp 209-211 °C (decomp.); 
IR (film) 3313, 2925, 1746, 1715, 1677, 1491, 1446, 1366, 1168 cm
-1
; 
1
H NMR (600 
MHz, CDCl3)  7.99 (d, J = 6.0 Hz, 1H), 7.34 (m, 14 H), 7.23 (s, 1H), 7.22 (s, 1H), 7.08 
(m, 4H), 6.48 (s, 1H), 5.98 (br s, 1H), 5.20 (br s, 1H), 4.63 (ddd, J = 7.2, 5.7, 4.5 Hz, 1H), 
3.63 (s, 3H), 2.89 (dd, J = 14.7, 5.9 Hz, 1H) 2.86 (dd, J = 14.3, 3.6 Hz, 1H), 1.40 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 177.2, 171.2, 154.8, 142.0 (3C), 138.5, 137.4, 136.0, 
133.7, 129.7 (6C), 128.8, 128.5, 128.1 (9C), 119.5, 79.8, 75.4, 57.9, 53.1, 52.2, 29.0, 
28.3; HRMS (ESI): Exact mass calcd for C39H40ClN4O5 [M+H]
+
 679.2682, found 
679.2713. 
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N-Boc-4-Cl-Phenylglycine-Trp(Boc)-O
t
Bu (108t). Following General Procedure E, the 
α-bromo nitroalkane (20.0 mg, 52.7 µmol) and ammonium salt of boc-protected ʟ-
tryptophan (25.0 mg, 63.6 µmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (15% ethyl acetate in hexanes) as a viscous oil (14.5 mg, 44%). 
[]  -17.6 (c 0.25, CHCl3); Rf = 0.43 (30% EtOAc/hexanes); IR (film) 3330, 2979, 1732 
(br), 1667, 1492, 1454, 1369, 1254, 1159 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.10 (br s, 
1H), 7.31 (m, 2H), 7.28 (s, 1H), 7.25 (s, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4 
Hz, 2H), 6.18 (br s, 1H), 5.79 (br s, 1H), 5.07 (br s, 1H), 4.82 (ddd, J = 6.0, 6.0, 6.0 Hz, 
1H), 3.11 (d, J = 6.0 Hz, 2H), 1.67 (s, 9H), 1.42 (s, 9H), 1.39 (s, 9H); 
13
C NMR (150 
MHz, CDCl3) ppm 170.2, 169.2, 154.8, 149.4, 136.6, 135.1, 134.1, 130.3, 129.0, 128.4, 
124.5, 123.9, 122.6, 118.6, 115.2, 114.6, 83.6, 82.8, 80.1, 57.9, 53.0, 28.2, 28.1, 27.9, 
27.2; HRMS (ESI): Exact mass calcd for C33H42ClN3NaO7 [M+Na]
+
 650.2603, found 
650.2625. 
 
N-Boc-4-Br-Phenylglycine-N-Me (S-3). Following General Procedure E, the -bromo 
nitroalkane (100 mg, 240 μmol) and N-methylamine hydrochloride (19.0 mg, 280 μmol) 
gave the N-methyl phenylglycine (single diastereomer), after flash column 
20
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chromatography (SiO2, 40% ethyl acetate in hexanes), as a white solid (50.7 mg, 63% 
yield). []  -106.1 (c 0.33, CHCl3); Rf = 0.24 (40% EtOAc/hexanes); mp = 179-181 C; 
IR (neat) 3321, 2977, 1661, 1488, 1367, 1165, 775 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.48 (d, J = 8.3 Hz, 2H), 7.25 (d, J = 8.3 Hz, 2H), 5.89 (br s, 2H), 5.11 (br s, 1H), 2.80 (d, 
J = 4.9 Hz, 3H), 1.42 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 170.1, 155.1, 137.6, 
132.1, 128.9, 122.3, 80.2, 57.9, 28.3, 26.6; HRMS (ESI): Exact mass calcd for 
C14H19BrN2NaO3 [M+Na]
+
 365.0471, found 365.0468. 
 
4-Br-Phenylglycine-N-Me (109). To a solution of the protected amine (136 mg, 400 
μmol) in CH2Cl2 (5 ml), trifluoroacetic acid (1.25 ml) was added, and the reaction stirred 
for 2 hours at rt. It was then diluted with CH2Cl2, and washed with water. The aqueous 
layer was brought to a pH of 12 by addition of 1M KOH, and extracted with ethyl 
acetate. The organic layers were dried and condensed to give the free amine as an oil 
(69.3 mg, 72% yield). []  -52.5 (c 0.04, CHCl3); Rf = 0.14 (5% MeOH/CH2Cl2); IR 
(neat) 3299.9, 2927, 1652, 1592, 1488, 1409, 1011 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.43 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 4.44 (br s, 1H), 2.90 (br s, 1H), 2.77 (d, 
J = 4.8 Hz, 3H), [NH2 not observed]; 
13
C NMR (150 MHz, CDCl3) ppm 173.2, 140.0, 
131.8, 128.6, 121.8, 59.2, 26.0; HRMS (ESI): Exact mass calcd for C9H12BrN2O [M+H]
+
 
243.0128, found 243.0124. 
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N-Boc-4-Cl-Phenylglycine-4-Br-Phenylglycine-N-Me (S-4). Following General 
Procedure D, the -bromo nitroalkane (88.0 mg, 230 μmol) and free amine (68.0 mg, 280 
μmol) provided the dipeptide (single diastereomer), after trituration with CH2Cl2, as a 
white solid (83.0 mg, 70% yield), with some residual succinimide impurity (13%). An 
analytical sample was purified by column chromatography (SiO2, 50% ethyl acetate in 
hexanes) for characterization. []  -26.5 (c 0.17, CHCl3); Rf = 0.11 (40% 
EtOAc/hexanes); mp = 250 C (decomposition); IR (film) 3285, 2978, 1676, 1643, 1523, 
1490 cm
-1
; 
1
H NMR (600 MHz, 5:1 CDCl3:DMSO-d6)  8.07 (d, J = 7.4 Hz, 1H), 7.38 
(d, J = 4.0 Hz, 1H), 6.82 (d, J = 7.4 Hz, 2H), 6.79 (d, J = 7.4 Hz, 2H), 6.76 (d, J = 7.4 Hz, 
2H), 6.70 (d, J = 7.6 Hz, 2H), 6.38 (d, J = 7.4 Hz, 1H), 4.87 (d, J = 7.1 Hz, 1H), 4.78 (d, 
J = 7.7 Hz, 1H), 2.07 (d, J = 4.6 Hz, 3H), 0.84 (s, 9H); 
13
C NMR (150 MHz, 5:1 
CDCl3:DMSO-d6) ppm 168.3, 168.2, 153.7, 136.8, 136.3, 131.7, 129.9, 127.8, 127.5, 
127.0, 120.0, 78.0, 56.1, 54.8, 27.0, 24.6; HRMS (ESI): Exact mass calcd for 
C22H25BrClN3NaO [M+Na]
+
 532.0609, found 532.0601. 
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4-Cl-Phenylglycine-4-Br-Phenylglycine-N-MeCF3CO2H (110). To a solution of the 
protected amine (47.4 mg, 90.0 μmol) in CH2Cl2 (1.2 ml), trifluoroacetic acid (0.4 ml) 
was added, and the reaction stirred for 5 hours at rt. It was then concentrated in vacuo, 
and column chromatographed (2% MeOH/CH2Cl2), giving the pure trifluoroacetate salt 
of the deprotected dipeptide (36.5 mg, 75%).  
 For characterization, an analytical sample was diluted with 
CH2Cl2, and washed with water. The aqueous layer was brought to 
a pH of 12 by addition of 1M KOH, and extracted with ethyl 
acetate. The organic layers were dried and concentrated to give the 
free amine as an oil. []  -16.7 (c 0.15, CHCl3); Rf = 0.21 (5% MeOH/CH2Cl2); IR 
(film) 3291, 2924, 1641, 1489, 1091, 1011 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.40 (d, J 
= 6.7 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.30 (m, 6H), 7.19 (d, J = 8.3 Hz, 2H), 5.99 (d, J 
= 3.8 Hz, 1H), 5.36 (d, J = 7.1 Hz, 1H), 4.55 (br s, 1H), 2.78 (d, J = 4.7 Hz, 3H); 
13
C 
NMR (150 MHz, CDCl3) ppm 172.4, 169.8, 136.7, 134.0, 132.1 (2C), 129.0, 128.8, 
128.1, 122.5, 59.2, 56.3, 26.5; HRMS (ESI): Exact mass calcd for C17H18BrClN3O2 
[M+H]
+
 410.0265, found 410.0274. 
20
D
204 
 
 
N-Boc-4-Br-Phenylglycine-4-Cl-Phenylglycine-4-Br-Phenylglycine-N-Me (111). 
Following General Procedure E, the -bromo nitroalkane (13.0 mg, 31 μmol) and 
trifluoroacetate salt (20.0 mg, 38 μmol) provided the tripeptide (single diastereomer), 
after trituration with CH2Cl2, as a white solid (18.6 mg, 83% yield), with some residual 
succinimide impurity (10%). The desired compound was characterized with residual 
succinimide impurity. []  -7.5 (c 0.16, CHCl3); Rf = 0.16 (50% EtOAc/hexanes); mp = 
235 C (decomposition); IR (film) 3279, 1668, 1634, 1489, 1367, 1011 cm-1; 1H NMR 
(500 MHz, DMSO-d6)  9.07 (d, J = 7.5 Hz, 1H), 8.75 (d, J = 7.5 Hz, 1H), 8.24 (d, J = 
4.5 Hz, 1H), 7.51 (d, J = 8.0 Hz, 3H), 7.48 (d, J = 8.0 Hz, 5H), 7.42 (d, J = 8.0 Hz, 3H), 
7.33 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.70 (d, J = 7.5 Hz, 1H), 5.31 (d, J = 
7.0 Hz, 2H), 2.53 (d, J = 4.5 Hz, 3H), 1.36 (s, 9H); 
13
C NMR (150 MHz, DMSOd6) ppm 
169.7, 169.5, 169.1, 155.3, 138.5, 132.7, 131.6, 131.5, 129.9, 129.6, 129.5, 129.4 (2C), 
128.6, 128.5, 121.2, 79.0, 57.3, 56.3, 55.6, 28.5, 26.0; HRMS (ESI): Exact mass calcd for 
C30H32Br2ClN4O5 [M+H]
+
 721.0422, found 721.0458. 
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Chapter III: Enantioselective aza-Henry Addition to Silyl Imines 
General Procedure A: Synthesis of N-TMS-Protected Imines 
According to the procedure of Collet and coworkers,
155
 in a flame-dried round bottom 
flask under argon, n-butyl lithium (1 equiv) was added to hexamethyldisilazane (1.1 
equiv) at 0 C. After stirring for 10 m, the aldehyde (1 equiv), in THF (10 M), was added 
via cannula. The reaction was allowed to stir at rt for 1 h before the solvent was removed. 
The crude material was treated with TMSCl (1 equiv), and allowed to stir for 1 h at rt. 
The reaction was then diluted with hexanes and filtered under argon. The solvent was 
removed, giving the crude imine which was then purified via distillation. 
General Procedure B: Bromonitromethane Addition to N-TMS-Protected Imines: 
Acetyl Bromide Quench 
A solution of the imine (1 equiv) and PBAM
156
 (0.10 equiv) in toluene (0.3 M) was 
cooled to -78 C. Bromonitromethane was added to the reaction mixture in aliquots (0.2 
equiv every 2 h) over 10 h.  The reaction was then stirred at -78 C for an additional 16 h 
before addition of acetyl bromide at -78 C (1 equiv).  The reaction was then stirred at -
78 C for 3 h and subsequently quenched at -78 C by the addition of water (200 eq).  
The reaction mixture was diluted with CH2Cl2 and dried (MgSO4). The solvent was 
removed in vacuo, and the crude reaction mixture was purified by column 
chromatography to give the α-bromonitro adduct as a mixture of inseparable 
diastereomers. 
General Procedure C: Bromonitromethane Addition to N-TMS-Protected Imines 
                                                          
155
 Vidal, J.; Damestoy, S.; Guy, L.; Hannachi, J. C.; Aubry, A.; Collet, A. Chemistry-a European Journal 
1997, 3, 1691. 
156
 Davis, T. A.; Wilt, J. C.; Johnston, J. N. J. Am. Chem. Soc. 2010, 132, 2880. 
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A solution of the imine (1 equiv) and PBAM (0.10 equiv) in toluene (0.3 M) was cooled 
to -78 C.  Bromonitromethane was added to the reaction mixture in aliquots (0.2 equiv 
every 2 h) over 10 h.  The reaction was then stirred at -78 C for an additional 16 h before 
its quench at -78 C with an acylating reagent (1 equiv).  The reaction was then warmed 
to 0 C and stirred for 20 h.  The solvent was removed in vacuo, and the crude reaction 
mixture was purified by column chromatography to give the α-bromonitro adduct as a 
mixture of inseparable diastereomers. 
General Procedure D: Amide Synthesis Using an Amine (Free Base) 
The amine (1.2 equiv) was added dropwise to a solution of α-bromo nitroalkane (1.0 
equiv, 0.2 M) and NIS (1.0 equiv) in THF and H2O (5.0 equiv) at 0 °C, followed by 
K2CO3 (2.0 equiv). The reaction mixture was stirred at 0 °C for 2 d. The resulting 
mixture was diluted with dichloromethane, dried with MgSO4 and then filtered through 
Celite. The filtrate was concentrated and subjected to purification by flash column 
chromatography on silica gel.  
General Procedure E: Amide Synthesis Using an Ammonium Salt 
K2CO3 (5.0 equiv) was added to the suspension of the ammonium salt (2.0 equiv) and the 
α-bromo nitroalkane (1.0 equiv, 0.2 M) in DME and H2O (5.0 equiv) at 0 °C, followed by 
NIS (100 mol%). The reaction mixture was placed under an atmosphere of O2 and stirred 
at 0 °C for 24 h. The resulting mixture was diluted with dichloromethane and then 
filtered. The filtrate was concentrated and subjected to purification by flash column 
chromatography on silica gel.  
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Fluorenylmethyl (1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate (182). 
Following General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and 
bromonitromethane (7.3 ml, 94 µmol), when quenched with fluorenylmethyl 
chloroformate (24.3 mg, 94 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a white solid (35.8 mg, 76%). The enantiomeric excess of both the major and minor 
diastereomers was determined to be 91% ee by chiral HPLC analysis (Chiralcel AD-H, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 12.0 min, tr(d1e2, major) = 38.8 min, 
tr(d2e1, minor) = 13.3 min, tr(d2e2, major) = 22.4 min). Rf = 0.29 (20% EtOAc/hexanes); 
mp = 154-156 C (dec); IR (film) 3307, 1701, 1566, 1508, 1493, 1246 cm-1; 1H NMR 
(400 MHz, CDCl3)  7.78 (d, J = 7.6 Hz, 4H), 7.58 (br s, 4H), 7.37 (m, 12H), 7.23 (br s, 
4H), 6.30 (br s, 2H), 5.96 (br d, J = 8.4 Hz, 1H), 5.65 (br s, 1H), 5.57 (br s, 1H), 5.48 (br 
s, 1H), 4.57 (m, 2H), 4.46 (br s, 2H), 4.34 (m, 2H); 
13
C NMR (100 MHz, CDCl3) ppm 
155.5, 155.3, 143.4 (2C), 141.3 (2C), 135.4, 135.3, 133.3, 132.8, 129.3 (2C), 128.3, 
128.2, 127.8 (2C), 127.1 (2C), 124.9 (2C), 120.1 (2C), 83.9, 80.5, 67.3 (2C), 57.9 (2C), 
47.0 (2C); HRMS (ESI): Exact mass calcd for C23H18BrClN2NaO4 [M+Na]
+
 523.0031, 
found 523.0057. 
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N-(2-Bromo-1-(4-chlorophenyl)-2-nitroethyl)-1,1,1-trimethylsilanamine (184). The 
N-TMS-imine
157
 (40.0 mg, 189 µmol) and bromonitromethane (16.0 µL, 227 µmol) were 
stirred at rt in CDCl3 for 1 h and then analyzed directly by NMR. 
1
H NMR indicated 81% 
conversion to the N-TMS-protected α-bromo nitroalkane (1.6:1 dr), with some N-TMS-
imine and bromonitromethane remaining. Notably, the peaks seen at 1.43 and 1.22 ppm, 
corresponding to the NH protons of each diastereomer, appear as doublets which 
integrate to a single proton.  The coupling constants for each peak (12.6 and 13.2 Hz, 
respectively) suggest the protons couple only to the neighboring benzylic methyne 
proton. These details indicate that the compound observed is the suggested N-TMS-
protected adduct, and not the free amine which would result from deprotection of the 
TMS group. 
N-TMS-protected α-bromo nitroalkane: 1H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.35 (m, 4H), 7.28 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 6.22 (d, 
J = 3.6 Hz, 1H), 5.82 (d, J = 9.0 Hz, 1H), 4.85 (dd, J = 12.6, 3.6 Hz, 1H), 4.49 (dd, J = 
13.2, 9.0 Hz, 1H), 1.43 (d, J = 12.6 Hz, 1H), 1.22 (d, J = 13.2 Hz, 1H), 0.00 (s, 9H), -0.02 
(s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 138.6, 138.3, 134.3, 134.1, 129.1, 128.9, 
128.2, 127.8, 91.1, 83.5, 61.1, 59.8, 0.0, -0.1. 
 
 
                                                          
157
 Commercially available. 
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N-((1R)-2-Bromo-1-(4-chlorophenyl)-2-nitroethyl)acetamide (187). Following 
General Procedure B, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
µL, 94 µmol), when quenched with acetyl bromide (11.6 µL, 94 µmol), provided the α-
bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 30% ethyl acetate in hexanes), as a viscous yellow oil (23.4 mg, 78%). The 
enantiomeric excess of the major and minor diastereomers were determined to be 93 and 
91% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 
mL/min, tr(d1e1, minor) = 10.2 min, tr(d1e2, major) = 18.6 min, tr(d2e1, minor) = 13.9 min, 
tr(d2e2, major) = 16.0 min). Rf = 0.18 (30% EtOAc/hexanes); IR (film) 3266, 2925, 1661, 
1566, 1538, 1373, 1094 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.39 (d, J = 6.4 Hz, 2H), 7.37 (d, J = 6.4 Hz, 2H), 7.30 (d, J = 8.5 Hz, 
2H), 7.27 (d, J = 8.8 Hz, 2H), 6.87 (br d, J = 8.5 Hz, 1H), 6.49 (br d, J = 8.0 Hz, 1H), 
6.37 (d, J = 4.5 Hz, 1H), 6.35 (d, J = 5.6 Hz, 1H), 5.91 (dd, J = 8.6, 4.4 Hz, 1H), 5.78 
(dd, J = 8.9, 5.6 Hz, 1H), 2.14 (s, 3H), 2.11 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
169.9, 169.7, 135.5, 135.4, 133.1, 132.7, 129.5, 129.4, 128.4 (2C), 83.9, 80.3, 56.0, 55.8, 
23.1 (2C); HRMS (CI): Exact mass calcd for C10H11BrClN2O3 [M+H]
+
 320.9636, found 
320.9628. 
 
Following General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and 
bromonitromethane (7.3 µL, 94 µmol), when quenched with acetyl chloride (6.7 µL, 94 
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µmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 30% ethyl acetate in hexanes), as a viscous yellow oil 
(25.0 mg, 83%). The enantiomeric excess of the major and minor diastereomers were 
determined to be 92 and 91% ee, respectively. 
 
2-Azido-N-((1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethyl)acetamide (199a). 
Following General Procedure C, the N-TMS-imine (50 mg, 236 µmol) and 
bromonitromethane (18.0 µL, 236 µmol), when quenched with azidoacetyl chloride (28.2 
µL, 236 µmol), provided the α-bromo nitroalkane (1:1 mixture of diastereomers), after 
flash column chromatography (SiO2, 15% ethyl acetate in hexanes), as a white solid (70.0 
mg, 82%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 91% ee by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 
0.6 mL/min, tr(d1e1, minor) = 10.5 min, tr(d1e2, major) = 17.2 min, tr(d2e1, minor) = 15.3 
min, tr(d2e2, major) = 18.5 min). Rf = 0.27 (30% EtOAc/hexanes); mp = 154-156 C 
(dec); IR (film) 3290, 3026, 2116, 1662, 1553, 1537, 1317, 1287 cm
-1
; 
1
H NMR (600 
MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.61 (br d, J = 8.9 Hz, 1H), 7.41 (d, J = 
8.3 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 8.5 Hz, 2H), 
7.22 (br d, J = 8.6 Hz, 1H), 6.35 (d, J = 4.1 Hz, 1H), 6.34 (d, J = 5.1 Hz, 1H), 5.91 (dd, J 
= 8.9, 4.4 Hz, 1H), 5.76 (dd, J = 9.1, 5.3 Hz, 1H), 4.18 (d, J = 16.9 Hz, 1H), 4.15 (d, J = 
17.0 Hz, 1H), 4.10 (d, J = 16.8 Hz, 1H), 4.09 (d, J = 16.9 Hz, 1H); 
13
C NMR (150 MHz, 
CDCl3) ppm 166.5, 166.2, 135.8, 135.7, 132.6, 132.1, 129.6, 129.5, 128.3 (2C), 83.6, 
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79.9, 55.7, 55.6, 52.4 (2C); HRMS (CI): Exact mass calcd for C10H10BrClN5O3 [M+H]
+
 
363.9635, found 363.9638. 
 
N-((1R)-2-Bromo-1-(4-chlorophenyl)-2-nitroethyl)-2-phenylacetamide (199b). 
Following General Procedure B, the N-TMS-imine (20 mg, 94 µmol) and 
bromonitromethane (7.3 µL, 94 µmol), when quenched with phenylacetyl chloride (13 
µL, 94 µmol), provided the α-bromo nitroalkane (2.4:1 mixture of diastereomers), after 
flash column chromatography (SiO2, 20% ethyl acetate in hexanes), as a white solid (32 
mg, 85%). The enantiomeric excess of the major and minor diastereomers were 
determined to be 93 and 94% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 8.6, 15.3 min, tr(minor) = 10.4, 17.1 min). 
Rf = 0.13 (15% EtOAc/hexanes); mp = 161-163 C (decomposition); IR (film) 3277, 
2922, 1653, 1563, 1531, 1494, 1353 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 2.4:1 mixture of 
diastereomers)  7.45 (m, 4H), 7.39 (m, 2H), 7.32 (m, 8H), 7.09 (d, J = 8.5 Hz, 2H), 7.06 
(d, J = 8.4 Hz, 2H), 6.68 (br d, J = 8.8 Hz, 1H), 6.26 (d, J = 3.8 Hz, 1H), 6.25 (d, J = 5.0 
Hz, 1H), 6.22 (br d, J = 8.5 Hz, 1H), 5.86 (dd, J = 8.8, 4.0 Hz, 1H), 5.71 (dd, J = 9.1, 5.1 
Hz, 1H), 3.75 (d, J = 16.2 Hz, 1H), 3.70 (d, J = 16.4 Hz, 1H), 3.69 (d, J = 16.4 Hz, 1H), 
3.66 (d, J = 16.6 Hz, 1H); 
13
C NMR (150 MHz, CDCl3) ppm 170.7, 170.4, 135.4, 135.3, 
133.8, 133.7, 133.1, 132.5, 129.5, 129.4 (3C), 129.3 (2C), 128.1 (2C), 127.9 (2C), 84.2, 
80.2, 55.7, 55.6, 43.6, 43.5; HRMS (ESI): Exact mass calcd for C16H14BrClN2NaO3 
[M+Na]
+ 
418.9769, found 418.9795. 
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N-((1R)-2-Bromo-1-(4-chlorophenyl)-2-nitroethyl)benzamide (199c). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
µL, 94 µmol), when quenched with benzoyl chloride (11 µL, 94 µmol), provided the α-
bromo nitroalkane (1.4:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 15% ethyl acetate in hexanes), as a white solid (25.2 mg, 70%). The enantiomeric 
excess of the major and minor diastereomers were determined to be 94 and 95% ee, 
respectively, by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 
mL/min, tr(d1e1, minor) = 8.6 min, tr(d1e2, major) = 19.5 min, tr(d2e1, minor) = 6.7 min, 
tr(d2e2, major) = 14.1 min). Rf = 0.15 (15% EtOAc/hexanes); mp = 147-150 C (dec); IR 
(film) 3299, 2923, 1641, 1564, 1521, 1343 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 
mixture of diastereomers)  7.87 (d, J = 7.3 Hz, 2H), 7.82 (d, J = 7.3 Hz, 2H), 7.59 (m, 
2H), 7.56 (br d, J = 8.9 Hz, 1H), 7.50 (m, 4H), 7.38 (m, 6H), 7.32 (d, J = 8.5 Hz, 2H), 
7.03 (br d, J = 8.4 Hz, 1H), 6.48 (d, J = 4.3 Hz, 1H), 6.45 (d, J = 5.1 Hz, 1H), 6.10 (dd, J 
= 8.5, 4.2 Hz, 1H), 5.97 (dd, J = 8.9, 5.1 Hz, 1H); 
13
C NMR (150 MHz, CDCl3) ppm 
167.1, 166.9, 135.5, 135.4, 133.2, 133.0 (2C), 132.8, 132.4 (2C), 129.6, 129.4, 128.9, 
128.4, 128.2, 127.2, 127.1, 84.2, 80.3, 56.3, 56.1; HRMS (ESI): Exact mass calcd for 
C15H12BrClN2NaO3 [M+Na]
+
 404.9612, found 404.9638. 
 
N-((1R)-2-Bromo-1-(4-chlorophenyl)-2-nitroethyl)pivalamide (199d). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
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µL, 94 µmol), when quenched with pivaloyl chloride (11.5 µL, 94 µmol), provided the α-
bromo nitroalkane (1.4:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 10% ethyl acetate in hexanes), as a white solid (22.7 mg, 67%). The enantiomeric 
excess of the major and minor diastereomers were determined to be 96 and 97% ee, 
respectively, by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 
mL/min, tr(d1e1, minor) = 5.5 min, tr(d1e2, major) = 9.5 min, tr(d2e1, minor) = 4.8 min, 
tr(d2e2, major) = 18.7 min). Rf = 0.21 (15% EtOAc/hexanes); mp = 142-146 C 
(decomposition); IR (film) 3319, 2969, 1643, 1560, 1543, 1350, 1213 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.39 (d, J = 8.5 Hz, 2H), 7.37 (d, J  
= 8.5 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 7.03 (br d, J = 8.5 Hz, 
1H), 6.50 (br d, J = 8.0 Hz, 1H), 6.39 (d, J = 3.9 Hz, 1H), 6.37 (d, J = 4.9 Hz, 1H), 5.88 
(dd, J = 8.4, 3.9 Hz, 1H), 5.74 (dd, J = 8.8, 5.0 Hz, 1H), 1.30 (s, 9H), 1.27 (s, 9H); 
13
C 
NMR (150 MHz, CDCl3) ppm 178.2, 177.9, 135.4, 135.3, 133.4, 133.0, 129.5, 129.4, 
128.2, 128.1, 84.4, 80.5, 55.5, 55.4, 39.1, 39.0, 27.4, 27.3; HRMS (ESI): Exact mass 
calcd for C13H16BrClN2NaO3 [M+Na]
+
 384.9925, found 384.9933. 
 
Methyl (1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate (199e). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
µL, 94 µmol), when quenched with methyl chloroformate (7.3 µL, 94 µmol), provided 
the α-bromo nitroalkane (1.3:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid (21 mg, 67%). The 
enantiomeric excess of both the major and minor diastereomers was determined to be 
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91% ee by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(major) = 12.1, 24.1 min, tr(minor) = 14.5, 22.4 min). Rf = 0.14 (10% EtOAc/hexanes); 
mp = 121-125 C; IR (film) 3301, 2922, 1701, 1567, 1534, 1494, 1351, 1252, 1093 cm-1; 
1
H NMR (600 MHz, CDCl3, 1.3:1 mixture of diastereomers)  7.40 (d, J = 8.5 Hz, 2H), 
7.39 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.5 Hz, 2H), 6.31 (br s, 
2H), 5.93 (br s, 1H), 5.69 (br dd, J = 8.7, 3.8 Hz, 1H), 5.58 (br s, 1H), 5.49 (br s, 1H), 
3.75 (s, 3H), 3,73 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 156.0, 155.7, 135.5, 135.4, 
133.5, 132.9, 129.5, 129.4, 128.2, 128.1, 84.4, 80.6, 57.9 (2C), 53.0 (2C); HRMS (CI): 
Exact mass calcd for C9H9ClNO2 [M-CHBrNO2]
+
 198.0316, found 198.0309. 
 
Benzyl (1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate (199f). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
µL, 94 µmol), when quenched with benzyl chloroformate (13.2 µL, 94 µmol), provided 
the α-bromo nitroalkane (1.3:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid (28.1 mg, 72%). 
The enantiomeric excess of the major and minor diastereomers were determined to be 91 
and 90% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 15% 
i
PrOH/hexanes, 0.7 mL/min, tr(d1e1, minor) = 17.9 min, tr(d1e2, major) = 31.3 min, tr(d2e1, 
minor) = 19.3 min, tr(d2e2, major) = 29.7 min). Rf = 0.19 (10% EtOAc/hexanes); mp = 
112-115 C; IR (film) 3308, 2924, 1699, 1567, 1532, 1494, 1350, 1249, 1093, 1015 cm-1; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.38 (m, 14H), 7.28 (d, J = 
7.8 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 6.31 (br s, 2H), 6.01 (br d, J = 6.8 Hz, 1H), 5.70 (br 
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s, 1H), 5.65 (br s, 1H), 5.52 (br s, 1H), 5.16 (s, 2H), 5.14 (s, 2H); 
13
C NMR (150 MHz, 
CDCl3) ppm 155.4, 155.1, 135.5 (2C), 135.4 (2C), 133.4, 132.8, 129.4 (3C), 128.6 (2C), 
128.5, 128.3 (2C), 128.2 (2C), 84.3, 80.7, 67.8 (2C), 57.9 (2C); HRMS (ESI): Exact mass 
calcd for C16H14BrClN2NaO4 [M+Na]
+
 434.9718, found 434.9708. 
 
Allyl (1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate (199g). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
µL, 94 µmol), when quenched with allyl chloroformate (10 µL, 94 µmol), provided the α-
bromo nitroalkane (1:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 10% ethyl acetate in hexanes), as a viscous white paste (27.8 mg, 85%). The 
enantiomeric excess of both the major and minor diastereomers was determined to be 
91% ee by chiral HPLC analysis (Chiralcel AD-H, 8% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(d1e1, minor) = 17.1 min, tr(d1e2, major) = 30.8 min, tr(d2e1, minor) = 16.2 min, tr(d2e2, 
major) = 33.4 min). Rf = 0.13 (10% EtOAc/hexanes); IR (film) 3307, 2925, 1699, 1568, 
1532, 1494, 1352, 1278, 1250, 1093 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.40 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 9.0 Hz, 2H), 7.30 (d, J = 8.4 Hz, 
2H), 7.26 (d, J = 9.0 Hz, 2H), 6.32 (br s, 2H), 6.00 (br d, J = 9.7 Hz, 1H), 5.93 (m, 2H), 
5.69 (dd, J = 9.1, 4.3 Hz, 1H), 5.63 (br d, J = 8.8 Hz, 1H), 5.50 (br dd, J = 8.0, 5.9 Hz, 
1H), 5.34 (d, J = 16.5 Hz, 2H), 5.27 (d, J = 10.5 Hz, 2H), 4.62 (m, 4H); 
13
C NMR (150 
MHz, CDCl3) ppm 155.2, 155.0, 135.5, 135.4, 132.8, 132.0, 131.9, 129.5, 129.4, 128.3, 
128.1, 118.6, 118.5, 84.3, 80.6, 66.6 (2C), 57.8 (2C); HRMS (ESI): Exact mass calcd for 
C12H12BrClN2NaO4 [M+Na]
+
 384.9561, found 384.9581. 
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2,2,2-Trichloroethyl (1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate 
(199h). Following General Procedure c, the N-TMS-imine (20 mg, 94 µmol) and 
bromonitromethane (7.3 µL, 94 µmol), when quenched with trichloroethyl chloroformate 
(13 µL, 94 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), as a viscous 
yellow oil (36 mg, 83%). The enantiomeric excess of the major and minor diastereomers 
were determined to be 92 and 91% ee, respectively, by chiral HPLC analysis (Chiralcel 
AD-H, 8% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 12.5, 19.2 min, tr(minor) = 14.9, 17.9 
min). Rf = 0.13 (10% EtOAc/hexanes); IR (film) 3307, 2921, 1717, 1568, 1520, 1494, 
1229, 1093, 1015 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  
7.42 (d, J = 8.2 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 
8.6 Hz, 2H), 6.34 (br s, 2H), 6.27 (br d, J = 8.9 Hz, 1H), 5.85 (br s, 1H), 5.72 (dd, J = 9.0, 
4.4 Hz, 1H), 5.52 (br dd, J = 8.8, 5.5 Hz, 1H), 4.78 (m, 4H); 
13
C NMR (150 MHz, 
CDCl3) ppm 153.9, 153.5, 135.8, 135.7, 132.8, 132.2, 129.6, 129.5, 128.2, 128.1, 94.9 
(2C), 83.9, 80.0, 74.9 (2C), 58.0 (2C); HRMS (CI): Exact mass calcd for 
C11H10BrCl4N2O4 [M+H]
+
 454.8549, found 454.8533. 
 
1-Benzyl-3-((1R)-2-bromo-1-(4-chlorophenyl)-2-nitroethyl)urea (199i). Following 
General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and bromonitromethane (7.3 
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µL, 94 µmol), when quenched with benzyl isocyanate (12 µL, 94 µmol), provided the α-
bromo nitroalkane (1.1:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 20% ethyl acetate in hexanes), as a viscous yellow oil (13 mg, 33%). The 
enantiomeric excess of the major and minor diastereomers were determined to be 92 and 
86% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 
mL/min, tr(major) = 10.0, 21.4 min, tr(minor) = 12.6, 23.7 min). Rf = 0.21 (30% 
EtOAc/hexanes); IR (film) 2926, 1727, 1582, 1495, 1455, 1365, 1233, 1092 cm
-1
; 
1
H 
NMR (600 MHz, CDCl3, 1.1:1 mixture of diastereomers)  7.37 (m, 6H), 7.30 (d, J = 8.6 
Hz, 4H), 7.27 (d, J = 9.9 Hz, 4H), 7.14 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 8.1 Hz, 2H), 6.28 
(d, J = 4.0 Hz, 1H), 6.26 (d, J = 5.8 Hz, 1H), 5.95 (br d, J = 9.1 Hz, 1H), 5.84 (dd, J = 
8.9, 4.0 Hz, 1H), 5.64 (dd, J = 9.1, 5.8 Hz, 2H), 5.31 (m, 2H), 4.35 (d, J = 5.7 Hz, 2H), 
4.32 (d, J = 5.6 Hz, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 156.7, 156.5, 138.2 (2C), 
135.1, 135.0, 134.0, 133.5, 129.3, 129.2, 128.8 (2C), 128.3, 128.2, 127.6, 127.4 (3C), 
85.2, 81.3, 57.0, 56.9, 44.6 (2C); HRMS (ESI): Exact mass calcd for C16H16BrClN3O3 
[M+H]
+
 412.0058, found 412.0074. 
Assignment of Absolute Configuration for N-TMS Imine Adducts by Chemical 
Correlation 
 
(R)-tert-Butyl 2-bromo-1-(4-chlorophenyl)-2-nitroethylcarbamate (84). As reported 
previously,
159
 a solution of the imine (81.0 mg, 338 µmol) and H,Quin(
6
(
9
Anth)
2
Pyr)-
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BAM•HOTf158 (10.9 mg, 16.9 µmol) in toluene (1.1 mL) was cooled to -20 °C and 
treated with bromonitromethane (63.0 mg, 406 µmol). The reaction mixture was stirred at 
-20 °C for 2 d, and then concentrated and directly subjected to purification by flash 
column chromatography on silica gel (10% ethyl acetate in hexanes) to give the α-bromo 
nitroalkane as a white solid (111 mg, 87%), which was determined to be 98% ee (each 
diastereomer) and 1:1 dr by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 
1 mL/min, tr(d1e1, minor) = 14.5 min, tr(d1e2, major) = 19.3 min, tr(d2e1, minor) = 15.7 
min, tr(d2e2, major) = 25.5 min tr(major) = 14.5, 19.3 min, tr(major) = 15.7, 25.5 min. 
Figure 1). 
 
 
 
                                                          
158
 Singh, A.; Yoder, R. A.; Shen, B.; Johnston, J. N. J. Am. Chem. Soc. 2007, 129, 3466-3467Shen, B.; 
Johnston, J. N. Org. Lett. 2008, 10, 4397-4400. 
Figure 1: HPLC trace of xx prepared via known method. 
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Following General Procedure C, the N-TMS-imine (20 mg, 94 µmol) and 
bromonitromethane (7.3 µL, 94 µmol), when quenched with Boc anhydride (20.5 mg, 94 
µmol), provided the α-bromo nitroalkane (1:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid (12.9 mg, 
36%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 80 and 81% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 
10% 
i
PrOH/hexanes, 1 mL/min, tr(d1e1, minor) = 14.5 min, tr(d1e2, major) = 19.5 min, 
tr(d2e1, minor) = 15.8 min, tr(d2e2, major) = 26.2 min. Figure 2). Rf = 0.49 (20% 
EtOAc/hexanes); spectroscopic data (
1
H NMR) was in complete accord with that 
previously reported.
159
 The absolute configuration at the benzylic carbon was therefore 
determined by chemical correlation. 
                                                          
159
 Shen, B.; Makley, D. M.; Johnston, J. N. Nature 2010, 465, 1027. 
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Fluorenylmethyl (1R)-2-bromo-1-(3-chlorophenyl)-2-nitroethylcarbamate (201a). 
Following General Procedure C, the N-TMS-imine
155
 (40.0 mg, 190 µmol) and 
bromonitromethane (15.0 µL, 190 µmol), when quenched with fluorenylmethyl 
chloroformate (49.0 mg, 190 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a white foam (59.8 mg, 63%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 82 and 83% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 15% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 13.9 min, 
tr(d1e2, major) = 26.2 min, tr(d2e1, minor) = 13.2 min, tr(d2e2, major) = 26.1 min). Rf = 
0.29 (20% EtOAc/hexanes); IR (film) 3309, 2923, 1704, 1567, 1514, 1333, 1248, 739 
cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.77 (d, J = 7.8 Hz, 
4H), 7.58 (br s, 4H), 7.41 (dd, J = 7.2, 7.2 Hz, 4H), 7.31 (m, 10H), 7.17 (br s, 2H), 6.29 
Figure 2. HPLC trace of xx prepared from N-TMS imine, BNM and Boc2O, in the presence of PBAM. 
                                                                         λ210 
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(br s, 2H), 6.05 (br d, J = 6.6 Hz, 1H), 5.69 (br s, 1H), 5.65 (br d, J = 9.0 Hz, 1H), 5.50 
(br s, 1H), 4.55 (m, 2H), 4.44 (br s, 2H), 4.23 (m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 
155.5, 155.1, 143.4 (2C), 143.3, 141.3 (2C), 136.3, 135.2 (2C), 130.5 (2C), 129.6, 129.5, 
127.8 (2C), 127.1 (3C), 127.0, 125.1, 124.9 (2C), 120.1 (3C); HRMS (ESI): Exact mass 
calcd for C23H18BrClN2NaO4 [M+Na]
+
 523.0031, found 523.0024. 
 
Fluorenylmethyl (1R)-2-bromo-1-(2,4-dichlorophenyl)-2-nitroethylcarbamate 
(201b). Following General Procedure C, the N-TMS-imine
155
 (20 mg, 81 µmol) and 
bromonitromethane (6.3 µL, 81 µmol), when quenched with fluorenylmethyl 
chloroformate (21 mg, 81 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a yellow viscous oil (30.2 mg, 70%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 90 and 91% ee, respectively, by chiral HPLC 
analysis (Chiralcel IA, 8% 
i
PrOH/hexanes, 0.7 mL/min, tr(d1e1, minor) = 41.2 min, 
tr(d1e2, major) = 44.4 min, tr(d2e1, minor) = 43.3 min, tr(d2e2, major) = 54.0 min). Rf = 
0.42 (30% EtOAc/hexanes); IR (film) 3316, 2925, 1713, 1568, 1515, 1477, 1451, 1256, 
1248 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.79 (br d, J = 
7.0 Hz, 4H), 7.55 (br m, 4H), 7.47 (br s, 2H), 7.42 (br t, J = 7.2 Hz, 6H), 7.30 (br m, 6H), 
6.51 (br s, 1H), 6.47 (br d, J = 4.7 Hz, 1H), 6.25 (br d, J = 8.8 Hz, 1H), 6.04 (br s, 1H). 
5.76 (br s, 1H), 5.72 (br s, 1H), 4.56 (br m, 2H), 4.45 (br s, 2H), 4.25 (br m, 2H); 
13
C 
NMR (150 MHz, CDCl3) ppm 154.5 (2C), 143.4, 143.3, 141.3 (2C), 130.7, 130.2, 129.7, 
128.1, 127.9, 127.8 (4C), 127.1 (4C), 124.9, 124.8, 124.7, 120.0 (4C), 82.3, 77.5, 67.5 
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(2C), 56.0, 55.6, 47.1 (2C); HRMS (ESI): Exact mass calcd for C23H17BrCl2N2NaO4 
[M+Na]
+
 556.9641, found 556.9644. 
 
N-((1R)-2-Bromo-1-(4-bromophenyl)-2-nitroethyl)acetamide (S-5). Following 
General Procedure B, the N-TMS-imine (40.0 mg, 160 µmol) and bromonitromethane 
(12.0 µL, 160 µmol), when quenched with acetyl bromide (12.0 µL, 160 µmol), provided 
the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 30% ethyl acetate in hexanes), as a yellow viscous oil (27.1 mg, 
46%). The enantiomeric excess of the major and minor diastereomers were determined to 
be 92 and 94% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 13.4, 16.2 min, tr(minor) = 9.6, 18.6 min). Rf = 
0.20 (40% EtOAc/hexanes); IR (film) 3287, 2925, 2853, 1667, 1586, 1568, 1531, 1490, 
1282, 1012 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.54 (d, 
J = 8.3 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 8.3 Hz, 2H), 7.20 (d, J = 8.4 Hz, 
2H), 6.90 (br d, J = 8.8 Hz, 1H), 6.51 (br d, J = 8.3 Hz, 1H), 6.36 (d, J = 4.5 Hz, 1H), 
6.34 (d, J = 5.7 Hz, 1H), 5.90 (dd, J = 8.7, 4.4 Hz, 1H), 5.76 (dd, J = 8.9, 5.8 Hz, 1H), 
2.14 (s, 3H), 2.10 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.9, 169.8, 133.7, 133.3, 
132.4, 132.3, 128.7 (2C), 123.6, 123.5, 83.8, 80.2, 56.0, 55.9, 23.1 (2C); HRMS (CI): 
Exact mass calcd for C10H11Br2N2O3 [M+H]
+
 364.9131, found 364.9146. 
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Fluorenylmethyl (1R)-2-bromo-1-(4-bromophenyl)-2-nitroethylcarbamate (201c). 
Following General Procedure C, the N-TMS-imine
160
 (40 mg, 160 µmol) and 
bromonitromethane (12.0 µL, 160 µmol), when quenched with fluorenylmethyl 
chloroformate (41 mg, 160 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a yellow solid (55.5 mg, 64%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 86 and 85% ee, respectively, by chiral HPLC 
analysis (Chiralcel IA, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 13.6 min, 
tr(d1e2, major) = 25.0 min, tr(d2e1, minor) = 12.7 min, tr(d2e2, major) = 44.9 min). Rf = 
0.38 (30% EtOAc/hexanes); mp = 103-105 C; IR (film) 3310, 3065, 1704, 1567, 1511, 
1491, 1335, 1249, 1075, 739 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.79 (d, J = 7.2 Hz, 4H), 7.56 (br m, 6H), 7.43 (t, J = 7.8 Hz, 6H), 7.34 
(br m, 4H), 7.17 (br m, 4H), 6.31 (br d, J = 5.4 Hz, 2H), 6.00 (br d, J = 9.0 Hz, 1H), 5.66 
(br s, 1H), 5.61 (br s, 1H), 5.48 (br dd, J = 6.0, 6.0 Hz, 1H), 4.58 (br m, 2 H), 4.46 (br s, 
2H), 4.24 (br m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 155.5, 155.1, 143.4 (2C), 141.3 
(2C), 132.4, 132.3, 128.5, 128.4 127.8 (2C), 127.6, 127.1 (3C), 124.9 (2C), 123.7, 123.5, 
120.1 (2C), 84.0, 80.4, 67.3 (2C), 57.8 (2C), 47.1 (2C); HRMS (ESI): Exact mass calcd 
for C23H18Br2N2NaO4 [M+Na]
+
 566.9526, found 566.9528. 
 
 
                                                          
160
 Betschart, C.; Schmidt, B.; Seebach, D. Helv. Chim. Acta 1988, 71, 1999-2021. 
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N-((1R)-2-Bromo-1-(4-fluorophenyl)-2-nitroethyl)acetamide (S-6). Following General 
Procedure B, the N-TMS-imine (40.0 mg, 205 µmol) and bromonitromethane (16.0 µL, 
205 µmol), when quenched with acetyl bromide (15.0 µL, 205 µmol), provided the α-
bromo nitroalkane (1:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 50% ethyl acetate in hexanes), as a yellow paste (33.2 mg, 53%). The 
enantiomeric excess of both the major and minor diastereomers was determined to be 
91% ee by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(major) = 11.1, 14.1 min, tr(minor) = 9.1, 16.6 min). Rf = 0.06 (40% EtOAc/hexanes); 
IR (film) 3313, 2925, 2853, 1699 (br), 1601, 1579, 1510, 1235, 1156 cm
-1
; 
1
H NMR (600 
MHz, CDCl3, 1:1 mixture of diastereomers)  7.35 (dd, J = 8.5, 5.1 Hz, 2H), 7.32 (dd, J = 
8.6, 5.2 Hz, 2H), 7.09 (m, 4H), 6.95 (br d, J= 8.6 Hz, 1H), 6.59 (br d, J = 8.0 Hz, 1H), 
6.36 (d, J = 4.8 Hz, 1H), 6.35 (dd, J = 5.7 Hz, 1H), 5.91 (dd, J = 8.6, 4.7 Hz, 1H), 5.80 
(dd, J = 8.8, 5.8 Hz, 1H), 2.12 (s, 3H), 2.10 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
170.0, 169.9, 163.0 (d, 
1
JCF = 247.5 Hz, 2C), 130.4 (d, 
4
JCF = 3.0Hz), 130.1 (d, 
4
JCF = 4.5 
Hz), 129.0 (d, 
3
JCF = 7.5 Hz), 128.9 (d, 
3
JCF = 7.5 Hz), 116.3 (d, 
2
JCF = 22.5 Hz), 116.2 
(d, 
2
JCF = 22.5 Hz), 83.9, 80.6, 56.0, 55.8, 23.1 (2C); HRMS (CI): Exact mass calcd for 
C10H11BrFN2O3 [M+H]
+
 304.9932, found 304.9943. 
 
Fluorenylmethyl (1R)-2-bromo-1-(4-fluorophenyl)-2-nitroethylcarbamate (201d). 
Following General Procedure C, the N-TMS-imine
155
 (40 mg, 205 µmol) and 
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bromonitromethane (16.0 µL, 205 µmol), when quenched with fluorenylmethyl 
chloroformate (53 mg, 205 µmol), provided the α-bromo nitroalkane (1.3:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a yellow solid (74.0 mg, 74%). The enantiomeric excess of both the major and minor 
diastereomers was determined to be 86% ee by chiral HPLC analysis (Chiralcel IA, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 13.2 min, tr(d1e2, major) = 20.0 min, tr(d2e1, 
minor) = 11.4 min, tr(d2e2, major) = 33.7 min). Rf = 0.35 (40% EtOAc/hexanes); mp = 
98-101 C; IR (film) 3315, 2925, 1713, 1607, 1568, 1511, 1352, 1230, 759, 740 cm-1; 1H 
NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.79 (d, J = 7.8 Hz, 4H), 7.59 
(br s, 4H), 7.43 (t, J = 7.5 Hz, 6H), 7.31 (m, 6H), 7.09 (br s, 4H), 6.32 (br s, 2H), 6.02 (br 
d, J = 8.8 Hz, 1H), 5.66 (br s, 2H), 5.52 (br s, 1H), 4.58 (br dd, J = 17.0, 10.1 Hz, 2H), 
4.46 (br s, 2H), 4.24 (br m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 163.0 (d, 
1
JCF = 249.2 
Hz, 2C), 155.5, 155.2, 143.4 (2C), 141.3 (2C), 130.1 (2C), 128.8 (2C), 127.8 (2C), 127.1 
(d, 
3
JCF = 4.8 Hz, 2C), 124.9, 124.8, 120.1 (2C), 116.3 (d, 
2
JCF = 22.1 Hz), 116.2 (d, 
2
JCF 
= 22.9 Hz), 84.1, 80.8, 67.3 (2C), 57.9, 57.8, 47.1 (2C); HRMS (CI): Exact mass calcd 
for C23H19BrFN2O4 [M+H]
+
 485.0507, found 485.0518. 
 
(E)-1,1,1-Trimethyl-N-(4-iodophenyl)silanamine (S-7). Following the General 
Procedure A, the aldehyde (2.0 g, 8.62 mmol) provided the imine (0.7 g, 27%) as a pale 
yellow oil. Rf = 0.27 (10% EtOAc/hexanes); bp = 85 °C/0.5 mm Hg; IR (film) 2952, 
1642, 1585, 1481, 1394, 1250, 1094, 1006, 836 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.90 
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(s, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 7.8 Hz, 2H), 0.27 (s, 9H); 
13
C NMR (100 
MHz, CDCl3) ppm 167.2, 137.7, 137.4, 98.2, -1.23.
161
 
 
Fluorenylmethyl (1R)-2-bromo-1-(4-iodophenyl)-2-nitroethylcarbamate (201e). 
Following General Procedure C, the N-TMS-imine (40.0 mg, 132 µmol) and 
bromonitromethane (10.0 µL, 132 µmol), when quenched with fluorenylmethyl 
chloroformate (34.0 mg, 132 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a yellow solid (65.0 mg, 83%). The enantiomeric excess of both the major and minor 
diastereomers was determined to be 88% ee by chiral HPLC analysis (Chiralcel AD-H, 
15% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 21.6 min, tr(d1e2, major) = 80.5 min, 
tr(d2e1, minor) = 20.5 min, tr(d2e2, major) = 45.1 min). Rf = 0.29 (20% EtOAc/hexanes); 
mp = 175-177 C; IR (film) 3309, 1703, 1566, 1512, 1246 cm-1; 1H NMR (600 MHz, 
CDCl3, 1.2:1 mixture of diastereomers)  7.77 (d, J = 7.2 Hz, 4H), 7.12 (br s, 4H), 7.57 
(br s, 4H), 7.41 (dd, J = 7.8, 7.8 Hz, 4H), 7.31 (br m, 4H), 7.02 (br s, 4H), 6.28 (br s, 2H), 
5.96 (br s, 1H), 5.62 (br s, 1H), 5.58 (br s, 1H), 5.44 (br s, 1H), 4.55 (br s, 2H), 4.44 (br s, 
2H), 4.22 (br m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 155.4, 155.2, 143.4, 143.3, 
141.3 (2C), 138.3 (2C), 133.9 (2C), 128.6, 128.5, 127.8 (2C), 127.1 (2C), 124.8 (2C), 
120.1 (2C), 95.4, 95.3, 83.9, 80.3, 67.3 (2C), 58.0 (2C), 47.1 (2C); HRMS (ESI): Exact 
mass calcd for C23H18BrIN2NaO4 [M+Na]
+
 614.9387, found 614.9395. 
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 HRMS was attempted, but the desired mass was not able to be detected. This is most likely due to the 
instability of the compound. 
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N-((1R)-2-Bromo-2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)acetamide (S-8). 
Following General Procedure B, the N-TMS-imine (40.0 mg, 163 µmol) and 
bromonitromethane (13.0 µL, 163 µmol), when quenched with acetyl bromide (12.0 µL, 
163 µmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 40% ethyl acetate in hexanes), as a yellow viscous oil 
(27.9 mg, 48%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 88% ee by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 
0.7 mL/min, tr(major) = 17.9, 21.6 min, tr(minor) = 13.7, 23.8 min). Rf = 0.10 (40% 
EtOAc/hexanes); IR (film) 3197, 2924, 2852, 1713, 1668, 1326, 1169, 1130, 1068 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.68 (d, J = 7.4 Hz, 2H), 
7.67 (d, J = 7.6 Hz, 2H), 7.50 (d, J = 7.9 Hz, 2H), 7.47 (d, J = 7.9 Hz, 2H), 6.89 (br d, J = 
8.0 Hz, 1H), 6.46 (br d, J = 6.9 Hz, 1H), 6.40 (d, J = 3.6 Hz, 1H), 6.39 (d, J = 5.2 Hz, 
1H), 6.03 (br d, J = 4.5 Hz, 1H), 5.87 (br dd, J = 8.2, 5.5 Hz, 1H), 2.16 (s, 3H), 2.13 (s, 
3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.9, 169.8, 138.6, 138.2, 131.7 (q, 
2
JCF = 11.9 
Hz), 131.4 (q, 
2
JCF = 17.1 Hz), 127.6 (2C), 126.3 (q, 
3
JCF = 3.6 Hz), 126.2 (q, 
3
JCF = 3.7 
Hz), 123.6 (q, 
1
JCF = 215.9 Hz), 123.5 (q, 
1
JCF = 215.5 Hz), 83.8, 80.0, 56.1, 56.0, 23.2 
(2C); HRMS (CI): Exact mass calcd for C11H11BrF3N2O3 [M+H]
+
 354.9900, found 
301.0186. 
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Fluorenylmethyl (1R)-2-bromo-1-(4-(trifluoromethyl)phenyl)-2-nitroethylcarbamate 
(201f). Following General Procedure C, the N-TMS-imine
155
 (40 mg, 163 µmol) and 
bromonitromethane (13.0 µL, 163 µmol), when quenched with fluorenylmethyl 
chloroformate (42 mg, 163 µmol), provided the α-bromo nitroalkane (1.3:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a white solid (57.9 mg, 66%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 80 and 76% ee, respectively, by chiral HPLC 
analysis (Chiralcel IA, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 8.9 min, 
tr(d1e2, major) = 30.7 min, tr(d2e1, minor) = 9.8 min, tr(d2e2, major) = 19.3 min). Rf = 0.37 
(30% EtOAc/hexanes); mp = 180-182 C (decomposition); IR (film) 3310, 2925, 1704, 
1568, 1515, 1326, 1251, 1170, 1129, 1069, 740 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 
mixture of diastereomers)  7.89 (d, J = 6.6 Hz, 4H), 7.66 (br s, 4H), 7.59 (br m, 4H), 
7.42 (t, J = 7.8 Hz, 8H), 4.33 (m, 4H), 6.35 (br s, 2H), 6.04 (br d, J = 5.4 Hz, 1H), 5.76 
(br s, 1H), 5.67 (br d, J = 7.8 Hz, 1H), 5.57 (br s, 1H), 4.60 (br m, 2H), 4.49 (br s, 2H), 
4.24 (br m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 155.4, 155.1, 144.4, 144.3, 143.3 
(2C), 141.5, 141.3, 131.6 (m, 2C), 127.8 (2C), 127.6, 127.4, 127.1 (2C), 126.2 (br m, 
2C), 124.8 (br m, 2C), 123.6 (q, 
1
JCF = 271.5 Hz), 123.5 (q, 
1
JCF = 271.5 Hz), 120.1, 
120.0, 83.8, 80.2, 67.3 (2C), 58.0 (2C), 47.1 (2C); HRMS (ESI): Exact mass calcd for 
C24H18BrF3N2NaO4 [M+Na]
+
 557.0294, found 557.0323. 
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Fluorenylmethyl (1R)-2-bromo-1-phenyl-2-nitroethylcarbamate (201g). Following 
General Procedure C, the N-TMS-imine
162
 (40.0 mg, 226 µmol) and bromonitromethane 
(17.5 µL, 226 µmol), when quenched with fluorenylmethyl chloroformate (58.0 mg, 226 
µmol), provided the α-bromo nitroalkane (1:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid (67.3 mg, 
63%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 65 and 66% ee, respectively, by chiral HPLC analysis (Chiralcel IA, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 14.9 min, tr(d1e2, major) = 22.2 min, 
tr(d2e1, minor) = 13.3 min, tr(d2e2, major) = 32.6 min). Rf = 0.24 (20% EtOAc/hexanes); 
mp = 174-177 C; IR (film) 3322, 1694, 1563, 1530, 1449, 1252 738 cm-1; 1H NMR (600 
MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.77 (d, J  = 7.2 Hz, 4H), 7.59 (br s, 4H), 
7.41 (m, 10H), 7.30 (m, 8H), 6.33 (br s, 2H), 5.99 (br d, J  = 6.6 Hz, 1H), 5.70 (br s, 1H), 
5.57 (br s, 1H), 5.52 (br s, 1H), 4.55 (m, 2H), 4.42 (br m, 2H), 4.24 (br m, 2H); 
13
C NMR 
(150 MHz, CDCl3) ppm 155.6, 155.3, 143.6, 143.5 (2C), 141.3 (2C), 134.7, 129.3, 129.2, 
127.8 (2C), 127.2, 127.1, 126.8 (2C), 125.0, 124.9, 120.1 (4C), 84.6, 80.9, 67.4 (2C), 
58.4 (2C), 47.1 (2C); HRMS (ESI): Exact mass calcd for C23H19BrN2O4 [M]
+
 466.0528, 
found 466.0515. 
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 Commercially available. 
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N-((1R)-2-Bromo-2-nitro-1-p-tolylethyl)acetamide (S-9). Following General Procedure 
B, the N-TMS-imine
160
 (40.0 mg, 209 µmol) and bromonitromethane (16.3 µL, 209 
µmol), when quenched with acetyl bromide (15.0 µL, 209 µmol), provided the α-bromo 
nitroalkane (1.2:1mixture of diastereomers), after flash column chromatography (SiO2, 
40% ethyl acetate in hexanes), as a yellow viscous oil (26.9 mg, 43%). The enantiomeric 
excess of both the major and minor diastereomers was determined to be 75% ee by chiral 
HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 0.7 mL/min, tr(major) = 12.6, 21.2 
min, tr(minor) = 16.4, 19.9 min). Rf = 0.23 (40% EtOAc/hexanes); IR (film) 3300, 2924, 
1667, 1607, 1574, 1532, 1516, 1324, 1267, 1178 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 
mixture of diastereomers)  7.22 (d, J = 8.3 Hz, 2H), 7.20 (d, J = 10.0 Hz, 2H), 7.19 (s, 
4H), 6.83 (br d, J = 7.9 Hz, 1H), 6.45 (br d, J = 7.3 Hz, 1H), 6.36 (d, J = 4.7 Hz, 1H), 
6.34 (d, J = 5.6 Hz, 1H), 5.90 (dd, J = 8.8, 4.7 Hz, 1H), 5.78 (dd, J = 9.1, 5.6 Hz, 1H), 
2.36 (s, 3H), 2.35 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
169.8, 169.7, 139.4, 139.3, 131.5, 131.2, 129.9, 129.8, 126.9, 126.8, 84.2, 80.9, 56.3, 
56.1, 23.2, 23.1, 21.1 (2C); HRMS (CI): Exact mass calcd for C11H14BrN2O3 [M]
+
 
301.0182, found 301.0186. 
 
Fluorenylmethyl (1R)-2-bromo-2-nitro-1-(p-tolyl)ethylcarbamate (201h). Following 
General Procedure C, the N-TMS-imine
160
 (40.0 mg, 209 µmol) and bromonitromethane 
(16.3 µL, 209 µmol), when quenched with fluorenylmethyl chloroformate (54.0 mg, 209 
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µmol), provided the α-bromo nitroalkane (1.1:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 10% ethyl acetate in hexanes), as a yellow solid (63.2 
mg, 63%). The enantiomeric excess of both the major and minor diastereomers was 
determined to be 70 and 71% ee, respectively, by chiral HPLC analysis (Chiralcel IA, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 13.4 min, tr(d1e2, major) = 38.4 min, 
tr(d2e1, minor) = 15.6 min, tr(d2e2, major) = 21.3 min). Rf = 0.24 (20% EtOAc/hexanes); 
mp = 105-108 C; IR (film) 3311, 3021, 1705, 1565, 1512, 1450, 1349, 1249, 738 cm-1; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.77 (d, J = 7.2 Hz, 4H), 
7.58 (br s, 4H), 7.41 (dd, J = 7.8, 7.8 Hz, 4H), 7.30 (br m, 4H), 7.12 (br s, 8H), 6.31 (br s, 
2H), 6.00 (br d, J = 7.8 Hz, 1H), 5.65 (br s, 1H), 5.59 (br d, J = 7.8 Hz, 1H), 5.49 (br s, 
1H), 4.54 (dd, J  = 10.7, 6.7 Hz, 1H), 4.53 (dd, J = 11.2, 6.8 Hz, 1H), 4.41 (br m, 2H), 
4.23 (dd, J = 13.3, 6.7 Hz, 2H), 2.36 (s, 3H), 2.35 (s, 3H); 
13
C NMR (150 MHz, CDCl3) 
ppm 155.5, 155.2, 143.6, 143.5 (2C), 141.3, 139.4 (2C), 131.2, 129.9 (2C), 127.8 (2C), 
127.1 (2C), 126.7, 126.6, 125.0, 124.9, 120.0 (2C), 84.5, 81.1, 67.4 (2C), 58.3, 58.2, 47.1 
(2C), 21.1 (2C); HRMS (ESI): Exact mass calcd for C24H21BrN2O4 [M]
+
 480.0685, found 
480.0675. 
 
(E)-1,1,1-Trimethyl-N-(naphthalen-2-ylmethylene)silanamine (S-10). Following the 
General Procedure A, the aldehyde (2.7 g, 17.3 mmol) provided the imine (2.9 g, 73%) as 
a pale yellow solid. Rf = 0.23 (5% EtOAc/hexanes); bp = 168 °C/1.1 mm Hg; mp = 39-41 
°C; IR (film)  2954, 1643, 1248, 859 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  9.18 (s, 1H), 
8.18 (s, 1H), 8.07 (dd, J = 8.5, 1.5 Hz, 1H), 7.95 (dd, J = 6.6, 2.4 Hz, 1H), 7.90 (m, 2H), 
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7.57 (ddd, J = 6.9, 6.9, 1.8 Hz, 1H), 7.54 (ddd, J = 6.9, 6.9, 1.7 Hz, 1H), 0.34 (s, 9H); 
13
C 
NMR (100 MHz, CDCl3) ppm 168.6, 136.4, 135.2, 133.1, 130.9, 128.9, 128.4, 127.9, 
127.3, 126.4, 123.7, -1.09; HRMS (ESI): Exact mass calcd for C11H9N [M+H-C3H9Si]
+
 
155.0735, found 155.0696.
 
 
 
N-((1R)-2-Bromo-1-(naphthalen-2-yl)-2-nitroethyl)acetamide (S-11). Following 
General Procedure B, the N-TMS-imine (40.0 mg, 176 µmol) and bromonitromethane 
(13.7 µL, 176 µmol), when quenched with acetyl bromide (13.0 µL, 176 µmol), provided 
the α-bromo nitroalkane (2:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 30% ethyl acetate in hexanes), as a yellow solid (32.6 mg, 55%). 
The enantiomeric excess of both the major and minor diastereomers was determined to be 
88% ee by chiral HPLC analysis (Chiralcel AD-H, 8% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(major) = 27.2, 40.2 min, tr(minor) = 22.2, 42.6 min). Rf = 0.23 (40% EtOAc/hexanes); 
mp = 125-129 C (decomposition); IR (film) 3279, 2925, 1661, 1565, 1538, 1509, 1373, 
1352 cm
-1
; 
1
H NMR (400 MHz, CDCl3, 2:1 mixture of diastereomers)  7.87 (m, 6H), 
7.82 (s, 1H), 7.80 (s, 1H), 7.55 (d, J = 6.0 Hz, 2H), 7.54 (d, J = 6.6 Hz, 2H), 7.44 (dd, J = 
8.5, 1.6 Hz, 1H), 7.39 (dd, J = 8.5, 1.7 Hz, 1H), 6.95 (br d, J = 10.0 Hz, 1H), 6.52 (br s, 
1H), 6.50 (d, J = 4.4 Hz, 1H), 6.48 (d, J = 5.5 Hz, 1H), 6.15 (dd, J = 8.8, 4.4 Hz, 1H), 
6.00 (dd, J = 9.1, 5.5 Hz, 1H), 2.19 (s, 3H), 2.16 (s, 3H); 
13
C NMR (100 MHz, CDCl3) 
ppm 169.9, 169.7, 133.3 (2C), 133.0 (2C), 131.9, 131.5, 129.3, 129.2, 128.0 (2C), 127.7 
(2C), 127.0 (2C), 126.9 (2C), 126.7, 126.6, 123.8, 123.7, 84.3, 80.5, 56.5, 56.4, 23.2 
(2C); HRMS (ESI): Exact mass calcd for C14H13BrN2NaO3 [M+Na]
+
 359.0007, found 
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359.0025. 
 
Fluorenylmethyl (1R)-2-bromo-1-(2-naphthalenyl)-2-nitroethylcarbamate (201i). 
Following General Procedure C, the N-TMS-imine (40.0 mg, 176 µmol) and 
bromonitromethane (13.7 µL, 176 µmol), when quenched with fluorenylmethyl 
chloroformate (46 mg, 176 µmol), provided the α-bromo nitroalkane (1.1:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 15% ethyl acetate in hexanes), 
as a yellow solid (57.0 mg, 63%). The enantiomeric excess of both the major and minor 
diastereomers was determined to be 83 and 84% ee, respectively, by chiral HPLC 
analysis (Chiralcel IA, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 24.9 min, 
tr(d1e2, major) = 57.7 min, tr(d2e1, minor) = 23.7 min, tr(d2e2, major) = 38.9 min). Rf = 
0.19 (20% EtOAc/hexanes); mp = 176-179 C (dec); IR (film) 3297, 2921, 2358, 1705, 
1563, 1512, 1325, 1241, 1040 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.89 (m, 8H), 7.80 (m, 6H), 7.62 (br m, 2H), 7.56 (m, 4H), 7.43 (m, 
6H), 7.33 (m, 4H), 6.45 (br s, 2H), 6.12 (br d, J = 7.2 Hz, 1H), 5.90 (br s, 1H), 5.71 (br s, 
2H), 4.60 (dd, J = 10.8, 6.7 Hz, 1H), 4.57 (br m, 1H), 4.46 (br m, 2H), 4.27 (br s, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 155.6, 155.3, 143.5, 143.4, 141.3 (3C), 133.4 (2C), 
133.1, 133.0, 131.5, 129.3 (2C), 128.1, 127.8 (4C), 127.1 (5C), 126.9, 126.6, 126.4, 
125.0, 124.9, 123.6, 120.0 (4C), 84.6, 80.7, 67.4 (2C), 58.6 (2C), 47.1 (2C); HRMS 
(ESI): Exact mass calcd for C27H21BrN2O4 [M]
+
 516.0685, found 516.0678. 
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Fluorenylmethyl (1R)-2-bromo-1-(4-methoxyphenyl)-2-nitroethylcarbamate (201j). 
Following General Procedure C, the N-TMS-imine
160
 (40 mg, 193 µmol) and 
bromonitromethane (15.0 µL, 193 µmol), when quenched with fluorenylmethyl 
chloroformate (50 mg, 193 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 15% ethyl acetate in hexanes), 
as a yellow solid (73.2 mg, 76%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 59 and 62% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 16.9 min, 
tr(d1e2, major) = 52.2 min, tr(d2e1, minor) = 18.3 min, tr(d2e2, major) = 27.3 min) = 18.3, 
27.3 min). Rf = 0.22 30% EtOAc/hexanes); mp = 109-112 C; IR (film) 3309, 2927, 
1704, 1566, 1514, 1251, 740 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of 
diastereomers)  7.79 (d, J = 7.2 Hz, 4H), 7.60 (br s, 4H), 7.42 (t, J = 7.2 Hz, 6H), 7.32 
(br s, 4H), 7.23 (br s, 2H), 6.91 (br d, J = 7.4 Hz, 4H), 6.31 (br s, 2H), 6.01 (br s, 1H), 
5.62 (br s, 2H), 5.49 (br s, 1H), 5.56 (m, 2H), 4.43 (br s, 2H), 4.25 (dd, J = 13.2, 6.7 Hz, 
2H); 
13
C NMR (150 MHz, CDCl3) ppm 160.2 (2C), 155.5, 155.3, 143.5 (2C), 141.3 (4C), 
128.1 (2C), 127.8, (2C), 127.1 (2C), 125.0, 124.9, 120.0 (2C), 114.6, 114.5, 84.3, 81.3, 
67.4 (2C), 58.1, 57.9, 55.3 (2C), 47.1 (2C); HRMS (ESI): Exact mass calcd for 
C24H21BrN2NaO5 [M+Na]
+
 519.0526, found 519.0540. 
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(E)-N-(4-(Benzyloxy)benzylidene)-1,1,1-trimethylsilanamine (S-12). Following 
General Procedure A, the aldehyde (5.0 g, 23.4 mmol) provided the imine (4.9 g, 74%) as 
a pale yellow solid. Rf = 0.13 (5% EtOAc/hexanes); bp = 185 °C/1.1 mmHg; mp = 38-39 
C; IR (film) 2955, 1645, 1602, 1578, 1509, 1248 cm-1; 1H NMR (600 MHz, CDCl3)  
8.93 (s, 1H), 7.77 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 7.5 Hz, 2H), 7.41 (dd, J = 7.4. 7.4 Hz, 
2H), 7.36 (dd, J = 7.3, 7.3 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 5.14 (s, 2H), 0.27 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 167.7, 161.4, 136.6, 132.4, 130.2, 128.6, 128.1, 127.5, 
114.8, 70.0, -1.0; HRMS (CI): Exact mass calcd For C14H12NO [M-C3H9Si]
+
 210.0919, 
found 210.0902.
163
 
 
Fluorenylmethyl(1R)-1-(4(benzyloxy)phenyl)-2-bromo-2-nitroethylcarbamate 
(201k). Following General Procedure C, the N-TMS-imine (40.0 mg, 141 µmol) and 
bromonitromethane (11.0 µL, 141 µmol), when quenched with fluorenylmethyl 
chloroformate (36.0 mg, 141 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 15% ethyl acetate in hexanes), 
as a white solid (52.6 mg, 66%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 72 and 74% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 37.3, 70.9 min, 
tr(minor) = 33.9, 106.6 min). Rf = 0.33 (30% EtOAc/hexanes); mp = 170-173 C 
                                                          
163
 Trimethylsilyl group fragmented during MS analysis. 
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(decomposition); IR (film) 3322, 3038, 2922, 1704, 1698, 1451, 1243, 1180 cm
-1
; 
1
H 
NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.79 (d, J = 7.2 Hz, 4H), 7.60 
(br m, 4H), 7.42 (br m, 12H), 7.35 (br m, 6H), 7.23 (br m, 4H), 6.99 (br d, J = 6.7 Hz, 
4H), 6.32 (br d, J = 5.2 Hz, 2H), 5.99 (br d, J = 8.3 Hz, 1H), 5.62 (br s, 1H), 5.57 (br s, 
1H), 5.49 (br dd, J = 5.3, 5.3 Hz, 1H), 5.08 (s, 2H), 5.57 (s, 2H), 4.55 (dd, J = 10.7, 6.6 
Hz, 2H), 4.43 (br m, 2H), 4.25 (br dd, J = 13.7, 6.8 Hz, 2H); 
13
C NMR (150 MHz, 
CDCl3) ppm 159.4 (2C), 155.5, 155.2, 143.5, 143.4, 141.3 (4C), 136.4 (2C), 128.7 (2C), 
128.2 (2C), 128.1 (2C), 127.8 (2C), 127.5 (2C), 127.1 (2C), 125.0, 124.9, 120.1 (2C), 
115.4 (2C), 84.4, 81.2, 70.0 (2C), 67.3 (2C), 58.1, 57.9, 47.1 (2C); HRMS (ESI): Exact 
mass calcd for C30H25BrN2NaO5 [M+Na]
+
 595.0845, found 595.0831. 
 
(E)-N-(3,5-(Dibenzyloxy)benzylidene)-1,1,1-trimethylsilanamine (S-13). Following 
General Procedure A, the aldehyde (1.52 g, 4.77 mmol) provided the imine (1.40 g, 76%) 
as a yellow solid. Rf = 0.36 (20% EtOAc/hexanes); bp = 210 °C/1.1 mmHg; IR (film) 
1594, 1447, 1294, 1156, 1054 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.90 (s, 1H), 7.46 (d, 
J = 10.8 Hz, 4H), 7.41 (t, J = 11.4 Hz, 4H), 7.35 (t, J = 10.2 Hz, 2H), 7.10 (d, J = 3.6 Hz, 
2H), 6.74 (J = 3.6 Hz, 1H), 5.11 (s, 4H), 0.28 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 
161.1, 137.9, 136.8, 136.7, 135.8, 128.8, 128.6, 128.4, 128.0, 127.9, 127.7, 127.6, 127.5, 
111.0, 107.7 (2C), 70.2, 70.1, 2.0; HRMS (ESI): Exact mass calcd for C24H27NO2Si [M]
+
 
389.1811, found 389.1798. 
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Fluorenylmethyl(1R)-1-(3,5-(dibenzyloxy)phenyl)-2-bromo-2-nitroethylcarbamate 
(201l). Following General Procedure C, the N-TMS imine (400 mg, 1.03 mmol) and 
bromonitromethane (80.0 µL, 1.03 µmol), when quenched with fluorenylmethyl 
chloroformate (270 mg, 1.03 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 20% ethyl acetate in hexanes), 
as a white solid (427 mg, 61%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 79 and 82% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 21.3 min, 
tr(d1e2, major) = 34.9 min, tr(d2e1, minor) = 24.1 min, tr(d2e2, major) = 41.0 min). Rf = 
0.21 (20% EtOAc/hexanes); mp = 181-183 C (dec); IR (film) 3321, 1697, 1598, 1565, 
1450, 1162, 739 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  
7.78 (br d, J = 7.2 Hz, 4H), 7.61 (br d, J = 4.8 Hz, 4H), 7.44-7.33 (m, 28H), 6.63 (br s, 
1H), 6.62 (t, J = 1.8 Hz, 1H), 6.56 (br s, 2H), 6.53 (br s, 2H), 6.29 (br s, 2H), 5.98 (br d, J 
= 6.6 Hz, 1H), 5.66 (br s, 1H), 5.54 (br s, 1H), 5.46 (br s, 1H), 5.04 (s, 4H), 5.03 (s, 4H), 
5.57 (dd, J = 10.8, 6.6 Hz, 1H), 5.43 (br s, 1H), 4.42 (br dd, J = 9.6, 7.8 Hz, 2H), 4.26 (br 
m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 160.4 (2C), 144.3, 143.4, 141.5, 141.3 (4C), 
136.5, 136.24 (2C), 136.22 (4C), 128.6, 128.5 (4C), 128.2, 127.8, 127.6 (4C), 127.1, 
127.08, 127.05, 127.0, 124.9, 124.7 (2C), 120.0, 106.2 (4C), 102.5 (2C), 84.4, 80.5, 70.3 
(4C), 67.5, 65.2, 58.4, 58.1, 50.3, 47.1; HRMS (ESI): Exact mass calcd for 
C37H31BrN2O6 [M]
+
 678.1365, found 678.1346. 
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N-((1R)-2-Bromo-1-(4-methoxyphenyl)-2-nitroethyl)acetamide (202j). Following 
General Procedure B, the N-TMS-imine (40.0 mg, 193 µmol) and bromonitromethane 
(15.0 µL, 193 µmol), when quenched with acetyl bromide (14.0 µL, 193 µmol), provided 
the α-bromo nitroalkane (1.1:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 30% ethyl acetate in hexanes), as a white solid (37.5 mg, 61%). 
The enantiomeric excess of the major and minor diastereomers were determined to be 70 
and 69% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 14.3, 19.4 min, tr(minor) = 11.2, 21.5 min). Rf = 
0.17 (40% EtOAc/hexanes); mp = 87-92 C; IR (film) 3278, 2926, 1661, 1612, 1567, 
1515, 1373, 1254, 1181, 1031 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.1:1 mixture of 
diastereomers)  7.25 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 5.4 Hz, 
2H), 6.88 (d, J = 8.2 Hz, 2H), 6.80 (br d, J = 8.5 Hz, 1H), 6.42 (br d, J = 8.0 Hz, 1H), 
6.34 (d, J = 4.8 Hz, 1H), 6.31 (d, J = 5.6 Hz, 1H), 5.84 (dd, J = 8.4, 4.8 Hz, 1H), 5.74 
(dd, J = 8.7, 5.7 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3) ppm 169,8, 169.7, 160.2 (2C), 128.4, 128.3, 126.4, 126.1, 114.6, 
114.5, 84.2, 81.1, 56.2, 55.9, 55.3 (2C), 23.2 (2C); HRMS (ESI): Exact mass calcd for 
C11H13BrN2NaO4 [M+Na]
+
 338.9956, found 338.9962. 
Also observed was the trans-imination dimer side product (S-
14), isolated as a 1.5:1 mixture of diastereomers after column 
chromatography (100 % hexanes), as a viscous yellow oil (trace 
amounts). The enantiomeric excess of both the major and minor 
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diastereomers was determined to be 22% ee, by chiral HPLC analysis (Chiralcel AD-H, 
3% 
i
PrOH/hexanes, 0.6 mL/min, tr(major) = 50.0, 53.5 min, tr(minor) = 40.9, 47.6 min). 
Rf = 0.11 (5% EtOAc/hexanes); IR (film) 3010, 2934, 2839, 1636, 1606, 1563, 1512, 
1305, 1252, 1305, 1252, 1167, 832 cm
-1
; 
1
H NMR (400 MHz, CDCl3, 1.5L1 mixture of 
diastereomers)  8.33 (s, 1H), 8.17 (s, 1H), 7.77 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 8.7 Hz, 
2H), 7.42 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 10.3 Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 6.95 (d, 
J = 8.6 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 6.27 (d, J = 8.7 Hz, 
1H), 6.23 (d, J = 9.7 Hz, 1H), 4.95 (d, J = 9.7 Hz, 1H), 4.93 (d, J = 8.7 Hz, 1H), 3.87 (s, 
3H), 3.85 (s, 3H), 3.84 (s, 3H), 3.81 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 163.9, 
163.7, 162.4, 162.3, 160.0, 159.9, 130.4 (2C), 129.4, 128.9, 128.2, 128.1, 114.7 (2C), 
114.3, 114.2, 114.0, 113.9, 84.0, 82.2, 55.4, 55.3, 55.2 (4C); HRMS (ESI): Exact mass 
calcd for C17H18BrN2O4 [M+H]
+
 393.0450, found 393.0445. 
 
N-((1R)-1-(4-(Benzyloxy)phenyl)-2-bromo-2-nitroethyl)acetamide (202k). Following 
General Procedure B, the N-TMS-imine (40.0 mg, 141 µmol) and bromonitromethane 
(11.0 µL, 141 µmol), when quenched with acetyl bromide (10.0 µL, 141 µmol), provided 
the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 30% ethyl acetate in hexanes), as a white solid (24.3 mg, 44%). 
The enantiomeric excess of the major and minor diastereomers were determined to be 61 
and 67% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 16.2, 30.0 min, tr(minor) = 19.3, 33.2 min). Rf = 
0.20 (40% EtOAc/hexanes); mp = 119-121 C (decomposition); IR (film) 3277, 2925, 
240 
 
1661, 1607, 1566, 1513, 1374, 1250, 1180, 737 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 
mixture of diastereomers)  7.39 (m, 10H), 7.26 (d, J = 8.7 Hz, 2H), 7.23 (J = 8.6 Hz, 
2H), 6.99 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 8.6 Hz, 2H), 6.70 (br d, J = 8.5 Hz, 1H), 6.36 
(d, J = 4.6 Hz, 1H), 6.34 (d, J = 5.4 Hz, 1H), 6.27 (br d, J = 6.0 Hz, 1H), 5.86 (dd, J = 
8.6, 4.6 Hz, 1H), 5.76 (dd, J = 8.9, 5.3 Hz, 1H), 5.08 (s, 2H), 5.07 (s, 2H), 2.13 (s, 3H), 
2.10 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.7, 169.5, 159.4 (2C), 136.4 (2C), 
128.6 (2C), 128.3, 128.2, 128.1, 127.4 (3C), 126.7, 126.3, 155.5, 155.4, 84.3, 81.0, 70.1 
(2C), 56.2, 55.8, 23.2 (2C); HRMS (ESI): Exact mass calcd for C17H17BrN2NaO4 
[M+Na]
+
 415.0269, found 415.0257. 
 
(E)-4-((Trimethylsilylimino)methyl)phenyl pivalate (S-15). Following General 
Procedure A, the aldehyde (3.0 g, 14.5 mmol) provided the imine (1.4 g, 34%) as a clear 
viscous oil. Rf = 0.17 (5% EtOAc/hexanes); bp = 130 °C/1.1 mmHg; IR (film) 2973, 
1754, 1699, 1603, 1276, 1202, 1114, 849 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.97 (s, 
1H), 8.07 (d, J = 8.7 Hz, 2H), 7.83 (d, J = 8.5 Hz, 2H), 1.38 (s, 9H), 0.27 (s, 9H); 
13
C 
NMR (150 MHz, CDCl3) ppm 176.5, 167.2, 154.9, 136.2, 131.6, 121.4, 39.2, 27.1, -0.2; 
HRMS (ESI): Exact mass calcd for C7H7NO [M-C8H16OSi]
+
 121.0528, found 121.0323. 
 
(R)-N-(1-(4-methoxyphenyl)-2-nitroethyl)acetamide (211). Following General 
Procedure C, the N-TMS-imine (40.0 mg, 193 µmol) and nitromethane (10.0 µL, 193 
µmol), when stirred at -20 °C for 5 d and quenched with acetyl chloride (14.0 µL, 193 
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µmol), provided the nitroalkane, after flash column chromatography (SiO2, 30% ethyl 
acetate in hexanes), as a yellow oil (10.1 mg, 22%). The enantiomeric excess of the 
product was determined to be 19% ee by chiral HPLC analysis (Chiralcel AD-H, 12% 
i
PrOH/hexanes, 1.0 mL/min, tr(major) = 8.8 min, tr(minor) = 6.5 min). [α]  +10.0 (c 
0.08, CHCl3); Rf = 0.1 (30% EtOAc/hexanes); IR (film) 3296, 2923, 1658, 1554, 1514, 
1252 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.23 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 
2H), 6.11 (br d, J = 6.0 Hz, 1H), 5.60 (dd, J = 6.0, 6.0 Hz, 1H), 4.91 (dd, J = 12.6, 6.0 
Hz, 1H), 4.70 (dd, J = 12.6, 6.0 Hz, 1H), 3.80 (s, 3H), 2.05 (s, 3H); 
13
C NMR (150 MHz, 
CDCl3) ppm 169.6, 159.9, 128.2, 127.7, 114.6, 78.1, 55.3, 50.9, 23.2; HRMS (ESI): 
Exact mass calcd for C11H14N2NaO4 [M+Na]
+
 261.0851, found 261.0844. 
 
N-Fmoc-4-Cl-Phenylglycine-N-α-MeBn (212). Following General Procedure D, the -
bromo nitroalkane (10 mg, 20 μmol) and α-methyl benzyl amine (97% ee, 3.0 µL, 20 
μmol) provided the amide (single diastereomer), after column chromatography (SiO2, 
20% ethyl acetate in hexanes), as a white solid (6.7 mg, 66% yield). []  -20.0 (c 0.04, 
CHCl3); Rf = 0.10 (20% EtOAc/hexanes); mp = 224-226 C; IR (film) 3298, 2923, 1684, 
1647, 1540 cm
-1
; 
1
H NMR (600 MHz)  7.76 (d, J = 7.2 Hz, 2H), 7.55 (br s, 2H), 7.40 (t, 
J = 7.8 Hz, 3H), 7.35 (m, 6H), 7.30 (m, 4H), 6.22 (br s, 1H), 5.84 (br s, 1H), 5.15 (br s, 
1H), 5.10 (br s, 1H), 4.35 (br s, 2H), 4.18 (br s, 1H), 1.39 (d, J = 6.0 Hz, 3H); 
13
C NMR 
(150 MHz) ppm 168.2, 155.5, 143.7, 143.6, 142.1, 141.2, 136.7, 129.3, 128.8, 128.6, 
20
D
20
D
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127.7 (2C), 127.0, 126.1, 125.0, 119.9, 67.1, 58.1, 49.4, 47.1, 21.1; HRMS (ESI): Exact 
mass calcd for C31H28ClN2O3 [M+H]
+
 511.1783, found 511.1807. 
 
N-N3Ac-4-Cl-Phenylglycine-Ala-OMe (215). Following a modified General Procedure 
E, the α-bromo nitroalkane (40.0 mg, 110 μmol) and the ammonium salt of ʟ-alanine 
(18.5 mg, 130 μmol), when stirred at 0 °C for 4 h, provided the dipeptide (single 
diastereomer), after column chromatography (SiO2, 50% ethyl acetate in hexanes), as a 
white solid (19.3 mg, 50% yield). []  -86.7 (c 0.03, CHCl3); Rf = 0.06 (30% 
EtOAc/hexanes); mp = 165-168 C (dec); IR (film) 3293, 2923, 2105, 1738, 1645, 1544, 
1492, 1222 cm
-1
; 
1
H NMR (600 MHz)  7.70 (d, J = 6.9 Hz, 1H), 7.36 (d, J = 8.5 Hz, 
2H), 7.32 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 7.3 Hz, 1H), 5.61 (d, J = 7.0 Hz, 1H), 4.56 (dq, 
J = 7.2, 7.2 Hz, 1H), 4.06 (d, J = 16.6 Hz, 1H), 4.01 (d, J = 16.6 Hz, 1H), 3.77 (s, 3H), 
1.31 (d, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz) ppm 173.0, 168.6, 166.5, 135.8, 134.6, 
129.2, 128.6, 55.9, 52.6, 52.4, 48.3, 17.9; HRMS (ESI): Exact mass calcd for 
C14H16ClN5NaO4 [M+Na]
+
 376.0783, found 376.0784. 
 
N-Fmoc-4-Cl-Phenylglycine-Leu-OMe (216). Following General Procedure E, the α-
bromo nitroalkane (55.0 mg, 110 μmol) and the ammonium salt of ʟ-leucine (24.0 mg, 
20
D
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132 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (32.1 mg, 55%). [α]  -
35.1 (c 0.61, CHCl3); Rf = 0.26 (30% EtOAc/hexanes); mp 146-148 °C; IR (film) 3318, 
2957, 2926, 1736, 1666, 1535, 1242, 739 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.75 (d, J 
= 7.8 Hz, 2H), 7.55 (br s, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.30 (br m, 6H), 6.27 (br d, J = 
6.0 Hz, 1H), 6.22 (br s, 1H), 5.26 (br d, J = 4.2 Hz, 1H), 4.59 (br d, J = 4.8 Hz, 1H), 4.36 
(br m, 2H), 4.18 (br m, 1H), 3.73 (s, 3H), 1.55 (br m, 2H), 1.40 (br m, 1H), 0.77 (br s, 
6H); 
13
C NMR (150 MHz, CDCl3) ppm 174.7, 173.0, 156.8, 143.7, 141.2, 136.6, 134.5, 
129.2 (2C), 127.7, 127.0, 125.0, 199.9, 67.2, 58.0, 52.5, 51.0, 47.0, 41.2, 24.7, 22.6, 21.6; 
HRMS (ESI): Exact mass calcd for C30H31ClN2NaO5 [M+Na]
+
 557.1819, found 
557.1842. 
 
N-Bz-4-Cl-Phenylglycine-Leu-OMe (217). Following General Procedure E, the α-
bromo nitroalkane (42.0 mg, 110 μmol) and the ammonium salt of ʟ-leucine (24.0 mg, 
132 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (20% ethyl acetate in hexanes) as a white solid (31.0 mg, 65%). [α]  -
21.3 (c 0.16, CHCl3); Rf = 0.14 (30% EtOAc/hexanes); mp 123-125 °C; IR (film) 3294, 
2924, 1742, 1640, 1530, 1209 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.81 (d, J = 7.2 Hz, 
2H), 7.64 (d, J = 6.0 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.42 (m, 4H), 7.33 (d, J = 8.4 Hz, 
2H), 6.42 (d, J = 8.4 Hz, 1H), 5.69 (d, J = 6.0 Hz, 1H), 4.62 (ddd, J = 9.0, 9.0, 5.4 Hz, 
20
D
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1H), 3.73 (s, 3H), 1.59 (ddd, J = 13.8, 8.4, 5.4 Hz, 1H), 1.46 (ddd, J = 14.4, 9.0, 6.0 Hz, 
1H), 1.31 (m, 1H), 0.80 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) ppm 173.0, 169.4, 166.6, 136.5, 134.4, 133.4, 131.9, 129.2, 128.7, 128.6, 
127.1, 56.8, 52.5, 51.1, 41.2, 24.7, 22.6, 21.6; HRMS (ESI): Exact mass calcd for 
C22H25ClN2NaO4 [M+Na]
+
 439.1401, found 439.1416. 
 
N-Cbz-4-Cl-Phenylglycine-Leu-OMe (218). Following General Procedure E, the α-
bromo nitroalkane (46.0 mg, 110 μmol) and the ammonium salt of ʟ-leucine (24.0 mg, 
132 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white paste (25.4 mg, 53%). [α]  -
41.4 (c 0.51, CHCl3); Rf = 0.22 (30% EtOAc/hexanes); IR (film) 3321, 2925, 2854, 1736, 
1667, 1495, 1237, 699 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.36 (br s, 9H), 6.30 (br s, 
1H), 6.17 (br s, 1H), 5.26 (br s, 1H), 5.10 (d, J = 12.0 Hz, 1H), 5.03 (d, J = 12.6 Hz, 1H), 
4.58 (ddd, J = 9.0, 9.0, 5.4 Hz, 1H), 3.72 (s, 3H), 1.56 (br m, 2H), 1.44 (br m, 1H), 0.78 
(d, J = 8.4 Hz, 3H), 0.76 (d, J = 7.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 174.8, 
173.0, 155.5, 136.6, 136.0, 134.5, 129.1, 128.6, 128.5, 128.2, 67.0, 58.1, 52.4, 50.9, 41.1, 
24.7, 22.6, 21.6; HRMS (ESI): Exact mass calcd for C23H27ClN2NaO5 [M+Na]
+
 
469.1506, found 469.1486. 
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N-Alloc-4-Cl-Phenylglycine-Leu-OMe (219). Following General Procedure E, the α-
bromo nitroalkane (40.0 mg, 110 μmol) and the ammonium salt of ʟ-leucine (24.0 mg, 
132 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (25.1 mg, 57%). [α]  -
49.1 (c 0.63, CHCl3); Rf = 0.24 (30% EtOAc/hexanes); mp 102-104 °C; IR (film) 3318, 
2957, 1737, 1666, 1534, 1237 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.32 (br s, 4H), 6.32 
(br d, J = 7.2 Hz, 1H), 6.14 (br s, 1H), 5.87 (br m, 1H), 5.27 (br m, 2H), 5.15 (d, J = 10.2 
Hz, 1H), 4.52 (m, 3H), 3.73 (s, 3H), 1.56 (ddd, J = 13.8, 8.4, 5.4 Hz, 1H), 1.42 (ddd, J = 
14.4, 9.0, 5.4 Hz, 1H), 1.29 (m, 1H), 0.79 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 173.0, 169.1, 155.4, 136.6, 134.4, 132.4, 129.1, 128.5, 
117.9, 66.0, 58.0, 52.4, 50.9, 41.1, 24.7, 22.6, 21.6; HRMS (ESI): Exact mass calcd for 
C19H25ClN2NaO5 [M+Na]
+
 419.1350, found 419.1344. 
 
N-Fmoc-4-Cl-Phenylglycine-Ala-OMe (220). Following General Procedure E, the α-
bromo nitroalkane (40.0 mg, 80 μmol) and the ammonium salt of ʟ-alanine (13.0 mg, 96 
μmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(30% ethyl acetate in hexanes) as a white solid (18.3 mg, 46%). [α]  -26.3 (c 0.32, 
20
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CHCl3); Rf = 0.13 (30% EtOAc/hexanes); mp 158-160 °C (dec); IR (film) 3311, 2963, 
1737, 1664, 1534, 1338, 1250, 739 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.75 (d, J = 7.8 
Hz, 2H), 7.53 (br s, 2H), 7.36 (m, 8H), 6.24 (br s, 1H), 6.11 (br s, 1H), 5.2 (br s, 1H), 
4.72 (br s, 1H), 4.37 (br m, 2H), 4.22 (br m, 1H), 3.75 (s, 3H), 1.31 (br s, 3H); 
13
C NMR 
(150 MHz, CDCl3) ppm 172.8, 168.7, 156.6, 143.8, 141.2, 136.0, 134.7, 129.8, 129.3, 
127.7, 127.0, 125.0, 120.0, 66.9, 58.1, 52.7, 48.4, 18.0; HRMS (ESI): Exact mass calcd 
for C27H25ClN2NaO5 [M+Na]
+
 515.1350, found 515.1362. 
 
N-Fmoc-4-Cl-Phenylglycine-Val-OMe (221). Following General Procedure E, the α-
bromo nitroalkane (40.0 mg, 80 μmol) and the ammonium salt of ʟ-valine (16.0 mg, 96 
μmol) provided the dipeptide (single diastereomer) after flash column chromatography 
(15% ethyl acetate in hexanes) as a white solid (18.5 mg, 44%). [α]  -39.4 (c 0.34, 
CHCl3); Rf = 0.27 (30% EtOAc/hexanes); mp 175-177 °C; IR (film) 3315, 2926, 1719, 
1582, 1495, 1227, 738 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.75 (d, J = 7.8 Hz, 2H), 7.56 
(br s, 2H), 7.35 (m, 8H), 6.21 (br s, 2H), 5.26 (br d, J = 3.6 Hz, 1H), 4.54 (br s, 1H), 4.38 
(br m, 2H), 4.18 (br s, 1H), 3.74 (s, 3H), 2.06 (br m, 1H), 0.72 (d, J = 4.8 Hz, 3H), 0.67 
(d, J = 6.0 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 171.9, 169.1, 155.5, 143.7, 141.2, 
136.8, 134.5, 129.3, 128.5, 127.6, 127.0, 125.0, 120.0, 67.1, 58.2, 57.1, 52.3, 47.1, 31.4, 
18.7, 17.3; HRMS (ESI): Exact mass calcd for C29H29ClN2NaO5 [M+Na]
+
 543.1663, 
found 543.1657. 
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N-Fmoc-4-Cl-Phenylglycine-Leu-O
t
Bu (223). Following General Procedure E, the α-
bromo nitroalkane (30.0 mg, 60.0 μmol) and the ammonium salt of ʟ-leucine (27.0 mg, 
120 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (21.3 mg, 62%). [α]  -
34.2 (c 0.78, CHCl3); Rf = 0.14 (20% EtOAc/hexanes); mp 146-149 °C; IR (film) 3312, 
2958, 2925, 1727, 1662, 1531, 1367, 1245, 1149, 762 cm
-1
; 
1
H NMR (600 MHz, CDCl3) 
 7.75 (d, J = 7.8 Hz, 2H), 7.56 (br s, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.33 (br s, 4H), 7.29 
(br s, 2H), 6.22 (br s, 1H), 6.09 (br d, J = 5.4 Hz, 1H), 5.20 (br d, J = 3.6 Hz, 1H), 4.47 
(br s, 1H), 4.34 (br s, 2H), 4.18 (br s, 1H), 1.51 (br m, 2H), 1.46 (s, 9H), 1.30 (br m, 1H), 
0.79 (br s, 6H); 
13
C NMR (150 MHz, CDCl3) ppm 171.6, 168.6, 155.4, 143.7, 141.2, 
136.8, 134.4, 129.2, 128.6, 127.7, 127.0, 125.0, 119.9, 82.4, 67.1, 58.2, 51.6, 47.1, 41.5, 
27.9, 24.8, 22.6, 21.9; HRMS (ESI): Exact mass calcd for C33H38ClN2O5 [M+H]
+
 
577.2464, found 577.1032. 
 
N-Bz-4-Cl-Phenylglycine-Leu-O
t
Bu (S-16). Following General Procedure E, the α-
bromo nitroalkane (23.0 mg, 60.0 μmol) and the ammonium salt of ʟ-leucine (27.0 mg, 
120 μmol) provided the dipeptide (single diastereomer) after flash column 
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chromatography (15% ethyl acetate in hexanes) as a white solid (16.2 mg, 58%). [α]  -
22.6 (c 0.27, CHCl3); Rf = 0.33 (30% EtOAc/hexanes); mp 116-118 °C; IR (film) 3299, 
2927, 1735, 1640, 1530, 1489, 1150 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.82 (d, J = 7.2 
Hz, 2H), 7.65 (d, J = 6.0 Hz, 1H), 7.50 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 7.8 Hz, 2H), 7.42 
(d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 6.21 (d, J = 8.4 Hz, 1H), 5.63 (d, J = 6.0 Hz, 
1H), 4.49 (ddd, J = 8.4, 8.4, 6.0 Hz, 1H), 1.54 (ddd, J = 13.8, 8.4, 5.4 Hz, 1H), 1.45 (s, 
9H), 1.40 (ddd, J = 14.4, 8.4, 6.0 Hz, 1H), 1.33 (m, 1H), 0.81 (d, J = 7.2 Hz, 3H), 0.80 (d, 
J = 6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 171.5, 169.0, 166.5, 136.8, 134.4, 
133.5, 131.8, 129.2, 128.7, 128.5, 127.1, 82.4, 56.9, 51.7, 41.5, 27.9, 24.8, 22.6, 21.9; 
HRMS (ESI): Exact mass calcd for C25H31ClN2NaO4 [M+Na]
+
 577.2464, found 
577.1032. 
 
N-Cbz-4-Cl-Phenylglycine-Leu-O
t
Bu (224). Following General Procedure E, the α-
bromo nitroalkane (25.0 mg, 60.0 μmol) and the ammonium salt of ʟ-leucine (27.0 mg, 
120 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (18.4 mg, 63%). [α]  -
39.2 (c 0.77, CHCl3); Rf = 0.19 (20% EtOAc/hexanes); mp 92-95 °C; IR (film) 3315, 
2957, 2927, 1727, 1662, 1529, 1493, 1241, 1149 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.32 (br s, 9H), 6.16 (br s, 1H), 6.07 (br s, 1H), 5.19 (br s, 1H), 5.10 (d, J = 12.0 Hz, 1H), 
5.02 (d, J = 12.6 Hz, 1H), 4.46 (ddd, J = 8.4, 8.4, 6.0 Hz, 1H), 1.49 (br m, 2H), 1.45 (s, 
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9H), 1.29 (br m, 1H), 0.79 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) ppm 171.6, 168.6, 155.4, 136.8, 136.1, 134.4, 129.2, 128.8, 128.5, 128.1, 
128.0, 82.4, 67.1, 58.2, 51.6, 41.5, 27.9, 24.7, 22.6, 21.9; HRMS (ESI): Exact mass calcd 
for C26H33ClN2NaO5 [M+Na]
+
 481.1870, found 481.1872. 
 
N-Alloc-4-Cl-Phenylglycine-Leu-O
t
Bu (225). Following General Procedure E, the α-
bromo nitroalkane (22.0 mg, 60.0 μmol) and the ammonium salt of ʟ-leucine (27.0 mg, 
120 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (17.9 mg, 68%). [α]  -
47.6 (c 0.86, CHCl3); Rf = 0.14 (20% EtOAc/hexanes); mp 84-86 °C; IR (film) 3314, 
2956, 2922, 1728, 1663, 1531, 1368, 1242, 1150 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.32 (s, 4H), 6.15 (d, J = 7.8 Hz, 2H), 5.87 (br s, 1H), 5.28 (br d, J = 15.0 Hz, 1H), 5.19 
(br d, J = 9.6 Hz, 2H), 4.55 (dd, J = 13.2, 5.4 Hz, 1H), 4.50 (dd, J = 13.8, 6.0 Hz, 1H), 
4.46 (ddd, J = 8.4, 8.4, 5.4 Hz, 1H), 1.53 (dd, J = 8.2, 5.6 Hz, 1H), 1.50 (ddd, J = 8.2, 5.5 
Hz, 1H), 1.45 (s, 9H), 1.31 (m, 1H), 0.80 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.5 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 171.7, 168.7, 155.3, 136.8, 134.4, 132.4, 129.1, 128.6, 
117.9, 82.4, 65.9, 58.1, 51.6, 41.5, 27.9, 24.7, 22.6, 21.8; HRMS (ESI): Exact mass calcd 
for C22H31ClN2NaO5 [M+Na]
+
 461.1814, found 461.1797. 
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(E)-N-(furan-2-ylmethylene)-1,1,1-trimethylsilanamine (227). Following General 
Procedure B, the N-TMS imine
160
 (40.0 mg, 239 µmol) and bromonitromethane (18.6 µL, 
239 µmol), when quenched with acetyl bromide (17.7 µL, 239 mmol), provided the α-
bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 15% ethyl acetate in hexanes), as a yellow oil (28.0 mg, 42%). The enantiomeric 
excess of the major and minor diastereomers were determined to be 48 and 36% ee, 
respectively, by chiral HPLC analysis (Chiralcel IA, 5% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(d1e1, minor) = 24.9 min, tr(d1e2, major) = 28.2 min, tr(d2e1, minor) = 26.2 min, tr(d2e2, 
major) = 35.5 min). Rf = 0.28 (20% EtOAc/hexanes); IR (film) 2924, 2852, 1712, 1463 
cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.42 (dd, J = 7.2, 1.2 
Hz, 2H), 6.54 (br d, J = 10.1, 1H), 6.43 (d, J = 3.4 Hz, 1H), 6.41-6.38 (m, 5H), 6.31 (br d, 
1H), 6.03 (dd, J = 9.0, 4.6 Hz, 1H), 6.99 (dd, J = 9.2, 5.6 Hz, 1H), 2.13 (s, 3H), 2.12 (s, 
3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.59, 169.55, 146.9, 146.5, 143.46, 143.45, 
110.84, 110.82, 109.8, 109.6, 81.4, 79.2, 51.5, 50.9, 23.01, 22.97; HRMS: Exact mass not 
observed.
164
 
 
(E)-N-(thiophen-2-ylmethylene)-1,1,1-trimethylsilanamine (229). Following General 
Procedure B, the N-TMS-imine
155
 (40.0 mg, 218 µmol) and bromonitromethane (17.0 
                                                          
164
 Exact mass could not be observed under ESI or APCI conditions. This may be due to the instability of 
the product. 
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µL, 218 µmol), when quenched with acetyl bromide (16.0 µL, 218 mmol), provided the 
α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column chromatography 
(SiO2, 10% ethyl acetate in hexanes), as a yellow oil (13.5 mg, 21%). The enantiomeric 
excess of the major and minor diastereomers were determined to be 39 and 37% ee, 
respectively, by chiral HPLC analysis (Chiralcel IA, 10% 
i
PrOH/hexanes, 1.0 mL/min, 
tr(d1e1, minor) = 10.2 min, tr(d1e2, major) = 15.3 min, tr(d2e1, minor) = 12.7 min, tr(d2e2, 
major) = 13.8 min). Rf = 0.32 (20% EtOAc/hexanes); IR (film) 3329, 1728, 1660, 1662, 
1515, 1410, 1237 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  
7.34 (ddd, J = 7.4, 5.1, 1.1 Hz, 2H), 7.11 (d, J = 3.5 Hz, 1H), 7.08 (d, J = 2.8 Hz, 1H), 
7.02 (m, 2 H), 6.60 (br d, J = 7.8 Hz, 1H), 6.47 (d, J = 5.0 Hz, 1H), 6.45 (d, J = 4.4 Hz, 
1H), 6.26 (br d, J = 7.9 Hz, 1H), 6.17 (dd, J = 8.8, 4.4 Hz, 1H), 6.09 (dd, J = 8.8, 5.2 Hz, 
1H), 2.14 (s, 3H), 2.11 (s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.6, 169.4, 136.9, 
136.4, 127.3, 127.34, 127.25, 127.09, 127.06, 126.6, 126.5, 83.4, 80.6, 52.9, 52.5, 23.1, 
23.0; HRMS (CI): Exact mass calcd for C8H10BrN2O3S [M+H]
+
 292.9590, found 
292.9604. 
 
(E)-1,1,1-trimethyl-N-(pyridin-3-ylmethylene)silanamine (223). Following General 
Procedure A, but without filtering and distillation, the aldehyde (3.0 g, 28 mmol) 
provided a quantitative amount of the imine (5.9 g), as a crude mixture with LiCl. For 
characterization, a small amount of this crude mixture was dissolved in CDCl3 and 
filtered to remove the LiCl. Rf = 0.1 (20% EtOAc/hexanes); IR (film) 1642, 1423, 1253, 
1030, 842 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.99 (s, 1H), 8.91, (s, 1H), 8.66 (d, J = 4.8 
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Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.35 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 0.26 (s, 9H); 
13
C 
NMR (150 MHz, CDCl3) ppm 165.4, 151.9, 151.1, 134.4, 133.8, 123.6, -1.3; HRMS 
(EI): Exact mass calcd for C9H14N2Si [M]
+
 178.0926, found 178.0918. 
 
(E)-1,1,1-trimethyl-N-(pyridin-3-ylmethylene)silanamine (240). Following General 
Procedure C, the N-TMS-imine (78% pure, 100 mg, 450 µmol) and bromonitromethane 
(34 µL, 450 µmol), when quenched with carbobenzyloxy chloroformate (64 µL, 450 
mmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 30% ethyl acetate in hexanes), as a yellow viscous oil (29 
mg, 17%).
165
 The enantiomeric excess of the major and minor diastereomers were 
determined to be 15 and 15% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 10.8 min, tr(d1e2, major) = 18.9 min, 
tr(d2e1, minor) = 12.4 min, tr(d2e2, major) = 15.9 min). Rf = 0.13 (30% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3, 1.2:1 mixture of diastereomers, as a mixture with pyridine 
carboxaldehyde)  8.67 (br s, 4H), 7.52 (dd, J = 11.2, 8.4 Hz, 2H), 7.28 (br s, 12H), 6.38 
(d, J = 8.8 Hz, 2H), 6.10 (d, J = 9.2 Hz, 2H), 5.79 (br m, 1H), 5.59 (br m, 1H), 5.17 (s, 
2H), 5.14 (s, 2H); HRMS (ESI): Exact mass calcd for C15H15BrN3O4 [M+H]
+
 380.0240, 
found 380.0261. 
 
                                                          
165
 Due to its instability, the product could only be isolated as a mixture with pyridine carboxaldehyde and 
was not able to be fully characterized. 
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N-((1R)-2-Bromo-2-nitro-1-(1-((4-nitrophenyl)sulfonyl)-indol-3-yl)ethyl)acetamide 
(252). Following General Procedure B, the N-TMS-imine (90% pure, 44 mg, 99 µmol) 
and bromonitromethane (8.0 µL, 99 µmol), when quenched with acetyl bromide (7.0 µL, 
99 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash 
column chromatography (SiO2, 30% ethyl acetate in hexanes), as a yellow solid (7.5 mg, 
15%). The enantiomeric excess of the major and minor diastereomers was determined to 
be 8 and 8% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 10.3 min, tr(d1e2, major) = 12.3 min, tr(d2e1, 
minor) = 14.6 min, tr(d2e2, major) = 15.3 min). Rf = 0.11 (30% EtOAc/hexanes); mp = 
129-131 C; IR (film) 3281, 2924, 1663, 1567, 1533, 1350, 1181, 740 cm-1; 1H NMR 
(600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  8.29 (m, 4H), 7.95 (m, 6H), 7.68 (s, 
2H), 7.59 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.41 (m, 2H), 7.34 (m, 2H), 6.70 
(d, J = 10.2 Hz, 1H), 6.54 (d, J = 4.8 Hz, 1H), 6.52 (d, J = 4.8 Hz, 1H), 6.46 (d, J = 8.4 
Hz, 1H), 6.14 (dd, J = 9.0, 4.8 Hz, 1H), 6.10 (dd, J = 8.4, 5.4 Hz, 1H), 2.13 (s, 3H), 2.10 
(s, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 169.9, 169.7, 150.8 (2C), 142.7, 142.5, 134.6 
(2C), 128.5, 128.1, 128.0, 126.4, 124.9, 124.8 (3C), 124.7, 124.6, 124.4, 124.3, 119.5, 
118.2, 117.7, 113.8, 113.7, 82.0, 80.1, 49.7, 49.1, 23.1, 23.0; HRMS (ESI): Exact mass 
calcd for C18H15BrN4NaO7S [M+Na]
+
 532.9743, found 532.9764. 
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N-((1R)-2-Bromo-2-nitro-1-(1-((4-methylhenyl)sulfonyl)-indol-3-yl)ethyl)acetamide 
(254). Following General Procedure B, the N-TMS-imine (40 mg, 108 µmol) and 
bromonitromethane (8.4 µL, 108 µmol), when quenched with acetyl bromide (8.0 µL, 
108 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after 
flash column chromatography (SiO2, 30% ethyl acetate in hexanes), as a yellow oil (15.0 
mg, 29%). The enantiomeric excess of the major and minor diastereomers was 
determined to be 55 and 56% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 6.3 min, tr(d1e2, major) = 8.4 min, 
tr(d2e1, minor) = 6.8 min, tr(d2e2, major) = 9.8 min). Rf = 0.13 (30% EtOAc/hexanes); IR 
(film) 3287, 2928, 1665, 1570, 1448, 1373, 1174, 1131, 1091, 910 cm
-1
; 
1
H NMR (600 
MHz, CDCl3, 1.2:1 mixture of diastereomers)  8.26 (s, 1H), 8.24 (s, 1H), 7.96-7.58 (m, 
8H), 6.33 (m, 8H), 7.09 (d, J = 4.8 Hz, 1H), 6.95 (d, J = 6.0 Hz, 1H), 6.58 (d, J = 6.0 Hz, 
1H), 6.55 (d, J = 5.4 Hz, 1H), 6.26 (dd, J = 8.4, 4.8 Hz, 1H), 6.18 (dd, J = 9.0, 6.0 Hz, 
1H), 2.35 (s, 3H), 2.34 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H); 
13
C NMR (150 MHz, CDCl3) 
ppm 170.6, 169.7, 145.6, 145.5, 134.6, 134.4, 134.3, 134.0, 130.3, 130.1 (3C), 126.8 
(3C), 126.3, 125.7, 125.6, 125.2, 125.0, 199.9, 119.2, 116.8, 116.5, 113.7, 113.5, 82.4, 
80.2, 55.8 (2C), 23.1, 22.9, 21.6 (2C); HRMS (ESI): Exact mass calcd for 
C19H18BrN3NaO5S [M+Na]
+
 502.0048, found 502.0040. 
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(E)-N-(2,2-dichloro-3-phenylpropylidene)-1,1,1-trimethylsilanamine (265). Following 
General Procedure A, the aldehyde (3.0 g, 15 mmol) provided the imine (1.2 g, 30%) as a 
while crystalline solid. Rf = 0.45 (20% EtOAc/hexanes); bp = 90 °C/0.6 mmHg; IR (film) 
2958, 1683, 1252, 845 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.26 (s, 1H), 7.36 (d, J = 6.0 
Hz, 2H), 7.30 (t, J = 7.2 Hz, 3H), 3.66 (s, 2H), 0.24 (s, 9H); 
13
C NMR (150 MHz, CDCl3) 
ppm 165.1, 134.3, 131.7, 127.8, 127.4, 89.6, 47.9, -1.5; HRMS (EI): Exact mass calcd for 
C12H17Cl2NSi [M]
+
 273.0507, found 274.0570. 
 
Bis((9H-fluoren-9-yl)methyl) (2,2-dichloro-3-phenylpropane-1,1-diyl)dicarbamate 
(267). Following General Procedure C, the N-TMS-imine (40.0 mg, 146 µmol) and 
bromonitromethane (11.0 µL, 146 µmol), when quenched with fluorenylmethyl 
chloroformate (38.0 mg, 146 µmol),  did not provide the desired α-bromo nitroalkane. 
Instead, the doubly-Fmoc protected aminal side product was isolated, after flash column 
chromatography (SiO2, 15% ethyl acetate in hexanes), as a white solid (41.8 mg, 86%). 
Rf = 0.18 (20% EtOAc/hexanes); mp = 139-141 C; IR (film) 3291, 1706, 1509, 1242, 
735 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.76 (br s, 4H), 7.59 (br d, J = 7.2 Hz, 4H), 
7.40-7.29 (m, 13H), 5.97 (br s, 1H), 5.51 (br s, 2H), 4.59 (br s, 2H), 4.47 (br dd, J = 10.2, 
6.6 Hz, 2H), 4.24 (br t, J = 6.0 Hz, 2H), 3.38 (br s, 2H); 
13
C NMR (150 MHz, CDCl3) 
ppm 154.5, 143.5, 141.3, 133.0, 131.6, 131.3, 128.2, 128.0, 127.9, 127.8, 127.7, 124.98, 
124.88, 120.0, 76.6, 67.4, 67.2, 49.0, 47.1, 47.0; HRMS (ESI): Exact mass calcd for 
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C39H32Cl2N2NaO4 [M+Na]
+
 685.1637, found 685.1614. 
 
(E)-1,1,1-trimethyl-N-((E)-3-phenylallylidene)silanamine (275). Following General 
Procedure A, the aldehyde (5.0 g, 38 mmol) provided the imine (2.6 g, 34%) as a yellow 
viscous oil. Rf = 0.38 (20% EtOAc/hexanes); bp = 80 °C/0.6 mmHg; IR (film) 1677, 
1632, 972, 749 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  8.72 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 
5.4 Hz, 2H), 7.39 (m, 3H), 7.12 (d, J = 15.6 Hz, 1H), 6.85 (dd, J = 16.2, 8.4 Hz, 1 H), 
0.25 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 170.4, 144.8, 135.6, 132.0, 129.4, 128.8, 
127.5; HRMS (ESI): Exact mass calcd for C9H9N [M-C3H8Si]
+
 131.0735, found 
131.0495.
166
 
 
Fluorenylmethyl ((2R,E)-1-bromo-1-nitro-4-phenylbut-3-en-2-yl)carbamate (276). 
Following General Procedure C, the N-TMS-imine (600 mg, 2.94 mmol) and 
bromonitromethane (22.8 µL, 2.94 mmol), when quenched with fluorenylmethyl 
chloroformate (762 mg, 2.94 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of 
diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), 
as a white solid (725 mg, 50%). The enantiomeric excess of the major and minor 
diastereomers were determined to be 64 and 63% ee, respectively, by chiral HPLC 
analysis (Chiralcel AD-H, 20% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 10.9 min, 
tr(d1e2, major) = 20.9 min, tr(d2e1, minor) = 15.1 min, tr(d2e2, major) = 32.2 min). Rf = 
                                                          
166
 Trimethylsilyl group fragmented during MS analysis. 
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0.37 (20% EtOAc/hexanes); mp = 162-164 C; IR (film) 3317, 1710, 1564, 1508, 1243, 
739 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.77 (d, J = 7.8 
Hz, 4H), 7.59 (dd, J = 12.0, 6.6 Hz, 4H), 7.42-7.30 (m, 18H), 6.70 (br d, J = 15.6 Hz, 
2H), 6.27 (br s, 2H), 6.16 (br dd, J = 15.0, 9.0 Hz, 1H), 6.11 (br dd, J = 15.6, 7.2 Hz, 1H), 
5.47 (br d, J = 7.8 Hz, 1H), 5.34 (br d, J = 6.6 Hz, 1H), 5.11 (br s, 1H), 5.08 (br s, 1H), 
4.56 (br m, 2H), 4.46 (br m, 2H), 4.25 (br s, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 
154.9, 143.7, 143.4, 141.3 (2C), 136.6, 136.2, 135.1, 135.0 128.9, 128.8, 128.7 (2C), 
127.8 (2C), 127.1 (2C), 126.9 (2C), 125.0, 124.9, 120.6, 120.0; HRMS (ESI): Exact mass 
calcd for C25H21BrN2NaO4 [M-Na]
+
 515.0582, found 515.0580. 
 
Fluorenylmethyl ((R,E)-1-oxo-4-phenyl-1-(S)-1-phenylethylamino but-3-en-2-yl) 
carbamate (277). Following General Procedure D, the -bromo nitroalkane (30 mg, 61 
μmol) and α-methyl benzyl amine (97% ee, 9.0 µL, 73 μmol) provided the amide (single 
diastereomer), after column chromatography (SiO2, 15% ethyl acetate in hexanes), as a 
white solid (10 mg, 33% yield). []  -28.5 (c 0.27, CHCl3); Rf = 0.31 (30% 
EtOAc/hexanes); mp = 139-141 C; IR (film) 3317, 3062, 1711, 1663, 1522, 1450, 1245, 
1051, 739 cm
-1
; 
1
H NMR (600 MHz)  7.77 (d, J = 7.2 Hz, 2H), 7.39 (d, J = 6.6 Hz, 2H), 
7.36 (m, 14 H), 6.42 (br s, 1H), 6.24 (br d, J = 7.8 Hz, 1H), 5.56 (br s, 1H), 5.16 (br m, 
1H), 4.68 (br s, 1H), 4.49 (br d, J = 6.6 Hz, 2H), 4.40 (br s, 1H), 3.61 (br s, 1H), 1.54 (d, 
J = 6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 167.0, 151.0, 143.8, 143.4, 141.3, 
141.2, 128.8, 128.6, 128.5, 127.8, 127.7, 127.0, 126.7, 126.1, 125.8, 125.0, 124.9, 120.0, 
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D
258 
 
67.1, 60.0, 55.5, 47.1, 21.6; HRMS (ESI): Exact mass calcd for C33H30N2NaO3 [M+Na]
+
 
525.2154, found 525.2175. 
 
Benzyl ((2R,E)-1-bromo-1-nitro-4-phenylbut-3-en-2-yl)carbamate (280). Following 
General Procedure C, the N-TMS-imine (1.0 mg, 4.9 mmol) and bromonitromethane (380 
µL, 4.9 mmol), when quenched with carboxybenzyl chloroformate (700 mL, 4.9 mmol), 
provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after flash column 
chromatography (SiO2, 10% ethyl acetate in hexanes), as an orange solid (1.1 g, 55%). 
The enantiomeric excess of the major and minor diastereomers was determined to be 69 
and 71% ee, respectively, by chiral HPLC analysis (Chiralcel OD-H, 10% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 22.5 min, tr(d1e2, major) = 36.3 min, tr(d2e1, 
minor) = 25.6 min, tr(d2e2, major) = 34.3min). Rf = 0.38 (20% EtOAc/hexanes); mp = 96-
98 C; IR (film) 3310, 3030, 1704, 1564, 1510, 1349, 1240, 968, 741 cm-1; 1H NMR (600 
MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.35 (m, 20H), 6.74 (d, J = 15.6 Hz, 2H), 
6.31 (d, J = 8.4 Hz, 2H), 6.18 (dd, J = 15.0, 5.4 Hz, 1H), 6.13 (dd, J = 15.6, 7.2 Hz, 1H), 
5.50 (br s, 1H), 5.36 (br s, 1H), 5.19 (d, J = 4.8 Hz, 2H), 5.17 (d, J = 4.8 Hz, 2H), 5.12 
(br m, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 155.2, 136.5, 136.1, 135.6, 135.1, 135.0, 
128.8 (2C), 128.7 (2C), 128.6 (2C), 128.4 (2C), 128.2 (2C), 126.9, 126.8, 120.7, 120.3, 
82.7, 81.9, 67.7, 67.6, 57.4, 56.9; HRMS (ESI): Exact mass calcd for C18H17BrN2NaO4 
[M+Na]
+
 427.0269, found: 427.0271. 
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Benzyl ((R)-2-oxo-2-(((S)-1-phenylethyl) amino) -1-((2R,3R) -3-phenyloxiran-2-yl) 
ethyl) carbamate (282). Following General Procedure D, the -bromo nitroalkane (30 
mg, 74 μmol) and α-methyl benzyl amine (97% ee, 18 µL, 150 μmol) provided the amide 
(single diastereomer), after column chromatography (SiO2, 15% ethyl acetate in 
hexanes), as a white solid (11 mg, 36% yield). []  -58.5 (c 0.34, CHCl3); Rf = 0.16 
(20% EtOAc/hexanes); mp = 142-144 C; IR (film) 3309, 2925, 1714, 1642, 1521, 1497, 
1454, 1240, 698 cm
-1
; 
1
H NMR (600 MHz)  7.34 (m, 15H), 6.57 (d, J = 6.6 Hz, 1H), 
5.98 (br s, 1H), 5.35 (dt, J = 6.6, 6.6 Hz, 1H), 5.13 (d, J = 12.0 Hz, 1H), 5.09 (d, J = 12.0 
Hz, 1H), 4.22 (br s, 1H), 3.87 (dd, J = 7.8, 7.8 Hz, 1H), 3.06 (d, J = 7.8 Hz, 1H), 1.61 (d, 
7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 166.9, 155.8, 142.5, 136.1, 128.8, 
128.53, 128.48, 128.3, 128.1, 128.0, 127.6, 126.1, 125.7, 67.0, 61.5, 60.4, 56.3, 49.6, 
22.0; HRMS (ESI): Exact mass calcd for C26H26N2NaO4 [M+Na]
+
 453.1790, found 
453.1812. 
 
(S)-tert-Butyl 2-((R)-2-(((benzyloxy) carbonyl) amino) -2-((2R,3R) -3-phenyloxiran-2-
yl) acetamido)-4-methylpentanoate (284). Following General Procedure E, the α-bromo 
nitroalkane (30 mg, 74 μmol) and the ammonium salt of ʟ-leucine (33 mg, 150 μmol) 
provided the dipeptide (single diastereomer) after flash column chromatography (30% 
20
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ethyl acetate in hexanes) as a yellow oil (11 mg, 32%). [α]  -34.7 (c 0.38, CHCl3); Rf = 
0.10 (30% EtOAc/hexanes); IR (film) 3321, 2958, 1728, 1670, 1501, 1241, 1150 cm
-1
; 
1
H 
NMR (600 MHz, CDCl3)  7.36 (m, 10 H), 6.62 (d, J = 7.8 Hz, 1H), 5.94 (br s, 1H), 5.14 
(d, J = 12.6 Hz, 1H), 5.10 (d, J = 12.6 Hz, 1H), 4.55 (ddd, J = 8.4, 8.4, 5.4 Hz, 1H), 4.24 
(br s, 1H), 3.96 (dd, J = 7.8, 6.0 Hz, 1H), 2.99 (d, J = 7.8 Hz, 1H), 1.73 (m, 3H), 1.49 (s, 
9H)1.01 (d, J = 7.2 Hz, 3H), 1.00 (d, J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
171.4, 155.7, 136.1, 135.8, 128.4 (2C), 128.1, 128.0, 125.6 (2C), 82.1, 67.0, 61.4, 60.1, 
56.2, 51.9, 41.5, 27.9, 24.9, 22.8, 22.0; HRMS (ESI): Exact mass calcd for C28H37N2O6 
[M+H]
+
 497.2646, found 497.2633. 
 
Benzyl ((2R,3S) -3-hydroxy-1-oxo-4-phenyl-1-(((S) -1-phenylethyl) amino) butan-2-
yl) carbamate (288). After stirring in a 1:1 mixture of EtOH:MeOH (0.01 M) for 5 hours 
at ambient temperature, in the presence of H2 (balloon) and 10% Pd/C (10 mg), the epoxy 
amide (9.1 mg, 21 μmol) provided the alcohol (single diastereomer) as a yellow oil (9.0 
mg, 99% yield). []  +36.4 (c 0.11, CHCl3); Rf = 0.11 (30% EtOAc/hexanes); IR (film) 
3299, 2922, 1706, 1652, 1537, 1250, 698 cm
-1
; 
1
H NMR (600 MHz)  7.29 (m, 15H), 
6.73 (d, J = 6.6 Hz, 1H), 5.83 (d, J = 7.8 Hz, 1H), 5.10 (m, 3H), 4.12 (dd, J = 8.4, 4.2 Hz, 
1H), 3.98 (br s, 1H), 3.78 (br s, 1H), 3.02 (dd, J = 13.8, 7.8 Hz, 1H), 2.93 (dd, J = 13.8, 
6.0 Hz, 1H), 1.52 (d, 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 170.1, 156.6, 142.6, 
137.3, 135.9, 129.2, 128.69, 128.66, 128.56, 128.3, 128.1, 127.4, 126.8, 125.8, 74.1, 67.3, 
56.0, 49.1, 40.8, 22.2; HRMS (ESI): Exact mass calcd for C26H28N2NaO4 [M+Na]
+
 
455.1947, found 455.1968. 
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Chapter IV: Application of UmAS to the Total Synthesis of Feglymycin 
General Procedure A: Bromonitromethane Addition to N-TMS-Protected Imines 
A solution of the imine (1 equiv) and PBAM (0.10 equiv) in toluene (0.3 M) was cooled 
to -78 C. Bromonitromethane was added to the reaction mixture in aliquots (0.2 equiv 
every 2 h) over 10 h. The reaction was then stirred at -78 C for an additional 16 h before 
its quench at -78 C with an acylating reagent (1 equiv). The reaction was then warmed to 
0 C and stirred for 20 h. The solvent was removed in vacuo, and the crude reaction 
mixture was purified by column chromatography to give the α-bromonitro adduct as a 
mixture of inseparable diastereomers. 
General Procedure B: Sulfone Synthesis 
tert-Butyl carbamate (1 equiv) and benzene sulfinic acid (2 equiv) were dissolved in a 2:1 
mixture of toluene and water (0.3 M). The aldehyde (1.2 equiv) and formic acid (2 equiv) 
were added and the reaction was then allowed to stir for a period of 11 to 15 days at rt. 
The mixture was filtered, and the resulting solid washed several times with ether to 
remove remaining aldehyde. The solid was then dried under vacuum at 60 C to give the 
pure sulfone. 
General Procedure C: Synthesis of N-Boc-Protected Imines 
To a round bottom flask, potassium carbamate (6 equiv) and sodium sulfate (7 equiv) 
were added. The flask was then flame dried and the contents placed under argon. The 
sulfone (1 equiv.) was then added to the flask, and dissolved in THF (0.1 M). The 
reaction mixture was then allowed to reflux for 4-5 hours. The solid salts were then 
filtered off, and the resulting mixture was concentrated in vacuo to give the pure imine. 
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General Procedure D: Bromonitromethane Addition to N-Boc-Protected Imines 
A solution of the imine (1 equiv) and PBAM or PBAMTfOH (0.01 or 0.05 equiv) in 
toluene (0.3 M) was cooled to -20 C and treated with bromonitromethane (1.2 equiv). 
The reaction was stirred at -20 C for 24 hours. The solvent was removed in vacuo, and 
the crude reaction mixture purified by column chromatography to give the -bromonitro 
adduct as a mixture of inseparable diastereomers. 
General Procedure E: Amide Synthesis Using an Amine (Free Base) 
The amine (1.2 equiv) was added drop wise to a solution of α-bromo nitroalkane (1.0 
equiv, 0.2 M) and NIS (1.0 equiv) in THF and H2O (5.0 equiv) at 0 °C, or rt, followed by 
K2CO3 (2.0 equiv). The reaction mixture was stirred at 0 °C, or rt, for 2 d. The resulting 
mixture was diluted with dichloromethane, dried with MgSO4 and then filtered through 
Celite. The filtrate was concentrated and subjected to purification by flash column 
chromatography on silica gel.  
General Procedure F: Amide Synthesis Using an Ammonium Salt 
K2CO3 (3.2 equiv) was added to the suspension of the ammonium salt (1.2 equiv) and the 
α-bromo nitroalkane (1.0 equiv, 0.2 M) in THF and H2O (5.0 equiv) at 0 °C, or rt, 
followed by NIS (1.0 equiv). The reaction mixture was stirred at 0 °C, or rt, for 2 d. The 
resulting mixture was diluted with dichloromethane, dried with MgSO4 and then filtered 
through Celite. The filtrate was concentrated and subjected to purification by flash 
column chromatography on silica gel.  
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Carboxybenzyloxy (1R)-1- (4 (benzyloxy) phenyl) -2-bromo -2-nitroethyl carbamate 
(316). Following General Procedure A, the N-TMS-imine (40 mg, 140 µmol) and 
bromonitromethane (11 µL, 140 µmol), when quenched with benzyl chloroformate (20 
µL, 140 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), after 
flash column chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid (38.4 
mg, 56%). The enantiomeric excess of the major and minor diastereomers was 
determined to be 67 and 67% ee, respectively, by chiral HPLC analysis (Chiralcel AD-H, 
10% 
i
PrOH/hexanes, 1.0 mL/min, tr(d1e1, minor) = 33.1 min, tr(d1e2, major) = 43.5 min, 
tr(d2e1, minor) = 35.7 min, tr(d2e2, major) = 38.5 min). Rf = 0.25 (20% EtOAc/hexanes); 
mp = 119-121 C IR (film) 3346, 3031, 1694, 1563, 1512, 1345, 1288, 1245, 738 cm-1; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  7.40 (m, 20H), 7.25 (d, J = 
8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 6.6 Hz, 2H), 6.99 (d, J = 6.6 Hz, 2H), 
6.31 (br s, 2H), 5.98 (br s, 1H), 5.65 (br m, 2H), 5.50 (br s, 1H), 5.16 (s, 2H), 5.14 (s, 
2H), 5.08 (s, 2H), 5.07 (s, 2H); 
13
C NMR (150 MHz, CDCl3) ppm 159.5, 159.4, 155.5, 
155.2, 136.4 (2C), 135.7 (2C), 135.6 (2C), 128.6 (4C), 128.5, 128.4, 128.2 (2C), 128.1 
(2C), 127.4 (4C), 115.4, 115.3, 84.6, 81.3, 70.1 (2C), 67.7, 67.6, 58.1, 58.0; HRMS (EI): 
Exact mass calcd for C23H21BrN2O5 [M]
+
 484.0634, found 484.0647. 
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Carboxybenzyloxy (1R)-1-(3,5 (dibenzyloxy) phenyl) -2-bromo-2-nitroethyl 
carbamate (317). Following General Procedure A, the N-TMS-imine (40 mg, 100 µmol) 
and bromonitromethane (8.0 µL, 100 µmol), when quenched with benzyl chloroformate 
(15 µL, 100 mmol), provided the α-bromo nitroalkane (1.2:1 mixture of diastereomers), 
after flash column chromatography (SiO2, 10% ethyl acetate in hexanes), as a white solid 
(32 mg, 53%). The enantiomeric excess of the major and minor diastereomers was 
determined to be 71 and 71% ee, respectively, by chiral HPLC analysis (Chiralcel IA, 
20% 
i
PrOH/hexanes, 1.0 mL/min, tr(minor) = 14.9 min, tr(major) = 16.9 min). Rf = 0.30 
(20% EtOAc/hexanes); mp = 126-128 C; IR (film) 3326, 3032, 1691, 1599, 1563, 1452, 
1264, 1160, 695 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 1.2:1 mixture of diastereomers)  
7.39 (m, 30H), 6.62 (dd, J = 4.2, 2.4 Hz, 1H), 6.61 (dd, J = 4.2, 2.4 Hz, 1H), 6.55 (d, J = 
1.8 Hz, 2H), 6.52 (s, 2H), 6.27 (br s, 2H), 5.99 (d, J = 8.4 Hz, 1H), 5.68 (br s, 1H), 5.57 
(d, J = 7.8 Hz, 1H), 5.46 (br s, 1H), 5.16 (s, 2H), 5.14 (s, 2H), 5.03 (s, 4H), 5.02 (s, 4H); 
13
C NMR (150 MHz, CDCl3) ppm 160.41 (2C), 160.39 (2C), 155.4 (2C), 136.3 (2C), 
136.2 (2C), 135.7 (2C), 128.62 (6C), 128.58 (2C), 128.4 (3C), 128.2 (3C), 127.6 (6C), 
106.2 (2C), 106.1 (2C), 102.5, 102.4, 84.7, 80.6, 70.3 (4C), 67.7 (2C), 58.5, 58.2; HRMS 
(EI): Exact mass calcd for C30H27BrN2O6 [M]
+
 590.1052, found 590.1036. 
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(S)-Benzyl 2-((R)-2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino)-2-(3,5-bis 
(benzyloxy) phenyl) acetamido) -3-methylbutanoate (319). Following General 
Procedure F, the α-bromo nitroalkane (50 mg, 74 μmol) and the ammonium salt of ʟ-
valine (37 mg, 150 μmol) provided the dipeptide (single diastereomer) after flash column 
chromatography (15% ethyl acetate in hexanes) as a white solid (36 mg, 63%). [α]  -
31.1 (c 0.24, CHCl3); Rf = 0.22 (30% EtOAc/hexanes); mp 165-167 °C; IR (film) 3302, 
2961, 1738, 1657, 1600, 1533, 1451, 1250, 1158 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  
7.77 (d, J = 7.2 Hz, 2H), 7.61 (br s, 2H), 7.34 (m, 19H), 6.74 (br s, 2H), 6.58 (br s, 1H), 
6.48 (br s, 1H), 6.32 (br s, 1H), 5.32 (br s, 1H), 5.16 (br m, 2H), 4.98 (br m, 4H), 4.60 (br 
m, 1H), 4.42 (br m, 1H), 4.36 (br m, 1H), 4.23 (br s, 1H), 2.08 (dqq, J = 7.2, 7.2, 7.2 Hz, 
1H), 0.71 (d, J = 5.4 Hz, 3H), 0.64 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 
171.3, 169.8, 160.4, 155.6, 143.8, 143.7, 141.2, 136.6, 135.1, 128.6 (2C), 128.5, 128.4, 
128.0, 127.7, 127.5, 127.1, 125.1, 119.1, 106.0, 102.3, 70.0, 67.2, 58.9, 57.2, 47.0, 31.4, 
18.8, 17.2; HRMS (ESI): Exact mass calcd for C49H47N2O7 [M+H]
+
 775.3378, found 
775.3381. 
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(S)-Benzyl 2-((R)-2-amino-2-(3,5-bis(benzyloxy)phenyl)acetamido)-3-
methylbutanoate (321). Following the procedure used by Boger and coworkers,
167
 upon 
treatment with TBAF (1 M in THF, 270 µL, 265 μmol) and iPrOH (25 µL, 330 μmol) in 
THF (0.03 M), the Fmoc-protected peptide (26 mg, 33 μmol) provided the free amine 
(single diastereomer) after flash column chromatography (30% acetone in hexanes) as a 
viscous yellow oil (22 mg, 87%). [α]  -27.2 (c 0.72, CHCl3); Rf = 0.31 (100% 
EtOAc/hexanes); IR (film) 3034, 2963, 1674, 1600, 1454, 1202, 1157 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3)  7.56 (br s, 1H), 7.29 (m, 15H), 6.85 (s, 2H), 6.58 (s, 1H), 5.12 (d, J 
= 12.0 Hz, 1H), 4.98 (d, J = 12.6 Hz, 1H), 4.95 (d, J = 11.4 Hz, 2H), 4.92 (d, J = 11.4 Hz, 
2H), 4.52 (br m, 1H), 2.64 (br s, 2H), 2.04 (dqq, J = 6.0, 6.0, 6.0 Hz, 1H), 0.64 (d, J = 6.6 
Hz, 3H), 0.60 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) ppm 172.0, 168.0, 160.5, 
136.4, 134.9, 134.5, 128.5, 128.4, 127.9, 127.5, 106.6, 103.9, 70.0, 67.5, 57.7, 56.9, 31.0, 
18.7, 17.1; HRMS (ESI): Exact mass calcd for  C34H37N2O5 [M+H]
+
 553.2697, found 
553.2687. 
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(5R,8R,11S)-Benzyl 5-(4-(benzyloxy) phenyl)-8-(3,5-bis (benzyloxy) phenyl) -11-
isopropyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate (322). Following 
General Procedure E, the α-bromo nitroalkane (74 mg, 150 μmol) and the free amine 
dipeptide (68 mg, 130 μmol) provided the tripeptide (single diastereomer) after flash 
column chromatography (40% ethyl acetate in hexanes) as a yellow foam (23 mg, 20%). 
[α]  -70.7 (c 0.08, CHCl3); Rf = 0.08 (30% EtOAc/hexanes); IR (film) 2922, 2361, 
1716, 1581, 1510, 1229, 913 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.38 (m, 25H), 7.01 (s, 
1H), 6.99 (s, 2H), 6.96 (s, 2H), 6.94 (s, 2H), 6.62 (br s, 1H), 6.57 (br s, 1H), 6.03 (br s, 
1H), 6.00 (br s, 1H), 5.13 (m, 11H), 2.72 (br s, 1H), 2.07 (br m, 1H), 0.90 (d, J = 6.0 Hz, 
3H), 0.87 (d, J = 6.0 Hz, 3H).
168
 
 
tert-Butyl (4-benzyloxy) (phenylsulfonyl) methylcarbamate (328). Following the 
General Procedure B, p-bezyloxybenzaldehyde (5.0 g, 23.6 mmol) gave the sulfone (5.6 
g, 52%), as a white powder. Rf = 0.46 (30% EtOAc/hexanes); mp = 98-100 C; IR (film) 
3340, 1694, 1601, 1507, 1225, 1198, 1161, 912 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  7.92 
(d, J = 7.8 Hz, 2H), 7.65 (t, J = 7.2 Hz, 1H), 7.55 (t, J = 7.8 Hz, 2H), 7.40 (m, 6H), 7.19 
(t, J = 6.6 Hz, 1H), 7.02 (d, J = 9.0 Hz, 2H), 5.88 (d, J = 10.8 Hz, 1H), 5.67 (d, J = 10.2 
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instability of the compound. 
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Hz, 1H), 5.10 (s, 2H), 1.27 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 160.0, 153.2, 
137.0, 133.8, 130.2, 129.4, 129.0, 128.6, 127.4, 125.3, 121.9, 115.1, 81.2, 73.4, 70.1, 
28.0.
169
 
 
(E)-tert-Butyl-4-benzyloxybenzylidenecarbamate (329). Following General Procedure 
C, the sulfone (3.4 g, 7.5 mmol) provided the imine (2.1 g, 91%) as a white paste. IR 
(film) 2977, 1708, 1600, 1511, 1368, 1252, 1224, 1150, 1007 cm
-1
; 
1
H NMR (600 MHz, 
CDCl3)  8.89 (s, 1H), 7.90 (d, J = 9.0 Hz, 2H), 7.42 (m, 4H), 7.36 (tt, J = 6.0, 1.2 Hz, 
1H), 7.04 (d, J = 9.0 Hz, 2H), 5.13 (s, 2H), 1.60 (s, 9H); 
13
C NMR (150 MHz, CDCl3) 
ppm 169.7, 163.3, 162.8, 136.0, 132.5, 128.7, 128.2, 127.5, 127.1, 115.1, 81.8, 70.2, 
27.9; HRMS (ESI): Exact mass calcd for C19H22NO3 [M+H]
+
 312.1594, found 312.1591. 
 
tert-Butyl (1R)-2-bromo-1-(4-benzyloxyphenyl)-2-nitroethylcarbamate (325). 
Following General Procedure D, the N-Boc-imine (1.0 g, 3.2 mmol) and 
bromonitromethane (300 µL, 3.2 mmol) provided the α-bromo nitroalkane (1.2:1 mixture 
of diastereomers), after flash column chromatography (SiO2, 10% ethyl acetate), as a 
white solid (1.3 g, 90%). The enantiomeric excess of the major and minor diastereomers 
was determined to be 92 and 90% ee, respectively, by chiral HPLC analysis (Chiralcel 
AD-H, 20% 
i
PrOH/hexanes, 1 mL/min, (Chiralcel AD-H, 10% 
i
PrOH/hexanes, 1.0 
mL/min, tr(d1e1, minor) = 15.6 min, tr(d1e2, major) = 12.4 min, tr(d2e1, minor) = 16.7 min, 
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 HRMS was attempted, but the desired mass was not able to be detected. This is most likely due to the 
instability of the compound. 
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tr(d2e2, major) = 20.7 min). Rf = 0.38 (20% EtOAc/hexanes); mp = 144-146 C; IR (film) 
3361, 2979, 1691, 1564, 1510, 1354, 1249, 1163, 735 cm
-1
; 
1
H NMR (600 MHz, CDCl3, 
1.2:1 mixture of diastereomers)  7.42 (m, 8H), 7.35 (t, J = 6.0 Hz, 2H), 7.25 (d, J = 7.2 
Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 6.6 Hz, 2H), 6.32 
(br s, 1H), 6.28 (br s, 1H), 5.65 (br s, 1H), 5.58 (br d, J = 4.2 Hz, 1H), 5.43 (br s, 1H), 
5.32 (br s, 1H), 5.08 (s, 2H), 5.07 (s, 2H), 1.47 (s, 9H), 1.46 (s, 9H); 
13
C NMR (150 MHz, 
CDCl3) ppm 159.3 (2C), 154.6 (2C), 136.5 (4C), 128.6 (2C), 128.2 (2C), 128.1 (2C), 
127.4 (2C), 115.3 (2C), 85.1, 82.0, 80.9 (2C), 70.1 (2C), 57.2 (2C), 28.2, 28.1; HRMS 
(ESI): Exact mass calcd for C20H23BrN2NaO5 [M+Na]
+
 473.0688, found: 473.0681. 
 
(S)-Di-tert-butyl 2-((S)-2- ((tert-butoxycarbonyl) amino) -3-phenylpropanamido) 
succinate (S-17). Upon treatment with EDC (590 mg, 3.1 mmol) in dichloromethane (0.1 
M), N-Boc ʟ-phenylalanine (540 mg, 2.0 mmol) and ʟ-aspartic acid di-tbutyl ester (500 
mg, 2.0 mmol) provided the dipeptide (single diastereomer) after an aqueous work up as 
a yellow foam (730 mg, 73%). [α]  +17.8 (c 1.94, CHCl3); Rf = 0.34 (30% 
EtOAc/hexanes); IR (film) 3313, 2979, 1739 (broad), 1518, 1369, 1250, 1162 cm
-1
; 
1
H 
NMR (600 MHz, CDCl3)  7.26 (dd, J = 10.2, 2.4 Hz, 2H), 7.20 (m, 3H), 6.91 (d, J = 7.8 
Hz, 1H), 5.01 (br d, J = 6.0 Hz, 1H), 4.62 (ddd, J = 9.0, 4.8, 4.8 Hz, 1H), 4.41 (br s, 1H), 
3.13 (dd, J = 14.4, 6.0 Hz, 1H), 3.02 (br dd, J = 12.6, 6.0 Hz, 1H), 2.84 (dd, J = 16.8, 4.2 
Hz, 1H), 2.67 (dd, J = 17.4, 4.8 Hz, 1H), 1.43 (s, 9H), 1.40 (s, 9H), 1.37 (s, 9H); 
13
C 
NMR (150 MHz, CDCl3) ppm 170.8, 169.9, 169.2, 155.1, 136.3, 129.3, 128.4, 126.7, 
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82.2, 81.4, 79.8, 55.3, 49.0, 38.3, 37.3, 28.1, 27.9, 27.7; HRMS (EI): Exact mass calcd 
for  C26H40N2O7 [M]
+
 492.2836, found 492.2812. 
 
(S)-Di-tert-butyl 2- ((S)-2- ((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -3-phenyl 
propanamido) succinate (S-18). Upon treatment with EDC (1.1 g, 5.7 mmol), HOBt 
(0.8 g, 5.7 mmol), and Et3N (1.6 mL, 11.4 mmol) in dichloromethane (0.25 M), N-Fmoc 
ʟ-phenylalanine (2.2 g, 5.7 mmol) and ʟ-aspartic acid di-tbutyl ester (1.6 g, 5.7 mmol) 
provided the dipeptide (single diastereomer) after aqueous work up as a white solid (3.3 
mg, 94%). [α]  +11.6 (c 0.61, CHCl3); Rf = 0.28 (30% EtOAc/hexanes); mp 65-67 °C; 
IR (film) 3311, 2978, 1729, 1664, 1530, 1368, 1251, 1154, 739 cm
-1
; 
1
H NMR (600 
MHz, CDCl3)  7.78 (d, J = 7.8 Hz, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 7.2 Hz, 
1H), 7.42 (dd, J = 7.8, 7.8 Hz, 2H), 7.27 (m, 7H), 6.86 (br d, J = 6.6 Hz, 1H), 5.34 (br d, 
J = 6.6 Hz, 1H), 4.66 (br m, 1H), 4.52 (br d, J = 5.4 Hz, 1H), 4.42 (dd, J = 10.8, 7.8 Hz, 
1H), 4.30 (br dd, J = 7.2, 7.2 Hz, 1H), 4.20 (dd, J = 7.2, 7.2 Hz, 1H), 3.18 (br dd, J = 
14.4, 6.6 Hz, 1H), 3.11 (br dd, J = 13.8, 6.6 Hz, 1H), 2.89 (dd, J = 16.8, 3.6 Hz, 1H), 2.71 
(dd, J = 17.4, 4.8 Hz, 1H), 1.47 (s, 9H), 1.43 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 
170.4, 170.1, 169.2, 155.7, 143.7, 141.2, 136.0, 129.4, 128.6, 127.7, 127.0, 125.0, 199.9, 
82.5, 81.6, 67.1, 55.7, 49.2, 47.1, 38.5, 37.3, 28.0, 27.8; HRMS (ESI): Exact mass calcd 
for C36H42N2NaO7 [M+Na]
+
 637.2890, found 637.2874. 
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(S)-Benzyl 2-((R)-2-amino-2-(3,5-bis(benzyloxy) phenyl)acetamido) -3-
methylbutanoate (334). Following the procedure used by Boger and coworkers,
167
 upon 
treatment with TBAF (6.5 mL, 6.5 mmol) and 
i
PrOH (6.2 mL, 8.1 mmol) in THF (0.03 
M), the Fmoc-protected peptide (500 mg, 810 μmol) provided the free amine (single 
diastereomer) after flash column chromatography (30% acetone in hexanes) as a yellow 
oil (206 mg, 87%). [α]  -7.3 (c 0.93, CHCl3); Rf = 0.10 (30% EtOAc/hexanes); IR (film) 
3377, 2978, 1732, 1676, 1509, 1455, 1369, 1252, 1156 cm
-1
; 
1
H NMR (600 MHz, 
CDCl3)  8.15 (d, J = 8.4 Hz, 1H), 7.28 (m, 5H), 4.70 (ddd, J = 8.8, 4.5, 4.5 Hz, 1H), 
6.37 (dd, J = 9.5, 3.8 Hz, 1H), 3.27 (dd, J = 13.8, 3.8 Hz, 1H), 2.90 (dd, J = 16.8, 4.5 Hz, 
1H), 2.70 (m, 2H), 1.48 (s, 9H), 1.46 (s, 9H) [NH2 not observed]; 
13
C NMR (150 MHz, 
CDCl3) ppm 174.0, 169.8, 155.4, 137.7, 129.2, 128.6, 126.8, 82.1, 81.4, 56.3, 48.7, 41.0, 
37.8, 28.0, 27.9; HRMS (EI): Exact mass calcd for C21H32N2O5 [M]
+
 392.2311, found 
392.2315. 
 
(6R,9R,12S)-Benzyl 6-(4- (benzyloxy) phenyl) -9-(3,5-bis (benzyloxy) phenyl) -12-
isopropyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate (335). 
Following General Procedure E, the α-bromo nitroalkane (40 mg, 70 μmol) and the free 
amine dipeptide (36 mg, 84 μmol) provided the tripeptide (single diastereomer) after 
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flash column chromatography (30% ethyl acetate in hexanes) as a yellow foam (33 mg, 
56%). [α]  +6.1 (c 0.18, CHCl3); Rf = 0.11 (30% EtOAc/hexanes); IR (film) 3296, 1726, 
1511, 1332, 1232, 1154 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  7.78 (br m, 2H), 7.60 (br m, 
2H), 7.35 (m, 14H), 6.99 (d, J = 7.2 Hz, 2H). 6.93 (d, J = 8.4 Hz, 2H), 6.74 (br s, 1H), 
6.68 (br s, 1H), 6.32 (d, J = 6.8 Hz, 1H), 6.07 (br s, 1H), 5.98 (br s, 2H), 5.06 (d, J = 8.0 
Hz, 2H), 4.40 (br m, 2H), 4.23 (br m, 1H), 3.21 (dd, J = 13.6, 5.6 Hz, 1H), 3.05 (dd, J = 
14.0, 6.8 Hz, 1H), 2.81 (dd, J = 17.2, 4.4 Hz, 1H), 2.61 (br m, 1H), 1.47 (s, 9H), 1.43 (s, 
9H); 
13
C NMR (150 MHz, CDCl3) ppm 181.2, 170.1, 169.6, 156.5, 148.1, 143.8, 141.3, 
141.2, 129.3, 128.6, 128.0, 127.7, 127.4, 127.0, 125.0, 120.0, 115.4, 82.4, 81.8, 70.0, 
67.1, 66.9, 54.2, 53.4, 49.1, 47.1, 28.0, 27.8; HRMS (ESI): Exact mass calcd for  
C51H55N3NaO9 [M+Na]
+
 876.3836, found: 876.3833. 
 
(6R,9R,12S)-Benzyl 6-(4- (benzyloxy) phenyl) -9-(3,5-bis (benzyloxy) phenyl) -12-
isopropyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate (336). 
Following General Procedure E, the α-bromo nitroalkane (44 mg, 74 μmol) and the free 
amine dipeptide (39 mg, 62 μmol) provided the tripeptide (single diastereomer) after 
flash column chromatography (15% ethyl acetate in hexanes) as a yellow viscous oil (37 
mg, 54%). [α]  -41.7 (c 0.24, CHCl3); Rf = 031 (30% EtOAc/hexanes); IR (film) 3340, 
2926, 1725, 1599, 1501, 1336, 1156, 1054 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  8.29 (d, J 
= 8.3 Hz, 1H), 8.02 (s, 2H), 7.40 (m, 28H), 7.12 (d, J = 2.0 Hz, 2H), 7.02 (d, J = 2.4 Hz, 
20
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2H), 6.80 (d, J = 10.2 Hz, 2H), 6.60 (br m, 2H), 5.30 (d, J = 14.8 Hz, 1H), 5.26 (d, J = 
15.2 Hz, 1H), 5.12 (d, J = 21.0 Hz, 3H), 5.06 (d, J = 20.0 Hz, 3H), 4.77 (br m, 2H), 3.41 
(br m, 1H), 3.25 (br m, 1H), 3.17 (br m, 1H), 2.90 (br m, 1H), 1.47 (s, 9H), 1.42 (s, 9H); 
13
C NMR (150 MHz, CDCl3) ppm 172.1, 169.1, 166.8, 164.2, 160.2, 156.6, 155.6, 150.4, 
136.14 (2C), 136.07 (2C), 135.7, 135.0, 129.6, 129.52, 129.45, 129.4, 129.1, 129.0, 
128.7, 128.64, 128.61, 128.56, 128.5, 128.11, 128.07, 127.7, 127.6, 127.5, 127.0, 106.5 
(2C), 83.0, 81.2, 70.4, 68.0, 67.0, 58.3, 54.9, 49.7, 49.1, 38.4, 37.3, 27.9, 27.8.
170
 
 
(S)-Methyl 2-((R)-2- ((((9H-fluoren-9-yl) methoxy) carbonyl) amino)-2- (3,5-bis 
(benzyloxy) phenyl)acetamido)-3-methylbutanoate (337). Following General 
Procedure F, the α-bromo nitroalkane (500 mg, 740 μmol) and the ammonium salt of ʟ-
valine (250 mg, 1.50 mmol) provided the dipeptide (single diastereomer) after flash 
column chromatography (20% ethyl acetate in hexanes) as a white solid (255 mg, 49%). 
[α]  -26.3 (c 0.64, CHCl3); Rf = 0.17 (30% EtOAc/hexanes); mp 174-176 °C; IR (film) 
3305, 2961, 1741, 1659, 1600, 1533, 1450, 1250, 1209, 1158, 1053, 737 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3)  7.77 (d, J = 7.2 Hz, 2H), 7.60 (s, 2H), 7.36 (m, 14H), 6.70 (s, 2H), 
6.59 (s, 1H), 6.21 (br s, 1H), 6.18 (br d, J = 7.2 Hz, 1H), 5.21 (br d, J = 3.0 Hz, 1H), 5.02 
(d, J = 12.0 Hz, 2H), 5.00 (d, J = 11.4 Hz, 2H), 4.55 (dd, J = 8.4, 4.8 Hz, 1H), 4.41 (dd, J 
= 10.2, 10.2, 1H), 4.36 (dd, J = 7.2, 7.2 Hz, 1H), 4.36 (dd, J = 7.2, 7.2 Hz, 1H), 4.22 (br 
s, 1H), 3.75 (s, 3H), 0.75 (d, J = 5.4 Hz, 3H), 0.68 (d, J = 6.6 Hz, 3H); 
13
C NMR (150 
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 HRMS was attempted, but the desired mass was not able to be detected. This is most likely due to the 
instability of the compound. 
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MHz, CDCl3) ppm 171.8, 169.1, 160.5, 155.5, 143.8, 143.7, 141.2, 136.5, 128.6, 128.0, 
127.6, 127.5, 127.0, 125.1, 119.9, 106.1, 102.3, 70.1, 67.2, 59.0, 57.2, 52.3, 47.1, 31.4, 
18.7, 17.3; HRMS (ESI): Exact mass calcd for C43H42N2NaO7 [M+H]
+
 699.3065, found: 
699.3083. 
 
